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The serine/arginine-rich (SR-) family proteins constitute a diverse group of pre-
mRNA splicing factors that are essential for viability. They can be characterised based on the 
presence of one or two RRMs and an RS domain. A subset, of which SRSF1 is the prototype, 
is capable of nucleocytoplasmic shuttling; a process governed by continual cyclic 
phosphorylation of the RS domain. In contrast, SRSF2, another member of the SR family, is 
unable to shuttle due to the presence of a nuclear retention sequence (NRS) at the C-terminus 
of its RS domain. When this NRS is fused to SRSF1, it prevents nucleocytoplasmic shuttling 
of the SRSF1-NRS fusion protein. In addition to its nuclear roles, SRSF1 is directly associated 
with the translation machinery and can activate mRNA translation of target transcripts via an 
mTOR-dependent mechanism. The specific mRNA translational targets that SRSF1 serves to 
regulate encode numerous factors including RNA processing factors and cell-cycle proteins.  
 
The aim of this work is to study the physiological relevance of SRSF1 cytoplasmic 
functions, as previous data have relied on overexpression systems. CRISPR/Cas9 editing was 
used to knock-in the NRS naturally present in SRSF2 at the SRSF1 genomic locus, creating 
an SRSF1-NRS fusion protein. After numerous attempts, it was only possible to obtain a 
single viable homozygous clone in mouse embryonic stem cells (mESCs), despite being able 
to successfully tag the genomic SRSF1 locus. This strongly suggests that the ablation of  
SRSF1 shuttling ability is highly selected against in mESCs. To assess the physiological 
importance of SRSF1 nucleocytoplasmic shuttling during development, a mouse model for 
SRSF1-NRS was also developed. SRSF1-NRS homozygous mice are born at correct 
Mendelian ratios, but are small in size and present with severe hydrocephalus. Finally, 
proteomics was used to identify interactors of endogenous cytoplasmic SRSF1 and those that 
bind the NRS of SRSF2 to gain insights into the mechanism of nuclear retention for non-
shuttling SR proteins. In summary, this work analyses the physiological relevance of 













Every cell of an organism contains the same genetic material consisting of DNA. 
DNA contains units known as genes, which are transcribed, processed, and eventually 
expressed as proteins that execute numerous cellular functions. Interspersed within the 
protein-coding DNA, termed exons, some sequence does not encode for protein. These 
sequences are called introns. 
During transcription, the full DNA sequence of the gene is copied into a molecule 
called messenger RNA (mRNA), which is the template for protein synthesis. Therefore, to 
produce a continuous, functional mRNA transcript, the cell removes the introns and joins the 
exons together in a process called mRNA splicing. To perform splicing, the cell requires 
certain proteins called splicing factors. One essential splicing factor is SRSF1, which can 
regulate specific mRNA transcripts.  
The distinct molecular machineries required to produce mRNA or protein molecules 
are in different compartments of the cell. First, mRNA is synthesised and spliced in the 
nucleus and is then exported into the cytoplasm to be translated into protein. SRSF1 is an 
unusual splicing factor with multiple roles in gene expression. In the nucleus, SRSF1 promotes 
mRNA splicing, and in the cytoplasm, it facilitates translation of this same spliced mRNA 
into protein. However, the role of SRSF1 in protein synthesis is not well understood. 
 This work aims to investigate the roles of SRSF1 function in protein synthesis and 
its relevance for physiology. Both cellular and whole organism models have been engineered 
to create a version of SRSF1 that is permanently retained in the nucleus and therefore unable 
to move to the cytoplasm to act on protein synthesis. This model has been used to investigate 
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1.1 Gene expression regulation and RNA binding 
proteins 
 
Gene expression is a highly complex process, which is subject to an unprecedented 
degree of post-transcriptional regulation. In response to cell-specific intra and extracellular 
cues, it is rapidly manipulated to shape the proteome. RNA binding proteins (RBPs) are key 
orchestrators in these intricate processes and crucial to maintain cellular homeostasis (Figure 
1.1). 
 
In human cells, over a thousand RBPs have been identified containing diverse binding 
domains to regulate many species of RNA including non-coding transcripts from their 
synthesis to degradation (Ray et al., 2013; Calabretta & Richard, 2015). Furthermore, recent 
Figure 1.1: RNA-binding proteins (RBPs) in gene expression regulation. RBPs act in a 
concerted manner to regulate every stage of gene expression, from transcription to mRNA 
translation, immediately as the nascent mRNA is synthesised. The resulting messenger 
ribonucleoprotein (mRNP) complex is highly dynamic, undergoing numerous remodelling 




studies to systematically map RNA binding sites revealed that many of these are highly 
disordered and contain binding sites for post-translational modifications such as 
phosphorylation (Castello et al., 2016). Together the RBP and its cargo RNA form highly 
dynamic mRNP particles, which are continually remodelled as the RNA cargo is processed. 
An important group of RBPs and RNA processing factors are the serine/arginine rich (SR) 
proteins. Different processes in gene expression are highly coupled and SR proteins are crucial 
at each step as they associate with a target mRNA from transcription to translation.  
 
1.2 Pre-mRNA Splicing 
 
Eukaryotic genomes are comprised of exons and introns, which are coding and not 
protein-coding respectively. On transcription, the pre-mRNA is extensively and precisely 
modified to remove introns and produce an exonic mRNA transcript by splicing. RNA 
splicing and the concept of introns was simultaneously discovered in 1977 by several groups, 
and rapidly identified as a ubiquitous process which has shaped the evolution of higher 
organisms (Berget et al., 1977; Chow et al., 1977; Goldberg et al., 1977; Klessig, 1977). The 
concept of “genes in pieces” revolutionised molecular biology and was instrumental in 
reshaping the central dogma into the highly regulated principles regarding gene expression 
that are currently understood (Gilbert 1978).  
Early work also identified the consensus sequences for splicing, the basic mechanisms 
of intron removal involving branch-site interactions and the formation of a lariat intermediate 
via transesterification (Gilbert, 1978; Sharp, 1985). The basis for this reaction mechanism 
evolved from group II self-splicing introns, which act as ribozymes with self-RNA as the 
catalyst (Sharp, 1985). Group II introns can adopt a tertiary structure that brings the active 
groups required for splicing in close proximity (Wahl et al., 2009). Such class of introns is 
likely to be the predecessor of spliceosomal introns, which are present in all eukaryotes, albeit 
with different abundance. The exact evolutionary mechanisms that gave rise to spliceosomal 
introns remain controversial and unclear at least for higher organisms, with much historical 
debate between the “introns-early” and “introns-late” hypotheses. The current consensus 
favours neither directly, but suggests that intron invasion coincided with the endosymbiosis 
events that triggered the onset of eukaryogenesis (Irimia & Roy, 2014). Intron number then 
rapidly expanded and persisted throughout evolution to facilitate the vital genome expansion 
and diversification that gave rise to higher eukaryotes. Early spliceosomal introns were 
capable of self-splicing similar to their group II ancestors, but over time this ability was lost 




catalysis, which became an early spliceosome (Rogozin et al., 2012; Irimia & Roy, 2014). 
Intron gain into a eukaryotic genome has recently been demonstrated experimentally for 
Saccharomyces cerevisiae by reverse splicing reactions, suggesting that intron gain in 
eukaryotes is possible via this mechanism (Lee & Stevens, 2016). 
For almost all splicing events to occur, the spliceosomal machinery assembles 
extremely proficiently in response to consensus sequences in the pre-mRNA transcript. In 
eukaryotes, the most important are the highly conserved 5’ and 3’ splice sites, corresponding 
to GU and AG consensus sequences respectively (Lee & Rio, 2014). The polypyrimidine tract 
and the branch point sequences are also significant, though less well conserved and defined 
by sequence alone. Throughout the splicing reaction, these consensus sites are verified at 
checkpoints by the spliceosome components to ensure fidelity of cleavage (Will & Lührmann, 
2011). During the evolution of higher eukaryotes, conservation of the exonic region of the 
5’SS has increased. For example, it is more strictly conserved in humans than yeast, which 
lack such complex regulation by auxiliary factors at splice sites in comparison to humans (Ast, 
2004).  
Despite the strong sequence requirements for canonical splicing, intron retention can 
occur in humans when consensus sequences are not recognised (Sibley et al, 2016). In 
addition, non-canonical splicing events can occur at a low frequency at cryptic splice sites. 
Such splice sites comprise a consensus akin to those at canonical splice sites, but are located 
far from the latter, imbedded in introns. Considering the volume of intronic sequence in 
vertebrate genomes, it is unsurprising that this can occur by chance (Sibley et al, 2016). 
 
1.2.1 The Spliceosome and the splicing cycle 
 
The spliceosome is the huge macromolecular machine that acts to catalyse the 
removal of introns and join exons to form a functional mRNA transcript. In most eukaryotes, 
including S. cerevisiae, the splicing process occurs co-transcriptionally concurrent with 
emergence of the nascent pre-mRNA transcript (Kornblihtt et al., 2013; Wallace & Beggs, 
2017). Therefore it is unsurprising that chromatin state, nucleosome positioning and 
associated chromatin modifiers also exhibit an interplay with splicing and can alter its 
outcome (Schwartz & Ast, 2010). 
 
The spliceosome consists of multiple RNA-protein complexes termed snRNPs and a 
plethora of associated factors. The latter include the serine/arginine (SR) proteins which are 




(Akerman, et al. 2015; Long & Cáceres 2009). SR proteins are highly relevant for the work 
presented in this thesis and will be discussed latterly in further detail (Section 1.4 and 1.6). 
 
1.2.1.1 Components of the Spliceosome 
 
The components of the major spliceosome were originally isolated by glycerol 
gradient fractionation followed by affinity chromatography in the presence of ATP. These 
components were active in splicing reactions in variable combinations on a transcript specific 
basis (Grabowski et al., 1985; Sharp et al., 1987). Further work verified the existence two 
distinct spliceosomes in mammalian cells: the major U2-dependent spliceosome and the minor 
U12- dependent spliceosome, which act to remove major or minor introns, respectively (Will 
& Lührmann, 2011).  
The minor intron class are scarce (<0.5% of all vertebrate introns) and were not 
discovered until nearly two decades after major introns. Contrary to original findings 
describing the AT/AC consensus sequence (after which they are sometimes named), it was 
later established that minor introns require a longer and more strictly constrained nucleotide 
stretch at the 5’ss and strict branch point. The minor spliceosome is absent from lower 
eukaryotes and composed of alternate spliceosome components: U11, U12, U4atac and 
U6atac, and U5, which is also present in the major spliceosome (reviewed in: Patel & Steitz 
2003; Turunen et al. 2013). Although it mainly functions to remove these specific, rare introns, 
it can also remove those spliced by the major spliceosome (Rogozin et al., 2012). Incidentally, 
the last eukaryotic common ancestor (LECA) contained both core and auxiliary factors 
(including SR proteins) for both major and minor spliceosomal machineries (Irimia & Roy, 
2014). Despite this, ancestral spliceosomal introns were most likely of the major type, 
although U12 introns do exist in lower organisms (Rogozin et al., 2012).  
The core machinery of the major U2-dependent spliceosome consists of five snRNP 
particles U1, U2, U4, U5 and U6. Each of these has both an RNA component, termed snRNA, 
and a proteinaceous scaffold (Wahl et al., 2009). The mechanism for pre-mRNA splicing has 
been highly characterised into a complex cycle (Figure 1.2) that requires over 150 proteins in 
two catalytic steps (Papasaikas & Valcarcel 2016; Zhou et al. 2002). Dynamic interaction 
networks of such protein (and RNA) facilitators are central to spliceosome function and drive 
transition between different spliceosomal complexes (Hegele et al., 2012).  
Aside the snRNPs and the SR protein family in mammals (discussed later), there are 




extensively characterised and some act as non-energy dependent moieties serving as 
scaffolding or recruiter proteins; although a significant proportion are RNA helicases of the 
SF2 superfamily (Cordin & Beggs 2013; Wahl & Lührmann 2015). Eight of such helicases, 
named Sub2, Prp5, Prp28, Brr2, Prp2, Prp16, Prp22 and Prp43 in yeast, are essential in 
eukaryotes and  act to monitor splicing fidelity at various splicing checkpoints and continually 
remodel the spliceosome throughout the cycle (Figure 1.2) (Cordin & Beggs, 2013; Bourgeois 
et al., 2016). 
 
Figure 1.2: The Splicing Cycle. The nascent pre-mRNA is immediately bound by RBPs that 
initiate co-transcriptional splicing. Intron/exon boundaries are defined by a multitude of 
factors including SR proteins. The U1/U2 snRNP is recruited to drive intron removal 
through downstream, dynamic interactions mediated by the U4.U5/U6 tri-snRNP and 
various RNA helicases (indicated in red for S. cerevisiae). At the end of the process, snRNPs 
are released from the spliced transcript and recycled for the next round of splicing. The 
different complex formations that determine splicing-stage are also illustrated. Adapted 
from (Lee & Rio, 2014; Matera & Wang, 2014; Papasaikas & Valcárcel, 2016). 
 
 
1.2.1.2 Spliceosome Assembly and Mechanistic Outline  
 
Biochemically, pre-mRNA splicing is described by two sequential transesterification 
reactions. The first step of splicing is initiated when the intronic branch point adenine directs 
nucleophilic attack via its 2’OH group to the 5’ phosphate group of the intronic guanine 
nucleotide of the 5’ss. This generates a lariat intermediate via a 2’-5’ phosphodiester bond. 




the 3’ss exonic phosphate group which simultaneously joins the exons to release the lariat 
intermediate.  
The splicing process is highly dependent on at least two magnesium ions (Mg2+) 
which, stabilise both the leaving and attacking reaction states. This is coordinated by the 
U2/U5/U6 snRNA, hence the U2/U5/U6 snRNPs are vital to catalyse the splicing reaction. 
(Hang et al. 2015; Papasaikas & Valcarcel 2016). U5 snRNP acts as a crucial molecular 
scaffold and is the only snRNP indispensable for both major and minor spliceosome function 
(Hang et al., 2015). Other metal ions are required for each step of catalysis in both humans 
and yeast, during which they bind to the U6 snRNA in a conformation highly reminiscent of 
the ancestral group II introns. Indeed, similarly to the latter, RNA interactions (U6 snRNA) 
are ultimately required for catalysis (Fica et al., 2013).  
Spliceosome assembly is initiated when the U1 snRNA of the U1 snRNP forms base 
pairs with the 5’ss. In higher eukaryotes, the presence of a phosphorylated SR protein, most 
likely bound to a regulatory sequence in the transcript, is crucial for the U1 complex to remain 
stable (Long and Cáceres, 2009; Wahl, Will and Lührmann, 2009). To form the E complex, 
the two subunits of U2AF, U2AF1 and U2AF2 bind to the polypyrimidine tract and the AG 
of the 3’ss respectively. Concurrent with this, the branch point just upstream is bound by the 
Branchpoint Binding Protein (BBP) (Matera & Wang, 2014). This drives recruitment of the 
U2 snRNP and thus forms the complete E complex. Single molecule studies indicate that 
U2AF1/2 and the U2 snRNP exist in stoichiometry with each other in a pre-A complex, known 
as the I complex, formation of which expels excess factor binding at the 3’ss and triggers 
remodelling into the A complex in an ATP-dependent mechanism (Chen et al., 2016). The E 
complex is committed to splicing, although splice site selection may not be fully decided until 
later in the cycle (Matlin et al. 2005; Chen et al. 2016). 
On assembly of the pre-spliceosomal A complex, the U4/U6.U5 tri-snRNP is 
recruited in a pre-assembled state to trigger transition to the catalytically inactive B complex. 
Disruption of U1 binding at the 5’ss occurs and is replaced by the U6 snRNA which binds in 
its place. Both events, and thus RNP remodelling, are mediated by the helicase Prp28. The U2 
snRNP is necessary for tri-snRNP association with which it directly interacts at two interfaces 
as shown by the cryo-EM structure in yeast (Plaschka et al., 2017). For activity in splicing, 
the B complex must undergo significant remodelling including removal of the U1 and U2 
snRNPs and recruitment of the essential factors Prp38, Snu23 and Spp381. The latter interacts 
with Brr2 which is the only helicase of the Ski2-like DEAH-box subfamily required for 




factors (Cordin & Beggs, 2013). Remodelling continues as the U2 and U6 snRNA form a 
helix that ultimately recruits NTC and NTR (nineteen complex and the NTC-related complex 
respectively) proteins for activation into its catalytically active state (Plaschka et al., 2017).  
Once activated the B complex performs the first catalytic step of splicing and 
transitions to the C complex which securely holds both the intron-exon lariat intermediate and 
the excised exon (Matera & Wang 2014; Bertram et al. 2017). This is activated into the C* 
complex for the second catalytic step by Prp8 and Prp16, which are necessary to position the 
3’ splice site close to the lariat for the nucleophilic attack. The second step of splicing in 
humans is dependent on Prp22, Prp18 and Slu7 proteins. Prp22 is bound among other factors 
to Prp8 and acts indirectly to hold the 3’ss prior to the second step of splicing after which it 
facilitates release of the nascent transcript by binding to the newly spliced 3’ exon (Zhang et 
al. 2017; Bertram et al. 2017). After the second catalytic step, the components of the 
spliceosome are released from the exon-ligated transcript and recycled for subsequent rounds 
of splicing. It is interesting to note that all of the steps of the splicing cycle are reversible, at 
least in vitro (Matera & Wang, 2014).  
The Exon Junction Complex (EJC) is deposited on the mRNA 24 nucleotides 
upstream of the newly ligated exon boundary to prepare it for nuclear export, however, the 
complex is also capable of non-canonical binding along the length of the transcript (Le Hir et 
al., 2001; Saulière et al., 2012). The EJC is a dynamic and multicomponent protein complex 
that consists of the key factors: eIF4AIII, Y14, MLN51 and Magoh, although numerous other 
components are known to comprise the peripheral EJC in a context-dependent manner. 
Knockdown of the components of the EJC has transcriptome wide ranging effects on splicing 
and downstream regulatory processes (Wang et al., 2014). Strikingly in the C* complex, the 
four components of the exon junction complex (EJC) eIF4AIII, MAGOH, Y14 and MLN51 
are already present on the spliced transcript (Bertram et al., 2017; Zhang et al., 2017). 
Throughout the splicing process, the nascent mRNA is continually modified before 
nuclear export, to prepare it for mRNA translation once it reaches the cytoplasm. On 
transcription, nascent pre-mRNA is modified through the addition of a 7-methlyguanosine cap 
to the 5’end of the transcript. This is directed by a suit of regulatory factors including the 
methyltransferase RNMT and the guanylyltransferase RNGT, and bound by the cap binding 
complex (composed of CBP80/20 in humans) (Cowling, 2010). Also concurrent with 
transcription is 3’ end formation and polyadenlylation of the pre-mRNA transcript which 




1.3 Splicing Regulation 
 
Analogous to other RNA processing events, the regulation of splicing occurs in a co-
transcriptional manner and is heavily reliant on the function of RBPs at each stage of pre-
mRNA synthesis (Bentley, 2014). Indeed, splicing factors such as the SR protein SRSF2, and 
those involved in capping are recruited by the elongating polymerase during transcription 
(Bentley, 2014).  
RNA processing, including splicing, can also be influenced by dynamic post 
transcriptional modifications of RNA, termed the epitranscriptome (Jiang et al., 2017). There 
is a huge diversity of RNA modifications that occur, one of the best studied being N6-
methyladenosine (m6A). m6A is present on between 0.2-0.6% of mRNAs and is deposited by 
the METTL family of methyltransferases (Roundtree et al., 2017). Binding sites for these 
enzymes are enriched in introns, consistent with a role for m6A in recruiting both the splicing 
machinery and factors for capping and polyadenylation of the mRNA transcript. Furthermore, 
m6A can function to promote export of the mRNA in which it resides (Zhao et al., 2016). In 
general, this mark serves to increase the processing of a transcript, including its translation in 
the cytoplasm (Zhao et al., 2016). 
m6A was shown to have a specific role in splicing regulation, as its reader, YTHDC1, 
is also a splicing factor. Remarkably, YTHDC1 is capable of differentially manipulating two 
SR proteins to exert adverse functions. It recruits SRSF3 to promote exon inclusion, which 
prevents SFS10 binding to function as a splicing repressor (Xiao et al., 2016). The m6A 
modification also has important post-transcriptional implications to regulate developmental 
processes and tissue-specific RNA processing events, for example splicing of the FTO gene 
during adipogenesis via SRSF2 binding (Zhao et al., 2014). 
 
1.3.1 Alternative splicing 
 
Alternative splicing occurs in approximately 95% of genes containing multiple exons, 
to create an unprecedented degree of proteome diversity and regulation (Figure 1.3). Such 
complexity is further increased by differential alternative splicing programmes that have 
evolved often due to changes in splicing factors present or their site usage in distinct tissues 
and cell types (Pan et al., 2008). For example in neural lineages alternative splicing is 
extensively used to shape neurogenesis, in particular the splicing factors nSR100/SRRM4 and 
PTBP1 are capable of antagonising one another (Vuong et al., 2016). nSR100/SRRM4 is a 




cassette exons, enriched in neural lineages. Modest downregulation of this factor causes an 
autism-like phenotype in mice models (Quesnel-Vallières et al., 2016).. Furthermore, 























Figure 1.3: Modes of alternative splicing. The pre-mRNA transcript can be customised 
during splicing to promote the formation of countless alternative isoforms. Schematics of 
common alternative splicing patterns are shown (a)-(h). Large boxes (various shades of 
blue) represent exons, introns are represented by thick black straight lines between exons. 
Dark blue dashed lines indicate alternative routes that exons can be joined in the spliced 





function. For instance, the PTBP1 transcript has an alternative exon 9, which can be 
selectively used or skipped to alter the regulatory capacity of PTBP1 protein. (Gueroussov et 
al., 2015). This not only demonstrates the subtle nature of splicing regulation and splicing 
factor dosage, but also how perturbing these processes can have wide-ranging phenotypic 
consequences despite being dispensable for viability 
 Alternative splicing produces numerous mRNA isoforms, however there is debate as 
to whether this equates to protein isoform diversity (Tress et al., 2017). On the other hand 
Genome Wide Association Studies (GWAS) have found that the non-coding regions of the 
genome, including splice sites, are highly heritable and can be linked to specific genetic traits. 
For example, a study conducted to investigate polymorphic transcript variation in human 
disease identified that splice patterns are often associated with SNPs that, particularly in B-
cells, correlate with high prevalence of autoimmune diseases due to improper alternative 
splicing or polyadenylation (Fraser & Xie, 2009). This alludes to the importance regulatory 
and intronic sequence regardless of its protein-coding capacity (Manning & Cooper 2017).  
 
1.4 SR Proteins 
 
SR proteins act to regulate each step of gene expression and have concerted nuclear 
function in transcription, splicing and alternative splicing. Intron removal during both 
alternative and canonical splicing is coordinated by SR and hnRNP proteins which bind to 
regulatory motifs known as intronic or exonic splicing enhancers or silencers (ISE, ESE, ISS 
or ESS respectively) to antagonise one another’s actions (Ast, 2004; Goren et al., 2006). Once 
bound SR and hnRNP proteins mediate bridging interactions of required factors for initiation 
of that splicing reaction.  
In intron definition, SR proteins bind to an intronic sequence to facilitate U1 binding 
to the upstream donor splice site and U2 to the downstream site. In exon definition, SR 
proteins bind to an exonic sequence to recruit U1 and U2/U2AF, and coordinate these factors 
across the exon (Rogozin et al., 2012) (Figure 1.5). SR-like proteins are also required for both 
canonical and alternative splicing (Wahl et al., 2009). hnRNP proteins represent the most 
diverse class of RNA binding proteins, and often act to antagonise the activity of SR proteins 
(Long and Cáceres, 2009). They were first identified as dynamic cellular components that 
consisted of multiple proteins and later found to crosslink to poly(A) containing mRNAs (Choi 





1.4.1 Structure and nomenclature 
 
SR proteins are ubiquitous in higher organisms and present in many other diverse 
species, such as plants and fungi, reflecting an early emergence in evolutionary history 
(Twyffels et al., 2011). Budding yeast is devoid of true SR proteins but has three SR-like 
proteins: Npl3, Gbp2 and Hrb1, likely to represent the ancestral basis from which SR proteins 
subsequently evolved. These have numerous functions in gene expression; a feature conserved 
to their metazoan counterparts, indicating the level of importance of such regulation for cells 
(Martínez-Lumbreras et al., 2016). In Caenorhabditis elegans there are seven SR homologues, 
depletion of which results in numerous phenotypic outcomes including lethality for the SRSF1 
homologue (Longman et al., 2000).  
Before its classification as an SR protein, SRSF1 (then SF2) was identified within a 
group of multiple factors, that were capable of complementing mRNA splicing in splicing 
deficient extracts in vitro (Krainer & Maniatis, 1985). SR proteins were characterised as a 
family using, among other methods, the monoclonal antibody 104 (m104) which binds to the 
phosphoepitope of phosphorylated SR proteins (Roth et al., 1990) and later demonstrated to 
be essential for splicing and alternative splicing (Krainer et al., 1990; Zahler et al., 1993).  
 SR proteins are defined by the presence of one or two RNA recognition motifs 
(RRMs) and an RS domain composed of serine/arginine repeats. RRM domains are 
widespread among RNA binding proteins and their flexibility permits diverse modes of 
binding between proteins (Maris et al., 2005). The SR family nomenclature is historically 
diverse leading to the agreement of a consensus terminology to identify them (Figure 1.4) 
(Manley & Krainer, 2010; Twyffels et al., 2011). RS repeats must comprise 40% of at least a 
50 amino acid region in the RS domain for classification as an SR protein (Twyffels et al., 
2011). For many SR proteins including SRSF1 and SRSF2, the RS domain acts as a nuclear 
localisation signal and is required for nuclear import  through a specific importin-β family 
receptor named transportin-SR (transportin-3, TNPO3), to which it binds directly (Cáceres et 
al., 1997; Kataoka et al., 1999). Transition into the nucleus through the nuclear pore in this 
mechanism is dependent on RS domain phosphorylation, which is also sufficient to act as a 





SR-like proteins also exist, such as Tra2α/β, which contain an RS domain but lack the 
highly repetitive characteristic of true SR proteins or an RRM motif, although many of these 
are able to bind RNA via different domains and mechanisms (Long and Cáceres, 2009). 
Genome-wide analyses revealed that RS-domain containing proteins participate in numerous 
aspects of gene expression regulation, including those involved in the cell cycle (Boucher et 
al., 2001). 
 
1.4.2 Shuttling SR proteins 
 
In humans, of the twelve canonical SR proteins, a subset exhibits nucleocytoplasmic 
shuttling and have numerous other post splicing and cytoplasmic roles (Long and Cáceres, 
2009). The shuttling SR proteins were originally defined as: SRSF1, SRSF3, SRSF4, SRSF7, 
and SRSF10 in HeLa cells (Cáceres et al., 1998). SRSF1 is the prototype for shuttling SR 
proteins and exhibits dynamic movement between cellular and sub-cellular compartments 
 
Figure 1.4: SR protein structure and nomenclature. SR proteins have a modular domain 
structure defined by one or two RRM domains at the N terminus (blue) and a C-terminal 
RS domain (green). Thin black lines indicate linker sequence that connects each domain. 
Current nomenclature is stated in the far-left column, followed by the previously used 





(Cáceres et al., 1998). This was determined by heterokaryon assays, which are the gold 
standard for determining shuttling capacity of a protein (Piñol-Roma & Dreyfuss, 1992).  
More recently, other SR proteins were demonstrated to shuttle, such as SRSF9 (Sapra 
et al., 2009; Fu et al., 2013). In contrast, SRSF2 was consistently found to be a non-shuttling 
SR protein due to the presence of a nuclear retention sequence (NRS) at its C-terminus 
(Cazalla et al., 2002). SR proteins exhibit differential shuttling abilities in differentiated and 
pluripotent cells. For example, heterokaryon assays to detect endogenous fluorescence 
demonstrated that all SR proteins are able to shuttle in pluripotent mouse P19 cells, whereas 
only SRSF1 always shuttles regardless of developmental stage or tissue type (Botti et al., 
2017). At a steady state in HeLa cells, SRSF1 is predominantly found in the nucleus and 
nuclear speckles, reflecting its roles as an essential factor for splicing (Misteli et al., 1997). 
SRSF1 is highly relevant to this work and discussed in detail in section 1.6. 
 
1.4.3 SR proteins in splicing and alternative splicing 
 
SR proteins are the master regulators of both canonical and alternative splicing and 
they are essential for both processes (Figure 1.5). They are required both for initial 
spliceosome assembly and in downstream processes such as cleavage and selection of the 5’ 
splice site (Krainer et al., 1990). Early work also demonstrated that SR proteins are required 
in alternative splicing for definition 5’splice sites and could influence splice site choice (Ge 
et al. 1991, Krainer et al. 1991). Consistent with this, SR proteins are present in purified 
extracts of the spliceosome and are required for splicing in vivo (Zhou et al., 2002; Ellis et al., 
2008) and act to mediate bridging interactions between the 5’ and 3’ splice sites (Long and 
Cáceres, 2009). In vertebrate genomes that contain a vast quantity of intronic sequence, this 
is particularly important to prevent potential cryptic splicing or mis-splicing events (Sibley et 
al., 2016). 
In canonical splicing SR proteins are required to recruit the U1 and U2 snRNPs to the 
required splice sites and initiate splicing of the transcript. Once bound, the RS domain of the 
SR protein transmits a multifaceted signal by contacting the RS domain in U2AF2, the 
branchpoint sequence and the 5’ splice sites in the target mRNA (Shen & Green, 2004). Within 
nuclear speckles, SRSF1 has been shown to simultaneously bind U2AF1 and U1 thus bridging 
the 5’ and 3’ splice sites (Ellis et al., 2008). SR proteins also act later in the splicing cycle to 
recruit the U4/U6.U5 tri-snRNP for incorporation into the spliceosome (Roscigno & Garcia-




functioning in an analogous manner to recruit the machineries of the minor spliceosome 
through interactions with the U5 snRNP (Shen & Green, 2007). 
In alternative splicing, SR proteins act in trans to promote both exon inclusion and 
exclusion on a similar measure (Pandit et al., 2013). They bind ESE/ESS and ISE/ISS cis-
regulatory sequences in the target mRNA, which are between 4 and 18 nucleotides in length. 
The positioning of these sequences within the transcript is crucial in determining the 
regulation they exert, which offers some explanation to SR proteins diverse splicing roles 
(Goren et al., 2006).  
 
Different SR family members are capable of degenerate binding, so have a natural 
degree of functional redundancy in vitro. Substrate binding is predominantly dictated by the 
RRM motifs of the SR protein, discussed later in the context of SRSF1. In canonical splicing, 
the RS domain is not required for substrate specificity, although its ablation can prevent 
alternative splicing function. Consistent with this, SR protein definition mediated by the RS 
domain is required for spliceosome recruitment and correct splicing at weak 3’ splice sites 
(Zhu & Krainer, 2000). SRSF10 is distinct from the other family members as it can act as a 
splicing repressor on dephosphorylation by preventing proper U1 snRNP binding; an action 
predominant during mitosis and heat shock (Shin et al., 2005).  
Alternative splicing is important for accurate control of the cell cycle and occurs in a 
tightly regulated fashion to regulate specific transcripts periodically. SR protein 
Figure 1.5: SR proteins in splicing. (a) SR proteins bind to regulatory enhancer sequences 
in the pre-mRNA transcript such as ESE/ESS (b) SR proteins can also act to antagonise exon 





phosphorylation is altered during the cell cycle and after DNA damage. The SR protein kinase 
CLK1 is a key factor in this and its own expression oscillates during the cell cycle in a negative 
feedback loop, among other transcripts encoding for mitotic and associated factors 
(Dominguez et al. 2016). SRSF1 also controls a cell cycle specific alternative splicing 
programme, which on its knockdown, causes apoptosis and cell cycle dysregulation. 
Interestingly, co-depletion of SRSF1 and the mitotic regulatory protein aurora kinase A have 
synergistic effects in mediating splicing outcome of certain transcripts (Moore et al., 2010).  
The EJC is known to physically interact with SR proteins, particularly shuttling SR 
proteins such as SRSF1, and the two exist in stoichiometry within the mRNPs (Singh et al., 
2012). In addition to this, CLIP-seq revealed that the EJC binding consensus is highly similar 
to that of SR proteins, alluding to their spatial proximity on a transcript (Saulière et al., 2012).  
 The splicing factor machineries, including SR proteins, are enriched at sites of active 
transcription although transcription is not required for their presence. SR proteins are also 
abundant in nuclear speckles which supply factors for transcription; when transcription is 
blocked, SR proteins relocate to nuclear speckles (Ellis et al., 2008). Speckle components are 
distributed to the correct sites on demand allowing the cell to be constantly primed for on-
demand splicing requirements. They can act to stabilise the nascent transcript and recruit the 
splicing machinery to facilitate pre-mRNA processing (Misteli et al., 1997).  
The SR protein SRSF2 has a direct and unique role in transcriptional elongation, and 
its depletion in liver tissue alters the elongation rate of RNA Polymerase II, causing it to stall 
at the gene body due to defective downstream transcript processing (Lin et al., 2008). SRSF1 
also able to couple transcriptional and alternative splicing regulation of the same transcript. 
For example, in T cells, SRSF1 binds to the promoter of CD3ζ and acts to increase its 
transcription in a dose-dependent manner as well as regulating alternative splicing of the CD3ζ 
mRNA through binding the 3’UTR (Moulton et al., 2015). This highlights the intrinsic 
coupling of splicing to transcription and indicates the multiple layers of control opportunities 
for SR protein mediated regulation.  
 
1.4.3.1 SRSF1 as splicing factor 
 
SRSF1 acts to control splicing and alternative splicing as described for SR proteins in 
general. Indeed, many studies that defined such general mechanisms for the SR family are 
based on SRSF1 datasets. Further detailed information on the SR protein family is described 




SRSF1 function in splicing is highly dependent on the dynamic phosphorylation of 
its RS domain, which modulates interactions with both the U1 snRNP and the ESE site. When 
SRSF1 is phosphorylated, its RRM can bind to the RRM of U1-70K to mediate spliceosomal 
E complex formation. However as the SRSF1 RS domain is progressively dephosphorylated, 
these RRM-RRM interactions are disrupted as SRSF1 preferentially binds to itself (Cho et al., 
2011). 
CLIP-seq and functional SELEX data determined the SRSF1 RNA binding motif in 
exons as the GA-rich sequence GGAGA (Pandit et al., 2013). SRSF1 is capable of binding to 
exons, introns and other non-coding RNA sequences in numerous cellular compartments. 
However, the consensus binding motifs for non-coding sequence, including intronic sequence, 
cannot be defined, at least from CLIP-seq datasets. Interestingly, only a small subset of CLIP-
seq identified RNA binding targets were annotated as being products of SRSF1-mediated 
alternative splicing, indicating that SRSF1 binding has regulatory functions other than splicing 
(Sanford et al., 2008). Despite this, genome wide studies to identify the effect of single 
nucleotide variant (SNV) genetic regulation on allele-specific alternative splicing events 
identified SRSF1 as one of the most influential factors, in part due to a strong consensus 
binding motif (Hsiao et al 2016). This study married in vivo and ENCODE data to demonstrate 
that SRSF1 ESE binding sites are both highly conserved and most frequently associated with 
SNVs that result in altered splicing. A proportion of these were in linkage disequilibrium with 
disease-associated loci, which eludes to their significance in maintaining proper splicing. 
 
1.4.4 RNA-binding capacities of SR proteins 
 
Different SR proteins are coordinated to bind transcripts in specific, mRNA 
dependent combinations (Björk et al., 2009). All SR proteins are RNA and mRNA binding 
proteins as shown by PAR-CLIP coupled to quantitative mass spectrometry, which also 
determined the regions on the mRNAs to which the protein binds (Baltz et al., 2012). There 
is some functional redundancy between SR proteins in splicing; however, they also play 
unique and essential roles in substrate specificity (Sanford et al., 2009). 
The RNA-binding landscape between SR proteins is highly complex and differs for 
each SR-family member, most likely in a context-dependent manner (Pandit et al., 2013). 
There are various CLIP-seq datasets for SRSF1, SRSF2, SRSF3 and SRSF4, which provide a 
wealth of knowledge regarding their RNA-binding landscapes including consensus binding 
motifs (Sanford et al., 2009; Änkö et al., 2012). Overall, these data suggest that SR protein 




sequences. Although, in accordance with binding to ESE/ESS during splicing, SR proteins 
show a slight preference for binding to exons. The binding consensus motifs for each SR 
protein are different, which is consistent with the lack of complete functional redundancy 
between family members. For example, SRSF3 and SRSF4, the smallest and largest SR 
proteins respectively, have distinct mRNA binding motifs (CU-rich and GA-rich 
respectively). Accordingly, they target different RNA transcripts within distinct mRNP 
particles, indicating a lack of binding redundancy in vivo (Änkö et al., 2010, 2012). Both 
proteins bind to the branch point sequence indicating a specific binding role at this region of 
the transcript during splicing (Änkö et al., 2012). However, SRSF4 binds significantly fewer 
target RNAs than SRSF3, suggesting that not only do SR proteins have distinct targets, but 
also the degree to which they bind them is also disparate. SRSF1 and SRSF2 binding patterns 
are similar as they both preferentially bind exons, which is not wholly reflective of their 
function, as binding per se does not dictate alternative splicing patterns. SRSF1 and SRSF2 
also have distinct binding profiles which are not functionally redundant, and perhaps most 
interestingly, they are able to co-regulate and coordinate other classes of splicing events 
(Pandit et al., 2013). 
 
1.4.5 SR proteins during development and differentiation 
 
SR protein expression in vivo varies between tissues in a pattern highly analogous to 
the antagonistic hnRNP proteins and the expression ratio between them is developmentally 
important (Hanamura et al., 1998). In C.elegans development, the homologue of SRSF1 is the 
only SR protein whose depletion by RNAi results in early embryonic development, whereas 
depletion of other SR proteins are viable (Longman et al., 2000). Phosphorylation of SR 
proteins is a crucial requirement for development, as RNAi of SRPK1 is lethal (Longman et 
al., 2000). Consistent with this, SR protein phosphorylation is also crucial for Ascaris 
lumbricoides (nematode roundworm) development. In very early embryos SR proteins are 
hyperphosphorylated but during the four to eight cell transition they become increasingly 
dephosphorylated. This coincides with zygotic gene activation (ZGA); marked by the onset 
of zygotic transcription, splicing and nuclear import of SR proteins. Dephosphorylation of the 
RS domain is required for such movement and necessary for A. lumbricoides development 
(Sanford & Bruzik, 2001). 
In DT40 chicken cells SRSF1 is essential for viability and exerts unique function as 
its knockdown cannot be rescued by expression of other SR proteins, despite such close 




function in viability is not affected when this domain is disrupted (Wang et al., 1998). In 
C.elegans, SR proteins appear to show some degree of functional redundancy, where only 
SRSF1 is essential for viability (Longman et al., 2000). Consistent with this, SR protein genes 
are essential in vertebrates and ablation of SRSF1, SRSF2 or SRSF3 in early development 
causes embryonic lethality in mice (Wang et al., 1998; Jumaa et al., 1999; Xu et al., 2005). In 
mouse models, homozygous deletion of SRSF1 results in embryonic lethality prior to E7.5. 
Interestingly, the conditional knockout in mature mouse cardiomyocytes is viable, indicating 
that SRSF1 is not required in these cells, perhaps through compensation of function by another 
SR protein (Xu et al., 2005).  
The homozygous SRSF2 mutation is lethal before E7.5, although heterozygotes are 
viable at the expected Mendelian ratio (Ding et al., 2004). SRSF3 is required for viability after 
E3.5; although prior to this point maternal protein/mRNA is responsible for development. It 
is likely that during development, SRSF3 is absolutely required in a non-redundant manner 
(Jumaa et al., 1999; Möröy & Heyd, 2007). In conditional knockout tissues of SRSF1 and 
SRSF2, loss of specific splicing events can cause lethality as seen with the conditional SRSF1 
knockout in the heart, that causes mice to die two months after birth due to heart failure, as 
SRSF1 is responsible for propagation of the correct CaMKIIdδ splice isoform (Xu et al., 
2005).  
In contrast, the SRSF2 heart specific knockout is viable although the mice develop a 
deleterious phenotype reminiscent of dilated cardio myopathy (Ding et al., 2004). 
Interestingly it is not required in terminally differentiated postmitotic cells such as 
cardiomyocytes (Xiao et al., 2007). In addition, SRSF2 is also required for T cell 
development, during which it regulates the crucial alternative splicing of the receptor tyrosine 
kinase CD45 and in pituitary gland development during which it regulates cell proliferation 
(Wang et al., 2001; Xiao et al., 2007). In the liver, SRSF2 is required to maintain metabolic 
homoeostasis through both transcriptional and alternative splicing regulation of numerous 
tissue-specific transcription factors. The liver specific conditional knockout of SRSF2 causes 
liver failure resulting in early death (Cheng et al., 2016). SRSF3 is also required for alternative 
splicing in liver homeostasis and although conditional knockout mice display gross hepatic 
abnormalities, they are viable (Sen et al., 2013). Interestingly, SRSF3 regulates distinct targets 
from SRSF2 in this tissue such as cell cycle regulators. In stark contrast, the reciprocal deletion 
for SRSF1 has no effect on liver function or lifespan. (Cheng et al., 2016). Taken together, 
these studies are particularly interesting as they highlight the functional individuality of SR 




During neural differentiation of multipotent P19 mouse cells, SR protein abundance 
is uniform, except for SRSF3 and SRSF4 that show increased expression. In this system, the 
mRNAs with which each SR protein associates are also distinct. SRSF3 and SRSF4 regulate 
mRNA transcripts that encode different functional groups raising the intriguing possibility 
that each SR protein regulates functional subsets of mRNA targets upon differentiation (Änkö 
et al., 2010). 
Mouse and conditional knockout models indicate that each SR protein has a very 
specific repertoire of splicing targets in different tissues during development, which are 
exclusive to the cell type and developmental stage. In addition, gross canonical and alternative 
splicing in these models remain unaffected (Möröy & Heyd, 2007). This raises interesting 
questions regarding SR proteins during development and the relevance of their splicing 
function in vivo. Considering that several SR proteins have numerous functions other than 
those in splicing, it is tempting to speculate that these could have an important physiological 
role during development that was not investigated in previous studies.  
 
1.5 mRNA Translation 
 
Once mRNP particles exit the nucleus via the nuclear pore, their cargo mRNA is 
translated into a polypeptide chain. mRNA translation is a highly complex process, which is 
tightly regulated during events such as lineage differentiation or certain stress responses, both 
on a global and transcript-specific level (Gebauer & Hentze, 2004; Sonenberg & Hinnebusch, 
2009). RBPs play a crucial role in all aspects of mRNA translation including binding to and 
regulating the assembly of ribosomal subunits (Wurth & Gebauer, 2014).  
Throughout evolution of higher organisms, ribosome size has increased to provide an 
interactive landing site for auxiliary factors and facilitate customised mRNA translational 
landscapes (Simsek et al., 2017). Many of these factors are not part of the canonical translation 
machinery for example cell cycle, metabolic and RNA processing proteins. Furthermore, they 
can be categorised as direct or indirect binders of ribosomes, including those that require RNA 
for the interaction and those that are specific for each ribosomal subunit (Simsek et al., 2017). 
The entire translation process is dependent on the presence of sufficient cofactors and an active 
tRNA pool (Schmidt et al., 2016). Due to the immense size and dynamics of the ribosome and 
its cofactor repertoire, gaining structural insight into ribosome assembly is not a small 




have been solved which provides insight into the molecular mechanisms of its function 
(reviewed in (Aitken & Lorsch, 2012; Hinnebusch, 2017)). 
In short, mRNA translation can be summarised into three phases: initiation, 
elongation and termination, all of which rely on the presence of the 80S ribosome, which, after 
several processing operations, is fully assembled at the start codon and poised for peptide 
synthesis. At each stage of the process, with an emphasis on initiation, there is a high degree 
of both internal and external regulation by various RNA binding proteins. 
 
1.5.1 Translation initiation, elongation and termination  
 
Cap-dependent translation initiation commences after two rate limiting steps: the 
association of the small 40S ribosome subunit and multiple cofactors, to form the 43S 
preinitiation particle and the formation of the eIF4F complex (comprised of eIf4A, eIF4E and 
eIF4G) on the mRNA cap (Chu et al., 2016). For the formation of the 43S particle, the small 
subunit must be charged with the initiator methionyl tRNA (met-tRNAi), which is held in 
place by GTP-bound eIF2 (Hinnebusch, 2017). eIF4E is sequestered by hypophosphorylated 
4E-BP1 (eIF4E binding protein 1), until the latter is phosphorylated to release eIF4E which 
binds the mRNA cap. The scaffolding protein eIF4G forms interactions with both the mRNA 
cap and PABP proteins bound to the poly(A) tail of the mRNA to cause transcript 
circularisation, which protects it from degradation (Wells et al., 1998). In mammals, eIF4G 
also contains binding sites for eIF3, which restrains the 40S particle in an open conformation 
for mRNA attachment (Schutz et al., 2008; Aitken & Lorsch, 2012). eIF4A is an ATP-
dependent DEAD-box RNA helicase which has three isoforms in mammals (eIF4AI-III). 
These have some functional redundancy, but also tissue and development-specific expression 
patterns; suggesting functional relevance for each isoform (Chu et al., 2016).  
Once the 43S pre-initiation complex is bound, it scans the 5’UTR of the bound mRNA 
for the start codon (AUG), facilitated by the binding of additional initiation factors eIF1, 
eIF1A, eIF2, eIF3 and eIF5 (Schmidt et al., 2016; Hinnebusch, 2017). eIF3 is the largest 
initiation factor complex and is required for optimal loading of the mRNA onto the 43S 
particle. It then scans for the initiation codon before stabilising the PIC-mRNA interaction 
(Aitken et al., 2016). At the start codon, the PIC-mRNA complex base pairs with the initiator 
tRNA in the ribosomal P-site. The initiation factors are released in an energy-dependent 
manner and the complex is remodelled into the elongation competent 80S particle upon 




and premature subunit association in the absence of an mRNA substrate is prevented by eIF6 
which sequesters the 60S ribosome (Sonenberg & Hinnebusch, 2009; Schmidt et al., 2016).  
Internal ribosome entry site or IRES-dependent translation initiation can also occur 
which relies on secondary mRNA structures to drive initiation by recruitment of auxiliary 
factors and the pre-initiation complex. This process is less dependent on levels of eIFs, 
particularly those involved in scanning, therefore it is often used during cellular stress when 
initiation factors may be limiting (Sonenberg & Hinnebusch, 2009).  
For translation elongation to proceed, the ribosome uses its three tRNA binding sites; 
the P site, to which the initiator codon binds, the acceptor (A) site and the exit (E) site which 
is the final site for tRNA binding. After initiation, eIF1A directs tRNA to the next codon of 
the open reading frame in a GTP dependent mechanism. On successful codon recognition, the 
tRNA is bound and the A site and GTP is hydrolysed. This triggers the release of eIF1A which 
can be recycled ready for the next round of elongation (Dever & Green, 2015). Once a peptide 
bond is formed between the tRNA in the A and the P site, translocation into the P and E sites 
can occur by binding eEF2. Peptide bond formation causes the small and large ribosomal 
subunits to rotate relative to each other to allow translocation along the transcript (Lareau et 
al., 2014). As soon as the bound tRNAs are released from the E site, the next mRNA codon 
binds its cognate amino-acyl tRNA and the subsequent round of elongation beings (Zaher & 
Green, 2009; Dever & Green, 2015). During the pioneer round of translation, the EJC complex 
is removed from the mRNA. If this does not occur and it persists to encounter an elongating 
ribosome, it triggers nonsense mediated decay of the transcript (Hug et al., 2015).  
In eukaryotes, translation termination relies on the recruitment of the release factors 
eRF1 and eRF3. eRF1 mediates highly accurate recognition of a stop codon in the ribosomal 
A site (Zaher & Green, 2009; Dever & Green, 2015). Both eRF1 and eRF3 are also involved 
in mRNA quality control pathways to regulate the production of mRNAs including aberrant 
transcripts. These factors represent the two classes of release factors that are essential and 
widely conserved in eukaryotes (Atkinson et al., 2008). eRF1 and eRF3 interact to form a 
distinct complex with the ribosome that is dependent on GTP. eRF3 increases the speed of 
nascent peptide release from the ribosome in such interactions, to cause GTP hydrolysis which 
allows eRF1 to be delivered to the A site (Dever & Green, 2015). Once the peptide chain has 
been released from the ribosome, the subunits are either recycled or can be reinitiated on the 
mRNA for subsequent rounds of translation by partially dissociating with the transcript (Dever 




Translational readthrough, by bypassing the stop codon, into the 3’UTR sequence can 
produce less protein but does not trigger non-stop decay as there is no connection with poly(A) 
sequence. The 3’UTR sequence could be used to control protein levels of such transcripts 
where potentially aberrant readthrough occurs (Arribere et al., 2016).  
 
1.5.2 Translation regulation and downstream effectors 
 
Initiation is the most comprehensively regulated stage of translation that requires 
numerous RNA binding proteins. For example, during periods of cellular stress the availability 
of core initiation factors is used to regulate translation (Sonenberg & Hinnebusch, 2009). 
Unsurprisingly, mutation of such RBPs involved in these processes can result in malignancies 
and tumorigenesis.  
The eIF4F complex and components are crucial for cap-dependent translation 
initiation via interactions with the kinase mTOR, which is responsible for the phosphorylation 
of downstream factors that promote transcript-specific translation such as S6K1 (Saxton & 
Sabatini, 2012). This has important implications in cancer as mTOR is a platform for 
numerous signalling pathways that are key for oncogenesis (Chu et al., 2016). mTOR is a 
central kinase in the control of cap-dependent translation and exists in two multiprotein 
complexes; mTORC1 and mTORC2, wherein it binds the cofactors Raptor and Rictor 
respectively (Hay & Sonenberg, 2004). mTOR is essential for viability and its disruption 
results in early embryonic lethality and impaired cellular differentiation (Gangloff et al., 2004; 
Murakami & Ichisaka, 2004). Raptor null embryos have a phenotype similar to mTOR 
knockouts and die shortly after implantation, consistent with the necessity of a functional 
mTORC1 complex in embryogenesis (Guertin et al., 2006). mTOR signalling can act to 
regulate translation throughout the cell-cycle in a transcript-specific nature. Interestingly, the 
RICTOR mRNA transcript is sufficient to mediate this effect and its translation is driven 
during the onset of S phase (Stumpf et al., 2013) 
The best characterised direct downstream effectors and phosphorylation targets of 
mTOR kinase are S6K1 and 4E-BP1, although the mTORC2 complex also targets Akt/PKB 
for phosphorylation (Guertin et al., 2006). Interestingly, Raptor can also bind S6K1 and 4E-
BP1, which once phosphorylated, releases eIF4E to drive cap-dependent translation initiation 
(Hay & Sonenberg 2004). Both mTORC1 and 2 are inhibited by rapamycin treatment, 
although mTORC1 is more acutely sensitive, and complete inhibition of both can be achieved 
through the use of inhibitors such as Torin1 that bind the mTOR active site (Fonseca et al., 




autophosphorylation (Hay & Sonenberg 2004). However, mTOR can also be activated by 
other factors bound to an mRNA. RNA binding proteins are crucial in these processes. SRSF1, 
for example, was shown to recruit mTOR to facilitate translation of a subset of mRNA targets, 
as discussed in detail later (Michlewski et al., 2008). In line with this, mass spectrometry 
independently identified SRSF1 as a Raptor interacting partner (Fonseca et al., 2015). 
Other kinases such as cyclin dependent kinase 1 (CDK1) can also activate 4E-BP 
proteins. This mechanism is prevalent during mitotic cap-dependent translation, during which 
it phosphorylates the δ isoform of 4E-BP. Although, this is in contrast to studies which claim 
that cap-dependent translation is suppressed during mitosis, it does illustrate the extensive 
translational control mechanisms during the cell cycle (Shuda et al., 2015). 
Regulation and rates of translation can vary depending on cell type and differentiation 
state. For example, in embryonic stem (ES) cells, translation is minimal and more reliant on 
fine-tuned transcript-specific responses but during differentiation there is a global increase in 
polysome associated mRNAs and protein synthesis (Sampath et al., 2008; Tahmasebi et al., 
2016). In this scenario, regulation is not uniform and transcripts can be categorised into 
varying groups, for example those which increase in abundance and/or translational efficiency 
during differentiation (Sampath et al., 2008). Given the abundance of free ribosomes in 
undifferentiated cells, it is likely that they remain translationally poised for differentiation. 
When context cues are received, these are able to rapidly activate both global and transcript-
specific translation; a process concurrent with an increase in 4E-BP phosphorylation (Sampath 
et al., 2008). This is not limited to cap-dependent translation. For example, in human ES cells 
the eIF4G1 homologue DAP5/eIF4G2, which is unable to stimulate cap-dependent 
translation, regulates a subset of mRNA targets in a cap-independent manner. During 
differentiation it selectively regulates the translation of the HMGN3 transcript which encodes 
a crucial chromatin binder important in differentiation (Yoffe et al., 2016). 
4E-BPs are essential for the translation of key pluripotency factors, including the TET 
(ten eleven translocase) enzymes and Nanog, in mouse ES cells, and their ablation prevents 
reprogramming ability (Tahmasebi et al., 2016). They are also crucial to repress the translation 
of factors that induce differentiation such as the transcription factor YY2. Remarkably, 
differential translation regulation of this transcript is coupled to the alternative splicing of an 
intron in the 5’UTR; providing an elegant example of the extensive coordination of layers of 
gene expression regulation (Tahmasebi et al., 2016). In mouse ES cells, differential translation 
rates are frequently observed for splice variants, particularly when the splicing event involves 




development, translational control is also exerted during the onset of meiosis in mammalian 
oocytes after nuclear envelope breakdown occurs, when mTOR/4E-BP/eIF4F-mediated 
regulation increases, particularly to regulate transcripts that contain a 5’terminal 
oligopyrimidine motif (5’TOP mRNAs). This is in contrast to the rapid dephosphorylation of 
4E-BP (and hence inactivation of translation) that occurs upon fertilisation (Susor et al., 
2015). Downregulation of the mTOR complex during meiosis in oocytes results in a high 
frequency of chromosome and spindle abnormalities and downregulation of specific 
transcripts without affecting global levels of translation or blocking meiotic progression 
(Susor et al., 2015). 
Translational elongation is also subject to regulation and its malfunction results in 
abnormalities, for example defects in neurogenesis and the onset of neurological disorders. 
This can be attributed partially to the highly complex nature of the nervous system and 
associated stringent translation requirements for example highly localised translation (Richter 
& Coller, 2015). Ribosome stalling can also result in a wide range of malignancies from 
protein misfolding to oncogenesis, with the best characterised example being FMRP in 
intellectual disability (Richter & Coller, 2015). 
Another major pathway in eukaryotic translational regulation is via micro RNAs 
(miRNAs). In short, miRNAs (~22nt long), whose biogenesis involves multiple proteins, most 
importantly Drosha and Dicer, bind to their target mRNA to trigger its degradation which 
requires Argonaute family proteins. miRNA binding ultimately results in a translational block 
of its target mRNA. There is extensive literature regarding this aspect of translational 
regulation, which will not be discussed in detail here.  
 
1.5.3 Methods to study mRNA Translation – Ribosome profiling  
 
Methods to study mRNA translation, particularly those which use a transcriptome-
wide approach have triggered a revolution of knowledge in the field. Pioneering ribosome 
profiling or footprinting techniques have facilitated understanding of temporal, transcript-
specific translational regulation (Ingolia, 2016). In such techniques, ribosomes are frozen on 
the mRNA, using the drug cyclohexamide, which halts translation through binding to the E 
site in the 60S subunits of elongating ribosomes. This ensures the ribosome remains bound to 
the target mRNA at the time of treatment and allows purification of ribosome/mRNA 
complexes. Ribosomes are then dissociated from their associated mRNAs and this mRNA 




Such methods have been revolutionary to gain an unprecedented understanding of 
targeted mRNA translation in numerous different cell types, stages of differentiation and 
growth conditions (Ingolia, 2014; Andreev et al., 2017). One study coupled ribosome profiling 
with inhibition of mTORC1 by the mTOR inhibitor Torin1 in mouse embryonic fibroblasts 
(MEFs) (Thoreen et al., 2012). Transcripts resistant to Torin1 encompassed both IRES 
containing transcripts and histone mRNAs, whereas those sensitive were highly enriched with 
5’TOP (5’terminal oligopyrimidine) motifs or had long and complex 5’UTR sequences. 
Regulation of the latter by mTOR was highly dependent on 4E-BP regulation, perhaps as 
eIF4G1 is highly necessary to bind eIF4E to the cap in 5’TOP mRNAs (Thoreen et al., 2012). 
Such motifs are enriched in ribosomal mRNA transcripts, and their regulation through mTOR-
dependent mechanisms has also been demonstrated in the context of the RNA binding protein 
La-related protein 1 (LARP1). LARP1 is capable of binding 5’TOP containing transcripts to 
repress their translation in an mTOR-dependent manner by holding the mRNA in a highly 
stable closed loop conformation in which eIF4E is bound by 4E-BP1 (Fonseca et al., 2015).  
To investigate translation initiation, cells can be treated with drugs such as 
harringtonine or lactimidomycin, which prevent new 80S complexes from initiating on the 
mRNA, while allowing those already engaged in elongation to progress along the mRNA 
(Ingolia et al., 2011; Lee et al., 2012). Additional methods such as translation complex profile 
sequencing (TCP-seq) serve to investigate translation termination and ribosome recycling – 
information that is lacking in the ribosome profiling datasets (Archer et al., 2016; Shirokikh 
et al., 2017). In TCP-seq, formaldehyde crosslinking, rather than cycloheximide, is used to fix 
both the ribosome and its associated complex on the bound mRNA (Archer et al., 2016). This 
facilitates the analysis of ribosome dynamics at each stage of translation as it does not 
discriminate against ribosomes composed of single subunits or transitionary complexes; for 
example, during the scanning phases of translation initiation when 40S subunits exist as the 
pre-initiation complex (Archer et al., 2016; Shirokikh et al., 2017). 
 
1.6 SRSF1: The founding member of the SR protein 
family 
 
SRSF1 has been extensively studied with respect to other members of the SR family 






1.6.1 SRSF1 Structure and nomenclature 
 
Shortly after the discovery of pre-mRNA splicing and the spliceosome, the minimal 
components of the reaction were defined in vitro (Krainer & Maniatis, 1985). Among those 
required for splicing initiation was the SR protein SF2 and the concurrently discovered ASF, 
later renamed SRSF1, which was micrococcal-nuclease sensitive and essential for in vitro 
splicing using S100 splicing deficient extracts.  
The first evidence for human SRSF1 was described when cDNA corresponding to a 
248 amino acid sequence was isolated from human cells (Ge et al., 1991; Krainer et al., 1991). 
Later gene mapping demonstrated that the corresponding gene was located at 17q21.3-q22 in 
humans and the analogous region of chromosome 11 in mice (Bermingham et al., 1995). 
Similar to other SR proteins, SRSF1 consists of two RNA-binding domains, RRM1 and 
RRM2 and C-terminal RS domain (figure). It was noted in early work, that SRSF1 resembled 
other splicing factors in such as Drosophila tra2, which also contains an RS domain (Long 
and Cáceres, 2009). Moreover, the budding yeast SR-like protein, Npl3 shares functional 
homology with SRSF1 in mRNA splicing as it has been shown to promote pre-mRNA splicing 
of target transcripts in a mechanism coupled to transcription (Kress et al., 2008). 
SRSF1 mRNA is itself subject to alternative splicing and the transcript encodes 
several highly conserved isoforms (Sun et al., 2010). The canonical isoform of SRSF1 
contains four exons, which encodes a protein of 248 amino acids in length. This transcript is 
the predominantly expressed isoform and is highly conserved between human and mouse on 
both the mRNA and protein level. Other splice isoforms of SRSF1 are not evolutionarily 
conserved and several are predicted to undergo NMD. Interestingly three of these are retained 
in the nucleus and isoform ratio changes to increase these on overexpression of the canonical 
248aa isoform (Sun et al 2010).  
SRSF1 binds RNA with high affinity via two dynamic N-terminal RRM domains, 
essential in splicing to provide a high degree of substrate specificity. The SRSF1 RRM1 is a 
canonical RRM domain, but the second is a pseudo RRM domain, characterised by a highly 
conserved heptapeptide. RRM2 has a distinct binding mode and acts to regulate splicing 
events through antagonising other splicing factors such as hnRNPA1. These actions are 
blocked or occur with a lower affinity when the conserved heptapeptide is mutated (Cléry et 
al., 2013). Conservation of this domain differs between SR protein family members and amino 
acid changes can be attributed to differential RNA binding. For example, the SRSF5 RRM 




(Cléry et al., 2013). The SR protein family have harnessed these distinct modes of RRM 
substrate recognition and utilised them to coordinate and delegate differential splicing events. 
 
1.6.2 SRSF1 Regulation and cellular localisation  
 
SRSF1, as other SR proteins, is extensively post-translationally modified; to date it 
has been shown to undergo methylation, particularly arginine methylation, phosphorylation, 
ubiquitination and acetylation (Sinha et al., 2010; Risso et al., 2012). Modifications also differ 
between cell types, for example, in activated T cells, SRSF1 is ubiqutinated and degraded by 
the proteasome to compensate for mRNA upregulation (Moulton et al., 2014).  
 
1.6.2.1 SRSF1 Phosphorylation 
 
Phosphorylation is the best understood and mechanistically characterised 
modification as it is key to the proper function and regulation of SRSF1 (Howard & Sanford, 
2014). The characteristic RS domain of SR proteins is composed of serine/arginine repeats, 
which undergo continual cyclic phosphorylation to dictate both cellular localisation and 
function (Figure 1.6). Deletion of the RS domain is lethal and phosphorylation of this domain 
is required for nuclear escape of all shuttling SR proteins. The SRSF1 RS domain can be 
considered as two parts separated by a short spacer domain: RS1, consisting of an unbroken 
stretch of eight SR repeats, and RS2, which contains additional but interrupted SR repeats. 
NMR studies show that this domain is highly disordered but undergoes a conformational 
change on phosphorylation to become a partially rigid, arched structure termed an “arginine 
claw” (Hamelberg et al., 2007; Xiang et al., 2013). RS1 forms contacts with RRM2 which 
ensures the balance of phosphorylation and if disrupted results in increased translocation of 
SRSF1 to the cytoplasm (Serrano et al., 2016). This demonstrates the essential and intrinsic 
coupling of phosphorylation and function of SR proteins.  
There are several mechanisms, via different kinases, that result in SRSF1 
phosphorylation in vivo. The main kinases responsible for RS domain phosphorylation are the 
nucleocytoplasmic shuttling SR protein kinases (SRPKs) and the exclusively nuclear Cdc2-
like kinase (CLKs) family (Ko et al., 2001; Ghosh & Adams, 2011).  
SRPK1 is the prototypical SRPK that specifically phosphorylates serine residues in 
the SR dipeptide in a highly processive fashion once tightly bound to a substrate (Aubol et al., 
2003). This action is restrictive and only phosphorylates approximately half (up to 12) of the 




largely cytoplasmic and regulated by a spacer element which facilitates this; alteration of this 
sequence results in aberrant nuclear translocation (Ding et al., 2006). Data from the yeast 
homologue of SRPK1, Sky1p, demonstrated that the spacer domain and hence cellular 
localisation is essential for cell viability (Ding et al., 2006). SRPK1 has a docking platform 
which mediates high-affinity interactions with a specific docking motif in SRSF1 (Ngo et al., 
2005). This motif is present in RRM2 which is more structured than the subsequent RS 
domain, thus can provide stability for docking and mediate directionality, although RS1 is 
also required (Serrano et al., 2016). Once bound, SRPK1 feeds the RS domain directionally 
through the docking groove to its active site. Progressive phosphorylation causes a 
concomitant accumulation of negative charge which decreases SRPK1 binding affinity and 
encourages dissociation of the kinase (Ngo et al., 2008). Cytoplasmic phosphorylation by 
SRPKs primes SRSF1 for nuclear import and speckle incorporation (Ngo et al., 2005). This 
mechanism of phosphorylation is consistent with the observation that SR proteins are 
hypophosphorylated in nuclear speckles and require further phosphorylation for speckle exit 
and to participate in splicing (Cáceres et al., 1997).  
 
Figure 1.6: Phosphorylation cycle of SRSF1. SRSF1 is highly dynamic and shuttles between 
the nucleus and the cytoplasm as dictated by the phosphorylation status of its RS domain. 
The cellular location of SRSF1 governs the regulatory functions that it exerts on its bound 
mRNA. Note the two RRMs (blue) and the RS domain (green) are depicted as a continuum 




SR proteins are hyperphosphorylated by CLKs, which govern nuclear distribution and 
facilitate splicing activity (Ngo et al., 2005; Ghosh & Adams, 2011). There are four members 
of the CLK family (CLK1-4), all of which phosphorylate Ser/Pro dipeptides in addition to 
Ser/Arg dipeptides. CLK1 lacks the docking groove characteristic of SRPK1 but binds SRSF1 
with a high affinity, via a distinct non-regiospecific mechanism which modifies up to 18 serine 
residues in the RS2 domain. The unique flexible N-terminus of CLK1, incidentally also an RS 
domain and nuclear localisation signal, is essential for this reaction as it directly binds the RS 
domain of SRSF1 (Aubol et al., 2014). Also required for the reaction is the formation of a 
cooperative CLK1-SRPK1 complex in which the latter acts a release factor for the tightly 
bound CLK1 substrate (Aubol et al., 2016). Specific Ser/Pro phosphorylation by CLK1 is 
required for SRSF1 exit from nuclear speckles and promotes RNA binding supporting SRSF1 
function in splicing (Keshwani et al., 2016).  
SRSF1 requires dephosphorylation mediated by protein phosphatase 1 (PP1) for 
nuclear export and post-splicing functions. SRSF1 Ser/Pro phosphorylation causes a structural 
change that enhances RS domain dephosphorylation by PP1 highlighting the balance between 
kinase and phosphatase action (Keshwani et al., 2016). The RS1 domain undergoes directional 
(N to C terminal) dephosphorylation by PP1 in a relatively inefficient reaction (Ma et al., 
2010).The RRM2 of SRSF1 directly binds PP1 and RRM1 allosterically sequesters the PP1 
to dampen its catalytic action. Dephosphorylation of SRSF1 is balanced and highly regulated 
to maintain proper protein localisation. PP1 directs this to mediate the recently proposed 
model of “goldilocks” dosing of SRSF1 phosphorylation (Aubol et al., 2017). 
 
1.6.2.2 Autoregulation  
 
All SR proteins and some other splicing factors autoregulate the level of their own 
expression through alternative splicing coupled to nonsense mediated decay (AS-NMD or 
unproductive splicing) (Lareau et al., 2007; Ni et al., 2007). SRSF1, for example, promotes 
inclusion of an intron after the canonical stop codon, which marks it as a premature 
termination codon (PTC) to elicit NMD of its own mRNA. For SRSF1, this exon is encoded 
in the ultraconserved sequence element in the 3’UTR although the location in the host 
transcript varies between SR family members (Lareau et al., 2007) . An ultraconserved region 
is classified as >200bp perfect conservation in mouse, rat and human genomes (Ni et al., 
2007). The unproductive splicing events themselves are also highly conserved between 
evolutionary kingdoms and actively selected for, being even present in fungi. Furthermore, 




as independent events and multiple occurrences after loss in some lineages (Lareau & Brenner, 
2015). Overall, this indicates the crucial nature of the process in maintaining optimum SR 
protein expression levels. Between cell types, the extent to which the PTC-containing 
isoforms prevail differs significantly, despite predictions that they account for approximately 
7% of transcripts. One study found that in HCT116 cell lines the PTC containing variant is 
equivalent to the canonical SRSF1 isoforms. Furthermore, in these cells, the PTC-containing 
isoform is regulated by micro RNA (miRNA) binding and reducing mRNA stability rather 
than by NMD per se, consistent with earlier speculations regarding miRNA regulation (Sun 
et al., 2010; Akaike et al., 2011). Interestingly there is degree of cross-regulation between SR 
family members as SRSF3 binds to the retained intron cassette within other SR protein mRNA 
transcripts (Anko et al 2012). SRSF1 also antagonistically regulates SRSF3 autoregulation 
through splicing repression of the unproductive SRSF3 isoform (Jumaa & Nielsen, 1997) 
The epithelial-to-mesenchymal transition (EMT) is a crucial process in early 
development and in the context of epithelial tumorigenesis. In this process, cells reorganise 
themselves from an epithelial state to a mesenchymal one through implementing a defined 
gene regulatory network to trigger specific signalling pathways particularly via the ERK1/2 
kinase (Valacca et al., 2010). During EMT, SRSF1 levels are differentially regulated by AS-
NMD which is attenuated through treatment with an ERK1/2 inhibitor. The splicing factor 
and ERK1/2 kinase substrate Sam68 is responsible for this regulation as it binds to the 
ultraconserved element in the 3’UTR of SRSF1 thereby influencing unproductive splicing of 
the transcript. This mechanism of regulation is able to drive EMT or the reverse process MET 
in SW480 cells. (Valacca et al., 2010).  
 
1.6.3 Roles in oncogenesis 
 
Considering the ubiquitous and essential nature of alternative splicing, it is 
unsurprising that its misregulation can have aberrant consequences, not least in oncogenesis. 
As master regulators of alternative splicing, SR and hnRNP proteins are obvious candidates 
for malfunction and indeed there are countless examples of their splicing dysregulation in a 
host of human malignancies. It was recognised that SR protein mediated dysregulation of 
alternative splicing could promote malignancy in early studies on breast cancer (Stickeler et 
al., 1999). SRSF1 itself is a protooncogene and is upregulated in numerous human cancers, as 
are several other SR proteins. Overexpression of SRSF1 is sufficient to drive tumorigenesis 
through alteration of alternative splicing programs and also in regulation of apoptotic 




of SRSF1 was shown to be mandatory to drive tumour formation in immortalised cells. SRSF6 
is also a proto-oncogene upregulated in several cancers such as lung and colon cancer, in 
which it promotes the formation of potent oncogene splice isoforms of transcripts such as 
MNK2. Interestingly, in colon cancer samples it is far more amplified than any other SR 
protein including SRSF1 (Cohen-Eliav et al., 2013). SRSF6 is also implicated in basal cell 
carcinomas and melanomas (Jensen et al., 2014) 
SRSF1 modulates the splicing pattern of the tyrosine kinase and protooncogene Ron 
through binding to either an enhancer or silencer within exon 12 of the transcript to mediate 
the inclusion or exclusion of exon 11 (Ghigna et al., 2005). Skipping of this exon results in a 
Ron isoform whose product is constitutively active and highly upregulated in many types of 
tumours. In this scenario, the amount of the malignant Ron isoform produced is dependent on 
SRSF1 levels. When SRSF1 is overexpressed, thus promoting exon 11 skipping in the Ron 
transcript, it promotes the loss of an epithelial phenotype and drives towards an aggressive 
mesenchymal state, in particular increasing cellular motility and tumour invasiveness (Ghigna 
et al., 2005).  
In breast cancer, SRSF1 is able to alter the splicing profiles for numerous genes 
including the kinases S6K1 and MNK2 by generating isoforms that promote transformation 
(Anczuków et al., 2012, 2015). In breast tissue, tumours formed are highly malignant and 
invasive. Overexpression of SRSF1 preferentially generates the MNK2b isoform, which 
results in eIF4E phosphorylation to drive oncogenic translation pathways. In MCF-10A cells, 
which model mammary acini structure, SRSF1 overexpression results in enlarged acini and 
increased proliferation in an mTOR signalling dependent mechanism (Anczuków et al., 2012). 
In addition, among other examples, increased levels of SRSF1 cause inactivation of the 
tumour suppressor gene BIN1 by promoting synthesis of an isoform unable to supress the 
oncogenic activity of its downstream target c-Myc (Karni et al., 2007). In breast cancer tissue 
versus normal breast tissue from the same patients, the SRSF1 genomic locus was highly 
amplified specifically in tumours. This indicates that in part increased SRSF1 can correlate 
with gene copy number, however it can also be significantly upregulated in tumours without 
gene amplification (Karni et al., 2007). Consistent with dysregulation of splicing, upregulation 
of SRSF1 nuclear functions is sufficient to drive tumorigenesis and increase in acinar size in 
the breast cancer model (Anczuków et al., 2012). 
SR proteins, particularly SRSF1 are also dysregulated in non-small cell lung cancer 
(NSCLC). SRSF1 upregulation has been proposed as a prognostic biomarker in NSCLC, 




upregulation can enhance the expression of the anti-apoptotic protein survivin through 
alternative splicing changes in tumours. However, in contrast to breast cancer models, in 
NSCLC, SRSF1 can directly increase the production of survivin protein through mRNA 
binding and consequently upregulation of its translation in an mTOR dependent mechanism 
(Ezponda et al., 2010). This indicates that the cytoplasmic roles of SRSF1 can influence 
cancer progression in a context dependent manner, concurrent with the fact that mTOR, 
specifically mTORC1 activation, is necessary for SRSF1-mediated transformation. 
Overexpression of SRSF1 causes increased phosphorylation of 4E-BP1 and S6K1 (both 
substrates for mTOR) to drive translation (Karni et al., 2008). In contrast to wt SRSF1, 
overexpression of the nuclear retained fusion protein SRSF1-NRS, not cause tumour 
formation in cellular transformation assays in p53 null immortalised liver progenitor cells, 
despite a constant proliferation rate between them (Shimoni-Sebag et al., 2013).  
For the most part, splicing factor mediated splicing changes are implicated in cancer 
but there are reports that alterations of their downstream roles are also pathogenic. For 
example, hnRNP A1 is increasingly localised in the cytoplasm in breast cancer and can alter 
transcript expression via translational regulation to drive tumorigenesis. In this context it 
enhances the translation and hence protein expression of RON by directly binding to the 
5’UTR of the mRNA which forms a G-quadruplex structure (Cammas et al., 2016). 
 
1.6.4 Functions of SRSF1 outside splicing 
 
The nuclear roles of SRSF1 in splicing are well understood, however, as a shuttling 
protein it also has several ill-defined cytoplasmic functions. Endogenous mRNA transcripts 
are associated with SRSF1 in both the nucleus and the cytoplasm whereas SRSF2 exclusively 
associates with nuclear mRNAs. In fact, a significant proportion of SRSF1 RNA binding 
capacity is for cytoplasmic RNAs and those in polysomes (Sanford et al., 2009; Sterne-Weiler 
et al., 2013). Many of the RNA binding targets of SRSF1 also overlap between cellular 
compartments, corroborating that SRSF1 moves with target transcripts throughout their 
processing lifetime (Sanford et al., 2008). Although the cytoplasmic roles of SRSF1 can be 
decoupled from those in splicing, it is believed that certain mRNA transcripts remain bound 
to SRSF1 throughout their processing until they are translated (Sanford et al., 2005). In such 
a model, SRSF1 is exported from the nucleus with its target mRNA as part of an mRNP 
particle. In HeLa cells, such mRNPs contain a high copy number of SR proteins which is in 





1.6.4.1 SRSF1 in mRNA translation  
 
A role for SRSF1 in mRNA translation was established by Western blotting of 
cytoplasmic extracts separated across sucrose gradients in which it was found in polysomal 
fractions to be directly associated with 80S ribosomal particles (Sanford et al., 2004). In 
addition to this, SRSF1 enhanced the translation of an mRNA reporter that harboured an ESE 
known to promote its binding. Interestingly, the presence of multiple ESEs, and presumably 
reciprocal increase in amount of SRSF1 bound to the transcript, caused an additive effect on 
translational stimulation which was unaffected by the presence of an intron (Sanford et al., 
2004). The correct phosphorylation state of the SRSF1 SR domain dictates shuttling 
propensity and SRSF1 must be dephosphorylated in the cytoplasm to interact with the 
translation machinery. The RS domain is required for mRNA binding in the cytoplasm but not 
for translational function, the latter requires RRM2. It was shown that mutating three residues 
of the conserved heptapeptide (WQD  AAA) of RRM2 abrogates SRSF1 function in 
translation, consistent with its requirement for SRSF1 splicing function (Sanford et al., 2005).  
SRSF1 activity can be modulated in response to growth factors which trigger a PI 3-
kinase and Akt signalling cascade. Using the aforementioned EDA reporter system, it was 
shown that Akt can target SRSF1 to alter cellular localisation and hence translation. In 
addition, overexpression of the other SR protein kinases SRPK1 and CLK1 cause SRSF1 to 
accumulate in the nucleus in a hyperphosphorylated state, indicating that phosphorylation-
mediated cellular location of SRSF1 is crucial for its varying functions (Blaustein et al., 2005).  
SRSF1-mediated translation occurs in an RNA-dependent mechanism that requires 
the translation initiation factor eIF4E and is increased by the presence of the m7G mRNA cap. 
SRSF1 is incapable of driving translation of known IRES-containing reporter constructs 
(Michlewski et al 2008). SRSF1 is able to stimulate mRNA translation in vivo via an mTOR 
dependent mechanism (Figure 1.7) (Michlewski et al 2008). Interestingly, this is not through 
direct interaction of the eIF4F complex or 4E-BP proteins but by modulating the 
phosphorylation status of the latter in a direct interaction with the mTOR kinase. Addition of 
SRSF1 to HeLa cell extracts decreased the rate 4E-BP1 dephosphorylation in an mTOR-
dependent manner. As shown using Co-IP experiments, SRSF1 interaction with mTOR is 
direct and RNA independent and triggers the phosphorylation of 4E-BP1. SRSF1 is also 
capable of direct binding to PP2A phosphatase; however, this may be indirect, perhaps 
mediated by an auxiliary factor, as PP2A was not pulled down by SRSF1. PP2A is the 
phosphatase responsible for dephosphorylation of 4E-BP proteins hence acting 




(inactive in translation) was incapable of mTOR binding suggesting that this region of the 
RRM2 is essential and hence mTOR is required for SRSF1 function in translation to releases 
eIF4E for incorporation into the eIF4F complex and drive cap-dependent translation of the 
transcript.  
It is interesting to note that the yeast SRSF1 homologue, Npl3 is also capable of 
nucleocytoplasmic shuttling and is able to regulate mRNA translation, for example it has a 
role in ensuring correct 80S monosome formation for successful translation initiation and 
termination (Estrella et al., 2009; Baierlein et al., 2013). Analogous roles for SRSF1 to Npl3 
in initiation or termination of translation have yet to be determined. However, similarly to 
SRSF1, Npl3 is modified by arginine methylation which dictates its association with the U1 
snRNP to facilitate a role in splicing (Muddukrishna et al., 2017). Together, this indicates that 
the high conservation of the shuttling and translational roles of SR proteins are highly 
important for cellular physiology. 
The mRNA transcripts translationally regulated by SRSF1 have been previously 
characterised in human cells in which it was transiently overexpressed (Maslon et al., 2014). 
Polysome profiling analysis after cell fractionation over sucrose gradients, coupled with RNA 
deep sequencing identified transcripts that transitioned from the sub to the heavy polysomal 
fractions on SRSF1 overexpression. These transcripts represent those whose translation was 
enhanced by SRSF1 overexpression. The number direct translational targets of SRSF1 were 
inferred when these data were overlapped with previous CLIP-seq datasets to total 505 mRNA 
transcripts. Remarkably, transcripts identified were enriched for those encoding cell, cycle 
and mitotic proteins including those encoding RNA processing and splicing factors (Maslon 
et al., 2014). Furthermore, many of these were regulated by SRSF1 at both the splicing and 
post-splicing level as they overlapped CLIP-seq data for SRSF1 (Sanford et al., 2008; Maslon 
et al., 2014). This provides strong indication that SRSF1 is capable of coupling splicing and 
translational regulation of its targets. Hence it is feasible to imagine an intricate regulatory 
network in which certain transcripts are bound by SRSF1 from alternative splicing to 
translation (such as the Clk1 mRNA), whereas others are regulated by SRSF1 at a single step 
alone.  
SRSF1 function in translation is required for proper cell cycle and mitotic progression 
and its depletion from the cytoplasm results in formation of a multipolar mitotic spindle 
phenotype and cell cycle arrest. This can be attributed to the requirement of SRSF1 in the 
translational regulation of important related proteins such as NDC80 and SMC4 which are 




2014). Concurrent with this, an independent genome-wide siRNA based study to establish 
mitotic regulators using high-throughput time-lapse microscopy of mitosis, identified SRSF1 
as a candidate which displayed aberrant phenotypes on depletion including mitotic delay 
(Neumann et al., 2010). In addition, specific mRNA transcripts are differentially regulated 
throughout the cell cycle, many of which are shown to be regulated by SRSF1. SRSF1 (and 
SRSF3) bind to interphase and post-mitotic chromatin in phosphorylation-dependent 
interactions with histone H3 but are released from mitotic chromosomes when both are 
phosphorylated by SRPK1 and Aurora B kinase respectively. SRSF1 is required in this 
process to remove HP1 proteins from chromosome to permit G0/G1 progression (Loomis et 
al., 2009). Such data offer an explanation into the mitotic defects and delay in G0/G1 entry 
that occur on SRSF1 knockdown (Loomis et al., 2009; Stumpf et al., 2013).  
Figure 1.7: SRSF1 in mRNA translation. SRSF1 acts to enhance the translation of specific 
target mRNA transcripts in an mTOR-dependent mechanism. SRSF1 is bound to cytoplasmic 
targets which facilitates mTOR recruitment to drive phosphorylation of 4E-BP. This releases 
eIF4E which binds to the capped mRNA to initiate translation of the SRSF1-bound substrate 




The physiological relevance of SRSF1-mediated translational in cell cycle regulation 
has yet to be dissected. Strikingly, it has recently been shown by proteomic analysis of 
polysome during the cell cycle, that splicing factors are recruited to and highly enriched on 
elongating ribosomes during mitosis (Aviner et al., 2017). In particular, this study exemplified 
hnRNPC as showing significant increase in association with polysomes (between G1 and M 
phase); though SRSF1 and other SR proteins were also enriched in the dataset. The authors 
show that this association during mitosis is not reciprocal for or dependent on the spliceosome 
suggesting a clear distinction of functions. Furthermore, hnRNPC was able to influence the 
translation of ribosomal proteins and translation factors (Aviner et al., 2017). hnRNPA1 was 
also shown to be involved in the translational regulation of specific transcripts (Roy et al., 
2014; Kim et al., 2017) 
 Other shuttling SR proteins have also been implicated in translational control. For 
instance, SRSF3 is capable of interacting with PDCD4 (programmed cell death factor 4), 
which represses translation through inhibiting eIF4e action. PCDC4 is a putative tumour 
suppressor frequently downregulated in tumours. In cancer models, SRSF3 was shown to 
antagonise PCDC4 expression at numerous post-transcriptional stages including splicing, 
mRNA export and translation. Interestingly, the type of SRSF3-mediated regulation is 
isoform-specific; it decreases the translational efficiency of one specific PDCD4 isoform, but 
influences the splicing and export of another (Park & Jeong, 2016). The translational activity 
in this context was previously shown to be dependent on binding of the 5’UTR of the transcript 
(Kim et al., 2013). 
  SRSF9 is also a shuttling SR protein that can regulate mRNA translation. For example 
it can upregulate Wnt/β-catenin signalling pathways by increasing the levels of the β-catenin 
protein (Fu et al., 2013). This was shown to be dependent on mTOR, suggesting that the 
mechanism of translational activation outlined for SRSF1 could be shared with other members 
of the shuttling SR family to potentiate translation. 
 
1.6.4.2 SRSF1 in genome instability and the cell cycle 
 
 In addition to the cell cycle defects caused by the ablation of SRSF1 function in 
mRNA translation, SRSF1 roles in splicing are also vital for proper cell cycle progression. 
SRSF1 ablation in DT40 cells which express a single cDNA copy of tetracycline inducible 
SRSF1 results in cell cycle arrest at G2 and concurrent apoptotic cell death, although the latter 
occurred in the absence of DNA laddering (Li et al., 2005). SRSF1 regulates the alternative 




apoptotic DNA laddering. ICAD isoform ratio must be properly maintained, but SRSF1 
depletion causes a shift in the ratio of ICAD isoforms towards less ICAD-L which inhibits 
DNA fragmentation despite apoptosis initiation (Li & Manley, 2005).  
SRSF1 is also required for the maintenance of genome stability and preventing R-
loop formation by associating with mRNA transcripts, concurrent with roles in transcription 
and splicing. This not only illustrates the crucial nature for the coupling of gene expression 
regulatory pathways but explains why SRSF1 depletion causes genomic rearrangements and 
increased mutagenic frequency in DT40 and HeLa cells (Li & Manley, 2005). Interestingly, 
transcription induced R-loop formation on SRSF1 knockdown can be counteracted by 
exogenous overexpression of RNase H (the enzyme that resolves these structures in vivo) but 
cannot prevent cell death. It was speculated by the authors that this may be due to ablation of 
other essential processes which SRSF1 orchestrates (Li & Manley, 2005).  
SRSF2 is also involved in the G2/M cell cycle transition and maintaining genome 
stability (R loops also formed on knockdown as for SRSF1). Its role in cell proliferation is 
dependent on p53, and loss of p53 is sufficient to ablate the cell cycle block induced on SRSF2 
deletion. This has implications for the role of SR proteins in cancer, especially if p53 is 
mutated (Xiao et al., 2007). SRSF1 is also capable of regulating p53 by preventing its 
proteasome-mediated degradation, which increases when SRSF1 is overexpressed. On 
induction of oncogenic or ribosomal stress, SRSF1 forms a crucial component of the RPL5-
MDM2 complex which acts to mediate the oncogene-induced senescence pathway via p53 
activation (Fregoso et al., 2013). 
 
1.6.4.3 SRSF1 role in mRNA export 
 
SRSF1, and other SR proteins including SRSF3 and SRSF7, act as adapters for the 
export of mRNP particles travelling to cytoplasm, by recruiting the export factor NXF1/TAP 
(Huang et al., 2003). This interaction is preferential for dephosphorylated SR proteins; hence 
such complexes assemble more readily after splicing. The mRNP is then able to directly 
interact with the nuclear pore complex to promote export of the mature mRNP to the 
cytoplasm (Lai & Tarn, 2004). Interestingly, this is not intron-dependent as SR proteins are 
capable of promoting the export of intronless transcripts (Huang & Steitz, 2001). For SRSF3 
and SRSF7, NXF1/TAP binding is mediated by interactions with an arginine-rich motif at the 
C-terminus of the single RRM domain that does not contact RNA (Hargous et al., 2006). 
However SRSF1, which contains two RRM domains, utilises the arginine-rich linker sequence 




can bind NXF1/TAP independently of RNA, an mRNA transcript is required for a stable 
association in vivo. Indeed, the 3’end of SR-protein bound target mRNA is thought to be 
necessary for NXF1/TAP binding.  
Extensive iCLIP experiments and RNA-sequencing of cytoplasmic poly(+) mRNA 
have shown that SR proteins target specific transcripts for export and there is little overlap 
between them (Muller-McNicoll et al., 2016). However, individual SR protein depletion had 
little effect on these numbers suggesting that there is some functional redundancy at least for 
export. The only outlier is SRSF3 whose roles in export cannot be compensated for by other 
SR proteins, indicating it is the most crucial for mRNA export. Interestingly, many transcripts 
targeted for export by all SR proteins are alternatively spliced, particularly with differential 
terminal exons and alternative polyadenylation marks, which may have different requirements 
for NXF1/TAP binding. This illustrates the roles that SR proteins play in the tight coupling of 
gene regulatory mechanisms (Muller-McNicoll et al. 2016).  
 
1.6.4.4 SRSF1 in Nonsense-Mediated Decay and mRNA stability 
 
Nonsense-mediated decay (NMD) is a translation-dependent mRNA degradation 
pathway that removes aberrant mRNA transcripts, which harbour a premature termination 
codon, thereby acting as a surveillance mechanism for faulty transcripts. It serves to regulate 
both a proportion of normal transcripts and those which are faulty in disease (Hug et al., 2015). 
SRSF1 has a role in enhancing nonsense mediated decay (NMD) response in targeting reporter 
constructs that contain a premature termination codon. This was observed on SRSF1 
overexpression and it requires a functional RS domain but not nucleocytoplasmic shuttling, 
although the exact mechanisms remain unclear. In addition to SRSF1, other SR proteins were 
also to elicit an NMD response to a lesser extent with the same reporter constructs (Zhang & 
Krainer, 2004). 
SRSF1 also plays a role in determining the stability of mRNA transcripts to which it 
is bound. In DT40 chicken cells that expressed a single copy of tetracycline inducible SRSF1 
cDNA, it was shown to destabilise a polyadenylated reporter construct by binding to the 
3’UTR of the transcript. This behaviour was shown to be an independent SRSF1 function that 
is not determined by its role in splicing, however the exact mechanism of action remains 
unclear (Lemaire et al., 2002). Therefore, although SRSF1 can travel with a newly transcribed 





1.6.4.5 SRSF1 in Protein sumoylation  
 
Further to its roles in numerous aspects of mRNA processing, SRSF1 also has a role 
in protein sumoylation; the process by which the post-translational modification SUMO (small 
ubiquitin-related modifier) is added to proteins (Pelisch et al., 2010). SRSF1 is capable of 
regulating cellular levels of sumoylation in a dose dependent manner specifically through 
interactions of its RRM2 domain with the SUMO E3 ligase PIAS1. This activity is 
independent of SRSF1 roles in splicing, despite the fact that sumoylation has a role during the 
splicing process (Pelisch et al., 2010). Interestingly, this function of SRSF1 appears to be 
important to remove R-loops (RNA:DNA hybrids) and DNA breaks. To do so SRSF1 
participates in a complex with PIAS1 and the DNA helicase RECQ5 to cause the 
SUMOylation of Topoisomerase I, which ultimately prevents genomic instability (Li et al., 
2015). 
 
1.7 SRSF2: A non-shuttling SR protein 
 
SRSF2 is a non-shuttling SR protein that resides constitutively in the nucleus and is a 
major component of and marker of nuclear speckles (Cáceres et al., 1998; Saitoh et al., 2004). 
Due to nuclear retention, SRSF2 is unable to partake in post-splicing roles analogous to other 
SR proteins. In contrast to shuttling SR proteins, SRSF2 does not bind NXF1/TAP, so does 
not play a direct role in export of its bound transcript mRNA. However, it may have an indirect 
role in export as SRSF2 knockdown results in changes in cytoplasmic mRNA fractions that 
are distinct from other SR proteins (Muller-McNicoll et al. 2016). SRSF2 binds distinct 
mRNA targets with more plasticity than its family counterparts, with its RNA binding 
consensus being SSNG (Fu & Ares, 2014); this could indicate a binding capacity for different 
types of transcripts in comparison to other SR proteins (Anko 2014). 
SRSF8, previously known as SRp46, is the processed retropseudogene of SRSF2, 
which contains large sequence homology (Soret et al., 1998). It is believed to not shuttle 
between the nucleus and the cytoplasm, but the propensity for this is untested. SRSF8 is 
functional as an SR protein and has distinct roles in splicing to SRSF2 and binds to different 
target mRNAs (Soret et al., 1998). It is an orthologue of SRSF2 that arose after C.elegans in 








1.7.1 SRSF2 and Nuclear retention 
 
SRSF2 remains sequestered in the nucleus due to a potent nuclear retention sequence 
(NRS) present at the very C-terminus of its RS domain (Cazalla et al., 2002). The NRS is not 
only unique amongst SR proteins, but it has virtually no homologues in the human genome at 
peptide or nucleotide level. By nature, all RS domains have a high propensity for disorder, but 
the SRSF2 RS domain shows an even further increase in disorder due to the NRS. A high 
level of disorder in a sequence is used to increase the binding capacity and plasticity of the 
protein (Calabretta & Richard, 2015; Castello et al., 2016). This distinct property of SRSF2 
may allow it to be uniquely modified or bind certain factors that other SR proteins cannot. 
SRSF2 is also highly phosphatase resistant, suggesting that in comparison to shuttling SR 
proteins, it is less readily dephosphorylated. Shuttling SR proteins require dynamic 
dephosphorylation for nuclear export, thus nuclear retention of SRSF2 could be explained by 
differential or inefficient dephosphorylation (Cazalla et al., 2002).  
 
When fused to a shuttling protein, the NRS is sufficient to ablate its transition into the 
cytoplasm. This has been demonstrated extensively both within and outside SR family 
proteins (Cazalla et al., 2002). The fusion protein SRSF1-NRS which does not shuttle to the 
nucleus but remains active in splicing, hence preserving cellular viability, is an important 
control to study the cytoplasmic functions of SRSF1 as it should behave in the antagonistic 
Figure 1.8: Nuclear retention of SRSF2 (a) Peptide sequence from the RS domain of SRSF2. 
The nuclear retention sequence (NRS) resides at the C-terminus of this domain, highlighted 
in red. (b) Domain structure of wt SRSF2 (non-shuttling), wt SRSF1 (shuttling) and the SRSF1-
NRS fusion protein, (non-shuttling). In the SRSF1-NRS fusion protein the entire wt SRSF1 
sequence is present. In each case, the NRS is highlighted and not drawn to scale. Figure 






fashion to shuttling SRSF1 (Sanford et al., 2004). Indeed, it has been used in this capacity in 
numerous studies, including those that address SRSF1 function as an oncogene (Anczuków et 
al., 2012). Although the functional capacities of the NRS for highly effective nuclear retention 
have been harnessed in numerous studies, the exact mechanism of its action are unknown. 
SRSF1 containing the entire SRSF2 RS domain was functional and able to fully 
rescue the conditional knockout in DT40 cells. Furthermore, when SRSF1 is fused to just the 
nuclear retention sequence (NRS) from the RS domain of SRSF2, it is capable of rescuing the 
viability of conditional knockout mouse embryonic fibroblasts (Lin et al., 2005). This strongly 
implies that both the RS domain and the shuttling roles of SRSF1 are not required for viability 
in this cell type.  
 
1.8 Aims and objectives 
 
The cellular roles of the SR protein family in splicing and alternative splicing 
regulation are exemplified by the prototype SR protein SRSF1, which continually shuttles 
between the nucleus and the cytoplasm due to continual phosphorylation of the RS domain. 
The nuclear functions of SRSF1, particularly in splicing, are well characterised and its mRNA 
targets have been previously described for this process in diverse systems. SRSF1 also has 
numerous cytoplasmic roles outside splicing, including the regulation of mRNA translation in 
an mTOR-dependent mechanism (Michlewski et al 2008). The direct translational mRNA 
targets of SRSF1 have been previously characterised for human cells in which it was 
transiently overexpressed (Maslon et al., 2014). However, in comparison to the wealth of 
knowledge for SRSF1 function in the nucleus, little is understood regarding its cytoplasmic 
roles or the functional relevance of SR protein shuttling.  
The overarching aim of this work is to further investigate the function of SRSF1 in 
the cytoplasm and examine the physiological consequences of its absence in both novel and 
highly relevant cell and animal model systems.  
To do this, there are three key aims for the project: 
(1) To create an endogenous model system for non-shuttling SRSF1 to further 
understand the cytoplasmic roles of SRSF1 in mouse ES cells. 
(2) To determine the interactome of shuttling and non-shuttling SRSF1 protein 
(3) To examine the physiological consequences of SRSF1 shuttling through creation 





























2.1 General Molecular Biology Methods 
 
2.1.1 Plasmid preparation 
 
To generate repair plasmids for CRISPR targeting in cells, the PCDNA3+ expression 
vector was used. Endogenous sequences were amplified from mouse genomic DNA, using 2x 
GoTaq Green Master Mix (Promega) and primers containing the appropriate restriction site 
overhangs (section 2.8). The thermal profile used was following the manufacturer’s protocol 
with an optimised annealing temperature of 62oC. Excess primers and PCR reaction 
components were removed from all PCR products using the PCR purification kit according to 
the manufacturer’s instructions (Qiagen). After sequence verification, clean PCR products 
were ligated overnight 4oC into the appropriately digested PCDNA3+ expression vector using 
DNA ligase (NEB). Ligation independent cloning was carried out using the same PCR 
amplification steps but insertion into the digested vector was via annealing of complementary 
primer overhangs. 
Overexpression constructs for mass spectrometry were generated from existing 
Cáceres lab stocks. After bacterial amplification, plasmids were prepped using the Plasmid 
Maxi kit (Qiagen) as per the manufacturer’s protocol. DNA was quantified by nanodrop and 
verified by Sanger sequencing.  
 
2.1.2 Site Directed mutagenesis  
 
PAM site mutations were generated on the CRISPR repair template using the 
QuickChange II site-directed mutagenesis kit (Agilent Genomics) and the appropriately 
designed primers (section 2.8). Plasmids were amplified using AccuPrime Pfx high fidelity 
DNA polymerase (ThermoFisher Scientific), with the thermal profile given in the 
manufacture’s guidelines. Plasmids were subsequently digested with DpnI to remove the non-
mutated plasmid. Reactions were transformed as detailed elsewhere and plasmids prepared 
using the Plasmid Mini kit (Qiagen). Successful mutations verified by Sanger sequencing, and 
plasmids purified to transfection grade using Plasmid Maxi kit (Qiagen).  
 
2.1.3 Agarose gel electrophoresis 
 
All agarose gels for electrophoresis were prepared using 1x TBE buffer (1 M Tris 
base, 1 M Boric acid, 0.02 M EDTA) supplemented with ethidium bromide (2 µl/100 ml). 




2.1.4 Bacterial DNA transformation 
 
For all cloning applications, DNA was transformed into sub-cloning efficiency DH5α 
E.coli bacterial cells (Invitrogen). 50µl thawed cells were used per transformation. After 
addition of DNA, cells were incubated on ice for 30 minutes then subjected to heat shock at 
42oC for 45 seconds, followed by 2 minutes on ice. 500 µl of SOC medium (2% (w/v) 
Tryptone, 0.5% (w/v) Yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM 
Glucose), was added and tubes were incubated at 37oC for 1 hour with shaking at 225 rpm. 
Transformants were plated on either Amplicillin or Kanamycin agar plates as appropriate.  
 
2.1.5 Western Blotting 
 
Cells were grown to 80-90% confluency in dishes and washed twice in ice cold PBS 
before being harvested on ice with a cell scraper in 1 ml PBS. Cells were pelleted by 
centrifugation at 1000 rpm for 4 minutes and the supernatant removed before lysis in the 
appropriate volume of lysis buffer (50 mM Tris-Cl pH 8, 150 mM NaCl, 1% NP40, protease 
inhibitors (complete mini EDTA-free, Roche)). For Western Blotting from mouse tissues, the 
sample was homogenised and lysed in the same lysis buffer used for cells. In both cases, lysis 
was performed for 15 minutes on ice and spun at 13000 rpm for 12 minutes. The cleared lysate 
was transferred to a clean Eppendorf on ice. Bradford assay to estimate protein concentration 
were carried out for each sample in duplicate using the BioRad reagent and homemade BSA 
standards. The latter were homemade by serial dilution from 5 mg/ml BSA (NEB). Protein 
concentration was equalised using lysis buffer and samples prepared for SDS-PAGE (10x 
reducing agent, 4x sample buffer, (x) µl lysate).  
For standard western blotting, precast 4-12% Bis-Tris gels were used (NuPAGE, 
Invitrogen). The benchmark prestained protein ladder (Invitrogen, 10748010) was run 
alongside all samples to calibrate molecular mass. Gels were transferred onto appropriately 
sized, preassembled nitrocellulose membrane stacks using the iBlot 2 dry blotting system 
(Invitrogen) as in manufacturers protocol, following programme P3 (20 V, 7 minutes). The 
membrane was stained briefly with Ponceau S to visualise successful transfer of proteins 
before blocking in 5% nonfat fat milk made up in PBS tween (0.1% (v/v)) for 1 hour with 
shaking. Unless otherwise stated, all antibodies were prepared in blocking solution and 
membranes were incubated for 1 hour at room temperature or overnight (4oC). For antibody 







Cells were plated in 10 cm dishes and grown until 90% confluent. For endogenous 
IPs cells were harvested 24 hours after plating. Transfected cells were harvested 48 hours post 
plating and 24 hours post transfection. Cells were washed twice with ice cold PBS and 
harvested on ice by scraping before lysis in 500 µl ice cold IP/lysis buffer (20 mM Tris-Cl pH 
8, 150 mM NaCl, 1 mM EDTA, 1% NP40, 0.2% Sodium Deoxycholate, 1 mM DTT, protease 
inhibitor tablets (complete mini EDTA-free, Roche)). Lysates were incubated on ice for 20 
minutes and subject to centrifugation at 13 000 rpm for 15 minutes. The supernatant was 
loaded on Protein G sepharose fast flow beads (GE healthcare). Prior to use, beads were 
washed three times in 1 ml PBS and resuspended to 50% slurry in IP/lysis buffer. Lysates 
were precleared using 20 µl Protein G beads per sample for 30 minutes at 4oC with rotation.  
After preclearing, protein concentration was determined using Bradford assay as 
described for Western Blotting. Protein concentrations were calibrated in an equal volume of 
IP/lysis buffer and incubated with 40 µl of T7-antibody coupled beads (Millipore) overnight 
rotating at 4oC. Beads were washed three times in 1 ml cold PBS and prepared to 50% slurry 
in IP/lysis buffer prior to use. After incubation beads were centrifuged for 2 minutes at 2000 
rpm to remove the unbound fraction. Beads were washed three times in IP/lysis buffer with 
rotation at 4oC for 5 minutes and twice without incubation. For mass spectrometry experiments 
the final two washes were performed using 1x TBS (Tris-buffered saline, in place of IP/lysis 
buffer) to remove excess detergent in the samples. Finally, beads were resuspended in 10 µl 
1x TBS before submission to the in house mass spectrometry facility. For other experiments, 
complexes were eluted from beads by heating at 95oC in 4x LDS sample buffer supplemented 
with 10x reducing agent (both NuPAGE, LifeTech) and subjected to SDS-PAGE.  
To visualise mass spectrometry samples prior to their analysis, a portion of IP beads 
were eluted in sample buffer and run on precast 4-12% Bis-Tris polyacrylamide gels as 
previously described. Gels were stained using either SilverQuest or Colloidal Blue Staining 
kits (both Invitrogen) following the manufacturer’s protocols. 
 
2.1.7 DNA Sequencing 
 
All Sanger sequencing, including that for genotyping, was performed by in-house 
local facility on the 3130/3730 genetic analyser (Applied Biosystems). Sequencing primers 
used are indicated where appropriate and in Table 2.1. Sequence analysis was carried out using 




2.1.8 Subcellular fractionation 
 
To fractionate cells for mass spectrometry, HeLa cells were grown in 15 cm dishes 
until confluent, washed twice in PBS and harvested by scraping. Cells were pelleted by 
centrifugation at 1000 rpm for 4 minutes and resuspended in 150 µl nuclei buffer A (NB-A) 
(85 mM KCl, 5.5% Sucrose, 10 mM Tris pH 7.5, 0.5 mM Spermidine, 0.2 mM EDTA, 250 
µM PMSF). 150 µl of nuclei buffer B (NB-B) (NB-A supplemented with 0.2% NP40) was 
added and samples mixed well by inversion. Lysates were incubated on ice for 5 minutes then 
spun at 2000 rpm for 3 minutes to pellet nuclei. The soluble supernatant was harvested as the 
cytoplasmic fraction. Nuclei were washed gently in 1 ml of nuclei release buffer (NB-R) (85 
mM KCl, 5.5% Sucrose, 10 mM Tris pH 7.5, 1.5 mM CaCl2, 3 mM MgCl2, 250 µM PMSF) 
and centrifuged at 1200 rpm for 3.5 minutes. Nuclei were resuspended in 150 µl NB-A and 
sonicated for 5 cycles of 30 seconds on/30 seconds off using the high setting on the Biorupter 
sonicator. Extracted protein was subjected to Western blotting, to ensure the purity of each 
fraction. 
 
2.2 Cell culture Techniques 
 
2.2.1 Cell Lines 
 
HeLa, NIH3T3 and mouse E14 embryonic stem (ES) cells were all obtained in house 
from lab stocks in liquid nitrogen storage. Murine Neural Stem Cells (ANS4), directly isolated 
from adult mouse brain tissue, were a gift from Steven Pollard’s Laboratory at the University 
of Edinburgh.  
 
2.2.2 Maintenance of cell lines  
 
All cell lines used were grown under standard culture conditions at 37oC with 5% 
CO2. NIH3T3 cells and HeLa cells were maintained in Dulbecco’s Modified Eagle Media 
(DMEM) (Gibco Thermo) supplemented with 10% fetal calf serum (FCS) and detached on 
passaging using 1x Trypsin-EDTA (diluted from 10x stocks in PBS, Sigma).  
Mouse E14 ES cells, were maintained in Glasgow Minimum Essential Media 
(GMEM) supplemented with 10% (v/v) FCS, 1% (v/v) Non-essential amino acids (LifeTech), 
1% (v/v) Sodium Pyruvate (Sigma), 0.1% (v/v) 2-mercaptoethanol (50 nM) (ThermoFisher), 




plates pre-coated with gelatin (0.1% (w/v) sterile stock from powder (Sigma)) and all cell 
washes were performed using sterile PBS (Sigma). 
Neural Stem Cells were grown on plates pre-coasted with 0.1% gelatin in 
DMEM/HAMS-F12 +HEPES + Sodium Bicarbonate +L-Glutamine (Sigma), supplemented 
with 7.25ml Glucose (Sigma), 1x MEM NEAA (Gibco), 1% Pen-Strep (Gibco), 0.16% (v/v) 
BSA Solution 7.5% (Gibco), 0.1% 2-mercaptoethanol (50 nM) (ThermoFisher), 1% (v/v) B27 
Supplement 50x (LifeTech/Gibco), 0.5% (v/v) N2 Supplement 100x (LifeTech/Gibco 17502-
048). Before use media was further supplemented with mouse EGF (final concentration 10 
ng/ml) (Peprotech), human FGF (final concentration 10 ng/ml) (Peprotech) and Laminin (final 
concentration 1 µg/ml) (Sigma L2020-1MG/ML). Cells were washed in sterile PBS (Sigma) 
and detached using Accutase solution (eBioSciences).  
 
2.2.3 DNA Transfections 
 
All DNA transfections were carried out using Lipofectamine 2000 (ThermoFisher 
Scientific) following the manufacturer’s protocol. Briefly, DNA was diluted in the appropriate 
volume of opti-MEM serum free media (Gibco). In a separate tube, the appropriate volume of 
lipofectamine was also diluted in opti-MEM media. The two mixes were combined at a 1:1 
ratio and incubated at room temperature for 20-30 minutes. For standard transfections, 
DNA/lipofectamine mixes were added dropwise to cells. For reverse transfections, cell 
suspension was added to the plate with the transfection mixes and cells allowed to adhere to 
the place. All media was replaced after 6-12 hours.  
 
2.2.4 Propidium Iodide staining 
 
 For Propidium Iodide staining prior to FACs analysis, mouse E14 cells were grown 
to confluency in a T75 flask and harvested by trypsinisation before collection by 
centrifugation at 1000rpm for 4 minutes. Cells were washed once in PBS before fixation in 
ice-cold 100% ethanol and incubation at 4oC for 24 hours. Cells were spun at 1000 rpm for 4 
minutes and washed once in PBS, before cell pellets were resuspended in PBS. RNase A was 
then used at 0.5 µg/ml (Roche) for 30 minutes at 37oC, before incubation with 50 µg/ml 
propidium iodide (Sigma) for 15 minutes on ice. The cell cycle distribution of the stained cells 






2.3 CRISPR Methodology in Cells 
 
2.3.1 Guide RNA Design  
 
The 20 nucleotide Guide RNA sequences required for Cas9 specificity were chosen 
using the online tool at http://crispr.mit.edu/ (Zhang Lab) and further design undertaken as in 
Ran et al 2013. Up to 200 bp of genomic DNA sequence at the appropriate locus was used 
(Ensembl genome browser) at each selection. Guide RNAs with the highest “score”, as 
determined by the program, were preferentially chosen. This score takes into account both 
base pair match number to the target region and any potential off-target binding. 
Complementary sequence to each guide was determined and Bbs1 restriction overhangs added 
to each end to facilitate ligation into the targeting vector (Ran, Hsu, Wright, et al., 2013).  
 
2.3.2 gRNA Cloning 
 
All gRNAs were ordered as custom single stranded DNA oligos (Sigma) with the 
appropriate reverse sequence and resuspended to 100 µM in dH2O. A full table of gRNA 
sequences used can be in section 2.8. Complementary oligos were annealed at 100 µM in 10x 
T4 DNA Ligase Buffer (NEB) by heating to 95oC for 2 minutes in a heat block which was 
subsequently allowed to cool slowly to room temperature. Successful annealing was 
confirmed by gel electrophoresis and introduced into either the PX461 or PX458 cloning 
vectors using Bbs1 (NEB) restriction cloning.  
 
2.3.3 Fluorescence activated cell sorting (FACS) 
 
Transfected cells were analysed for GFP+ fluorescence and single cell sorted using 
the BD FACS Jazz flow cytometer (BD Biosciences). Suitable and stringent fluorescence 
gating was applied to cells which were directly sorted into either 96-well plates or falcon tubes 
containing appropriate cell medium. Cells sorted into the latter vessel were subsequently 
plated at a density of 100 or 200 cells/ml in 10 cm dishes for colony expansion. For cell cycle 
analysis of clones, the FACs Fortessa LRII was used. 
 
2.3.4 Isolation of Clones 
 
Clonal cell populations were isolated from 10 cm dishes after 8-10 days of colony 
expansion. Individual colonies were isolated under a dissection microscope using a P20 Gilson 




incubation for 5 minutes at 37oC, trypsin was quenched using 70 µl of appropriate warm 
media. Dispersed clones were transferred to fresh 96-well plates containing 100 µl of media. 
After 24 hours growth, growth media was replaced to remove any residual trypsin.  
 
2.3.5 Genomic DNA extraction 
 
After replica plating, cells were grown in 96-well plates for 2-3 days until 
overconfluent. To extract genomic DNA, cells were washed twice with PBS and lysed either 
in 50 µl DirectPCR Lysis Reagent (Cell) (Viagen Biotech), supplemented with 0.5 µg/µl 
proteinase K, as per the manufacturer’s instructions or in 40 µl of homemade Proteinase K 
buffer (50 mM Tris pH 8.9, 1.5 mM MgCl2, 0.5% (v/v) Tween and 0.5 ul/ul Proteinase K. 
Cells were incubated overnight in a homemade humidity chamber at 55oC. Genomic DNA 
precipitated the following day using 100 µl 100% ethanol supplemented with 150 mM NaCl 
for a minimum of 30 minutes at -20oC. Plates were spun using at a low speed and resultant 
genomic DNA pellets washed 3 times in 70% ethanol before resuspension in 30 µl TE buffer 
or dH2O.  
 
2.3.6 PCR-based genotyping 
 
Genotyping PCR screening reactions for mice and cells were carried out using 2x 
GoTaq Green Master Mix (Promega) following the manufacturers guidelines. 1 or 2 µl of the 
cell lysate was used for amplification. The forward SRSF1 Ex4 screening primer and reverse 
SRSF1 3’UTR screening primer were used at a final concentration of 1.0 µM. All primer 
sequences can be found in section 2.8. The thermal profile used was optimised to: initial 
denaturing 95oC 2 minutes, then 35 cycles of: second denaturing 95oC 30 seconds, annealing 
62oC 30 seconds, extension 72oC 1 minute, before final extension 72oC 5 minute. PCR 
products were separated by standard gel electrophoresis on 1 or 1.5% (w/v) TBE agarose gels. 
 
2.3.7 Sub-cloning PCR products  
 
To identify heterozygous CRISPR clones, PCR products were subcloned first then 
multiple transformants sequenced to identify the allele frequency. PCR products generated by 
a Taq polymerase, which have a 3’ A overhang, were cloned into the PGEM T-easy vector 
(Promega), following the manufacturers protocol. For cloning of sequencing libraries, blunt-
ended PCR products were cloned into the pCRII-TOPO blunt end vector system following the 




2.4 Targeting methodologies for CRISPR mice  
 
2.4.1 Microinjection Reagents 
 
For blastocyst injections, Cas9 RNA was used in combination with in vitro transcribed 
gRNAs and a DNA oligo repair template. Mix components were synthesised and assembled 
as follows. gRNA sequence from PX458 was amplified using oligos complementary to guide 
sequence and containing the T7 promoter sequence at the 5’ end of the forward primer (section 
2.8) PCR was performed using GoTaq 2x Green Master Mix in a 50 µl reaction volume with 
200 ng template DNA. PCR thermal programme used was follows: initial denaturing 95oC 2 
minutes, then 35x cycles of: second denaturing 95oC 30 seconds, annealing 56oC 30 seconds, 
extension 72oC 20 seconds, before final extension 72oC 5 minutes. 
 
PCR product was purified using the PCR purification kit (Qiagen) as per the 
manufacturer’s instructions. A second PCR amplification step was performed using the entire 
elute (30 µl) from this cleanup of the first PCR reaction using the same thermal cycling profile.  
RNA synthesis was carried out from the amplified DNA using the MEGAscript T7 
Transcription kit (Invitrogen, AM1334) following the manufacturer’s instructions. The entire 
purified PCR product (approximately 1 mg) was used with incubation at 37oC overnight. 
Transcribed RNA was purified using the RNAeasy kit (Qiagen) following the “cleanup” part 
of the manufacturer’s protocol. RNA was quantified using the Nanodrop, with dilution as 
appropriate. Injection mixes were prepared in a total volume of 20 µl as follows: Cas9 RNA, 
50 ng/µl, guide RNAs, 25 ng/µl, repair template oligo, 75 ng/µl. Mixes were centrifuged at 
maximum speed, 4oC for 30 minutes to remove impurities, before the supernatant was 
transferred to a fresh tube. 
 
2.5 High throughput screening of clonal populations 
 
2.5.1. Generation of CRISPR clone pools 
 
Mouse E14 ES cells were grown and transfected as previously described for CRISPR 
experiments. Both wt cells and were targeted in parallel experiments (see Chapter 3, section 
3.3.6 for details of clone 1). For wt mESCs, the original CRISPR strategy was repeated (same 
repair oligo and gRNA); SRSF1-NRS-T7 (clone 1) cells were retargeted with a new repair 




To determine the base allele frequency either wt or SRSF1-NRS-T7 (clone 1) cell 
populations, t=0, 1x106 cells were harvested at the time of transfection, by centrifugation at 
1000 rpm for 4 minutes and pellets snap frozen on dry ice. The rest of the cells were reverse 
transfected as previously and FACs sorted 48 hours later. Prior to FACs sorting, 1x106 cells 
of both wt and SRSF1-NRS-T7 (clone 1) cells were harvested for t=1. FACs sorted cells were 
divided into two pools; one for passaging in flasks, and the other pool plated in 10 cm dishes 
at a low density for picking clones. Clones were picked into 96-well plates as previously 
described. Cells in flasks were passaged and 106 cells collected for time points two to seven 
over 18 days. Collected cell pellets were lysed and the genomic DNA extracted using the 
DNeasy blood and tissue kit (Qiagen, 69504) as the manufacturer’s protocol. Genomic DNA 
was resuspended in 100 µl AE buffer provided with the kit and quantified using the Qubit 
high sensitivity dsDNA assay (ThermoFisher Scientific).  
 
2.5.2 Miseq Library Preparation 
 
Library Preparation for Miseq experiments was carried out following the Illumina 
protocol for 16S Metagenomic Sequencing Library Preparation (available at: 
https://support.illumina.com/downloads/16s_metagenomic_sequencing_library_preparation.
html) with various adaptations. For all PCR steps Q5 high fidelity DNA polymerase (NEB) 
was used to amplify 2 µl of genomic DNA obtained as previously (section 2.4.1). Nextera 
adapter primers, containing indices were custom ordered from IDT (section 2.8). Libraries 
were quantified using both the Qubit high sensitivity double stranded DNA assay and the 
Bioanalyser Agilent High Sensitivity. 5 µl of each library at 5 nM was pooled and sequenced 
on the MiSeq platform (Edinburgh Genomics, Ashworth Building, Kings Buildings, 
University of Edinburgh). All data analyses from the high throughput Miseq experiments were 
carried out by Martijn Kelder of Andrew Wood’s Lab at the IGMM, University of Edinburgh.  
 




Coverslips for immunofluorescence (round, 16 mmFisher Scientific) were sterilised 
with 100% ethanol before use. Cells were plated onto coverslips in 12 well plates at a density 
of 1x104 cells/ml, except for reverse transfection of the T7-SRSF1 plasmid into mESCs, when 
1x105 cells/ml were used. Cells were rinsed with PBS and fixed with 4% (w/v) 




washed 3x for 5 minutes with PBS and permeabilised with 0.2% (v/v) Triton X-100 for 10 
minutes at room temperature. Cells were washed 3x for 5 minutess with PBS. Coverslips were 
incubated in block (1% (w/v) BSA, 0.01% (v/v) Triton in PBS) for 1 hour before primary 
antibody application (used as stated in section 2.9). Cells were washed 3 times for 5 minutes 
in PBS with 0.01% (v/v) Triton X-100, and incubated with Alexafluor secondary antibodies 
488 (FITC) or 594 (Texas Red) (Abcam) for 1 hour and washed 3 times for 5 minutes in PBS 
with 0.01% (v/v) Triton X-100. Cell nuclei were stained with DAPI (50 mg/ml) for 10 minutes 
and rinsed briefly in dH2O. Coverslips were mounted onto slides using Vectashield mounting 
medium (Vector Labs) and sealed with nail varnish before imaging.  
 
2.6.2 Heterokaryon Assays 
 
Heterokaryon assays were principally performed as described in Cáceres et al (1998), 
with a few modifications. Mouse E14 ES cells were plated on sterile, gelatin coated coverslips 
in 12 well plates at a density of 1x105 cells/ml. Cells were grown to confluency in a T75 flask 
(Corning), harvested 48 hours after plating the and resuspended at 1x106 cells/ml. Media was 
removed from the mouse E14 ES cells and resuspended HeLa cells were added at a 1:1 ratio 
in the presence of 50 µg/ml (in 100% ethanol) cyclohexamide (CHX) for 3 hours. The 
concentration of CHX was increased to 100 µg/ml for 30 minutes before media was removed 
and cells washed in sterile PBS. Coverslips were inverted onto a drop of prewarmed 50% PEG 
1000 for 2 minutes, then washed twice in sterile PBS to remove the PEG. Cell fusions were 
placed in heterokaryon growth media (complete ES cell media supplemented with 100 µg/ml 
CHX) for 2 hours before fixation as for Immunofluorescence. 
 
2.7 Mass Spectrometry 
 
Samples sent for Mass spectrometry analysis were prepared as in section 2.1.6. 
Subsequent to immunoprecipitation, 10 µl of T7-antibody coupled beads were washed twice 
in 1x TBS before submission to the IGMM in house mass spectrometry facility, which 
performed analysis and data processing. All mass spectrometry experiments were carried out 
using the using the Q-Exactive hybrid quadrupole Orbitrap mass spectrometer 
(ThermoFisher). Prior to injection into the machine, molecules were separated by nano liquid 
chromatography using the Dionex UPLC (UltiMate 3000 RSLCnano system, ThermoFisher).  
For peptide Mass Spectrometry experiments, Robot IPs were carried out prior to 




(Dynabeads) and the Kingfisher Duo (ThermoFisher Scientific) robot used to perform the IP. 
Protein complexes were washed in Lysis buffer (see 2.1.6), before elution and processing 
analogous to manually performed IPs.  
Raw data were analysed using MaxQuant software and protein annotations were 
obtained from the latest release of the UniProt database both by Jimi Wills of the IGMM in 
house mass spectrometry facility. Gene Ontology (GO) analysis was performed using online 




CRISPR targeting vector PCR 
primers 
Sequence 5’-3’ 
SRSF1 Exon 1 FWD GCGGGTACCATGTCGGGAGGTGGTGTGAT 
SRSF1 Exon 1 REV TACGGATCCTGTACGAGAGCGAGATCTGC 
SRSF1 3’UTR FWD CAGATGGGTTAATCTAGAGATGATTGGTGACACTTTTT 







SRSF2 NRS FWD AATGGATCCCCTCCGCCCGTGTCGAAGC 
SRSF2 NRS REV TCGTATGAATTCGGAAGAAACTGCTCCCTCTTC 
CRISPR modified targeting 
vector PCR primers 
Sequence 5’-3’ 
SRSF1-T7 linker FWD 
GATCCCCCGGCGCCGGCGCCATGGCATCGATGACAGGTGG
CCAACAGATGGGTTAAG 




















Site directed mutagenesis Sequence 5’-3’ 
mutPAM A SRSF1 FWD  CCCAAGCTTGGTACCATGTC 
mutPAM B1 SRSF1 REV TCTGCTTCTTCTTGGGGAGT 
mutPAM B2 SRSF1 REV CAGTTACTCCCCAAGAAGAA 
mutPAM C1 SRSF1 FWD ACTCCCCAAGAAGAAGCAGA 
mutPAM C2 SRSF1 FWD AGAAGAAGCAGAGGATCACC 
mutPAM D SRSF1 REV GTGTCACCAATCATCTCTAGATTA 
gRNAs Sequence 5’-3’ 
Cas9n A FWD CACCGGCTATGACGGGGAGAATAGCG 
Cas9n A REV AAACCGCTATTCTCCCCGTCATAGCC 
Cas9n B FWD CACCGGTACGGCTTCTGCTACGACTA 
Cas9n B REV AAACTAGTCGTAGCAGAAGCCGTACC 
Cas9 wt A FWD CACCGGGGCTCTCGTACATAAGATGAT 
Cas9 wt A REV AAACATCATCTTATGTACGAGAGCCCC 
Retargeting Clone 1 gRNAs Sequence 5’-3’ 
Cas9 wt A FWD CACCGGGGAGGGGATCCTGTACGAGAG 
Cas9 wt A REV AAACCTCTCGTACAGGATCCCCTCCCC 
SRSF1 knockin screen PCR 
primers 
Sequence 5’-3’ 
SRSF1 Exon 4 FWD TTGATGGGCCCAGAAGTCC 
SRSF1 3’UTR REV ATAGGGCCCTCTAGACAATTTCATCTGTGACAATAGC 
Mouse Microinjection gRNA 
PCR primers 
Sequence 5’-3’ 






Cas9 wt A REV AAAAGCACCGACTCGGTGCC 





























Mouse UBE sexing PCR Sequence 5’-3’ 
UBE1XA FWD  GGCAGCAGCCCATCATAATCCAGATC 
UBE1XB REV TGGTCTGGACCCAAACGCTGTCCACA 









FWD Index PCR primers for 
Miseq (I5) 
Sequence 5’-3’ 






S503 NRS t=1 
AATGATACGGCGACCACCGAGATCTACACTATCCTCTTCGTC
GGCAGCGTC 
S505 NRS t=2 
AATGATACGGCGACCACCGAGATCTACACGTAAGGAGTCG
TCGGCAGCGTC 
S506 NRS t=3 
AATGATACGGCGACCACCGAGATCTACACACTGCATATCGT
CGGCAGCGTC 
S507 NRS t=4 
AATGATACGGCGACCACCGAGATCTACACAAGGAGTATCG
TCGGCAGCGTC 
S508 NRS t=5 
AATGATACGGCGACCACCGAGATCTACACCTAAGCCTTCGT
CGGCAGCGTC 
S510 NRS t=6 
AATGATACGGCGACCACCGAGATCTACACCGTCTAATTCGT
CGGCAGCGTC 
S511 NRS t=7 
AATGATACGGCGACCACCGAGATCTACACTCTCTCCGTCGT
CGGCAGCGTC 
S502 WT t=0 
AATGATACGGCGACCACCGAGATCTACACCTCTCTATTCGTC
GGCAGCGTC 
S503 WT t=1 
AATGATACGGCGACCACCGAGATCTACACTATCCTCTTCGTC
GGCAGCGTC 
S505 WT t=2 
AATGATACGGCGACCACCGAGATCTACACGTAAGGAGTCG
TCGGCAGCGTC 
S506 WT t=3 
AATGATACGGCGACCACCGAGATCTACACACTGCATATCGT
CGGCAGCGTC 
S507 WT t=4 
AATGATACGGCGACCACCGAGATCTACACAAGGAGTATCG
TCGGCAGCGTC 
S508 WT t=5 
AATGATACGGCGACCACCGAGATCTACACCTAAGCCTTCGT
CGGCAGCGTC 
S510 WT t=6 
AATGATACGGCGACCACCGAGATCTACACCGTCTAATTCGT
CGGCAGCGTC 
S511 WT t=7 
AATGATACGGCGACCACCGAGATCTACACTCTCTCCGTCGT
CGGCAGCGTC 
REV Index PCR primers for 
Miseq 
Sequence 5’-3’ 






N701 NRS t=1 
CAAGCAGAAGACGGCATACGAGATTAAGGCGAGTCTCGTG
GGCTCGG 
N701 NRS t=2 
CAAGCAGAAGACGGCATACGAGATTAAGGCGAGTCTCGTG
GGCTCGG 
N701 NRS t=3 
CAAGCAGAAGACGGCATACGAGATTAAGGCGAGTCTCGTG
GGCTCGG 
N701 NRS t=4 
CAAGCAGAAGACGGCATACGAGATTAAGGCGAGTCTCGTG
GGCTCGG 
N701 NRS t=5 
CAAGCAGAAGACGGCATACGAGATTAAGGCGAGTCTCGTG
GGCTCGG 
N701 NRS t=6 
CAAGCAGAAGACGGCATACGAGATTAAGGCGAGTCTCGTG
GGCTCGG 
N701 NRS t=7 
CAAGCAGAAGACGGCATACGAGATTAAGGCGAGTCTCGTG
GGCTCGG 
N702 WT t=0 
CAAGCAGAAGACGGCATACGAGATCGTACTAGGTCTCGTG
GGCTCGG 
N702 WT t=1 
CAAGCAGAAGACGGCATACGAGATCGTACTAGGTCTCGTG
GGCTCGG 
N702 WT t=2 
CAAGCAGAAGACGGCATACGAGATCGTACTAGGTCTCGTG
GGCTCGG 
N702 WT t=3 
CAAGCAGAAGACGGCATACGAGATCGTACTAGGTCTCGTG
GGCTCGG 
N702 WT t=4 
CAAGCAGAAGACGGCATACGAGATCGTACTAGGTCTCGTG
GGCTCGG 
N702 WT t=5 
CAAGCAGAAGACGGCATACGAGATCGTACTAGGTCTCGTG
GGCTCGG 
N702 WT t=6 
CAAGCAGAAGACGGCATACGAGATCGTACTAGGTCTCGTG
GGCTCGG 






Primary Antibody Technical specifications Concentration 




T7 tag Mouse monoclonal, Novagen (69522) 1:10000, 
1:5000 
Tubulin  Mouse monoclonal, Sigma (T8328) 1:1000 
H3 Rabbit polyclonal, Abcam (1791) 1:50000 
XRN2 Rabbit polyclonal, Bethyl Labs (A301-103A)  1:1000 
HnRNPC Mouse monoclonal, Santa Cruz, (sc32308) 1:3000 
Staufen 1 Rabbit polyclonal, Proteintech (14225-1-AP) 1:500 
Ncbp1 Rabbit polyclonal, Bethyl Labs (A301-794A) 1:2000 
SafB Mouse monoclonal, ThermoFisher (RG2236804) 1:1000 
Secondary 
Antibody  
Technical specifications Concentration  
Anti-mouse BioRad 1:10000 
Anti-rabbit BioRad 1:10000 
Alexafluor (488 ) Invitrogen 1:10000 

















Investigation of cytoplasmic functions of SRSF1 

















3.1.1 CRISPR/Cas9 Gene Editing 
 
To accurately understand the genetic mechanisms responsible for a given phenotype, 
an ability to test the cellular system in a controlled manner is required. Genomic mutagenesis 
and manipulation has enabled this from the advent of molecular biology, for example using 
chemical mutagens. However, this approach was essentially random with very little control 
over the mutagen target site. Traditional homology directed gene targeting strategies have 
been widely used to enable the production of knockout/knockin models. Although, not only 
are these methods are highly costly, time consuming and characterised by poor efficiency, but 
the targeted genomic loci often retained exogenous sequence as result, for example loxP 
recombination sites (Sander & Joung, 2014). Such problems were partially solved on a 
molecular level through the development of TAL effector nucleases (TALENs) and Zinc 
finger nucleases (ZFNs), which provided a tool to direct nuclease activity to specific loci; 
albeit in a fairly inefficient manner (Wang & Qi, 2016).  
More recently, the development of the CRISPR/Cas9 gene editing tools have 
revolutionised both the editing field and molecular biology in general. In its endogenous 
function, CRISPR (clustered interspersed palindromic repeats)-Cas systems form the basis for 
an adaptable bacterial immune response against the invasion of foreign DNA (Figure 3.1). 
Fundamentally, all CRISPR/Cas systems consist of a site-specific RNA-directed DNA 
nuclease, although there are numerous types of CRISPR-Cas systems, that have evolved to 
serve diverse bacterial species. The first to be harnessed for gene editing applications and the 
most popular CRISPR/Cas system is a type-II system from Streptococcus pyogenes that 
utilises a Cas9 nuclease (Lewis & Ke, 2017).  
In type-II CRISPR systems, the RNA guide (gRNA) exists within a duplex formed of 
tracrRNA:crRNA that forms base pairs with a target DNA sequence (Doudna & Charpentier, 
2014). Once in contact with the target, the nuclease induces a double-stranded break (DSB) 
in the bound DNA. Importantly, for cleavage to occur the complex must recognise a short 
consensus region termed a Protospacer adjacent motif (PAM) site downstream of the base-
paired DNA sequence to facilitate recognition of a correct target. Crystal structures of Cas9 
in complex with its target DNA sequence have demonstrated that the PAM forms interactions 
with arginine residues in the C-terminal domain of Cas9. Mismatches in this site abolish 
cleavage as it is the necessary moiety for nuclease activity and DNA binding. Furthermore, 




gRNA binding (Doudna & Charpentier, 2014). For the S.pyogenes Cas9 nuclease, the PAM 
must have the consensus sequence -NGG, although there is some tolerance for the -NAG motif 
(Hsu et al., 2013). Given the correct binding conditions, the nuclease induces a double-
stranded break in the target DNA with highly predictable cleavage patterns due to the tight 
binding sequence constraints. More recently, spCas9 has been engineered to recognise 
alternate PAM sites thus facilitating targeting at non-NGG consensus regions (Komor et al., 
2016). 
The Cas9 activity can be easily manipulated through the use of a sequence-specific 
gRNA template to direct the Cas9 complex to any genomic locus of choice (Ran et al. 2013). 
These qualities have revolutionised gene editing and hundreds of different applications of the 




Figure 3.1: The S.Pyogenes CRISPR/Cas9 targeting system. (a) in the bacterial system, the 
crRNA is produced from the CRISPR-repeat array. A separate tracrRNA is required to bind 
each crRNA to facilitate Cas9 cleavage at the encoded sequence. (b) In the repurposed 
CRISPR editing system, the crRNA and the tracrRNA exist as a chimeric RNA that is 
incorporated into Cas9 to direct activity.  
 
In the repurposed CRISPR/Cas9 toolkit, the bacterial crRNA and tracRNA are fused 
into a single chimeric gRNA that can direct nuclease activity; which is highly advantageous 
from both a technical and design standpoint (Cong et al., 2013; Hsu et al., 2013; Ran, Hsu, 




perfect homology with the genomic target site. At the genomic locus, this site must be 
followed by the -NGG consensus PAM to facilitate cleavage by Cas9.  
On the generation of a single stranded nick or a double-stranded break the genomic 
locus is repaired by the cell’s DNA repair machineries. There are two mechanisms in which 
this could occur: non-homologous end joining (NHEJ) or homology directed repair (HDR). 
The route favoured is scenario-specific and can depend on many factors, but once committed 
to, is subject to tight regulation. For example, RAD51 is fundamental to repair pathway choice 
on generation of a DSB and tightly regulates HDR outcome (Ceccaldi et al., 2016). 
Interestingly, RAD51 recruitment following a DSB can be influenced by the heterochromatic 
environment in which the break occurs. In pericentromeric heterochromatin, RAD51 is 
recruited only after DNA replication has occurred, whereas in centromeric heterochromatin 
its recruitment occurs throughout the duration of the cell cycle (Tsouroula et al., 2016). This 
could influence gene editing studies as it implies that targeting efficiency may vary dependent 
on chromosomal location and epigenetic topography of the DNA at the target region.  
In general, the NHEJ pathway, can occur via numerous mechanisms during which 
DNA lesions are repaired in an error prone manner (Bothmer et al., 2017). It is a highly 
flexible process that can involve numerous factors which differ depending on the scenario of 
each DNA break. Furthermore, NHEJ is the predominant DNA repair mechanism when cells 
are not in S/G2 phase (Lieber, 2011). Usually, NHEJ is not the favoured outcome of a CRISPR 
targeting event as it can result in unwanted indels including premature termination codons, 
which may trigger mRNA degradation pathways such as NMD (Hendel et al., 2015). 
Furthermore, NHEJ can also target each allele differently resulting in heterozygous indels 
(Shalem et al., 2015). However, it can be useful when the objective is simply to ablate gene 
function.  
In contrast to NHEJ, the HDR pathway proceeds with high fidelity in well 
characterised mechanisms; the major being route being homology repair (HR). HR requires 
the presence of a long region of homologous sequence to repair the lesion, hence its prevalence 
over NHEJ during S/G2 due to chromatid proximity (Lieber, 2011; Ceccaldi et al., 2016). 
Indeed, cell synchronisation has been shown to increase HDR-mediated gene targeting in 
HEK293T cells (Lin et al., 2014). HDR can be harnessed for gene editing to create customised 
insertions or base changes by providing the cell with a repair template that has sequence 
homology to the targeted genomic locus. There are several ways to supply the exogenous 




transduction; although it is unclear which method may be the most universally efficient 
(Graham & Root, 2015).  
CRISPR/Cas9 targeting has been revolutionary in generating knockout models on 
both a gene specific and genome-wide level. Large libraries of gRNAs have been frequently 
used to implement genome-wide knockout screens. These have been particularly useful in 
contrast to shRNA library screening, since CRISPR approaches favour complete loss of 
function of a gene (Sander & Joung, 2014). This has been harnessed in diverse studies, 
particularly in cancer biology to identify novel drivers of carcinogenesis in numerous 
scenarios. The sequence-specific targeting ability of the CRISPR/Cas9 system has also been 
exploited to recruit other factors to the DNA, facilitated by catalytically dead Cas9 mutants 
(dCas9). These proteins do not possess nuclease activity but are still programmable with 
gRNA specificity. Most frequently, this has been used to modulate transcription whereby the 
dCas9 is fused to transcriptional activators/repressors that act on the target gene or 
surrounding sequence (Shalem et al., 2015). Recently, Cas9 has been engineered to reduce off 
target effects (Slaymaker et al., 2016).  
 
3.1.2 Physiological roles of cytoplasmic SRSF1 
 
The functions of SRSF1 in both canonical and alternative splicing have been 
extensively studied and are extremely well characterised. However, although SRSF1 is the 
prototype for shuttling SR proteins, the exact mechanisms and extent of cytoplasmic activity 
remain elusive in a physiological context.  
SRSF1 is known to participate in several cytoplasmic roles, including mRNA 
translation (see Chapter 1). Briefly, SRSF1 enhances the mRNA translation of a specific 
subset of target transcripts including those encoding RNA processing factors, mitotic and cell-
cycle associated factors. It does so through enhancing the phosphorylation of 4E-BP in an 
mTOR dependent manner, which causes the release of eIF4e to enable translation of its bound 
mRNA (Michlewski et al., 2008; Maslon et al., 2014). 
A particularly useful tool to study the cytoplasmic SRSF1 functions is the chimeric 
SRSF1-NRS protein, which contains the potent nuclear retention sequence (NRS) from 
SRSF2 and is actively retained in the nucleus, representing a non-shuttling SRSF1. Complete 
ablation of SRSF1 function results in cell death and early embryonic lethality in animal 
models, due to a loss of the essential nuclear roles of SRSF1 (Xu et al., 2005). The use of the 




permits SRSF1 ablation in the cytoplasm while preserving nuclear SRSF1. The latter is 
sufficient to preserve cellular viability in conditional SRSF1 knockout mouse embryonic 
fibroblasts (MEFs) (Lin et al., 2005; Xu et al., 2005). In a physiological setting, wild type 
SRSF1 strictly controls its own homeostasis via an unproductive splicing feedback loop (Sun 
et al., 2010). Forced overexpression of either SRSF1 or SRSF1-NRS may perturb this system 
and other roles of SRSF1, therefore its physiological relevance must be questioned.  
In addition to using overexpression systems, previous work on SRSF1 in the 
cytoplasm has been limited to mostly human cell lines. Considering that SRSF1 exhibits a 
differential expression pattern across tissue types (Zahler et al., 1993; Hanamura et al., 1998), 
there are distinct possibilities that this has consequences for SRSF1 function. To date, little is 
understood regarding the tissue-specific roles of SRSF1 function in the cytoplasm or their 
physiological relevance, both on a cellular level and for the whole organism.  
SRSF1 is essential for viability as demonstrated from both DT40 chicken cell and 
mouse models (Wang et al., 1996; Xu et al., 2005). However, there have been conditional 
SRSF1 knockout mouse models described that have differential effects. For instance, Cre-
induced ablation of SRSF1 during the onset of cardiogenesis is not lethal and mice are born 
as normal, although it was noted by the authors that this phenotype is representative only of a 




To facilitate an understanding of SRSF1 function in the cytoplasm and its 
physiological relevance, work described here aims to create an endogenous system of non-
shuttling SRSF1. To do this, CRISPR/Cas9 gene editing tools were designed to target the 
nuclear retention sequence (NRS) from the non-shuttling SR protein SRSF2 to the endogenous 
SRSF1 genomic locus. Mouse embryonic stem cells mESCs were targeted to generate cell 
lines that endogenously expressed either the T7-tagged SRSF1 or the nuclear retained version; 
the SRSF1-NRS-T7 fusion protein.  
In summary, the main aims are as follows: 
(1) To design and optimise a CRISPR/Cas9-based strategy to create an endogenous 
model of non-shuttling SRSF1 in mouse embryonic stem cells 
(2) To investigate the phenotypic and physiologically relevant consequences of non-






The main aim of the following work was to target the nuclear retention sequence 
(NRS) from SRSF2, followed by a T7 tag to the endogenous SRSF1 locus using the 
CRISPR/Cas9 gene editing tools. The T7 tag is a small epitope tag consisting of 11 amino 
acids, which has been successfully used with SRSF1 for diverse biochemical applications and 
does not perturb canonical SRSF1 function (Cáceres et al., 1997). Therefore, a T7 tag alone 
was targeted to mESCs to create an SRSF1-T7 knockin line. This acts as proof-of-concept for 
CRISPR targeting and efficiency of it at the SRSF1 genomic locus, but also serves as an 
invaluable tool to dissect SRSF1 function while maintaining endogenous levels of the protein. 
Complete SRSF1 knockout systems are inviable as they remove the essential, nuclear roles of 
SRSF1. The SRSF1-NRS-T7 knockin approach permits the study of the consequences of the 
absence of cytoplasmic SRSF1. Previous work conducted by others, suggest that the 
cytoplasmic functions of SRSF1 are not required for viability, at least in MEFs (Lin et al., 
2005). 
To establish the SRSF1 knockin models, mouse ES cells were targeted as proof-of-
concept prior to generation of the mouse model. Mouse ES cells are diploid with a stable 
karyotype compared to other cultured cell lines such as HeLa or HEK293T cells, making them 
suitable to generate physiological models of early development (approximately E3.5-E4.5). 
With addition of the correct growth factors, they can be maintained in culture in a pluripotent 
state and passaged indefinitely (Martello & Smith, 2014). Furthermore, mESCs harbour an 
open chromatin state, which may facilitate nuclease binding and increase chances of 
successful HDR on generation of DSBs (Chen, Rinsma, et al., 2016). In this chapter, the 
generation of SRSF1-NRS-T7 and SRSF1-T7 systems will be discussed in detail. 
 
3.3.1 CRISPR/Cas9 targeting strategy 
 
To generate the SRSF1-NRS-T7 and SRSF1-T7 cell lines, several rounds of CRISPR 
targeting were undertaken with various modifications at each stage to improve targeting 
efficiency. A summary of the workflow used to generate the corresponding clones is shown 
in Figure 3.3 and targeting attempts undertaken are shown in Table 3.1.  
The NRS-T7 or T7 insertions were targeted to the C-terminus of SRSF1, downstream 
of the final exon (exon 4) of the genomic sequence. Protein sequence between human and 
mouse is identical but the genomic regions are different, thus all targeting was designed 




translational readthrough into the inserted sequence, targeting constructs were designed to 
remove the canonical stop codon of the SRSF1 transcript on a successful integration event. 
This strategy should not hamper mRNA processing of the transcript as use of the SRSF1-NRS 
fusion construct has been previously documented to produce a functional protein (Cazalla et 
al., 2002).  
The NRS sequence is naturally present at the C-terminus of SRSF2, so the described 
targeting approach maintains a similar endogenous positioning of this domain. It is unknown 
whether, for example, proximity to an SR domain is required for its retention function. 
Furthermore, considering that the RRM domains of SRSF1 are important for RNA binding, 
particularly in splicing, it is prudent to minimalise any potential interference that the NRS may 
have on these roles. Positioning the NRS sterically away from such domains may fulfil this 
requirement; although once established, the cellular models should be analysed by RNA-seq 
to ensure this is the case and splicing is unaffected. Given that the molecular basis of TAP-
binding is mediated through the second RRM, it is unlikely that SRSF1-NRS-T7 affects 
mRNA export therefore, in the CRISPR model, mRNA export should be unaffected. 
 
3.3.2 CRISPR/Cas9 design 
 
In the initial targeting strategy, the CRISPR/Cas9 nickase system was used in mouse 
ES cells (E14s). The nickase system, utilises a Cas9 catalytic mutant (Cas9n) that contains a 
single point mutation in the RuvC1 domain of the nuclease. Specifically, the D10A Cas9n was 
used although there are other catalytically inactive mutants available (Sander & Joung, 2014). 
Cas9n is unable to induce a DSB but facilitates single-stranded nicking of the target DNA 
(Ran et al. 2013). This approach requires a pair of Cas9n enzymes to generate two single 
stranded nicks on opposing strands of the genomic DNA. It has been demonstrated that the 
D10A nickase can generate breaks that are repaired by HDR (Bothmer et al., 2017). The 
SRSF1 genomic locus was targeted through the action of a pair of single gRNAs designed to 
facilitate double nicking in close proximity to Exon 4 (Figure 3.2). All gRNAs used contained 
overhangs to facilitate Bbs1 directed restriction site cloning into the pX461 vector (Ran et al. 
2013), which also contains GFP to enable FACs sorting of transfected cells. Each guide 
sequence was designed to be 18-22 nucleotides in length with an additional guanine residue 
upstream top facilitate transcription by the U6 promoter in the plasmid.  
When this approach was initially designed, it was proposed that the Cas9 nickase has 
fewer off-target effects than its nuclease counterpart (Ran et al. 2013). Latterly, however, 




and it has been proposed that single paired nicks can result in a low frequency of HDR is some 
cell types (Komor et al., 2016).  Therefore, further targeting events, were directed by the Cas9 
nuclease, which utilises a single gRNA to generate a double stranded break. This is useful 
when the genomic sequence of interest is not amenable to Cas9 gRNA design or guide 
performance is poor for this region. Logically, this system should also increase the likelihood 
of a successful HDR-mediated targeting event as only a single cleavage by Cas9 is required 
(Komor et al., 2016).  
To implement the Cas9 nuclease approach the gRNA was cloned into the pX458 
targeting vector, which also contains GFP for downstream FACs sorting (Ran et al. 2013). 
The gRNA used in the nickase approach was predicted to be a highly robust sequence for 
targeting the desired region using the Zhang Lab gRNA design tool and had generated a 
knockin clone. Thus it was used again here with an additional G upstream as this has been 
shown to reduce off-target effects when using the nuclease approach (Cho et al., 2014). After 
CRISPR/Cas9 cleavage to generate a double-stranded DNA break, the cell repairs the locus 
through either through non-homologous end joining (NHEJ) or homology directed repair 
(HDR). Integration of an insert of choice following cleavage requires successful HDR as it 
ensures a high-fidelity repair and reduces indel formation via NHEJ. The repair template used 
for CRISPR targeting experiments must contain arms of homologous sequence to the locus 
targeted to facilitate HDR, in this case the C-terminal and 3’UTR regions of SRSF1 (Figure 
3.2). The length of the arms should be a minimum of 60bp, although this is proportional to the 
size of the insert; the longer the insert, the longer the homology arms for efficient insertion. 
This maximises the chance of the cell recognising the supplied repair template as self-DNA, 











3.3.2.1 Repair Template Design 
 
The repair templates used to target SRSF1 for initial CRISPR targeting experiments 
were double stranded DNA plasmids that contained large regions of homology with the 
genomic SRSF1 locus. To generate these, the SRSF1 gene was PCR amplified from mouse 
genomic DNA (primer sequences Table 2.1). Both intronic and 3’UTR sequence was included 
in this plasmid to maximise the length of the homology arms for targeting and to maintain 
proper post-transcriptional processing of the SRSF1 transcript if a larger proportion of the 
Figure 3.2: CRISPR/Cas9 strategy to target the SRSF1 genomic locus (a)(i) Initial approach 
undertaken using the Cas9 nickase and a pair to gRNAs. (ii) Optimised strategy using the 
Cas9 nuclease. Note the same sequence gRNA as in one of the nickase gRNAs was used 
here. (b) Repair template design (i) Initial targeting repair template as a dsDNA plasmid. 
Black dashed lines indicate the PCDNA3+ cloning vector sequence that contained the 
insert for targeting. The entire SRSF1 sequence including intros was used to create long 
arms of homology. (ii) Optimised ssODN design in latterly used targeting. Only a partial 
sequence of SRSF1 Exon 4 was included in shorter homology arms. Note the SRSF1-T7 
repair template contains a small peptide linker (P-G-A-G-A) as rationalised in the main 




vector was integrated. This is particularly important for SRSF1 so as not to perturb the 
autoregulatory feedback loop or the generation of alternatively spliced isoforms. The nuclear 
retention sequence from SRSF2 was also amplified from mouse genomic DNA. The T7 tag 
sequence is short and exogenous, thus annealed oligos were used for cloning in the targeting 
vector. Integration of PCR products into the PCDNA3+ plasmid was carried out using 
restriction site cloning or ligation independent cloning. The resultant plasmid contained 
SRSF1 followed by the NRS and the T7 epitope tag sequence or SRSF1 followed by the T7 
tag alone. The sequence fidelity of targeting vectors was confirmed by Sanger sequencing 
(data not shown), and expression confirmed using western blotting following transient 
transfection (Figure 3.4).  
 
3.3.2.2 Screening primer design  
 
Screening primers were designed to amplify the insertion and additional sequence 
outside the region targeted to ensure that targeting occurred at the correct genomic locus. The 
resultant amplicon contains a large proportion of 3’UTR sequence, as this region is 
ultraconserved and must be intact to maintain the autoregulatory feedback loop for the SRSF1 
transcript (Sun et al., 2010). It is crucial that SRSF1 homeostasis is not perturbed in targeted 
cells as improper expression can have aberrant consequences such as cellular transformation 
(Karni et al., 2007). Amplification of integration events using the primers designed are shown 
in Figure 3.3.  
 
3.3.3 CRISPR targeting and Optimisation in mESCs 
 
The first round of CRISPR targeting using the initial described strategy in mESCs 
resulted in the survival of few clones (32 and 28 for SRSF1-NRS-T7 and SRSF1-T7 
respectively). It is possible that this is due to poor transfection efficiency or extensive cell 
death after FACs sorting. To overcome this, an alternative flow cytometer was used which 
exerts less pressure on the cells during the sorting process.  
PCR-screening of clones obtained from the first round of targeting indicated that 
CRISPR targeting had occurred to generate what appeared to be both NRS-T7 and T7 
integration events. However, these represented false positive events, as after clonal expansion 
insertions were no longer present. It is likely that the double stranded repair template persisted 





Figure 3.3: Overview of workflow used for CRISPR targeting strategy in mESCs. 
Successfully transfected cells were selected for using FACs sorting for GFP+ cells 
(the Cas9 plasmid contains GFP). Clones were expanded from single cells over a 
maximum of three weeks, depending on growth rate, before genomic DNA was 





process. Furthermore, sequencing revealed that Cas9 cleaved the genomic DNA and the 
transfected repair template extensively to leave indels at the PAM site of the gRNA consensus 
region. To prevent this in future rounds of targeting, a single nucleotide of the PAM site in the 
targeting vector was mutated using site directed mutagenesis, which is sufficient to ablate 
Cas9 cleavage (Ran et al. 2013). The directed mutations do not cause a change in amino acid 
sequence and mutated targeting vectors were expressed in cells as previously described 
(Figure 3.4 (b)). 
Targeting was repeated using the modified repair templates and 96 clones for each 
SRSF1-NRS-T7 and SRSF1-T7 targeting were screened by PCR. Several of these were 
chosen for further investigation by western blotting (Figure 3.4 (c)). No positive clones were 
obtained for the SRSF1-NRS-T7 insertion. A single SRSF1-T7 clone was obtained (clone C3 
42), however, it was unusable as the epitope tag, though expressed, was not detected by the 
T7 antibody (data not shown). This problem was unforeseen as the epitope does not behave 
this way when fused to the N-terminus of SRSF1. It is possible that at the C-terminus, the 
tertiary structure of the SRSF1-T7 fusion protein results in masking of the epitope tag as it 
becomes buried within the protein. However a larger SRSF1 protein could be identified by the 
SRSF1 mAb96 (Figure 3.4 (c)) which recognises the N-terminal region of SRSF1 in a 
phosphorylation independent manner (Hanamura et al., 1998).  
To ensure detection of the T7 tag upon integration at the SRSF1 genomic locus, 
several new targeting constructs were designed that contained variants of the T7 epitope. 
Either a small peptide linker (P-G-A-G-A) or multiple T7 (x2 or x3) tags were added prior to 
the tag sequence (Figure 3.4(d)(i)). Inclusion of a proline residue in the peptide linker 
sequence was an attempt to create steric changes in the peptide chain to reveal the epitope 
from burial in SRSF1. As proof of principle, these were cloned into the PCDNA3+ vector and 





Figure 3.4: Optimisation of homology repair templates for CRISPR targeting. (a) 
Transient overexpression of initial repair templates generated. Western blotting with 
SRSF1 antibody to confirm expression in mESCs. Blotting with tubulin antibody is shown 
as a loading control (b) Western blotting to demonstrate expression of repair template 
subsequent to PAM-site optimisation in mESCs. Blotting with tubulin antibody is shown 
as a loading control (c) mESC clones generated with the genomic SRSF1-T7 insertion 
that is undetectable by the T7 antibody (blank blot for T7 antibody not shown). For 
example, clone C342 contains a homozygous SRSF1-T7 as a band larger than that of wt 
SRSF1 in the EV (empty vector) or gRNA only controls can be detected with the SRSF1 
antibody. Blotting with tubulin antibody is shown as a loading control (d)(i) Schematic 
outlining repair template design to ensure the T7 tag is detectable with the T7 antibody. 
(ii) Expression of optimised targeting vectors in HEK293T cells as detected by Western 




3.3.4 Generation of homozygous SRSF1-T7 mESC clones 
 
To improve targeting efficiency, single stranded DNA oligonucleotides (ssODNs) 
were designed for use as the repair templates for both SRSF1-T7 and SRSF1-NRS-T7 
targeting (Figure 3.2(b)(ii). These oligos contain the appropriate PAM site mutation. In 
addition, Cas9 nuclease was used to direct DNA breaks at the C-terminus of SRSF1. With this 
approach, it was possible to successfully generate several homozygous SRSF1-T7 knockin 









3.3.5 Generation of homozygous SRSF1-NRS-T7 mESC clones 
 
The optimised CRISPR targeting strategy was implemented to generate SRSF1-T7 
clones with good efficiency and relative ease. This demonstrates that the SRSF1 genomic 
locus is targetable at the given site in Exon 4. In a subsequent round of targeting, an increased 
number of clones were screened with the rationale that targeting efficiency and HDR-
mediated repair of NRS-T7 is much lower than for the tag alone. This may be feasible, 
considering the insertion is 90 bp larger in size.  
Using this approach, what appeared in genomic DNA screening as a single 
homozygote SRSF1-NRS-T7 clone was obtained (Figure 3.6). However, downstream analysis 
of the protein and sequence data revealed that this clone expressed an almost wild type SRSF1 
protein. This clone, referred hereafter as Clone 1, is the closest to a homozygous knockin in 
mESCs that could be generated in this work. It harbours an NRS-T7 insertion on both alleles, 
illustrating that targeting of the insert is possible. However, one of the alleles contains two 
single base pair deletions that create a frameshift mutation resulting in a premature termination 
codon that prevents expression of the SRSF1-NRS-T7 fusion protein from this allele (Figure 
3.6). Clone 1 expresses an intact SRSF1-NRS-T7 protein from a single allele, thus can be 
considered heterozygous for the insertion, which provides a useful tool to study SRSF1 
cytoplasmic function.  
Western blotting demonstrates that the truncated protein produced from allele 2 is not 
in stoichiometry with the reciprocal from allele 1. This is reproducible and is not an artefact 
of the blotting signal, but possibly due to reduced protein production from this allele. 
Concurrent with this, a late shift in open reading frame which disrupts the UTR sequence, 
such as that occurs from the indels in allele 1, has been shown to reduce protein production 
from the transcript (Arribere et al. 2016). Such translational readthrough, by bypassing the 
stop codon, can produce less protein but does not trigger non-stop decay as there is no 
connection with poly(A) sequence (Arribere et al., 2016). Alternatively, as a premature 
Figure 3.5: Screening of SRSF1-T7 knockin mESCs. (a) Outline of PCR screening strategy in 
the context of wt SRSF1 or SRSF1-T7 knockin cells. The approximate size of the amplicon is 
indicated in bp. (b) Example of gDNA screening of two knockin clones (11 and 15) alongside 
wt mESCs for comparison using the outlined PCR screen. (c) Western blotting to 
demonstrate that SRSF1-T7 knockin clone express the correctly sized protein that can be 
detected by SRSF1 and T7 antibodies. Homozygous and heterozygous clones (e.g. 1 and 11 
respectively were generated. (d) Example of correct Sanger sequencing verification for 




termination codon is generated, the mRNA transcript produced from allele 1 may be subject Figure 3.6: Screening of SRSF1-NRS-T7 knockin mESCs. (a) Outline of PCR screening 
strategy in the context of wt SRSF1 or SRSF1-NRS-T7 knockin cells. The approximate size 
of the amplicon is indicated in bp. (b) Example of gDNA screening of Clone 1 knockin clone 
alongside wt mESCs for comparison using the outlined PCR screen. (c) BamHI diagnostic 
digest of Clone 1 cells (producing products of 167 bp and 682 bp) or wt cells (do not contain 
BamHI site so are undigested). . (d) Western blotting to demonstrate that SRSF1-NRS-T7 
knockin clone is not homozygous as indicated by gDNA screening, but expresses wt SRSF1 
protein as detected by the SRSF1 antibody. (e) Sanger sequencing verification for knockin 






to degradation by NMD causing a reduction in protein expression (Hug et al., 2015). Depletion 
of the core NMD factor UPF1 in these cells may help delineate this in the future. 
 
3.3.6 Frequency of homozygous SRSF1-NRS-T7 alleles decline over 
time 
 
Targeting attempts in multiple cell types failed to generate SRSF1-NRS-T7 
homozygous knockin lines, with the mESC Clone 1 cells being the closest achieved (Table 
3.1). Considering this, one could conclude that there is significant negative selection against 
the generation of the desired knockin. If the NRS-T7 insertion is lethal in undifferentiated 
cells those that are successfully targeted initially, may die during the period of clonal 
expansion, (approximately 16-21 days). It is an attractive possibility that the cytoplasmic roles 
of SRSF1 are required in these cells for viability, perhaps for the translational regulation of 
essential mESC-specific mRNA transcripts. However, it is also feasible that the observed 












0/128 1/124 Nickase T7 tag not 
recognised by 
T7 antibody 
Insert peptide linker 
upstream of T7-tag. 
Switch to ssODN repair 
template. 
1/441 10/126 Nuclease Unsuccessful 
for SRSF1-NRS-
T7 




To investigate the possibility that targeted mESCs cells die during clonal expansion, 
SRSF1-NRS-T7 Clone 1 cells were retargeted in an attempt to repair the indels on the 
compromised SRSF1-NRS-T7 allele. Remarkably, the 5’ proximal single bp deletion in allele 
1 generates a novel Cas9 PAM recognition site that is not present in the second allele. Since 
the –NGG PAM consensus is the only sequence absolutely required for Cas9 cleavage, this 
was harnessed to permit design of a new gRNA sequence to specifically target the 
Table 3.1: Overall summary of CRISPR targeting in mESCs. Numbers indicated are the total 
achieved encompassing all stages of the optimisation processes except changing from Cas9 




compromised allele 1 but not the intact SRSF1-NRS-T7 allele 2. In addition, a new repair 
ssODN was used which contains an additional base pair change that destroys the BamHI site 
to aid the detection of repair in the population during downstream analyses. To monitor the 
frequency of repaired allele 1 in the population, genomic DNA was harvested throughout the 
period of clonal expansion and the region of interest subject to high throughput sequencing 

















All data analysis for this experiment was carried out by Martijn Kelder of Andrew 
Wood’s Lab at the IGMM. The allele frequency in the population was calculated by extracting 
the number of reads which contain the entire repaired sequence, including the destruction of 
the restriction site. The first time point, prior to transfection of the CRISPR machinery (t=0) 
represents the base line frequency of the alleles in the population, which is approximately 1:1. 
As expected, the proportion of reads generated from allele 2 is constant over the time course, 
as it is not targeted by Cas9 in this experiment (Figure 3.8 (a)). There are slight fluctuations 
over time; however, this is most likely due to PCR or pipetting-based error. In contrast, upon 
CRISPR targeting (t=1), there is a drastic reduction in the frequency of allele 1 reads in the 
population, indicating that allele-specific targeting using CRISPR-Cas9 was successful and 
led to repair. In theory, if targeting leads to repair of the locus, a reduction in allele 1 frequency 
should be accompanied by an increase frequency of reads containing the restriction site 
change; indicative of successful homology directed repair. Initially, this is the case and repair 
occurs at a frequency of around 1% but decreases over the time course to barely detectable 
levels in the population (Figure 3.8 (b)). Therefore, homozygous SRSF1-NRS-T7 cells are 
generated but most likely die during clonal expansion due to negative selection pressure, 
substantiating the data obtained by single clone analysis. 
Figure 3.7: Retargeting Clone 1 SRSF1-NRS-T7 cells and the timeline used. (a) Clone 1 cells 
were retargeted using Cas9 nuclease and a gRNA specific for allele 1 targeting which will not 
cleave allele 2. The novel PAM site generated by the indels in allele 1 is indicated. A new 
ssODN repair template was used to mutate, and so remove, the existing BamHI site to 
remove to detect successful retargeting events. (b) Timeline of workflow used for 
retargeting. Genomic DNA was harvested from cells over the indicated time course. 






Figure 3.8: Repair of SRSF1-NRS-T7 is possible but declines rapidly over time (a) Over 
time the frequency of allele 1 decrease to a steady level of expression within the 
population. (b) Homology directed repair inferred by reads containing the repaired 
sequence. This peaks after targeting but declines to baseline frequency. (c) NHEJ events 
occur with high frequency after targeting and are maintained in the population. Reads 
were normalised to allele 2 in this instance which remains untargeted in the strategy 
used. Data were generated (prior to plotting) by Martijn Kelder of Andrew Wood’s Lab at 




It is possible to infer the frequency of NHEJ events in the population of cells after 
targeting, as represented by reads that do not match unrepaired or repaired allele 1 sequence 
when normalised to allele 2 (figure 3.8). Using this approach, the pattern of NHEJ events is 
the converse for HDR and rapidly increases to a sustained plateau. These cells most likely 
contain additional compensatory mutations to preserve expression of a wild type SRSF1 
protein.  
In addition to high throughput sequencing, the same pool of Clone 1 cells were subject 
to clonal growth and screening analogous to the approach used to generate Clone 1 cells. The 
rationale being that if targeting is extremely inefficient, screening more clones may eventually 
generate SRSF1-NRS-T7 homozygotes. From screening an additional 430 manually picked 
clones, preliminary analysis of the sequenced PCR amplicon indicates that a single clone was 
successfully repaired and persisted during the period of clonal expansion. This demonstrates 
that the SRSF-NRS-T7 homozygous insertion is viable in mESCs. 
Overall, these data indicate that de novo generation of SRSF1-NRS-T7 would only be 
observed if over >1000 clones were initially screened, as on retargeting cells already contain 
one copy of the SRSF1-NRS-T7 knockin. Interestingly, there also are several clones that are 
partially repaired or those that are completely repaired over the region tested, but contain 
additional mutations that result in a new premature termination codon. In summary, there is a 
high degree of selection against generation of homozygous SRSF1-NRS-T7 mESCs using the 
described CRISPR/Cas9 targeting approach.  
 
3.3.7 Targeting differentiated cell lines to generate SRSF1-NRS-T7 
knockin clones  
 
Data from the Clone 1 retargeting experiment and failure to target hundreds of 
manually screened clones demonstrate that there is strong negative selection towards 
generation of SRSF1-NRS-T7 in mESCs. The SRSF1-NRS-T7 mutation may be unfavourable 
when cells are maintained in an enforced pluripotent state. To determine if this is the case, the 
SRSF1-NRS-T7 knockin was targeted to two cell types that represent different stages during 
differentiation.  
Firstly, mouse neural stem cells (mNSCs) were targeted using the optimised CRISPR 
design strategy to generate either SRSF1-T7 or SRSF1-NRS-T7 cells. These are further 
differentiated in comparison to embryonic stem cells as they are committed to the neural 




in culture (Conti et al., 2005). Furthermore, they have been shown to be amenable to effective 
CRISPR/Cas9 targeting (Bressan et al., 2017). In comparison to mESCs, neuronal stem cells 
exhibit a longer cell cycle to mESCs with an increased G1 phase (Pauklin & Vallier, 2013). 
Therefore, if targeting problems in mESCs are due to cell cycle problems this may circumvent 
that. For example, ablation of SRSF1 function in translation may exhibit different 
consequences for cell cycle regulation on transition from the pluripotent state. This is feasible 
considering that SRSF1 is capable of specifically regulating mRNAs involved in cell cycle 
and mitotic processes (Maslon et al., 2014). 
Following a series of experiments, successful targeting of the NSCs with the SRSF1-
NRS-T7 insertion could not be achieved. This is likely due to several technical problems, 
including those with FACs-based sorting methods which prevented screening of large 
numbers of clones; the few colonies that were screened did not contain either the NRS-T7 or 
T7 insertion (data not shown).  
Secondly, mouse NIH3T3 cells were similarly targeted with each insertion. NIH3T3 
cells are fibroblasts and thus mimic most aspects of a fully differentiated cell type, although 
they are immortalised by spontaneous transformation on SV40 infection. These did not 
represent an ideal candidate for the creation of CRISPR/Cas9 knockins as they can have a 
variable karyotype. However, in theory, if the roles of cytoplasmic SRSF1 were required for 
the maintenance of stemness, then differentiated systems such as 3T3 cells should be amenable 
to targeting with the NRS-T7 insertion. Again, targeting data were inconclusive as numerous 
technical issues prevented large numbers of clones from being screened, such as poor survival 
rates on single-cell clonal expansion; but no knockins were obtained (data not shown).  
 
3.3.8 Cellular localisation of knockin clones 
 
SRSF1 is the prototype for shuttling SR proteins and moves continually between the 
nucleus and the cytoplasm at a steady state. The T7-tag at the N-terminus does not perturb this 
movement as demonstrated by heterokaryon assay when the T7-SRSF1 fusion protein is 
overexpressed (Cáceres et al., 1998). To determine the cellular location of SRSF1 in the 
mESC lines generated, immunofluorescence was performed against the endogenous T7 tag 
(Figure 3.9). Both the SRSF1-T7 and the SRSF1-NRS-T7 (Clone 1) cells were used for 
comparison. Although Clone 1 cells do express wt (shuttling) SRSF1, this protein is not 






Figure 3.9: Immunofluorescence of endogenously tagged mESCs using the T7 antibody. 
SRSF1-T7 and SRSF1-NRS-T7 (clone 1) cells express endogenous SRSF1 that is nuclear at a 
steady state as detected by the T7 antibody (1:5000). Wt mESCs are given as a control for 
background detection of the T7 antibody. Nuclei are stained with DAPI.  Scale bar 
represents 20uM. 
 
In mESCs, tagged SRSF1 appears nuclear for both the shuttling and the non-shuttling 
SRSF1 (Figure 3.9). SRSF1-NRS-T7 is strictly nuclear and mimics the nuclear staining of the 




abberrantly affected by the NRS fusion, similar to that previously described (Cazalla et al., 
2002). Given that wild type SRSF1 function is predominantly in the nucleus, and shuttling is 
a transient dynamic property it is unsurprising that SRSF1-T7 protein is not detected in the 
cytoplasm using this assay. Furthermore, previous immunoflourescence data for endogenous 
SRSF1 have documented similar findings (Cáceres et al., 1998). Treatment with inhibitors of 
transcription, such as actinomycin D, causes shuttling SR proteins including SRSF1 to 
accumulate in the cytoplasm (Cáceres et al., 1998). This approach could have been undertaken 
here, however it does not confirm shuttling propensity. To truly determine if the tagged 
proteins are capable of nucleocytoplasmic shuttling, it would be necessary to perform 
interspecies heterokaryon assays. This is the gold standard assay for the detection of shuttling 
proteins (Piñol-Roma & Dreyfuss, 1992; Gama-Carvalho & Carmo-Fonseca, 2006). 
For heterokaryon assays, tagged mESCs were fused with HeLa cells in the presence 
of cyclohexamide to inhibit mRNA translation, and immunoflourescence performed against 
the T7 tag. In this assay, if T7-tagged SRSF1 protein from in the knockin cells is capable of 
nucleocytoplasmic shuttling, it should be detected in the HeLa cells after cell fusion. This 
demonstrates shuttling as the HeLa cells do not express this protein so it must have migrated 
from the mouse cells if detected by the T7-antibody. In contrast if the protein cannot shuttle, 
such as in the SRSF1-NRS-T7 fusion protein, no signal should be observed from the T7-
antibody staining in the fused HeLa cells.  
The attempts at heterokaryon assays performed were inconclusive, as no shuttling of 
SRSF1-T7 was observed in the cells tested (data not shown). It is possible that this was due 
to inefficient cell fusion or suboptimal cell density ratio between the cell types. Moreover, due 
to the colony-type growth of mESCs, there are additional problems for imaging as these cells 
appear three dimensional whereas the HeLa are flat on the slide. Therefore, even if shuttling 
has occurred between species, it is unlikely to be observed using the methods here. In the 
future, the use of a high resolution confocal microscope would help to delineate this and scan 
through the focal plane of the mESCs to the HeLa cells.  
 
3.3.9 Cell cycle analysis of knockin clones 
 
SRSF1 presence in the cytoplasm is required for the translational regulation of target 
mRNAs involved in cell cycle related processes such as the core kinetochore complex protein 
NDC80 (Maslon et al., 2014). Consistent with this, siRNA mediated knock-down of SRSF1 




be rescued by expression of shuttling SRSF1 and not the nuclear retained counterpart (Maslon 
et al., 2014).  
The SRSF1 Clone 1 mESCs generated express a single copy of the SRSF1-NRS-T7 
fusion protein. Although these cells exhibit a growth pattern analogous to the SRSF1-T7 cells 
with no gross changes, it is possible that there are subtle mitotic changes or changes in DNA 
content in the population. Given the previous data from human cells, and the fact that ESCs 
display a markedly different cell cycle and translational regulation thereof, this is an 
interesting possibility in relation to SRSF1 (Maslon et al., 2014). To determine if this is the 
case, SRSF1-T7 and SRSF1-NRS-T7 cells were subject to treatment with propidium iodide 
prior to analysis by FACS to analyse the cell cycle and DNA content  (Dominguez et al., 
2016).  
Consistent with normal growth patterns observed for the knockin cell lines, there is 
little difference in DNA content between clonal lines in comparison to untagged mESCs. 
Furthermore, there are similar proportions of the population engaged at each stage of the cell 
cycle, namely G1, S and G2/M phases. This suggests that the T7 tag does not perturb SRSF1 
roles in cell division and these lines have normal DNA content, unaltered by CRISPR 
targeting. It is likely that for the SRSF1-NRS-T7 cells, expression of a single copy of the wild 
type, shuttling SRSF1 protein is sufficient to prevent cells from displaying aberrant mitotic 
phenotypes observed on SRSF1 knockdown. Indeed, expression of a single copy of SRSF1 in 
conditional knockout MEFs is sufficient to rescue cell death (Lin et al., 2005). In the future, 
it would be interesting to knockdown the residual copy of shuttling SRSF1 in the Clone 1 cells 
and repeat PI staining and FACs analysis. Design of an siRNA specific for allele could permit 







SRSF1-NRS-T7 (Clone 1) 
Figure 3.10: FACs analysis of SRSF1-T7 and SRSF1-NRS-T7 clone 1 mESCs. Cells were 
treated with propidium iodide prior to analysis. There are no gross changes in cell cycle 
observed, between SRSF1-T7 and SRSF1-NRS-T7 (clone 1 cells). Wt E14 cells are shown for 
comparison. Cell count is given on the Y-axis of each graph. P2, P3 and P4 represent cells 




3.4 Conclusions and discussion  
 
SRSF1 is a highly dynamic shuttling SR protein that has numerous roles in both the 
nucleus and the cytoplasm. The nuclear functions of SRSF1, particularly in splicing, have 
been extremely well characterised; though in comparison little is understood regarding 
cytoplasmic function. SRSF1 is involved in the translational regulation of a specific subset of 
mRNA transcripts via an mTOR-dependent mechanism (Michlewski et al., 2008; Maslon et 
al., 2014).  
Here, work aimed to create an endogenous model system in mouse embryonic stem 
cells to investigate the cytoplasmic roles of SRSF1, particularly those that have implications 
for mRNA translation. CRISPR/Cas9 was successfully designed to target the nuclear retention 
sequence from SRSF2 and a T7 epitope tag to the C-terminus of the SRSF1 at the endogenous 
genomic locus. In this system, the SRSF1-NRS-T7 fusion protein is restricted to the nucleus 
and cannot function in the cytoplasm. The SRSF1-T7 reciprocal cell line was designed as a 
control for targeting and to create a tool for downstream analysis. 
Both homozygous and heterozygous SRSF1-T7 mESC lines were generated with 
relative ease once the optimal targeting protocol was in place (Figure 3.5). These cells exhibit 
a nuclear staining pattern by immunofluorescence analogous to wt SRSF1 however whether 
the tagged SRSF1 in these cells is capable of shuttling remains to be determined as 
heterokaryon assays were inconclusive due to technical problems.  
In stark contrast, the generation of intact SRSF1-NRS-T7 homozygous cells was not 
achieved due to high rates of negative selection, as demonstrated by a decline in targeting 
frequency over time in the population (Figure 3.7). There are several potential reasons why 
this may be the case; either technical or biological.  
Technically, the efficiency of generating a successful knockin may be extremely low 
using the targeting strategy implemented. Although the SRSF1-T7 knockins were generated 
with ease using the analogous strategy, in this context the inserted sequence is significantly 
smaller. Considering that the HDR template was delivered to cells as a ssODN of less than 
300bp, by nature the homology arms are proportionally larger than in the SRSF1-NRS-T7 
targeting design. This alone could provide inherent targeting advantages for generating 
SRSF1-T7 as there is a longer matched genomic sequence that is recognised for HDR to occur. 
In addition, when the targeting strategy was designed, CRISPR-targeting was at the pioneer 
stage as a gene editing tool. Therefore, the design of the strategy is similar to the first CRISPR 




have systematically demonstrated ways to manipulate this protocol to enhance the success of 
required targeting. For example, using cell synchronisation or other methods to increase HDR 
frequency may have helped in improving the efficiency of generating a successful knockin 
(Lin et al., 2014). Changing the guide RNA used or the method for delivery of the CRISPR 
reagent may also have helped (Graham & Root, 2015). Also numerous additional 
CRISPR/Cas systems have been repurposed for mutagenesis, which have different consensus 
sequences for cleavage and thus may have been more suitable for targeting the SRSF1 locus 
as they do not require the -NGG PAM consensus, but have alternative cleavage requirements 
(Lewis & Ke, 2017; Mitsunobu et al., 2017).  
Mouse embryonic stems cells were used in the targeting approach described which 
exhibit a markedly different cell cycle profile than differentiated cells. On average, the cell 
cycle of undifferentiated cells is comparatively fast to differentiated cells, with mESCs 
undergoing mitosis every 11-16 hours, mainly due to an extremely short G1 phase of just 1.5 
hours (Burdon et al., 2002; Orford & Scadden, 2008). mESCs are grown in an artificial 
scenario due to the presence of Leukaemia inhibitory factor (LIF) in growth media. It is 
possible that this contributes to the negative selection observed in the generation of 
homozygous SRSF-NRST7 knockin mESCs.  
LIF is a signalling molecule that acts to suppress differentiation through activation of 
the transcription factor Stat3 and other complex signalling pathways including ERK and PI3K 
(Martello & Smith, 2014). This facilitates growth of embryonic stem cells in culture in the 
absence of feeder cells. Continuous stimulation of these pathways results in a scenario that is 
not wholly representative of those in vivo. It has been shown that LIF has an effect on mTOR 
activity although there are conflicting reports from mouse and human systems (Easley et al., 
2010; Cherepkova et al., 2016) . Considering that SRSF1 acts in translation via this pathway 
and that maintenance of stemness requires mTOR signalling could explain why these cells 
could struggle to tolerate a lack of SRSF1. Perhaps maintenance in LIF pushes the system too 
far in terms of lack of translational regulation of a particular SRSF1 target mRNA meaning 
that only very few cells in a population could tolerate lack of cytoplasmic SRSF1. 
Furthermore, the clones seen to be repaired to the homozygous SRSF1-NRS-T7 genotype 
were not subject to downstream analysis. It is possible that these cells contain auxiliary 
genomic aberrations that bypass such strict requirements for SRSF1 cytoplasmic function. 
Indeed, in the described experiment, cells had undergone two rounds of CRISPR-targeting 





Biologically, there are numerous reasons why the generation of homozygous SRSF1-
NRS-T7 knockins could be subject to intense negative selection. It is possible that SRSF1 is 
required for the translational regulation of pluripotency transcription factors. Other mRNA 
binding proteins and splicing factors such as PTBP1 have been shown to be involved in the 
alternative splicing to translation-control axis. For example, through the control of 
transcription factor YY2. Furthermore, 4E-BP proteins are required for maintenance of a 
pluripotent state and removal of their exerted regulation causes differentiation (Tahmasebi et 
al., 2016). Considering that SRSF1 is known to act in translation in a mechanism involving 
these proteins it is possible that SRSF1 may play a role in this, albeit of specific factors. 
Perhaps if cells lose such regulation on generation of homozygous SRF1NRS-T7 that cannot 
act in translation, they cannot be maintained by LIF in a pluripotent state. The Nat1 protein is 
able to control mESC differentiation through translational regulation (Sugiyama et al., 2016) 
so it is feasible that an analogous control mechanism might in play for shuttling SRSF1. In 
light of this, it would be interesting to investigate the differentiation potential of any repaired 




























Investigating the mechanisms of nuclear retention of 
















The nuclear roles of SR proteins in constitutive and alternative splicing are well 
understood. In this capacity, they have been shown to interact with both core and auxiliary 
splicing factors in a dynamic manner, as was described for the prototype SR protein SRSF1 
(Akerman et al. 2015). Many such interactions of SRSF1 are not reliant on RNA thus direct 
protein interactions of SRSF1 have a crucial role in its function. SRSF1 also interacts with 
components of other RNA processing complexes such as the exon junction complex (EJC) 
within which it physically interacts with the core helicase EIF4AIII (Saulière et al., 2012).  
However, a subset of SR proteins is capable of nucleocytoplasmic shuttling; also 
exemplified by SRSF1. In the cytoplasm, SRSF1 can act in translation to enhance the 
translation of a subset of mRNA targets in an mTOR-dependent mechanism. SRSF1 can 
interact directly with the mTOR kinase as well as polysomes and PP2A (Michlewski et al., 
2008). However, in comparison to the nuclear roles of SRSF1, there is still much to be 
understood regarding the role of SRSF1 in the cytoplasm, particularly regarding its protein 
interactors.  
Much of the existing functional SRSF1 interactome data are reliant on overexpression 
systems. SR proteins, including SRSF1 are capable of autoregulation through unproductive 
splicing, suggesting that the tuning of their expression level is vital for cellular homeostasis 
(Lareau et al., 2007; Sun et al., 2010). When SRSF1 is overexpressed, it is possible that some 
of the identified interactions are artificial, therefore overexpression datasets may not 
accurately represent biologically relevant targets. Furthermore, there is a lack of data for 
SRSF1 function in varying tissue-types or undifferentiated cell systems. 
 
4.1.2 Mechanisms of nuclear retention of the SRSF2 NRS 
 
 SRSF2 is a non-shuttling protein that contains a potent nuclear retention sequence 
(NRS) at the extreme C-terminus of its RS domain. Fusion of this sequence to shuttling SR 
proteins, such as SRSF1, causes their constitutive retention in the nucleus. This sequence has 
been extensively biochemically characterised by Cazalla et al (2002), however, the direct 
interacting partners of this sequence and how it exerts its retention capacity are unknown. It 
is possible that this sequence enables SRSF2 to specifically bind to certain interaction 







To identify the interactome of SRSF1 in the nucleus and the cytoplasm and uncover 
the mechanism of nuclear retention for the NRS from SRSF2, mass spectrometry was carried 
out using various approaches. Firstly, three epitope tagged constructs, T7-SRSF1, T7-SRSF1-
NRS and T7-SRSF2 were overexpressed in HeLa cells. In this context, SRSF1-NRS and 
SRSF2 are strictly nuclear, and only SRSF1 should be present in the cytoplasm. To determine 
the relevant binding partners of these, immunoprecipitation was performed against the T7 tag 
on each construct and binding partners subject to mass spectrometry. The resulting datasets 
were subsequently overlapped to infer both the compartment-specific SRSF1 interactome and 
factors which uniquely bind the NRS sequence. To further delineate specific binding partners 
of the latter, the NRS peptide sequence alone was also used for IP-MS analysis. Finally, to 
identify the SRSF1 binding partners in mouse embryonic stem cells, IP-MS was performed 
on cells in which SRSF1 contained an endogenous T7 tag.  
In summary, the main aims of the following work are: 
(1) To characterise the nuclear and cytoplasmic binding partners of SRSF1 
(2) To determine the interactome of the NRS from SRSF2 




4.3.1 IP-MS to investigate the binding partners of SRSF1, SRSF1-NRS 
and SRSF2  
 
4.3.1.1 Workflow and data processing 
 
In the first IP-MS approach, T7-tagged constructs were overexpressed in HeLa cells 
and immunoprecipitations carried out against the T7 tag using T7 antibody coupled beads 
(Figure 4.1). RNase was not used in these experiments as little difference in total protein 
obtained was observed by Coomassie staining on RNase treatment (Figure 4.1(c)). Therefore, 
it is possible that any protein interactions observed in downstream analysis are mediated by 
RNA. Beads were washed stringently before elution and samples subjected to mass 
spectrometry to determine the bound proteins for each bait. Each IP was performed in 
biological triplicate and run on the mass spectrometer in technical duplicate. The empty vector 
(EV) control was used to determine non-specific binding partners of the T7 tag, which aids 




to facilitate interaction analysis in both cellular compartments. In theory, only the SRSF1 
dataset should be enriched for cytoplasmic binding partners as the SRSF1-NRS and SRSF2 
should not shuttle into the cytoplasm. However, accuracy of compartment annotation should 
be treated with caution especially since, it is possible that numerous proteins exist in both the 
nucleus and the cytoplasm. All mass spectrometry experiments were carried out by the in 
house IGMM facility. Raw data counts were analysed using MaxQuant by Jimi Wills from 
the facility. 
The total number of interactions observed for each T7-tagged construct is extremely 
large (>700 each, data not shown), with a significant amount of binding in the EV control, 
suggesting that the T7 IP contains a certain degree of non-specific interactions. To dissect the 
bona fide interaction partners of the bait proteins, harsh thresholds were applied to the dataset 
for downstream analysis. Firstly, a student’s t-test was used to determine the statistical 
significance of each interaction. Using this approach, the data were highly reproducible 
between both biological and technical replicates and a p-value threshold of <0.01 was applied 
to the data. Interactions that did not meet these requirements were discounted from the 
downstream analysis as were any duplicated gene names in the list. Secondly, the fold 
enrichment over the EV control was calculated and the data filtered at both 10-fold and 100-
fold enrichment. Fold enrichment in this calculation, refers to ratio over the EV control of the 
average LFQ (label-free quantification) intensity value for each interaction as determined 
using the Max Quant analysis software by the mass spectrometry facility. The algorithm used 
to determine the LFQ value by the Max Quant software is based on the extracted ion counts 
of identified peptides rather than MS/MS spectral counts as in other methods. The LFQ 
intensity value directly reflects the peptide intensities determined. This makes it ideal for use 
for quantification and sample comparison in studies such as these which do not rely on 
metabolic labelling (Cox et al., 2014).  
To put biological context to interactome datasets, particularly when large, Gene 
Ontology (GO) analysis can be used to group gene sets into classified functional groups. A 
GO term annotation can contain any number of genes and a range of analogous functions. To 
determine the GO terms associated with the significantly enriched interacting partners for each 
bait, the PANTHER database (Gene Ontology Consortium) was used as it contains current 
GO annotations. Each GO analysis was performed using default parameters for the biological 






Figure 4.1 The Interactome of shuttling and non-shuttling SR proteins using IP-MS. (a) 
Schematic of T7-tagged overexpression plasmid constructs used as bait for the T7 IP. (b) 
Overexpression of constructs depicted in (a) in HeLa cells. Note the blot for the EV 
construct is not shown as any protein produced is not detectable in this assay (c) RNase 
optimisation of IP protocol. Samples sent for MS analysis without RNAse treatment. 
Coomassie stained gel shown is representative of replicas used (d) Total number of hits 
identified as significantly enriched (>100 fold increase), over the EV control for each IP. 
p-value <0.01. (e) Overlap of interactions between SRSF1, SRSF2 and SRSF1-NRS datasets. 




4.3.1.2 Overexpressed SR proteins have large but highly similar 
interactomes 
 
The significantly interacting partners for each T7-IP either 10-fold or 100-fold 
enriched over the EV control with a p-value of less than 0.01 are shown in Figure 4.1). There 
are several hundred significantly interacting partners at each fold cut-off, with approximately 
100 of these being lost between the 10-fold and 100-fold thresholds. The SRSF1-NRS fusion 
protein has the largest number of binding factors, and, naturally, displays a high degree of 
overlap with the T7-SRSF1 and T7-SRSF2 datasets. However, it also has several more 
exclusive interacting partners, 50 at 100-fold cut-off, than the other two tagged proteins (Table 
4.1).  
There are 361 common interactors of T7-SRSF1, T7-SRSF1-NRS and T7-SRSF2 
(Figure 4.1 (e)). Exclusive interactions at the decided statistical thresholds are minimal, 
suggesting that the core interactomes of these three proteins are highly similar. In general, the 
datasets are reflective of the known functions of SR proteins in the nucleus. Indeed, many of 
the shared interacting proteins corroborate this as there is a large enrichment for pre-mRNA 
splicing and RNA processing proteins in the data. For example, other SR proteins (SRSF-3, -
4, -5, -6, -7 and -9), hnRNP proteins and alternative splicing factors such as TRA2A and 
TRA2B. Core components of the spliceosome are also highly enriched in all three datasets 
such as U2AF35/65, the U4/U6 proteins Prp3 and Prp4 and the U1 snRNP factors SNRPA 
and SNRPC. Interestingly, numerous members of the Exosome complex are also found in all 
three datasets. The highest enriched in this category is EXOSC10 which is the human 
homologue of S.cerevisiae Rrp6, and a 3’-5’ exonuclease with several nuclear roles such as 
during rRNA and snoRNA processing. Furthermore, there are several other significantly 
enriched factors that support a function for SRSF1 and SRSF2 in rRNA processing and 
ribosome biogenesis including numerous DExH/DEAD-box helicases known to be involved 
in such processes. 
Group No. of proteins Protein Name 
T7-SRSF1 6 APC2, ARHGEF2, COPB2, RFC5, TLN2, YWHAE 
T7-SRSF1-NRS 50 ACTL6A, AP2A1, AP2B1;AP1B1, AP2M1, C8orf33, 
C9orf114, CCAR1, DDX28, DHX15, EIF2S2, EIF2S3; 
EIF2S3L, FXR2, G3BP2, GRWD1, GTF3C3, HBA1, 
HIST1H2BN; HIST1H2BM; HIST1H2BH; 
HIST2H2BF; HIST1H2BC; HIST1H2BD; HIST1H2BK; 
H2BFS, HIST1H4A, HIST2H3A; HIST3H3; 




HNRNPD, HP1BP3, LUC7L2; C7orf55-LUC7L2, 
LUC7L3, MAP4, MMTAG2, MRPL19, MRPL38, 
MRPL53, NOL9, PEG10, PGAM5, PHF5A, POLR2H, 
PPP1CC, RPL12, RPL23, RPL9, RPS10; RPS10-
NUDT3, RPS11, RPS17L;RPS17, RPS25, RPS5, 
SRSF11, STAU1, SUPT16H, TSR1, U2AF1;U2AF1L4, 
YTHDC2 
T7-SRSF2 8 C1QBP, DDX23, HIST2H2BE; HIST1H2BB; 
HIST1H2BO; HIST1H2BJ, MAK16, MRPL21, 
MRPS18C, SRSF2, THUMPD1 
T7-SRSF1 and T7-
SRSF1-NRS 
26 ASF1B; ASF1A, C14orf166, C18orf21, CENPV, 
DDX47, EIF6, ELMSAN1, EXOSC5, FXR1, MRPL54, 
NAP1L1, NEMF, NOM1, POLR1D, POM121; 
POM121C, RBBP6, REPIN1, RFC4, RPLP0;RPLP0P6, 







33 AURKAIP1, CHTOP, EMG1, ERH, FOXK1, HNRNPC; 
HNRNPCL4; HNRNPCL1; HNRNPCL3; HNRNPCL2, 
HNRNPUL2; HNRNPUL2-BSCL2, LARP7, MRPL10, 
MRPL16, MRPL32, MRPL37, MRPL45, MRPL46, 
MRPL48, MRPL50, MRPL51, MRPL52, MRPS30, 
NHP2, PINX1, POLR3B, POP4, PRPF4B, RBM19, 
RPL22, RPP38 
SAFB, SNRNP70, SRSF10, XRCC5, XRCC6, YTHDC1 
GO term analyses reflects a similar trend of interactome overlap. Between SRSF1, 
SRSF1-NRS and SRSF2 (Figure 4.2(a)) hits are significantly enriched for functional groups 
such as RNA processing, gene expression and RNA metabolism. This is consistent with their 
role as RNA processing factors and strongly implies that the data represent biologically  
Table 4.1: Summary of exclusive interactions between SR proteins tested. Interacting 
proteins significantly enriched over the EV control that are unique within the sample(s) 
identified by the Group column (p-value <0.01, >100 fold enriched). This is considering the 
ratio of each dataset separately with respect to the EV control. The Group column indicates 
the exclusive dataset examined that are not included in the 361 common interactors, no. of 










Figure 4.2 Gene Ontology (GO) term analysis for SR protein interactions. Top 20 
significantly enriched GO terms for (a) the 361 common interactors of all bait proteins, (b) 
T7-SRSF1, (c) T7-SRSF1-NRS, (d) T7-SRSF2, all 100 fold enriched over EV control where 






relevant hits. Individually, the top 20 GO term groups are largely similar when grouped by 
significance of enrichment. However, the GO annotation groups that are the most enriched in 
the data are not necessarily those with the lowest p value. Discounting p value, the highest 
scoring GO terms are more specific and include categories such as snoRNA processing and 
nuclear polyadenylation. This is consistent between SRSF1, SRSF1-NRS and SRSF2. 
 
4.3.1.3 Cytoplasmic binding partners of SRSF1 
 
These data can be used to identify putative interactors of SRSF1 in the cytoplasm by 
comparing hits for SRSF1, which shuttles to the cytoplasm and SRSF1-NRS which does not. 
In simplistic terms, factors that do not bind SRSF1-NRS (or SRSF2 which is also nuclear), 
could represent cytoplasmic interactors of SRSF1. There are 6 proteins that significantly bind 
SRSF1 but not SRSF1-NRS or SRSF2 Table 4.1. None of these can be found in the top 100 
binding partners for SRSF1 and none has any previously annotated significant interactions 
with SRSF1 (STRING DB analysis, data not shown), so their functional relevance is unlikely. 
However, SRSF1 is predominantly a nuclear protein that shuttles to the cytoplasm transiently, 
therefore it may be impossible to delineate cytoplasmic binding partners using the approach 
described here which could further enrich for SRSF1 interactions in the nucleus. 
 
4.3.1.4 Factors for nuclear retention 
 
There are 33 proteins that bind to both SRSF1-NRS and SRSF2 with 100-fold 
enrichment over the EV control that do not bind SRSF1 with this level of significance (Figure 
4.1, Table 4.1). They can be filtered out on either fold enrichment, significance or both i.e. 
both significance and fold enrichment must be criteria for inclusion in a section. It is possible 
that these are specific for the NRS sequence and thus factors involved in the nuclear retention 
of SRSF2.  
The STRING database tool permits visualisation of functional interaction networks 
as inferred from numerous database annotations for a particular gene. These include protein-
protein interaction data, both experimentally validated and predicted, as well as functional 
systems data used to infer biological pathways in which the group of proteins may be involved. 
The latter is advantageous as it considers indirect or previously unannotated interactions that 
may group similarly interacting factors. This is particularly useful here as the NRS sequence 




SRSF2. Furthermore, the SRSF2 NRS peptide sequence does not share homology with any 
known functional domains that may hamper interactome prediction. 
The functional STRING interaction network for the proteins shared between SRSF2 
and SRSF1-NRS is shown in (Figure 4.3). Note that for this analysis, SRSF2 was added 
manually to the search list. The interactors within this group do occur more frequently than 
by chance over the background of the whole genome. The nodes form several clusters within 
the network, although only one is associated directly with SRSF2. It is possible that the other 
groups represent unannotated interaction networks in which SRSF2 or SRSF1 is present.  
 
Figure 4.3 STRING network analysis of nuclear interactions. These were defined as those 
33 proteins shared between T7-SRSF1-NRS and T7-SRSF2 (Table 4.1). Lines between nodes 
infer the confidence of the interaction based on the thickness. Image shown is output of 
STRING tool, found at: https://string-db.org/cgi/ 
 
The group of hits that closely associate with SRSF2 based on previous annotation 




scaffolding matrix protein that binds to S/MAR DNA situated around the nuclear envelope. 
One hypothesis could be that SAFB interacts with the NRS of SRSF2 in close proximity to 
the nuclear pore to hold it in the nucleus. Despite multiple attempts, it was not possible to 
validate any interactions of SAFB observed in MS by IP-WB (data not shown). However, it 
is likely that this was due to technical problems resolving the SAFB complex from its tightly 
associated DNA matrix. It is possible that the stringent lysis procedures required to resolve 





Figure 4.4 Validation of SR protein interactors. Validation of hnRNPC interactions 
observed by IP-MS for SRSF2 and SRSF1-NRS in HeLa cells. Two loading controls are shown 
as T7 western blot was performed on a second gel to avoid secondary antibody cross-
reactivity. Biological replicates (a) and (b). 
 
A high confidence interaction with HNRNPC can be seen in the STRING network 
analysis. It was possible to validate the interaction of HNRNPC with T7-SRSF2 and T7-
SRSF1-NRS by IP-WB (Figure 4.4). However, it is unclear from these data whether T7-
SRSF1 is also capable of binding as there are inconsistencies between replicates making it 
unlikely that any interaction with SRSF2 is specific for nuclear retention.  
CHTOP is another interesting interaction partner in this group as it is known to 
interact with PRMT complex which has been shown to be involved in the arginine methylation 
of SRSF2 to control its nuclear localisation (Larsen et al., 2016). This may be another 
interesting target to explore in the future. 
 
4.3.2 MS using Peptides to investigate the NRS interactome 
 
SRSF2 does not exhibit nucleocytoplasmic shuttling but resides constitutively in the 
nucleus, due to the unique and potent nuclear retention sequence (NRS) at the very C-terminus 
of the RS domain (Cazalla et al., 2002). This domain is dominant and when fused to SRSF1 
in the SRSF1-NRS fusion protein, it becomes trapped in the nucleus. In general, SR proteins 
are highly intrinsically disordered due to the RS domains. However, SRSF2 is predicted to 
have the highest propensity for disorder at the C-terminus, possibly due to the NRS domain 
(Haynes & Iakoucheva, 2006). The NRS is also highly phosphatase resistant and this property 
will be transferred to SRSF1 in context of the SRSF1-NRS fusion protein (Lin et al., 2005). 
Considering that SR protein dephosphorylation is required for nuclear export after splicing, 
this could be partly why SRSF2 evades nuclear escape. However, the exact mechanism for 
nuclear retention by this sequence is unknown. Interestingly the NRS shares virtually no 
sequence homology with any known proteins or domains suggesting that a unique mechanism 
or binding of an auxiliary factor could be responsible. To investigate this possibility and 
determine the direct interacting partners of the SRSF2 NRS sequence, peptide sequences were 
designed as shown (Figure 4.5). 
Each peptide was biotinylated to enable streptavidin pull-down prior to MS analysis. 
They also contain a small linker (SGSG) to enable flexibility of the peptide once coupled to 




facilitate comparison with the NRS and discount non-specific interactions in downstream 
analysis. Peptide 2 is the equivalent region from SRSF8, a vertebrate-specific SR protein and 
a pseudogene of SRSF2 (Soret et al., 1998). This sequence shares much homology with that 
from SRSF2, though it is unknown whether this sequence acts as an NRS in the same manner. 
Peptide three is the SRSF2 NRS in which each Serine and Arginine residue has been changed 
to an Alanine residue. Alanine is resistant to phosphorylation so interacting partners of this 
peptide and the true NRS are presumably not dependent on phosphorylation. Finally, peptide 
four is a scrambled NRS sequence to facilitate removal of any non-specific interaction partners 
detected.  
 
In this experiment, both nuclear and whole cell lysates (WCL) were used to allow 
comparison between cellular compartments. Interactions of the NRS sequence with 
cytoplasmic proteins, inferred as those made in the whole cell extract and not the nuclear 
fraction, should be treated with caution considering the NRS is not present in the cytoplasm 
in vivo. However, numerous proteins persist in all cellular domains in different abundancies, 
thus it is conceivable, that SRSF2 could bind an abundant protein present in the whole cell 
lysate that is only in the nucleus in small quantities but nonetheless still binds SRSF2. In this 
scenario, it is possible that the approach taken may overlook low abundance protein 
interactions. 
Figure 4.5 Peptide IP-MS in HeLa cells: Summary of peptide MS in HeLa cells. (a) Table to 
outline the peptide design implemented and the rationale for each. (b) Western blotting of 
fractionated cell extract to ensure clean subcellular compartments. Anti-XRN2 exclusively 
marks nuclear fractions; anti-tubulin is the cytoplasm -exclusive. In the whole cell extract, 





Peptides were coupled to streptavidin beads via their biotin linker and immobilized 
on a column before the cell or nuclear extracts was washed through the column. After washing, 
the beads were eluted and the peptide bound proteins subject to mass spectrometry analysis. 
Data were analysed in an analogous manner to the HeLa cell MS experiments. The IP and 
downstream MS was performed in triplicate for each peptide. The average LFQ value of each 
binding peptide was calculated for each peptide IP. A ratio of this was then taken between the 
sample peptide-IP and the scramble control. A student’s t-test was calculated for each ratio to 
determine the reliability of the values. A vast number of proteins appeared in the raw data for 
which the LFQ values were all 0. This indicates that they were not present in any of the 
peptide-IP samples and thus were discounted from downstream analysis. To obtain a 
significant list of interaction partners, cut-offs were set at anything with a p-value under 0.05 
and with a ratio of over 20 (meaning over 20-fold enriched over the scramble peptide control). 
Using this approach, the values shown in Table 4.2 were obtained for each peptide-IP. For the 
nuclear fractions, the top hit is Involucrin (IVL), a component of human skin. However, IVL 
is also found in the whole cell lysate, but does not bind the SRSF2 NRS peptide. This is 
unlikely to represent a biologically relevant significant interaction and indicates that this 
experiment contains a high degree of contaminants.  
For the whole cell lysate data, there are no significant hits that are unique to the NRS 
peptide, although there are few – 8 in total - that are also significant for SRSF8. Five out of 
eight of these proteins are nuclear and have a role in transcription and related processes. For 
example, DNA ligase 3, which is involved in the nuclear DNA repair pathway that recruits 
XCCR6. Although this protein is not found in the peptide data, related factors such as 
XRCC5/6 are found to be specific for the SRSF1-NRS and SRSF2 overexpression datasets. 
This suggests that SRSF2 may participate in these processes through interactions of the NRS 
in the RS domain. None of the proteins identified in either the nuclear or WCL datasets have 
any annotation for function in nuclear retention, however they do show an overall enrichment 
for nuclear proteins. Many common contaminants and substantial binding of the scramble 
peptide suggest that this data is not reliable to assess a mechanism for SRSF2 nuclear 
retention.  
Group Gene Name Gene symbol Compartment 
NRS only Involucrin IVL Cytoplasmic 
NRS and 
SRSF8 
MAPK regulated corepressor 
interacting protein 2 





Fibroblast growth factor 
receptor 1  
FLG Nuclear and 
Cytoplasmic 
Prostaglandin E synthase 2 GBF1 Nuclear 
Mitogen-activated protein 
kinase kinase kinase kinase 4 
MAP4K4 Cytoplasmic 
E3 ubiquitin-protein ligase 
RBX1 
RBX1 Nuclear and 
Cytoplasmic 
 
Histone deacetylase complex 
subunit SAP30 
SAP30 Nuclear 






kinase kinase kinase kinase 4 
MAP4K4 Cytoplasmic 
E3 ubiquitin-protein ligase 
RBX1 
RBX1 Nuclear and 
Cytoplasmic 
Paired amphipathic helix 
protein Sin3b 
SIN3B Nuclear 
Comparison with the HeLa IP-MS overexpression data for SRSF2 show very little 
overlap with hits from the peptide IP-MS, with CCDC137 being the only protein significantly 
present in both datasets. It is likely that this protein does represent a bone fide target of SRSF2, 
however it is unlikely to be specific for the NRS sequence as it also binds SRSF1. Considering 
that this factor does not bind to the Alanine mutant NRS, it is possible that interactions are 
mediated through generic binding of RS dipeptides in SR proteins. Furthermore, this 
interaction could depend on phosphorylation of these residues.  
Group Gene Name Gene 
symbol 
Compartment 
NRS and SRSF8 ATP-binding cassette sub-
family D member 1 





Table 4.2: Enriched interactors for IP-MS using peptides in nuclear extracts. Summary 
of significant hits for each peptide experiment, as shown by the Group column. Each 
dataset was obtained in triplicate. There are no significantly enriched hits for the NRS 




ER membrane protein 
complex subunit 1 
EMC1 ER Membrane 
Histone H2A type 2-B HIST2H2AB Nucleus, 
Chromosome 








WD repeat-containing protein 
82 
WDR82 Nucleus 
NRS, SRSF8 and 
NRS-Ala 
Histone H2A type 2-B HIST2H2AB Nucleus, 
Chromosome 
Considering the lack of overlap or significantly bound hits it is likely that this dataset 
is not representative of the biologically relevant interactions of the NRS peptide. However, 
there were significant problems with the synthesis and subsequent solubility of the NRS 
peptide, perhaps as it is so highly disordered. Even after numerous attempts with different 
solvents, the NRS peptide failed to solubilise, despite the other three in the experiment easily 
dissolving in the required solvent. Therefore, when used for this experiment it was only 
partially in solution which could have had an adverse effect on the data. In addition, all of the 
sequences tested are short and disordered thus by nature have a tendency for highly 
promiscuous binding profiles. To properly address NRS-binding proteins, the rest of the 
proteins domains may be required to stabilise any NRS-specific interactions. In addition, 
interactions that trap SRSF2 in the nucleus may be dependent on phosphorylation, which was 
not addressed here. The use of a phosphomimetic NRS peptide would perhaps delineate this.  
 
4.3.3 IP-MS in mESCs 
 
To determine the binding partners of SRSF1 in mouse embryonic stem cells (mESCs), 
the CRISPR generated SRSF1-T7 and SRSF1-NRS-T7 (clone 1) cell lines were used for IP-
Table 4.3: Enriched interactors for IP-MS using peptides in whole cell extracts. Summary 
of significant hits for each peptide experiment, as shown by the Group column. Each 
dataset was obtained in triplicate. There are no significantly enriched hits for the NRS 





MS as described previously against the T7-tag. SRSF1-T7 cells are homozygous for a T7 tag 
at the endogenous SRSF1 locus. The SRSF1-NRS-T7 clone 1 cells, contain the intact NRS-
T7 inset on one allele and an NRS-T7 insertion on the other allele that also has two single 
base pair deletions which result in the formation of a truncated protein only slightly larger 
than wild type SRSF1. The protein produced from this allele does not contain a T7 tag and 
therefore any binding partners of this protein should not be specifically pulled down by the 
T7 antibody. It should be noted that the T7 tag is C-terminal as opposed to the N-terminal 
used for the HeLa cell approach.  
In this system, there is no overexpression of SRSF1 and the protein is expressed at 
endogenous levels in both cell lines (Figure 4.6). This is advantageous over the HeLa cell 
dataset which was reliant on the overexpression of each bait protein. By nature, an endogenous 
IP-MS should portray a more reliant picture of the binding landscape of the bait protein as 
overexpression may result in promiscuous non-specific binding events that do not occur or are 
irrelevant in vivo. Conversely, there is the disadvantage that less prolific or transient 
interactions may be missed in an endogenous IP. These data are particularly important 
considering that Mass Spectrometry data for SRSF1 in mouse embryonic stem cells does not 
exist in the literature.  
The IP against the endogenous T7 tag was performed in biological quadruplicate and 
WT (untagged) mouse ES cells were used as the background control. Proteins that 
significantly bind in WT cell extract at similar levels to the tagged cells can be discounted 
from the downstream analysis as they most likely result from non-specific binding to the T7 
antibody. 
Unsurprisingly, far fewer interacting factors in total were identified in these data in 
comparison to the HeLa cell dataset, presumably due to endogenous expression of the bait 
protein. To determine interacting factors that are significantly enriched in the tagged versus 
the untagged cells, the average LFQ intensity value was calculated for each replicate and used 
to calculate a ratio over the WT cells. The student’s t-test was also performed to determine the 
accuracy between replicates for each sample and a p-value threshold of <0.05 was set for 









The resultant analysis at 100-fold enrichment over WT cells, demonstrates that there 
were 41 and 32 significantly interacting factors for SRSF1-T7 and SRSF1-NRS-T7 (clone 1), 
respectively (Figure 4.6 (c)). This is strikingly fewer than the equivalent observed in the HeLa 
cell overexpression data and exemplifies the potential benefits of using an endogenous system. 
It is also possible that this reflects differences in the function of SRSF1 between species or 
cell type. It would be interesting to delineate this further with comparison to endogenous data 
from human cells.  
The top 20 significantly interacting partners for SRSF1-T7 and SRSF1-NRS-T7 are 
shown in Figure 4.6(d). Concurrent with SRSF1 function, there are several splicing factors in 
this list, including CLASRP (or SRSF16), whose exact function is unclear in the literature. It 
was identified in a Y2H screen as a CLK4-interacting protein which also contains an RS 
domain and is thought to be involved in alternative splicing regulation of Clk-related kinases 
(Katsu et al., 2002). The most enriched proteins in this dataset for each bait are the shuttling 
SR protein SRSF10 and NIFK, which is nuclear. NIFK or MKI67 FHA domain-interacting 
nucleolar phosphoprotein, interacts with the cell cycle regulator MKI67 and localises to 
mitotic chromosomes (Booth et al., 2014; Pan et al., 2015). Interestingly, MKI67 is also one 
of the top 20 significantly enriched binding partners for both SRSF1-T7 and SRSF1-NRS-T7, 
suggesting interactions with this complex. Furthermore, MKI67 has been shown to bind PP1 
(Booth et al., 2014), the phosphatase responsible for SR protein dephosphorylation.  
Within the top 20 hits, there is a striking enrichment of rRNA processing and 
ribosome biogenesis factors both for SRSF1-T7 and SRSF1-NRS-T7 such as MAK16, UTP18 
and UTP23. Another interesting observation is the number of transcriptional regulators in this 
list. For example, for SRSF1-NRS-T7 the catalytic component of the PRC complex, Ezh1, 
was identified.  
Figure 4.6 Endogenous IP-MS in mESCs: Summary of the interactome of endogenously 
tagged SRSF1-NRS-T7 and SRSF1-T7 mouse ESCs. (a) Coomassie stained gel as an 
example of samples sent for IP-MS analysis. (b) Western blotting of mouse ESCs to 
demonstrate fusion protein expression. (c) Number of significant hits obtained for SRSF1-
T7 or SRSF1-NRS-T7 (clone1) cells, fold enrichment indicates over wild type (untagged) 
cells. pvalue <0.05. (d) Identity of the 20 most enriched proteins over wt cells for either 
SRSF1-T7 or SRSF1-NRS-T7 (e) Overlap between the SRSF1-T7 and SRSF1-NRS-T7 datasets 
at 10-fold (top) or 100-fold (bottom) enrichment over wt cells. Table corresponds to 





Gene Ontology analysis for the SRS1-T7 and SRSF1-NRS-T7 interactomes were 
performed using panther as previously described, except the input list used was for 10-fold 
cut-off as opposed to 100-fold. Redundant GO terms were then removed using the GOtrim 
software (Jantzen et al., 2011). The significantly overrepresented GO terms for each dataset 
can be seen in figure 4.7. Categories such as RNA processing, RNA splicing, splice site 
selection and spliceosome are present, consistent with known SRSF1 functions. It is 
 
Figure 4.7 Gene Ontology (GO) analysis for mESC targets. Results represent the 10-fold 






encouraging that this is the case for the knock-in systems as it demonstrates that the tagged 
and fusion proteins are both capable of normal splicing interactions. Interestingly, there are 
subtle differences in GO term enrichment. For example, SRSF1-T7 is enriched for RNA-
transport associated factors, whereas SRSF1-NRS-T7 is not. This could illustrate cytoplasmic 
targets of SRSF1 or those that are lost by SRSF1 binding in the nucleus due to forced nuclear 
retention. 
 
4.3.3.1 Cytoplasmic interactors of SRSF1-T7  
 
The datasets for SRSF1-T7 and SRSF1-NRS-T7 were overlapped to infer on 
cytoplasmic interactors of SRSF1 (Figure4.6). Those that do not bind to the nuclear retained 
SRSF1-NRS-T7 could be important for SRSF1 function in the cytoplasm. STAU1 is the only 
protein that is significantly enriched for SRSF1-T7 but does not bind SRSF1-NRS-T7 or WT 
cells at all. Despite multiple attempts, this interaction could not be validated by IP:WB in any 
of the cell lines (Figure 4.8). It is possible that this is due to technical difficulties however, as 
the antibody used appears to bind numerous non-specific bands with high affinity 
(demonstrated by the Input samples). In this scenario, it is unclear whether lack of enrichment 
in the IP is for these reasons or the MS data represent a false positive interaction with SRSF1. 
In the future, this interaction could be further investigated following antibody optimisation to 
facilitate correct detection of Staufen 1 protein in the Input samples. STAU1 is a cytoplasmic 
dsRNA binding protein that has numerous cytoplasmic roles such as mRNA translation and 
quality control pathways (Vessey et al., 2008). Somewhat conversely, it also has roles in 
mRNA stabilisation particularly during stem cell differentiation and neurogenesis (Kretz, 
2013).  
Overlap also demonstrated a significant enrichment in the SRSF1-T7, data for SF3A1. 
SRSF1-NRS-T7 also bound SF3A1 although not in all four replicates, meaning it is not 
significant using the chosen p-value cut-off. An interaction between SRSF1 and SF3A1 was 
also experimentally validated by Akerman et al (2012) in HeLa cells, suggesting that 
functional conservation of interactions between species does exist for SRSF1 at least for its 
roles in splicing.  
The nuclear-cap binding protein 1 (NCBP1, NCBP80) was observed from the data to 
interact with SRSF1-T7 and not SRSF1-NRS-T7. However, this protein is absent from the 
dataset overlap as it is highly enriched in two of four replicas and thus failed the prescribed 
significance threshold. Despite this, it was possible to validate this interaction by IP:WB for 




validate this interaction for several reasons. Firstly, as in Figure 4.8, NCBP1 also appears to 
bind WT cells so it is possible that this represents a false positive interaction. Secondly, to 
determine the subcellular location of putative interactions, through for example fractionation.  
 
 
4.3.4 Overlap of data with previous dataset  
 
A recent study used probabilistic PPI network prediction coupled with IP-MS to 
determine the dynamic interaction networks of SR proteins in the spliceosome (Akerman et 
al., 2015). In this analysis, SRSF1 was used as the prototype SR protein in analogous T7-
SRSF1 overexpression system to that used here. In this study SRSF1 did not require RNA to 
bind to spliceosomal proteins although some of the interactions found by IP-MS are nuclease 
sensitive. This could explain why such a little difference was observed on the gel with RNase 
treatment. Akerman et al (2015) found 204 proteins that are significantly enriched for SRSF1 
in the IP-MS dataset and predicted a further 554 that were not experimentally validated by IP-
MS. The data obtained here for T7-SRSF1 (100-fold enrichment) have approximately a 34% 
(133/395) overlap with the total (predicted and IP-MS) dataset from Akerman et al. 
Furthermore, over half (83/133) of these were also obtained in the authors IP-MS data. 
Figure 4.8: Validation of selected targets from mESCs obtained from endogenously 
tagged mouse ES cells. (a) IP-WB to validate interactions with NCBP1. (b) IP-WB to confirm 






Interaction group Number of 
Proteins 
Gene name 
Common in all datasets 3 BCLAF1, PWP1, SRSF1 
mESCs and HeLa o/e 13 ABCF1, CCDC137, DDX31, DKC1, 
DNAJC9, ISG20L2, MKI67, MRPL11, NIFK, 
NOL6, REXO4, RRP8, UTP18 
mESCs and Akerman et al  10 ACIN1, BUD13, CACTIN, CLASRP, DHX8, 
PRPF38B, RBM15, SAP30BP, SF3A1, 
SRSF10 
Exclusive to mESCs 15 ABT1, AW146154, BLM, BRD7, 
C12ORF66, CFAP20, H2AFJ, HP1BP3, 
MAK16, MRPS30, POLR2H, SGOL2, 
STAU1, UTP23, YTHDC1 
Figure 4.9: Overlap of IP-MS targets with known SRSF1 binding partners. Overlap of data from 
HeLa cells and mouse ES cells with previously published datasets for the interactome for T7-
SRSF1 (Akerman et al. 2015) shown in orange. (a) Overlap with published SRSF1 data and the 
endogenous SRSF1-T7 mESC interactome. (b) Overlap between mouse (blue) and human (red) 
interacting partners of SRSF1 (c) Overlap of published data with those obtained in HeLa cells 
for T7-SRSF1. (d) Overlap of mouse (blue) and human (red) data with published SRSF1 








4.4.1 Investigation of the SRSF1 interactome in human cells 
 
The overwhelming observation from these data is the high degree of common binding 
partners between the SR proteins, despite their differential shuttling capacities and RNA 
binding targets. Furthermore, an extremely large number of interactions were observed in 
these datasets that withstand the application of harsh statistical cut-offs. This remains a large 
caveat in processing the data to achieve the desired informatic aims and results, most likely, 
from utilising an overexpression system and whole cell extracts. It is also clear from the empty 
vector control that the T7-antibody exhibits a high degree of promiscuous binding when 
exposed to the cell extract, particularly to ribosomal proteins. The latter are a common 
contaminant in mass spectrometry data partially due to their abundance and here comprise a 
large proportion of the dataset. For example, discounting ribosomal associated and processing 
factors, MRP and RP genes alone comprise around a third of the 361 common interacting 
partners between each bait. A similar pattern is reflected in the GO analysis as associated 
terms such as translation and ribosome biogenesis are overrepresented.  
Out of context, such ribosome protein interactions may be viewed as non-specific, 
however they were retained in the dataset here as SR proteins are RNA processing factors. It 
is feasible that they could also play a role in ribosome biogenesis or the processing of 
ribosomal protein mRNAs. This argument is supported by the large number of proteins in the 
dataset that are known to function in these processes such as several members of the DEAD-
box family of RNA helicases and nucleolar GTPases. It should be noted that such groups of 
proteins do not bind significantly in the EV control. SR-proteins do bind to polysomes in the 
cytoplasm (Sanford et al., 2008), but it is also possible that they bind to unassembled or 
partially synthesised ribosomal subunits in the nucleus, perhaps to influence their export or 
timing of assembly. In addition to this, RP proteins can have other roles in the cell other than 
in a ribosomal context. For example, it has been shown that RPL5 interacts specifically with 
SRSF1 to control a signalling axis in cellular senescence that also involves p53 (Fregoso et 
al., 2013).  
The most significantly overrepresented group of genes in each of the datasets are those 
associated with RNA processing (Figure 4.2), indicating that the data are a reliable 
Table 4.4: Overlap of IP-MS targets with known SRSF1 binding partners. Selected 




representation of known SR protein function. SRSF1 and SRSF2 do not interact significantly 
with each other, despite both binding other SR proteins including their endogenous 
counterparts and SRSF3, 4, 5, 6,7 and 9. SRSF10 significantly binds T7-SRSF2 and T7-
SRSF1-NRS and the latter also binds SRSF11. This reflects the RNA binding profiles of these 
proteins as determined by CLIP datasets, which show that they have distinct transcript targets 
for example during splicing. These data may change on the addition of RNase and in the 
future, it would be valuable to compare protein pull down both with and without RNase 
treatment as it may facilitate analysis of more subtle interactions that are directly dependent 
on RNA binding.  
There are subtle differences between each dataset, demonstrating that although each 
bait binds to the same group of factors they might do so with different affinities. This could 
equate to functional differences or illustrate binding transience. To further delineate this in the 
future, a quantitative approach such as SILAC would be required as the method used here 
cannot be used directly to infer interaction stoichiometry.  
 
4.4.2 Endogenous interactome in mouse ESCs 
 
Here work aimed to investigate the interactome of endogenous SRSF1 in mouse 
embryonic stem cells using the tagged SRSF1-T7 and SRSF1-NRS-T7 (clone 1) cell lines. 
The latter contains a single copy of a non-shuttling SRSF1 protein, restricted to the nucleus 
by the NRS from SRSF2, but also expresses an untagged shuttling SRSF1 protein. To identify 
the proteins bound to both shuttling and non-shuttling SRSF1 protein, IP-MS was performed 
against the T7-tag.  
The striking difference between the mouse and human dataset is the drastically 
reduced number of SRSF1 binding partners in mESCs. This is most likely due to using an 
endogenous system rather than overexpressing the protein; particularly as in each experiment, 
the extracts were prepared using the same conditions. In hindsight, it may have been prudent 
to optimise the IP-wash conditions to be specific to the mESC IP in order to enrich for loosely 
associated or transient binding partners of SRSF1. However, it is also possible that the 
differences in interaction numbers are representative of mouse or stem cell-specific SRSF1 
binding profiles.  
 Comparison of the SRSF1-NRS-T7 and SRSF1-T7 datasets was used to delineate 
factors that bind endogenous SRSF1 in each cellular compartment. A highly specific 




that it could be an important cytoplasmic interactor of SRSF1 in mESCs. This interaction 
could not be validated by IP-WB; although this was preliminary data, which requires antibody 
optimisation to draw definitive conclusions. Despite this, Staufen 1 is an intriguing candidate 
to pursue in the future, especially as it is not found in previously published data for SRSF1 
(Figure 4.9) (Akerman et al. 2015). Staufen 1 in s a double-stranded RNA binding protein that 
has roles in aspects of RNA processing, including Staufen-mediated decay and cytoplasmic 
RNA localisation (Gong et al., 2009). In mice, it is also required during development for 
neurogenesis and synapse formation (Vessey et al., 2008). The mRNA targets of Staufen1 
include transcripts involved in cell cycle regulation (Boulay et al., 2014) which has also been 
demonstrated for SRSF1 (Maslon et al., 2014). It is possible that Staufen 1 and SRSF1 bound 
to a common mRNA or each other, serve to regulate the cell cycle either in a concerted or 
antagonistic fashion. Although not functionally validated, other cell cycle proteins were also 
enriched in the cytoplasmic dataset for SRSF1 such as Blm, which is a helicase involved in 
the DNA damage response (Yusa et al., 2004). Considering that the cytoplasmic roles of 
SRSF1 are required for mitotic progression (Maslon et al., 2014), this would be an interesting 



























Investigation of SRSF1 function in the cytoplasm 

















5.1.1 Generation of animal models using CRISPR targeting 
 
The existence of animal models in the past has been reliant on traditional gene 
targeting strategies which can be inefficient both financially and temporally. For such 
approaches in mice, embryonic stem cells are targeted with a mutation via homologous 
recombination and then injected into wild type blastocysts to produce chimeric animals 
containing a germline mutation (Wang et al., 2013). CRISPR/Cas9 targeting has been 
revolutionary for highly efficient generation of animals carrying customised genomic 
modifications; dramatically reducing the number of stages required to produce transmitting 
lines (Graham & Root, 2015). This was exemplified in mice but has been reproduced in 
numerous diverse species to date from zebrafish and flies to pigs and cattle. 
Mouse models can be generated in a single step through direct zygotic injection of the 
CRISPR/Cas9 machineries. This approach can be used for a variety of applications such as 
the simultaneous introduction of multiple mutations or generation of single-gene conditional 
mutants (Wang et al., 2013; Yang et al., 2013).  
 
5.1.2 Physiological roles of SRSF1 
 
SRSF1 is ubiquitously expressed, however, expression level can vary both across 
tissue types and during development (Hanamura et al., 1998). SRSF1 is known to govern 
numerous and diverse tissue-specific splicing programmes, which, if dysregulated, have 
disastrous consequences. Complete ablation of SRSF1 function causes embryonic lethality 
prior to E9.5 in mice, presumably due to SRSF1 deficient splicing, although no absolute 
conclusions are ostensible (Xu et al., 2005). Concurrent with this, it was shown that the 
nuclear functions of SRSF1 are sufficient to rescue lethality in conditional knockout mouse 
embryonic fibroblasts (MEFs) by transient overexpression of the SRSF1-NRS fusion protein 
(Lin et al., 2005). 
Other conditional SRSF1 knockout mouse models have been previously established, 
although all with respect to SRSF1 roles in splicing. For example conditional knockout of 
SRSF1 in the heart causes post-natal lethality due to mis-splicing of CaMKII mRNA that 
results in a hypercontractile heart phenotype (Xu et al., 2005). Recently a novel role for SRSF1 
in proliferation of smooth muscle cells was established using a smooth muscle cell-specific 




splicing mediated generation of a truncated form of p53 that drives the expression of KLF5 to 




In contrast to SRSF1 nuclear function, little is understood about the cytoplasmic roles 
of SRSF1 in physiological and developmental context. To examine this further, a mouse 
model of non-shuttling SRSF1 was designed and implemented using a CRISPR-based 
strategy. Analogous to the previously discussed mESC targeting, the nuclear retention 
sequence (NRS) from the non-shuttling SR protein SRSF2 was targeted to the endogenous 
SRSF1 locus. In addition to this sequence a T7 tag was also added at the 3’end of the insert to 
facilitate downstream phenotyping.  
In summary, the overall aims for the following work are: 
(1) To generate a mouse model for the SRSF1-NRS-T7 insertion using CRISPR 
targeting. 
(2) To investigate the phenotypic and physiological consequences of the SRSF1-


















5.3.1 CRISPR targeting strategy to generate homozygous SRSF1-NRS-
T7 mice 
 
To target mice with the SRSF1-NRS-T7 insertion, the strategy shown in Figure 5.1 
and Figure 5.2 was used. CBA x C57BL6 F1 males and females were crossed to generate 
CBAB6F2 zygotes for targeting. Guide RNAs and Cas9 RNA were microinjected to early 
mouse embryos at the single-cell stage. When the targeting strategy was implemented, data 
from mouse ES cells indicated that homozygosity for SRSF1 NRST7 could result in 
embryonic lethality. For this reason, CRISPR targeting was designed to preferentially generate 
heterozygous animals that could be crossed to facilitate study of potential embryonic lethal 
phenotypes. To increase the frequency of heterozygous animals generated, wt SRSF1 and 
SRSF1-NRS-T7 repair templates were delivered at 1:1 ratio to preserve the wild type SRSF1 
allele. To prevent re-cleavage by the Cas9 nuclease after a successful HDR event, the PAM 
site of the wt SRSF1 oligo was mutated. Integration of the SRSF1-NRS-T7 allele destroys the 
PAM site inherently thus no mutation is required in this case.  
 
 
Figure 5.1: CRISPR targeting design for microinjection to mouse zygotes. The genomic SRSF1 locus 
was targeted in Exon 4. The gRNA was used with Cas9 nuclease RNA to generate a double stranded 
break. Repair templates were delivered as single stranded DNA oligonucleotides. The wt and NRS 




targeted locus. Both alleles are shown for clarity. See Materials and Methods for details of sequence 
design for targeting reagents. 
In the approach implemented, the CRISPR reagents could potentially act either prior 
or subsequent to DNA replication at the single cell stage to generate uniformly mutated or 
mosaic animals, respectively. Therefore, founder mutant mice from initial screening should 




Figure 5.2: Schematic for CRISPR targeting and mouse breeding program. The Cas9 reagents were 
injected to single cell mouse zygotes to generated mosaic founder animals. Genotyping 
conformation was performed after each cross. The founders are the N1 generation. A single round 
of backcrossing was performed as minimum before intercrossing heterozygous mice.  
 
5.3.2 Generation of viable heterozygous SRSF1-NRS-T7 mice 
 
From microinjection CRISPR targeting, 57 pups were born, and genomic DNA from 
ear-clip tissue subject to PCR screening and subsequent sequence verification of successful 
mutagenesis events by Sanger sequencing (Figure 5.3). Several examples of successful 
targeting events can be observed in these data, including generation of heterozygotes such as 
animals 31 and 36 (Figure 5.3(a)(i)). Mouse 2 appears to be a compound heterozygote as there 
is no band at 700bp indicative of wild type SRSF1, but two larger bands between 800 and 
900bp in size. In addition to this, auxiliary indels were present in some animals such as mouse 
10 which contained a large deletion to result in a truncated version of SRSF1.  
To ensure there was an equal allelic ratio in heterozygous mice, the PCR product was 
sub-cloned and 96 representative colonies sequenced for each sample. For example, mouse 2 
and 31 contained the SRSF1-NRS-T7 allele in equal proportion with a second allele. Mouse 
31 was a true heterozygote with approximately 50% of the PCR sequences each for wild type 
SRSF1 allele and SRSF1-NRS-T7. Mouse 2 was a compound heterozygote, and contained 
approximately 50% each of the SRSF1-NRS-T7 allele and an SRSF1-NRS-T7 allele with an 
additional insertion upstream of the NRS-T7 sequence. These data suggest that the founder 
mice are not extensively mosaic, at least in ear tissue, from which the genomic DNA was 
obtained for the screening process.  
Two heterozygous founder mice (F0 generation) were backcrossed to C57BL/6 wild 
type mice. This segregates out any unlinked mutations resulting from the initial targeting that 
may be present. Considering that CRISPR targeting can have off-target effects that would not 
be identified in the screening process, this step is paramount and ideally should be repeated 
several times (Eisener-Dorman et al., 2010).  
After a single round of backcrossing, 32 pups were obtained and genotyped as the N1 
generation. Of these, 10 animals, for example numbers 709 and 710, were confirmed by 
sequencing to be heterozygous for the correct SRSF1-NRS-T7 allele (Figure 5.3(c)). In 
addition, the larger allele from the compound heterozygotes segregated with wild type SRSF1, 
for example mice 698-700 (Figure 5.3(c)). These animals were not used in further 




to display an overt phenotype. Multiple N1 founder mice with the correct heterozygous 
SRSF1-NRS-T7 insertion were subsequently intercrossed in an attempt to generate F1 























Figure 5.3: Genotyping screens of CRISPR targeted mice. (a) Schematic of PCR screening design to 
detect (i) SRSF1-NRS-T7 allele or (ii) wt SRSF1 allele. The amplicon size is illustrated in bp. (b) 
Screening of F0 generation after the initial CRISPR targeting. Representative image shown. (c) 
Screening of animals after a single round of backcrossing (N1 founder generation). Representative 
image shown. Asterisk indicates samples containing a genomic insertion that were subject to 
further investigation. (d) Genotyping SRSF1+/NRS intercross. Representative image shown from first 
cohort of pups. Arrowhead indicates 500bp, each ladder interval 100bp. Asterisk indicates samples 





5.3.3 Generation of SRSF1-NRS-T7 homozygous mice is possible 
 
Data from targeting attempts in mouse embryonic stem cells (Chapter 3) suggest that 
there is intense selection against the generation of homozygous SRSF1-NRS-T7 insertion in 
this cell type. Embryonic stem cells are representative of the inner cell mass of E3.5 embryos, 
thus it is conceivable that generation of homozygous animals is highly selected against or 
occurs with skewed Mendelian genetics. To determine if this is the case, pairs of N1 
heterozygous SRSF1+/NRS mice were intercrossed.  
In total, 69 pups were born from these crosses and genotyped as previously using PCR 
screening followed by Sanger sequencing. Surprisingly, 14 homozygous mice were born in 
addition to 38 heterozygotes and 17 wild type mice (Figure 5.4(a)). These numbers are not 
statistically different from the expected Mendelian ratio of 1:2:1. Therefore, mice 
homozygous for the SRSF1 NRS-T7 allele are viable and born at the expected Mendelian 
ratio. Contrary to expectations based on ES cell data, these data indicate homozygosity for 










To ensure that the SRSF1NRS/NRS and SRSF1+/NRS mice generated express the SRSF1-
NRS-T7 fusion protein, liver samples from homozygous, heterozygous and wild type mice 
were subject to Western blotting (Figure 5.4(b)). As expected, SRSF1+/+ mice express the 
canonical SRSF1 isoform as detected at approximately 33kDa using the SRSF1 antibody. A 
similar band was not detected for SRSF1NRS/NRS mice, instead a larger protein of approximately 
49kDa was detected, consistent with the previously observed molecular mass (Chapter 3) for 
Figure 5.4: Generation of SRSF1 NRS-T7 knockin mice. (a) Homozygous SRSF-NRST7 mice are 
present at Mendelian ratios, with no significant difference from expected numbers as shown by 
Chi-squared test. (b) Western Blotting of the SRSF1-NRS-T7 fusion protein, which can be detected 




the SRSF-NRS-T7 fusion protein. Consistent with their genotype, SRSF1+/NRS mice express 
both the wt and chimeric SRSF1 protein. Data were corroborated through use of the T7 
antibody on the same liver tissue samples from each mouse to detect a band at 49kDa for 
SRSF1NRS/NRS and SRSF1+/NRS mice but not wild type mice. Therefore, in targeted mice, the 
correctly modified SRSF1 protein is expressed and homozygous mice are reliant on the 
SRSF1-NRS-T7 chimeric protein. 
 
5.3.3.1 Homozygous SRSF1-NRS-T7 mice develop hydrocephaly 
 
 SRSF1NRS/NRS mice are born at the expected Mendelian ratio, however, it rapidly 
became apparent that these mice are phenotypically abnormal and develop hydrocephaly. 
From the first cohort of pups generated by the N1 SRSF1+/NRS intercrosses, there were three 
SRSF1NRS/NRS animals. One of these, mouse number 1023 developed swelling at the top of the 
head consistent with hydrocephaly at 2-3 weeks of age. Latterly, a second SRSF1-NRS 
homozygous mouse, number 1009, developed similar swelling at the top of the head indicative 
of hydrocephaly at 7 weeks of age. These mice were immediately euthanised in accordance 
with local ethical guidelines. Hydrocephaly can result in pain, distress and neurological 
damage, thus the remaining SRSF1-NRS-T7 homozygous mouse, number 1006, was 
euthanised at 7 weeks before any symptoms of hydrocephaly could develop. Similar events 
were not observed in any of the wild-type or heterozygous littermates in this batch of pups, 
suggesting that this is specific for SRSF1NRS/NRS animals.  
 A second cohort of 44 pups was obtained from additional SRSF1+/NRS N1 intercrosses, 
which were monitored daily for symptoms of hydrocephaly. At the age of 15-16 days, five of 
this cohort developed swelling at the top of the head analogous to that observed in the previous 
cohort and were euthanised (figure 5.5). Hydrocephaly is characterised as an accumulation of 
cerebral spinal fluid (CSF) in brain ventricles that exerts pressure on the skull causing it to 
bend (Vogel et al., 2012). Consistent with this, pressurised fluid was seen to escape from the 
brains of these pups during post-mortem dissection.  
Subsequent genotyping demonstrated that all five mice that displayed hydrocephalus 
were homozygous for the SRSF1-NRS-T7 allele. However, all the eight control littermate 
pups (two wild-type, six heterozygotes) examined at the same stage were devoid of all 
symptoms of hydrocephaly. Given that hydrocephaly can cause mice to suffer pain and 
neurological damage, the remaining SRSF1-NRS-T7 homozygous mice were euthanised at 2-
3 weeks before any potential hydrocephalus symptoms could arise on authority of the named 





Taken together, data from the described cohorts of intercrossed mice illustrate that 
there is a high risk of hydrocephaly associated with presence of a homozygous SRSF1-NRS-
T7 insertion; seven of the fourteen homozygous pups developed hydrocephaly within two 
months. This is significantly different from the incidence of hydrocephaly in heterozygous 
Figure 5.5: Hydrocephaly in SRSF1-NRS-T7 homozygous mice. (a) Homozygous mice, which 
present obvious bending of the skull indicative of hydrocephaly, are shown on the left-hand side 
of an unaffected counterpart, which has a normal head morphology. (b) wt and heterozygous mice 
are normal in appearance. Representative images of each genotype shown for comparison. (c) 
Close up of mice 1360 and 1363 shown in (a) to indicate domed skull shape in the hydrocephalic 




and wild type mice from these intercrosses (Fisher’s test, p<0.001, Figure 5.6). Hydrocephaly 
can arise spontaneously in the C57BL/6 background, although at a much lower incidence than 

















In broad terms, hydrocephaly can be categorised either as communicating or non-
communicating hydrocephalus, which results from poor CSF movement or a blockage within 
the ventricles, respectively (Sotak & Gleeson, 2012). However, it can also be caused by an 
overproduction of CSF (Vogel et al., 2012). At present, the underlying cause or categorisation 
of this phenotype is unknown. The observed phenotype is unlikely to have a strong sex bias 
as four of the hydrocephalic SRSF1-NRS-T7 mice were female. The asymptomatic SRSF1-
NRS-T7 homozygous pups were euthanised at 2-3 weeks, and one at 7 weeks. Brains from 
these mice were dissected and fixed in formamide for later investigation. Although the animals 
did not present any deleterious symptoms at the time of death, it will be particularly interesting 
Figure 5.6: Incidence of hydrocephaly in SRSF1-NRS-T7 homozygous mice. (a) Contingency tables 
to demonstrate the statistically significant incidence of hydrocephaly in SRSF1NRS/NRS mice in 
comparison to (i) wt or (ii) heterozygous littermate controls. (b) Data presented as stacked bar 




to determine the presence of any pre-clinical signs of hydrocephaly, for example by taking 
histological sections of fixed brain tissue. 
 
5.3.3.2 Homozygous SRSF1-NRS-T7 mice are growth restricted 
 
In addition to the previously described hydrocephaly phenotype, the SRSF1-NRS-T7 
homozygous mice were often visibly smaller than heterozygous and wild type littermates, for 
example mice 1362 and 1369 (Figure 5.7). To investigate if this was indeed the case 
empirically, mice from the SRSF1-NRS-T7 heterozygous intercrosses were weighed at 14-18 
days old. Of these, all the homozygotes had a reduced body weight in comparison to littermate 
controls (Figure 5.7). These data suggest that there is a variable growth restriction phenotype 
associated with homozygosity for SRSF1-NRS-T7. 
A metric such as body weight is highly affected by age of the animal, thus by nature, 
will be more variable between, as opposed to within litters as they were of varying age. To 
account for this, the weight of homozygous animals was calculated relative to the mean weight 
of the heterozygotes and wild type mice within each litter. The SRSF1NRS/NRS pups were on 
average 30% lighter in weight than littermate controls (Student’s t-test, p<0.0001).  
Overall, these data provide evidence to suggest that a homozygous SRSF1-NRS-T7 
insertion may interfere with normal growth. In human cells, SRSF1 has roles in the 
translational regulation of numerous cell cycle proteins and its knockdown induces a 
multipolar spindle cellular phenotype that can only be rescued by shuttling SRSF1 protein. 
Considering that the cell cycle is tightly controlled during development and its misregulation 
can result in deleterious growth (Ciemerych & Sicinski, 2005), it is an intriguing possibility 
that the lack of cytoplasmic SRSF1 could contribute to the observed growth restriction 
phenotype in SRSF1 NRS-T7 homozygous mice.  
Almost all of the hydrocephalus pups were also small in size with a lower body weight 
than control littermates. Both phenotypes are as a direct result of homozygosity for SRSF1-
NRS-T7, but whether they are linked is yet to be understood. It is possible that they are linked 










Figure 5.7: Small body size phenotype of SRSF1-NRS-T7 homozygous mice. (a) Weight of each 
mouse by litter number. Litter 6-8 are a day older than 1-5. (b) Two examples of visibly small 
homozygous mice adjacent to wild type littermates. The reduced body size phenotype appears to 
maintain proper proportion of the animal. (c) Example of normal sized SRSF1-NRS-T7 homozygous 




5.3.4  Embryonic Phenotypes of SRSF1-NRS-T7  
 
To determine if the small body size and hydrocephalus phenotypes observed 
postnatally originate during embryonic development, heterozygous SRSF1+/NRS F1 mice were 
bred and E12.5 embryos and placentas were harvested from four female mice. As expected 
from the postnatal breeding data homozygote SRSF1-NRS-T7 embryos were present at 
Mendelian ratios (Figure 5.8 (b)). Interestingly, one of the four SRSF1-NRS-T7 homozygous 













It is conceivable that this could be related to the high incidence of postnatal 
hydrocephaly observed in SRSF1-NRS-T7 homozygous mice. However, as only a single 
homozygote was affected, it is possible that this is either sporadic and unrelated, or there is a 
range of phenotypic penetrance. In future, it will be interesting to histologically examine the 
brains of the unaffected homozygous embryos to determine if there are any developmental 




Figure 5.8: Analysis of E12.5 embryos. (a) Genotype screening of E12.5 embryo tail-clip genomic 
DNA. The same PCR strategy was used as previously for postnatal screening. (b) Embryos are 
present at Mendelian ratios, with no significant difference from expected values. Arrowhead 





Figure 5.9: Appearance of SRSF1-NRS-T7 E12.5 embryos. Representative image (a) wt, (b) 
heterozygous and (c) homozygous SRSF1-NRS-T7 embryos observed to be grossly phenotypically 
normal. (d) SRSF1-NRS-T7 homozygous embryo with exencephaly. There are obvious gross 
morphological differences in the brain compared to littermates (above). The right hand images of 
the rotated embryo highlights the observed neural tube defect. Scale bars show represent 2 mm. 
 
To determine if the small body size phenotype observed postnatally in SRSF1-NRS-
T7 homozygous mice also occurs during embryogenesis, both embryos and placentas were 
weighed. 2 of 4 homozygous embryos were clearly smaller than both heterozygous and wild 
type littermates at E12.5. Embryo weight is strongly affected by slight differences in 
developmental stage and the maternal uterine environment, thus the weight of SRSF1NRS/NRS 
embryos was calculated relative to controls (heterozygous and wild type) from the same litter. 
Note that embryo 15 (SRSF1+/NRS) was excluded from analyses as it was damaged during 
processing. The same calculation was performed for placenta weight. These data demonstrate 
that on average, SRSF1-NRS-T7 homozygous embryos are 22.8% smaller than the control 




shown). However, only 2 of 4 of the SRSF1-NRS-T7 homozygous embryos are affected 
(Figure 5.10). To determine if there is indeed a significant bimodal distribution of weight in 
homozygous embryos, further numbers of embryos will be required for analysis. It is 
conceivable that the growth restriction phenotype observed at E12.5 in the SRSF1NRs/NRS 






















Figure 5.10: Embryo Weight at E12.5. (a) Half of the SRSF1-NRS-T7 homozygous embryos have a 
lower body weight than littermate controls. Note that the small heterozygote in litter two was 
damaged during the weighing process thus its weight appears lower than reality. (b) Placenta 
weight for each embryo shown in (a). Weight does not correlate with genotype. (c) the observed 
lower weight is not sex-linked in embryos as demonstrated by amplification of the UBE1 locus. 




The small body size observed in postnatal homozygous SRSF1-NRS-T7 mice was not 
sex linked, however considering that only a subset of embryos had low body weight, it is 
possible that it could be linked to sex at E12.5. To determine if this is the case, half of the 
embryos were sexed by PCR amplification of the UBE1 locus from genomic DNA obtained 
from embryo tail tissue. The UBE1 gene is encoded on the X/Y chromosomes and its 
amplification results in a larger (approximately 200bp) or smaller amplicon in females and 
males respectively. Of the eleven embryos tested, two were homozygous with low body 
weight: embryo 1 and 9 which are female and male respectively as determined by a larger or 
smaller PCR amplicon (Figure 5.10(b)). Therefore, concurrent with data from postnatal mice, 
the observed phenotypes in homozygous SRSF1-NRS-T7 embryos do not appear to correlate 
with gender (Figure 5.10(b)). However as only half of the embryos were tested, it will be 
necessary to sex the other embryos to fully conclude that this is the case. 
 
5.4 Discussion and conclusions 
 
The aim of this work was to investigate the physiological roles of the 
nucleocytoplasmic shuttling protein SRSF1. To do so, both heterozygous and homozygous 
SRSF1-NRS-T7 knock-in mice were successfully generated via CRISPR targeting at the 
endogenous SRSF1 locus. The insertion is comprised of a T7 epitope tag for screening 
purposes and a nuclear retention sequence (NRS) from the closely related non-shuttling SR 
protein SRSF2, that when fused to SRSF1 prevents nucleocytoplasmic shuttling (Cazalla et 
al., 2002).  
These data reveal that there are several, obvious and severe characteristics associated 
with homozygosity for SRSF1-NRS-T7, although in contrast heterozygous animals appear 
phenotypically normal. Assuming that in vivo the SRSF1-NRS-T7 fusion protein behaves as 
previously described (Cazalla et al., 2002) and it is not capable of nucleocytoplasmic 
shuttling; aberrant phenotypes in SRSF1NRS/NRS mice are likely due to lack of shuttling SRSF1 
function. This indicates the functional importance of SRSF1 presence in the cytoplasm, or at 
least, outside its roles in splicing. The latter should be unaffected by the C-terminal NRS 
fusion as the N-terminal RRM domains of SRSF1 are required for splicing function, in 
particular substrate specificity (Cléry et al., 2013). However, to derive absolute conclusions 
from these data, it is essential that knock-in mice are subject to RNA-sequencing to ensure 
that, as predicted, splicing remains largely unaffected. Further to this, heterokaryon assays 




the endogenous SRSF1-NRS-T7 fusion protein. Thus, at present, alternative roles of SRSF1 
in the nucleus, but not in splicing cannot be dismissed, such as mRNA stability or export. 
Homozygous mice are highly susceptible to developing hydrocephaly, initially 
observed by exaggerated doming of the skull due to accumulation of cerebrospinal fluid 
(Vogel et al., 2012). One of the major causes of hydrocephalus is defective cilia in the brain 
and it can be observed in numerous classes of ciliopathies. In healthy individuals motile cilia 
in the brain contract to drive movement of CSF through the ventricular system, although 
hydrocephaly can also arise from defective immotile primary cilia for example in Bardet-Biel 
syndrome (Sotak & Gleeson, 2012). The development of hydrocephalus in mouse models has 
previously been linked to the development of abnormal body movement, for example in the 
hydrocephalus with hop gait (hyh) mutant mouse (Bronson & Lane, 1990). It is possible that 
the homozygous mice described here to suffer hydrocephaly could also display similar 
phenotypes if monitored closely. It would be interesting to assay, for example the gait of 
homozygous mice, to determine if hydrocephaly is accompanied by ataxia or degenerative 
movements indicative of extensive CNS problems. 
Interestingly, several diverse RNA binding proteins have been described to cause 
hydrocephaly on knockout. The Musashi family of RNA binding proteins are developmentally 
regulated and expressed specifically in neural precursor lineages. Mice lacking these in the 
brain develop obstructive hydrocephaly (Sakakibara et al., 2002). Hydrocephaly is also a 
phenotype in PTB brain conditional knockout mice due to specific loss of ependymal cilia in 
the brain and loss of adherens junctions in specific neural lineages (Shibasaki et al., 2013). 
The Rbfox2 RNA binding protein has also been implemented in the regulation of brain 
development and its perturbation results in deleterious phenotypes including hydrocephaly 
(Gehman et al., 2012). 
In addition to the hydrocephaly phenotype, homozygous mice are visibly smaller in 
size than both wild type and heterozygous counterparts. The latter appear unaffected 
indicating that expression of a single copy of shuttling SRSF1 facilitates normal growth. The 
cause of these observations remains an open question, although there are mouse models of 
small body size in existence, several of which are caused by misregulation of the cell cycle 
during development (Ciemerych & Sicinski, 2005). SRSF1 regulates the mRNA translation, 
in particular that of mRNA transcripts that encode cell cycle and mitotic proteins (Michlewski 
et al., 2008; Maslon et al., 2014). This raises the interesting possibility that the translational 
roles of SRSF1 in regulation of such transcripts could be linked to the observed phenotypes. 




body weight (Pende et al., 2004). S6K1 is an important regulator of mRNA translation. 
Considering that SRSF1 also functions to regulate the translation of specific mRNAs, it is an 
intriguing speculation that an analogous scenario is occurring in SRSF1-NRS-T7 homozygous 
mice. However, a significant proportion of the mouse knockout strains in existence have 
reduced body weight as a phenotype indicating that this is a highly variable and multigenic 
trait (Reed et al., 2008). Considering this, it could be that the effects on body size in 
SRSF1NRS/NRS mice are due to several perturbations of SRSF1 cytoplasmic function or the 
translational misregulation of numerous target mRNAs. 
To investigate the potential physiological roles of the SRSF1-NRS-T7 allele during 
prenatal development, E12.5 embryos were subject to analysis. Analogous to the postnatal 
dataset, homozygote embryos are present at Mendelian ratios. A subset of the homozygous 
embryos are small in size in comparison to control littermates, however further numbers are 
required to determine if this is statistically significant. Furthermore, one of the homozygous 
embryos had exencephaly, meaning development of the brain outside of the skull. Given the 
observed postnatal hydrocephaly phenotype it is of great interest to investigate potential links 
between the two in the future. For example, sectioning and histological analysis of the 
unaffected embryos may facilitate the detection of latent pre-clinical symptoms of brain 
developmental abnormalities. In addition, examination of postnatal brains of unaffected 
homozygous mice may also similarly inform on any specific consequences of homozygosity 
for SRSF1-NRS-T7 in development of the CNS.  
In summary, the data presented here clearly demonstrate the successful generation of 
an animal model to determine the physiological consequences of the SRSF1-NRS-T7 allele. 
Preliminary analyses of this model demonstrate that there are significant consequences that 
result from the manipulation of the SRSF1 shuttling function in vivo. In the future, it will be 
highly interesting to mechanistically determine the causes for the observed phenotypes with 
regard to SRSF1 function. Considering the fundamental role that SRSF1 has in development 



































 RNA binding proteins are crucial for the regulation of all aspects of gene expression 
in a highly dynamic and physiologically contextual manner. The SR protein family are an 
essential group of such factors that are evolutionarily conserved in metazoans in terms of both 
structure and function (Long and Cáceres, 2009). SR proteins were originally described as 
splicing factors, required for both constitutive and alternative splicing. SRSF1 is the 
archetypal SR protein and represents a subset of the SR family that continuously shuttles 
between the nucleus and the cytoplasm. Such dynamics are governed by the continual 
phosphorylation of the eponymous Serine/Arginine (SR) repeats of the C-terminal RS domain, 
whereas the RNA-binding function of SRSF1 is mediated by the N-terminal RRM domains.  
 Further to its nuclear roles, SRSF1 is involved in numerous other cellular processes 
outside splicing and indeed in the cytoplasm. Importantly, SRSF1 is involved in mRNA 
translation and is directly associated with the translation machinery. The translational 
functions of SRSF1 are exerted in a previously outlined mTOR-dependent mechanism 
(Michlewski et al 2008). Latterly, studies in human cells defined the direct translational 
mRNA targets of SRSF1, including those encoding RNA processing and splicing factors but 
also, remarkably, numerous cell cycle and mitotic proteins (Maslon et al., 2014). 
 SR proteins, including SRSF1, are known to exhibit tissue specific expression profiles 
and their phosphorylation state differs during development (Hanamura et al., 1998; Sanford 
& Bruzik, 2001). Despite this, little is understood regarding the cytoplasmic roles of SRSF1 
in a physiological context. To address this, both cellular and animal models were developed 
in which SRSF1 is exclusively nuclear.  
 
6.1 Development of cellular models to study SRSF1 cytoplasmic 
function 
 
The nuclear roles of SRSF1 in splicing are essential for cell viability and thus were 
maintained in model systems generated. The non-shuttling SR protein SRSF2 contains a 
potent nuclear retention sequence (NRS) at the very C-terminus of its RS domain (Cazalla et 
al., 2002). When fused to SRSF1 in the context of the SRSF1-NRS fusion protein, it is 
sufficient to ablate shuttling while maintaining cellular viability. The primary aim of the work 
herein was to develop an endogenous model system that harbours the non-shuttling SRSF1 
protein to study the physiological consequences of the absence of cytoplasmic SRSF1. To do 
so, CRISPR gene targeting was used to knockin the SRSF2 NRS to the endogenous SRSF1 




6.1.1 Generation of non-shuttling SRSF1 is highly selected against in 
mESCs 
 
 Despite extensive rounds of targeting, it was not possible to generate homozygous 
SRSF1-NRS-T7 knockin mouse ES cells with the CRISPR strategy implemented, potentially 
due to extremely poor knockin efficiencies. However, this is unlikely as the endogenous locus 
of SRSF1 is amenable to targeting, as illustrated by the successful generation of both 
homozygous and heterozygous SRSF1-T7 knockin mESCs. Furthermore, only SRSF1-NRS-
T7 Clone 1 cells could be generated which do contain the NRS-T7 insertion but with 
additional mutations that results in heterozygous SRSF1-NRS-T7 protein expression. High 
throughput sequencing of CRISPR targeted mESCs populations demonstrated that the 
generation of homozygous SRSF1-NRS-T7 clones is fundamentally possible, but targeted 
cells rapidly die over time due to intense negative selection pressures meaning just a single 
clone was recovered (Chapter 3, 3.3.6). Taken together, this strongly suggests that 
undifferentiated mouse ESCs struggle to tolerate a lack of shuttling SRSF1 under the growth 
conditions required to maintain pluripotency.  
The SRSF1-NRS-T7 mESC targeting strategy used here, was rationalised by previous 
work in which the SRSF1-NRS fusion protein was sufficient to preserve viability in 
conditional SRSF1 knockout mouse embryonic fibroblasts (MEFs) (Lin et al., 2005). MEFs 
are, in many aspects, physiologically diverse from mESCs. For instance, they are fully 
differentiated, which may alter cells’ tolerance for ablation of SRSF1 cytoplasmic function. 
Interestingly, in the previously published study, MEFs complemented with a version of 
SRSF1 that lacked the RS domain were viable but grew slowly. Furthermore, the shuttling 
capacity of the ΔRS SRSF1 protein could not be determined, but it was present in both the 
nucleus and the cytoplasm (Lin et al., 2005) The RS domain is required for SRSF1 function 
in translation (Michlewski et al 2008), thus it is an intriguing possibility that ablation of 
SRSF1 cytoplasmic function causes growth retardation and represents partial lack of tolerance 
for cytoplasmic SRSF1 in this scenario. 
A recent study proposed that the tendency for SR proteins to exhibit 
nucleocytoplasmic shuttling is dictated by cellular differentiation state. It was demonstrated 
that all SR proteins are capable of shuttling to variable extents in pluripotent P19 mouse cells, 
but not HeLa cells. SRSF1 was considered to have high shuttling ability, whereas SRSF2 had 
a lower ability to shuttle (Botti et al., 2017). Consequently, it is possible that in mESCs, the 
NRS sequence does not act with similar potency in the SRSF1-NRS fusion protein as in HeLa 




ability of SRSF1 in mESCs to an extent that will perturb cytoplasmic SRSF1 function 
sufficiently to cause aberrant consequences. Alternatively, considering that in P19 cells 
SRSF2 shuttling is passive and coupled to binding mRNA targets for export that are distinct 
from SRSF1 (Muller-McNicoll et al., 2016; Botti et al., 2017), the isolated NRS domain, that 
does not contribute to SRSF2-specific mRNA binding, is likely to confer complete nuclear 
retention in context of the SRSF1-NRS-T7 fusion protein analogous to differentiated cells 
(Cazalla et al., 2002).  
In either scenario, this indicates that undifferentiated cells may be more reliant on 
SRSF1 shuttling function which could provide explanation regarding the observed negative 
selection in generating homozygous SRSF1-NRS-T7 mESCs. There are several possible 
reasons for the latter. Undifferentiated cells have a distinct and rapid cell cycle profile from 
differentiated cells, characterised by a short G1 phase and altered cell-cycle checkpoints 
(Boward et al., 2016). In human cells, SRSF1 regulates the translation of cell-cycle related 
mRNA transcripts and its knockdown causes mitotic defects which are independent from its 
roles in splicing (Maslon et al., 2014). It is plausible that in mESCs, SRSF1 acts in analogous 
mechanisms to regulate mitosis through translation of specific targets. 
A single copy of non-shuttling SRSF1 does not affect the overall cell cycle profile of 
targeted mESCs, as SRSF1-NRS-T7 Clone 1 cells appear normal; as expected from the 
presence of wt SRSF1 in these cells (Chapter 3, Figure 3.10). However, it is possible that 
complete lack of shuttling SRSF1 protein lowers the tolerance threshold for mitotic problems 
sufficiently to promote cell cycle arrest in targeted cells. Indeed, such problems cannot be 
rescued by nuclear retained SRSF1. Feasible mRNA targets of SRSF1 whose downregulation 
could cause an aberrant cell cycle phenotype, include the cyclin kinase CDK1, or the 
condensin complex proteins SMC2 and SMC4 (Maslon et al., 2014). These proteins are highly 
conserved in mice and essential for proper cell cycle progression and chromosome 
segregation. Therefore, if the absence of SRSF1 results in reduced levels of translation of 
corresponding mRNA transcripts, there may be insufficient protein for consistent, accurate 
cell proliferation. 
 
6.2 Interactome studies of shuttling and non-
shuttling SR proteins 
 
The potent nuclear retention sequence (NRS) naturally present in SRSF2 can ablate 




unique peptide sequence and the mechanism of its function is currently unknown. To 
determine any protein interactors that could be responsible for the NRS function in nuclear 
retention, IP-MS studies were performed in both human and mouse ES cells.  
 
6.2.1 Factors for nuclear retention of SRSF1-NRS-T7 
 
Work described in Chapter 2 to determine the interactomes of SRSF1, SRSF-NRS 
and SRSF2 illustrate that on overexpression, these SR proteins bind and share a significantly 
high number of protein binding partners. Data could be corroborated by a clear overlap with 
a previously published dataset for SRSF1 in the same cell type (Akerman, et al. 2015). 
Consistent with the known nuclear roles of SR proteins, gene ontology analysis using the data 
obtained demonstrated an enrichment for RNA processing factors and those involved in 
splicing. The datasets obtained from IP-MS studies in HeLa cells were overlapped. In theory, 
factors that significantly bind to SRSF1-NRS and SRSF2 but not SRSF1 could be involved in 
nuclear retention. 
Taking this approach, few proteins were identified, presumably because the 
proportion of interactions shared between all three datasets was so large. Indubitably, an 
interaction conferring nuclear retention could be with a shared binding factor but with 
differential affinity. In future, it would be interesting to use a quantitative MS approach such 
as SILAC to delineate if this could be the case. Alternatively, it is possible that the mechanism 
of nuclear retention for the NRS is not dependent on protein binding but perhaps RNA-binding 
specificities or events that dictate bound mRNA nuclear export. For example, mRNP 
remodelling at the nuclear pore through an auxiliary factor could remove SRSF2 from an 
mRNA to which both proteins are bound, independent of physical association with SRSF2. It 
is also possible that posttranslational modification of the SRSF2 protein and/or specifically 
the NRS could contribute to nuclear retention function. Such a model would be consistent 
with those previously described for SR proteins, which is dependent on RS domain 
dephosphorylation (Lin et al., 2005). In general, phosphorylation is crucial to SR protein 
function, but other modifications are also present. Indeed in pluripotent cells, SRSF2 
movements are also proposed to be dependent on arginine methylation (Botti et al., 2017).  
 
6.2.2 SRSF1 has species-specific protein binding partners 
 
To determine the endogenous binding partners of SRSF1 and the SRSF1-NRS-T7, 




used in similar interactome studies as human cells (i.e. IP-MS approach). The overwhelming 
observation from these data was the significant reduction in binding partners identified in 
either dataset in comparison to the equivalent in the overexpression system used for SRSF1 
in HeLa cells. Indeed, only 16 common proteins were identified that bound T7-tagged SRSF1 
in human and mouse cells (Figure 5.9). This implies either that SRSF1 overexpression could 
amplify promiscuous or transient binding partners, or that in mouse cells SRSF1 has a diverse 
interactome.  
Considering the observed negative selection in generating homozygous SRSF1-NRS-
T7 knockin mESCs, it was interesting to determine if the interactome of shuttling SRSF1-T7 
cells could implicate binding partners responsible and thus important in SRSF1 cytoplasmic 
function. In total 25 cytoplasmic partners of SRSF1 were inferred as those which bound the 
shuttling SRSF1-T7 but not the nuclear retained version. Of these, none were strikingly 
apparent as those involved in translation. However, the proteins that did not appear in any 
previously known dataset for SRSF1 or are significantly enriched in SRSF1-NRS-T7 Clone 1 
cells include factors such as BRD7, BLM, C12ORF66 and CFAP20. The Bloom helicase 
(BLM) is involved in sister chromatid exchange and DNA-damage response pathways and is 
frequently dysregulated in cancer (Luo et al., 2000). Considering the roles of SRSF1 in mitosis 
and as an oncogene, it would be an interesting target to follow up in the future (Karni et al., 
2007; Maslon et al., 2014). Furthermore, the BLM mRNA transcript was found to be 
translationally regulated by SRSF1 (Maslon et al., 2014), which raises interesting possibility 
of a functional protein and mRNA interactome overlap.  
 
6.2.3 SRSF1-NRS-T7 and mRNA export 
 
At present, it is unknown from data presented here, whether homozygosity or SRSF1-
NRS-T7 could influence SRSF1 function in mRNA export. It is possible that the observed 
negative selection in the generation of homozygous SRSF-NRS-T7 result from abnormal 
export of SRSF1 target transcripts. Nearly all members of the SR protein family (SRSF1-7) 
act as adapters for the NXF1-mediated export of specific mRNAs. Crucially, each SR protein 
serves to regulate distinct mRNA transcripts in this manner (Muller-McNicoll et al., 2016). 
Interestingly, SRSF1 is involved in the export of the repeat-expansion transcript C9ORF72, 
which is involved in the development of neurological diseases in humans. In Drosophila 
models, SRSF1 depletion prevents neurotoxicity through ablation of C9ORF72 export to 
prevent toxic RNA foci accumulation in the cytoplasm (Cooper-knock et al., 2014; 




In the IP-MS data obtained here, ALREF, NXF1, CHTOP export adapter proteins 
bind to SRSF1-NRS, SRSF1 and SRSF2 suggesting that NRS does not affect protein 
interactions with export factors. Considering this and the fact that SRSF1 target mRNA 
binding should be unaffected by the NRS sequence, it is unlikely that export is dysregulated 
to the extent that it could demonstrate the phenotypes observed. Corroborating this data, the 
export factor RBM15 binds to SRSF1-NRS and SRSF1 but not SRSF2 suggesting this in an 
SRSF1-specific interaction but one unaffected by NRS binding. In the mESC endogenous 
interactome data, RBM15 and CHTOP also bind to endogenous SRSF1 and SRSF1-NRS with 
similar binding affinity (at least in IP-MS enrichment).  
 
6.3 Generation of a mouse model to study SRSF1 
cytoplasmic function 
 
 To investigate the relevance of SRSF1 shuttling function in a physiological and 
developmental model, CRISPR targeting of mouse zygotes was used to generate an 
endogenous model for SRSF1-NRS-T7. Contrary to expectations from mESC targeting data, 
homozygous SRSF1-NRS-T7 mice are born at normal Mendelian ratios. However, it was 
rapidly apparent that these mice exhibit several striking postnatal phenotypes that are absent 
in heterozygous or wild type littermates. 
 
6.3.1 SRSF1-NRS-T7 knockin mice develop hydrocephaly 
 
 Homozygous SRSF1-NRS-T7 mice present severe postnatal hydrocephaly 
characterised by abnormal doming of the skull in comparison to unaffected littermates 
(Chapter 5 Figure 5.5), (Vogel et al., 2012)). Hydrocephalus is a common phenotype of both 
primary and motile cilia dysregulation in the brain; it is observed in numerous ciliopathies 
which are often caused by multiple genes and are not transmitted in a Mendelian pattern 
(Valente et al., 2013). The latter is consistent with the observed variable penetrance of 
hydrocephaly in SRSF1-NRS-T7 homozygous mice over the time monitored (Figure 5.5).  
Primary cilia are organelles found at the cell surface that transmit diverse biological 
signals including morphogenic cues during development such as Sonic Hedgehog and Wnt 
signalling pathways (Valente et al., 2013). Motile cilia in the brain are distinct from primary 
cilia and are present in several parts of the brain to exert diverse function. (Spassky & Meunier, 
2017). An important example when understanding hydrocephaly are the cilia in the ependyma 




is dysregulated or blocked, the CSF accumulation can be sufficient to cause hydrocephalus. 
On the other hand, overproduction of CSF can also result in hydrocephalus (Narita & Takeda, 
2015). 
Primary cilia such as those in the brain are laid down during embryogenesis from the 
modification of mother centrioles in a cell cycle dependent mechanism (Banizs et al., 2005; 
Spassky & Meunier, 2017). SRSF1 has been linked to centriole biogenesis although the 
mechanism of this action is yet to be identified (Balestra et al., 2013). Given that centrioles 
and cilia formation are tightly linked, it is conceivable that this is relevant for the phenotypes 
observed in homozygous SRSF1-NRS-T7 mice. Perhaps a lack of SRSF1-mediated 
translation of specific centriole components could result in dysregulated cilia biogenesis 
during SRSF1-NRS-T7 homozygous mice development. This could contribute to the observed 
neural tube defect in one of the E12.5 homozygous embryos (Figure 5.8). Interestingly in 
HeLa cells, SRSF1 was found to regulate the translation of both CDC42SE2 and DAAM1 
mRNA (Maslon et al., 2014), which are both effectors in different branches of the Wnt 
signalling pathway; dysregulation of which has been implicated in neural tube defects (Keller, 
2002). It is tempting to speculate that this could contribute to both the embryonic and postnatal 
phenotypes observed in the homozygote SRSF1-NRS-T7 mice. Furthermore, both SRSF1 and 
SRSF9 – which incidentally is the closest SR protein paralogue of SRSF1 (Sun et al., 2010)- 
can manipulate the Wnt/β-catenin branch of the Wnt signalling pathway. In this context, 
SRSF1 overexpression enhances the level of β-catenin protein through translational regulation 
of the reciprocal mRNA transcript in an mTOR dependent mechanism (Fu et al., 2013). 
Numerous other signalling pathways have also been implicated in the development of 
hydrocephaly such as the planar cell polarity pathway (PCP) and mTOR signalling (Spassky 
& Meunier, 2017). Furthermore, hydrocephaly can be of the communicating or non-
communicating form both of which are underpinned by diverse and complex molecular 
mechanisms It will be crucial to determine into which category the observed hydrocephaly 
falls and if any of the likely signalling pathways is affected. This could have relevance to 
SRSF1 function, particularly in the translation regulation of pathway-associated factors.  
Several other RNA binding proteins and splicing factors have been shown to cause 
hydrocephaly or aberrant neurogenesis when their function is mutated or lost such as PTBP1, 
RBFOX1, MBNL2 and SRRM4 (Vuong et al., 2016). The dysregulation of PTBP1 function 
in radial glial cells can cause aberrant neural differentiation thus it would be interesting to see 
if SRSF1 may have similar functions in these processes (Vuong et al., 2016). Interestingly, in 




state but translocates to the nucleus on traumatic nerve injury. The authors propose that 
cytoplasmic SRSF1 in these cells is inactive, but there is no further comment on functions it 
may perform there (Hulse et al., 2014, 2016). 
 
6.3.2 SRSF1-NRS-T7 knockin mice are small in size 
 
In addition to developing hydrocephalus, SRSF1-NRS-T7 mice were observed to 
have a considerable reduction in body size in comparison to both heterozygous and wild type 
littermates. This is in proportion over the entire body of the mouse and appears to present both 
postnatally and at the E12.5 stage of embryo development (Figure 5.7). Similar to the 
hydrocephalus phenotype, this is not fully penetrant within litters and does not appear to be 
sex-linked. It is unclear whether affected mice would have reached comparable weights as 
control animals if they survived longer into adulthood.  
Size of an adult organism can be governed by either proliferation of individual cells, 
or the overall number of cells generated during development that comprise the adult organism. 
In turn, this is regulated by a finely tuned balance between apoptosis and cell proliferation in 
existence during development that can also contribute to overall body size (Yang & Xu, 2011; 
Lloyd, 2013). At present, the causes of the observed small phenotype in SRSF1-NRS-T7 
homozygous mice are unknown; however, considering the known cytoplasmic roles of 
SRSF1, several speculations could be made. For example, SRSF1 is involved in both 
translational regulation and cell cycle control; two processes inherently linked to cell size, 
proliferation rate and thus overall organism size.  
The IGF/PI3K/AKT/mTOR signalling axis is heavily involved in the regulation of 
cell growth and thus cell and overall organism size (Lloyd, 2013). Several studies have 
demonstrated that ablation of members of this pathway such as mTOR itself or S6K1 cause 
small cell and body size, which if viable result in mice that display an overall reduction in 
body size (Gangloff et al., 2004; Pende et al., 2004). Moreover, ablation of S6K1 specifically 
in skeletal muscle does not affect cell proliferation but is essential for the increase in cell size 
(Ohanna et al., 2005). It will be interesting to determine in the future if SRSF1-NRS-T7 
homozygous cells exhibit a slower growth rate or if the total cell number is less and if this is 
linked to SRSF1 function in the mTOR signalling pathway (Michlewski et al 2008).  
Other signalling pathways that can be dysregulated in terms of size involve the kinase 
Akt, which acts upstream of PI3K. The latter is a crucial determinant in heart size in adult 




phosphorylate SRSF1 in the cytoplasm (Blaustein et al., 2005), thus perhaps SRSF1 could 
acts as a similar downstream effector in regulating organ size. Maybe if there is no effector of 
Akt activity then expression of certain transcripts is dysregulated (Blaustein et al., 2005; 
White et al., 2010). With regards to organ size, it is interesting to note that SRSF3 conditional 
knockout hepatocytes grow slowly and fail to differentiate (Sen et al., 2013). Similar to 
SRSF1, SRSF3 is capable of cytoplasmic function and can influence mRNA translation of 
specific targets (Kim et al., 2013; Park & Jeong, 2016); tempting speculations regarding both 
SRSF1 and SRSF3 function in mRNA translation during proper organogenesis.  
Ablation of core components of the cell cycle in mice cause embryonic lethality at 
various stages of both pre and postnatal development (Ciemerych & Sicinski, 2005). However, 
depletion of key cell cycle regulation genes, although not essential for viability, also has 
marked effects on body size in mouse models that could prove relevant for SRSF1 
translational roles. For example, Cyclin D1 knockout mice are smaller than wild type 
littermates and had other skeletal abnormalities (Fantl et al., 1995). In addition, mice lacking 
the phosphatases cdc25a and cdc25c, which mediate CDK function during the cell cycle are 
also small in size but do not display defects in cell cycle progression (Ferguson et al., 2005). 
SRSF1 enhances the translation of the cyclin D kinase 1 (CDK1) and CDC27, which regulate 
cyclin functions to enable cell cycle progression and proper mitosis respectively (Maslon et 
al., 2014). Taken together, it is highly feasible that cell cycle control is implicated in the size 
phenotype observed in SRSF1-NRS-T7 homozygous mice and it would be intriguing to 
interrogate cells from these mice for cell cycle abnormalities.  
It is also possible that SRSF1 could enhance the translation of crucial mitogens and/or 
growth factors during particular developmental stages such as EGF or IGF to influence growth 
rate or downstream metabolism. Indeed, preliminary data implicate the cytoplasmic roles of 
SRSF1 in the regulation of cellular glucose uptake and other metabolic processes (M.Maslon, 
unpublished data). Consistent with this, SRSF1 regulates the translation of both the fatty acid 
Acyl-CoA synthase, AASDH and FUT8, an alpha-(1,6)-fucosyltransferase (Maslon et al., 
2014). Interactome data for SRSF1 (Chapter 2) also indicates that SRSF1 is capable of binding 
mitochondrial proteins, including numerous components of the mitochondrial ribosome in 
both HeLa and mouse ES cells. It is possible that SRSF1 translationally regulates such 
metabolite production or metabolic enzymes that if deficient could result in poor energy 





6.3.3 Further comments for observed phenotypes of SRSF1-NRS-T7 
mice 
 
 Although the phenotypes observed in homozygous mice are severe, it appears that 
they are of variable penetrance and not sex-linked. For example, some mice were small with 
no hydrocephalus, some just hydrocephalus, some completely visually unaffected and so on. 
It is unknown if asymptomatic homozygous mice that were euthanised, would have developed 
problems with age. It is possible that these mice already had pre-clinical symptoms that were 
not visually apparent. Furthermore, perhaps the lack of SRSF1 shuttling function during 
development could contribute to the postnatal phenotypes observed. A feasible scenario could 
be that SRSF1 regulates the translation of an important developmental-stage specific 
transcription or splicing factor, which if expressed with incorrect dosage could disturb the 
balance of downstream gene expression profiles. With this is mind, further complexities could 
also be realised, considering that SRSF1 expression is likely to be highly tissue and 
developmentally specific.  
 
6.4 Physiological relevance of SRSF1 shuttling 
function 
 
 Data presented here demonstrate that homozygosity for the SRSF1-NRS-T7 allele is 
viable but highly selected against in undifferentiated cells and results in serious phenotypic 
consequences in a mouse model. Contrary to data from previously described models using 
mouse embryonic fibroblasts (Lin et al., 2005), this indicates that the ability of SRSF1 to 
shuttle is crucial for proper development and cellular homeostasis. Indeed, the  
nucleocytoplasmic shuttling is required for the oncogenic potential of SRSF1 (Shimoni-Sebag 
et al., 2013) indicating that cytoplasmic function could have relevance for disease models of 
SRSF1 dysregulation. In future, the model systems created herein for studying SRSF1 
function could serve as tools to dissect the molecular mechanisms that contribute to 
cytoplasmic SRSF1-mediated oncogenesis. Thus, the SRSF1-NRS-T7 model could be highly 
relevant to further understand molecular mechanisms in cancer.   
In conclusion, this work indicates that the nucleocytoplasmic shuttling functions of 
SRSF1 are highly physiologically relevant and SRSF1 function outside those in splicing 
should be considered with equal importance. Henceforth, it will be truly exciting to use the 
novel SRSF1-NRS-T7 model system to further and fully dissect the cytoplasmic function of 




6.5 Future Work 
 
The work presented in this thesis, describes the creation of a mouse model for non-
shuttling SRSF1 that has striking phenotypic aberrations. Due to time constraints, causes for 
the latter have only received preliminarily investigations thus far; ergo the natural progression 
is to fully characterise the developmental and molecular mechanisms that could be responsible 
for the phenotypes observed in the homozygous SRSF1-NRS-T7 mice generated.  
Prior to commencing phenotypic investigations, there are several pressing controls 
that should be undertaken. Firstly, it is crucial to perform RNA-sequencing on cells derived 
from SRSF1-NRS-T7 homozygous mice to ensure that SRSF1-mediated splicing remains 
grossly unaffected in comparison to wild type cells. Given that SRSF1 acts to regulate the 
expression of target transcripts during multiple and inherently coupled processing steps, it is 
possible that there are subtle changes in splicing. Nonetheless, SRSF1 function in splicing is 
essential for viability thus if there were gross splicing changes in the SRSF1-NRS-T7 mice 
they would not be viable. Although subtle changes in alternative splicing through insertion of 
the NRS-T7 to endogenous SRSF1 cannot be discounted when delineating phenotypic causes, 
most of the published evidence indicates that the non-shuttling SRSF1 protein should be fully 
functional in nuclear roles. The strongest evidence for this being that the SRSF1-NRS fusion 
protein could fully rescue MEFs deficient in shuttling SRSF1, suggesting that nuclear roles of 
SRSF1 were grossly unperturbed (Cazalla et al., 2002; Lin et al., 2005). 
Secondly, it is necessary to ensure that in the model generated, the NRS functions as 
previously described and confers nuclear retention to the SRSF1-NRS fusion protein. To do 
this, heterokaryon assays should be further optimised and repeated to demonstrate the knockin 
protein is indeed incapable of shuttling into the cytoplasm.  
Lastly, it cannot be yet ruled out that the NRS-T7 insertion is affecting mRNA export 
in the mouse model created thus it is necessary to eliminate this as a phenotypic cause. The 
225 unique export targets of SRSF1 in p19 cells have been previously identified by the 
overlapping of RNA-seq from whole cell extracts and cytoplasmic fractions on SR protein 
depletion (Muller-McNicoll et al., 2016). A similar approach could be used to ensure that 
export of these mRNAs is unaffected in homozygous mice perhaps with or without a block of 
export by for example depletion of NXF1 or a similar mRNA export factor. Furthermore, 
overlapping SRSF1 export targets and the known translational targets may indicate transcripts 





6.5.1 Creating cell lines from knockin SRSF1-NRS-T7 mice  
 
To further understand the molecular and biochemical mechanisms that underpin the 
cytoplasmic roles of SRSF1, and to alleviate the requirement to continuously breed mice, it 
will be necessary to derive stably maintained cell lines as an in vitro model of the system 
created. The logical starting point from a technical perspective, is to derive mouse embryonic 
fibroblasts (MEFs) from homozygous SRSF1-NRS-T7 knockin mouse embryos, which would 
provide a differentiated cellular system for further analysis. To continue from work in Chapter 
3, it would also be interesting to determine if it is possible to derive viable and stably 
pluripotent homozygous SRSF1-NRS-T7 mESCs, either derived from reciprocal homozygous 
mice or by reprogramming SRSF1-NRS-T7 MEFs. However, this is more technically 
challenging and large numbers of mice are required, which limits the potential attempt 
number. If achieved, it would be interesting to determine if homozygous SRSF1-NRS-T7 cells 
are capable of differentiation into for example neurons, which could be used to investigate the 
potential cause of hydrocephaly.  
To continue from work in Chapter 4, and pursue both the protein factors responsible 
for nuclear retention and those that SRSF1 binds in the cytoplasm. It would be interesting to 
perform quantitative mass spectrometry such as SILAC for endogenous SRSF1 in both wt and 
SRSF-NRS-T7 cell lines. Indeed, if generation of mESCs from the mouse model is possible, 
it would be prudent to use these and compare resultant data to those obtained from the SRSF1-
T7 mESCs. 
 
6.5.2 Translational roles of SRSF1 in the SRSF1-NRS-T7 mouse model 
 
All previous datasets for SRSF1 function in translation and its targets therein were 
obtained in differentiated human cell lines. However, mRNA translation and its regulation is 
not wholly ubiquitous between species or cellular differentiation state. Therefore, it is feasible 
that SRSF1 regulates diverse, specific mRNA transcripts in adult mice or during mouse 
development in comparison to those found for human cells. This is of particular interest given 
the aberrant phenotypes of SRSF1-NRS-T7 knockin mice.  
During mRNA translation, the ribosome protects a small fragment of associated 
mRNA termed a footprint which is typically 25 to 30 nucleotides in length. Recently, 
numerous methods, namely ribosome profiling and variations thereof, have been described to 
accurately measure translation state at nucleotide resolution under given conditions (Ingolia 




footprint by freezing ribosomes on the bound mRNA using cyclohexmide then subjecting 
bound transcripts to deep sequencing analysis. In the future, such methods could be used to 
determine the translational targets of SRSF1 in the mouse model created. 
This could be approached in several ways. To investigate SRSF1 in translation 
initiation and the 40S subunit scanning process, translation complex profiling (TCP-seq) could 
be used, which is a modified version of the ribosome profiling protocol that enriches for pre-
initiation complexes on the mRNA (Archer et al., 2016; Shirokikh et al., 2017). Alternatively, 
use of Harringtonine to freeze initiating ribosomes would derive similar information (Ingolia 
et al., 2012). Furthermore, ribosome footprinting and sequencing of monosome and polysomal 
fractions separately would facilitate quantitative understanding of the translational abundance 
of SRSF1 translationally regulated transcripts (Heyer & Moore, 2016). It would also be 
interesting to perform ribosome profiling coupled to cell synchronization to reveal quantitative 
translatome dynamics during the cell cycle and in mitosis, which could be highly relevant in 
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Supplementary Table 1: IP-MS interactome of overexpressed SR proteins in HeLa cells (described Section 4.3.1). Fold enrichment over EV (empty 
vector control cells) and p-values for all hits obtained in the IP-MS experiments in HeLa cells that overexpressed either T7-SRSF1, T7-SRSF1-NRS or T7-
SRSF2. Only processed data values are shown, raw intensity values and LFQ values omitted for ease. For processing methods used, see Section 4.3.1.1 
for details. Where N/A is shown for p-value and 1.00 is shown for fold enrichment, this represents a scenario where there was no binding in either 
condition tested. All values shown to two decimal places. Hits are in alphabetical order according to Gene Name as imputed from the UniProt database. 
Protein ID refers to the given UniProt ID for each protein identified. Where multiple proteins are listed, this indicates that the interacting peptide 
identified could map to multiple proteins or isoforms of a protein. Database search to map the raw data hits was carried out by Jimi Wills of the IGMM 
Mass Spectrometry facility. 
Gene Name Protein ID Protein Name 














4.09 1.64E-04 4.51 1.85E-06 1.70 3.05E-01 
AATF Q9NY61 Protein AATF 4009022.50 1.10E-05 9301803.49 1.85E-08 2676352.76 1.21E-03 
ABCF1 F5GYK6 ATP-binding cassette sub-family F 
member 1 
2323383.50 1.48E-07 5193165.94 1.27E-07 1371286.87 5.86E-09 
ABCF2 Q9UG63 ATP-binding cassette sub-family F 
member 2 







Actin, alpha skeletal muscle;Actin, 
alpha cardiac muscle 1;Actin, gamma-
enteric smooth muscle;Actin, aortic 
smooth muscle 
13.78 2.43E-03 40.74 7.40E-07 10.00 1.97E-02 
ACTB P60709 Actin, cytoplasmic 1;Actin, 
cytoplasmic 1, N-terminally processed 
3.79 1.78E-08 5.60 1.99E-10 2.51 6.99E-08 
ACTG1 P63261 Actin, cytoplasmic 2;Actin, 
cytoplasmic 2, N-terminally processed 
2.47 5.50E-03 2.38 4.46E-02 0.85 7.52E-01 
ACTL6A O96019 Actin-like protein 6A 405367.81 5.34E-02 1478035.87 1.09E-03 53989.61 3.41E-01 
ADAM15 Q13444 Disintegrin and metalloproteinase 
domain-containing protein 15 
2.79 2.25E-02 1.13 8.62E-01 0.91 8.52E-01 
ADAM9 Q13443 Disintegrin and metalloproteinase 
domain-containing protein 9 
2.18 1.28E-03 1.89 7.59E-03 1.49 6.15E-02 







Gene Name Protein ID Protein Name 










ADSSL1 Q8N142 Adenylosuccinate synthetase isozyme 1 3.29 2.72E-04 4.50 5.68E-06 1.25 7.01E-01 
AGRN O00468 Agrin; 2.81 4.89E-05 3.90 8.34E-08 1.79 2.61E-03 
AHSG P02765 Alpha-2-HS-glycoprotein 25.53 4.83E-03 15.54 2.85E-02 1.81 5.89E-01 
AIFM1 O95831 Apoptosis-inducing factor 1, 
mitochondrial 
15.17 1.72E-01 13.59 3.77E-01 25.98 1.38E-03 
ALB A0A0C4DG
B6 
Serum albumin 1.41 5.31E-01 3.59 2.78E-05 1.41 4.03E-01 
ALDH9A1 P49189 4-trimethylaminobutyraldehyde 
dehydrogenase 
1.83 5.05E-02 1.48 5.19E-01 1.20 5.34E-01 
ALDOA J3KPS3 Fructose-bisphosphate aldolase 2.37 2.67E-03 0.43 2.16E-01 1.09 7.61E-01 
ALYREF Q86V81 THO complex subunit 4 12544.43 5.88E-10 40493.24 7.45E-11 13897.67 4.77E-11 





Annexin;Annexin A2;Putative annexin 
A2-like protein 
3.30 1.31E-05 7.90 1.43E-07 3.60 3.49E-04 





AP-2 complex subunit beta;AP-1 
complex subunit beta-1 
33.41 6.31E-07 128.66 4.60E-06 35.29 1.42E-08 
AP2M1 C9JJD3 AP-2 complex subunit mu 78.99 2.99E-07 309.69 2.81E-08 71.35 8.26E-04 
APC2 O95996 Adenomatous polyposis coli protein 2 574628.32 8.03E-04 208017.13 1.52E-01 94869.99 3.41E-01 
APOE E9PEV4 Apolipoprotein E 2.10 5.59E-02 2.24 4.04E-07 1.47 5.09E-04 
ARG1 P05089 Arginase-1 0.00 1.29E-01 0.00 1.29E-01 0.00 1.29E-01 
ARHGEF2 V9GYF5 Rho guanine nucleotide exchange 
factor 2 





Histone chaperone ASF1B;Histone 
chaperone ASF1A 






ATPase family AAA domain-
containing protein 3A;ATPase family 
AAA domain-containing protein 







Gene Name Protein ID Protein Name 










3B;ATPase family AAA domain-
containing protein 3C 
ATIC C9JLK0 Bifunctional purine biosynthesis 
protein PURH 
3.90 1.54E-05 4.29 5.21E-08 2.21 2.90E-04 
ATP5A1 P25705 ATP synthase subunit alpha, 
mitochondrial 
3.89 2.32E-06 5.16 3.78E-09 2.38 7.26E-06 
ATP5C1 P36542 ATP synthase subunit gamma, 
mitochondrial 
5.44 2.45E-03 9.93 2.01E-02 4.64 1.65E-02 
ATXN2L H3BUF6 Ataxin-2-like protein 14.73 3.56E-07 29.35 4.32E-09 11.66 1.28E-06 
AURKAIP1 Q9NWT8 Aurora kinase A-interacting protein 1857409.20 1.08E-02 7190657.05 1.73E-11 2234536.71 4.30E-07 
BAG2 O95816 BAG family molecular chaperone 
regulator 2 
5.25 3.00E-04 7.67 7.05E-07 2.62 3.07E-02 
BBX C9JA69 HMG box transcription factor BBX 2787690.02 2.06E-09 6060211.23 2.97E-08 1931178.84 4.56E-10 
BCAS2 O75934 Pre-mRNA-splicing factor SPF27 4977533.12 1.12E-10 15430085.76 1.08E-12 4429470.94 4.50E-07 
BCL9 O00512 B-cell CLL/lymphoma 9 protein 1.55 4.17E-02 0.00 8.99E-05 0.00 8.99E-05 
BCLAF1 E9PK09 Bcl-2-associated transcription factor 1 6250120.07 4.04E-09 15245083.53 1.47E-09 9697325.13 2.99E-10 
BIN2 S4R418 Bridging integrator 2 3.42 7.52E-02 1.64 7.07E-01 1.51 5.05E-01 
BMS1 Q14692 Ribosome biogenesis protein BMS1 
homolog 
5405392.52 8.36E-09 13042824.04 2.57E-10 4115624.74 4.42E-11 
BRIX1 Q8TDN6 Ribosome biogenesis protein BRX1 
homolog 
1008.12 4.85E-12 2690.85 1.65E-12 614.43 1.36E-06 
BYSL Q13895 Bystin 8062032.89 1.13E-09 22145522.49 1.43E-11 8478850.42 3.81E-06 
C11orf98 E9PRG8 Uncharacterized protein C11orf98 51820025.70 3.03E-12 107370143.92 5.29E-12 39148194.30 9.67E-16 
C14orf166 Q9Y224 UPF0568 protein C14orf166 111.30 2.02E-05 215.44 1.66E-07 66.10 9.62E-04 
C15orf62 A8K5M9 Uncharacterized protein C15orf62, 
mitochondrial 
1.21 7.95E-01 0.00 3.18E-07 0.83 6.79E-01 







Gene Name Protein ID Protein Name 










C19orf53 Q9UNZ5 Leydig cell tumor 10 kDa protein 
homolog 
1819.32 2.45E-09 4445.23 1.54E-10 1570.17 6.52E-07 
C19orf84 K7EN44 Uncharacterized protein C19orf84 766.90 2.02E-09 2070.28 3.98E-06 978.23 4.26E-08 
C1QBP Q07021 Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
6.82 4.18E-01 0.00 3.41E-01 105.65 1.49E-07 
C3orf17 Q6NW34 Uncharacterized protein C3orf17 1947761.15 1.31E-08 5493433.67 2.26E-06 1473678.69 1.61E-07 
C4B;C4A F5GXS0 Complement C4-B; Complement C4-A 
alpha chain 
2.82 5.29E-02 0.00 6.05E-02 0.00 6.05E-02 
C7orf50 C9JQV0 Uncharacterized protein C7orf50 22984532.18 3.82E-14 46554268.58 5.56E-13 12768637.69 7.37E-06 
C8orf33 Q9H7E9 UPF0488 protein C8orf33 94.49 7.90E-13 238.46 4.36E-11 57.99 3.56E-07 
C9orf114 Q5T280 Putative methyltransferase C9orf114 490251.88 7.12E-02 3097304.95 4.02E-07 598574.39 1.02E-02 
CAD F8VPD4 CAD protein 0.97 9.62E-01 0.47 3.35E-01 1.25 7.15E-01 
CAPRIN1 Q14444 Caprin-1 21.32 2.55E-11 73.41 1.02E-14 26.78 6.95E-13 
CARM1 K7EK20 Histone-arginine methyltransferase 
CARM1 
2.55 5.96E-02 1.56 3.30E-01 1.21 6.61E-01 
CBLN1 H3BQD0 Cerebellin-1 0.00 5.08E-02 0.00 5.08E-02 0.00 5.08E-02 
CCAR1 F5H3E1 Cell division cycle and apoptosis 
regulator protein 1 
213119.16 1.46E-01 2094800.67 6.46E-04 26573.28 3.41E-01 
CCAR2 Q8N163 Cell cycle and apoptosis regulator 
protein 2 
62982.19 1.56E-01 518894.95 1.48E-02 53871.30 1.76E-01 
CCDC137 I3L0U5 Coiled-coil domain-containing protein 
137 
9928582.10 7.46E-12 18771452.64 4.85E-15 6954365.61 1.74E-13 
CCDC59 Q9P031 Thyroid transcription factor 1-
associated protein 26 
4373082.31 2.04E-09 9063665.86 2.64E-11 3458757.91 3.55E-10 
CCDC86 Q9H6F5 Coiled-coil domain-containing protein 
86 
42023407.28 9.65E-10 127096867.69 5.81E-10 45747604.28 1.68E-11 
CCT2 F5GWF6 T-complex protein 1 subunit beta 2.68 2.99E-05 2.21 1.83E-02 1.76 2.56E-03 
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CCT4 P50991 T-complex protein 1 subunit delta 3.11 3.10E-05 3.48 1.34E-08 1.80 6.01E-05 
CCT5 P48643 T-complex protein 1 subunit epsilon 3.20 6.32E-06 4.15 2.68E-05 1.98 4.78E-05 
CCT6A P40227 T-complex protein 1 subunit zeta 3.02 1.44E-06 3.59 2.29E-05 1.55 9.88E-03 
CCT6B Q92526 T-complex protein 1 subunit zeta-2 7.63 4.10E-03 0.00 1.46E-01 0.00 1.46E-01 
CCT7 Q99832 T-complex protein 1 subunit eta 3.34 1.29E-05 4.06 1.10E-09 2.06 8.11E-04 
CCT8 P50990 T-complex protein 1 subunit theta 3.00 3.15E-05 3.57 4.72E-08 1.71 5.33E-04 
CD320 Q9NPF0 CD320 antigen 2.90 3.97E-02 4.99 2.65E-03 2.83 1.89E-03 
CD3EAP O15446 DNA-directed RNA polymerase I 
subunit RPA34 
26094533.50 1.20E-11 48373198.10 2.02E-13 13526128.20 4.70E-13 
CD97 P48960 CD97 antigen 2.76 2.19E-03 1.34 5.88E-01 1.38 2.06E-01 
CDC5L Q99459 Cell division cycle 5-like protein 244.93 1.90E-11 724.00 5.06E-14 221.95 1.42E-11 
CDK12 Q9NYV4 Cyclin-dependent kinase 12 4458910.12 3.69E-11 9031184.97 5.23E-11 4209738.41 8.74E-08 
CDK13 Q14004 Cyclin-dependent kinase 13 2805742.19 3.29E-10 4096339.22 8.45E-09 1329084.57 8.44E-04 
CDKN2A Q8N726 Tumor suppressor ARF 4500750.04 1.87E-11 11779845.11 6.32E-11 4036540.32 2.44E-05 
CEBPZ Q03701 CCAAT/enhancer-binding protein zeta 517.77 1.12E-08 1156.80 1.32E-12 350.77 1.64E-08 
CENPV Q7Z7K6 Centromere protein V 1879094.33 1.21E-08 4559722.07 8.39E-08 976098.18 1.04E-02 
CFL1;CFL2 E9PP50 Cofilin-1;Cofilin-2 3.86 6.71E-06 5.71 5.69E-08 2.92 2.55E-02 
CHERP J3QK89 Calcium homeostasis endoplasmic 
reticulum protein 
1453938.35 8.09E-04 4948587.66 2.65E-09 1901602.56 1.26E-09 
CHTOP Q5T7Y7 Chromatin target of PRMT1 protein 649462.75 1.11E-02 2737644.57 1.63E-03 911882.11 6.32E-03 
CIRBP Q14011 Cold-inducible RNA-binding protein 1130454.80 1.09E-03 7792080.88 1.24E-08 2385753.52 1.13E-09 
CLTC Q00610 Clathrin heavy chain 0.00 4.76E-06 0.00 4.76E-06 0.00 4.76E-06 
CMAS Q8NFW8 N-acylneuraminate cytidylyltransferase 1100328.06 8.88E-10 2798602.97 2.30E-10 802220.79 8.82E-04 
CMSS1 C9J384 Protein CMSS1 6874336.87 1.18E-06 21065713.53 1.12E-10 10140065.27 1.20E-12 
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COPA P53621 Coatomer subunit alpha 9.62 2.78E-06 16.88 2.39E-06 7.45 9.76E-07 
COPB2 P35606 Coatomer subunit beta 1130.79 6.08E-04 1486.33 5.00E-02 373.18 1.48E-01 
CP E9PFZ2 Ceruloplasmin 3.12 3.16E-06 3.85 8.97E-07 1.84 1.22E-03 
CPS1 P31327 Carbamoyl-phosphate synthase 
[ammonia], mitochondrial 
3.11 2.68E-03 3.35 1.58E-03 0.79 7.21E-01 
CREBBP Q92793 CREB-binding protein 2.23 9.16E-04 0.07 2.72E-04 0.00 6.54E-05 
CRELD2 Q6UXH1 Cysteine-rich with EGF-like domain 
protein 2 
1.12 8.33E-01 0.00 1.56E-03 0.00 1.56E-03 
CRIM1 Q9NZV1 Cysteine-rich motor neuron 1 protein 2.48 1.06E-04 3.08 5.97E-07 1.55 2.76E-02 
CSDE1 E9PLT0 Cold shock domain-containing protein 
E1 
13.60 8.91E-10 23.63 8.91E-10 10.50 2.19E-02 
CSE1L P55060 Exportin-2 1.32 5.38E-01 0.48 3.24E-01 2.58 1.04E-01 
CSRP1 P21291 Cysteine and glycine-rich protein 1 3.96 5.34E-04 3.99 5.25E-02 3.11 5.06E-04 
CTCF P49711 Transcriptional repressor CTCF 6439805.01 2.65E-07 14723834.74 6.82E-10 6235191.67 2.08E-12 
CTGF P29279 Connective tissue growth factor 2.71 1.68E-02 5.61 1.63E-05 1.41 3.65E-01 
CTSZ Q9UBR2 Cathepsin Z 4.36 1.39E-01 9.51 4.39E-06 4.98 5.73E-02 
CYR61 O00622 Protein CYR61 3.46 2.34E-07 4.86 3.97E-09 2.26 2.86E-04 
DAP3 P51398 28S ribosomal protein S29, 
mitochondrial 
108.40 8.07E-04 674.11 2.14E-07 337.22 2.76E-09 
DARS H7BZ35 Aspartate--tRNA ligase, cytoplasmic 4.65 4.39E-06 4.22 4.28E-03 2.29 8.37E-07 
DAZAP1 K7EQ55 DAZ-associated protein 1 3.53 4.81E-05 2.22 2.19E-05 0.84 3.34E-01 
DCD P81605 Dermcidin 0.16 2.96E-01 0.05 2.37E-01 0.01 2.18E-01 
DDX1 Q92499 ATP-dependent RNA helicase DDX1 15.21 8.97E-06 33.12 1.22E-11 9.65 1.82E-03 
DDX10 E9PIF2 Probable ATP-dependent RNA 
helicase DDX10 
1617127.56 2.56E-07 3874775.18 1.27E-05 1479226.25 1.93E-07 
DDX17 H3BLZ8 Probable ATP-dependent RNA 
helicase DDX17 
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DDX18 Q9NVP1 ATP-dependent RNA helicase DDX18 850.19 5.16E-09 2662.19 5.24E-10 638.90 4.26E-06 
DDX20 Q9UHI6 Probable ATP-dependent RNA 
helicase DDX20 
314.92 1.59E-08 591.76 4.04E-07 253.80 7.80E-04 
DDX21 Q9NR30 Nucleolar RNA helicase 2 2352.94 1.50E-08 5793.07 1.88E-18 2232.66 6.10E-10 
DDX23 F8VVA2 Probable ATP-dependent RNA 
helicase DDX23 
500342.98 1.46E-01 296792.83 3.41E-01 773868.14 7.91E-04 
DDX24 G3V529 ATP-dependent RNA helicase DDX24 31668313.97 7.80E-12 74947003.35 1.20E-14 24066698.99 1.09E-10 
DDX27 B7Z6D5 Probable ATP-dependent RNA 
helicase DDX27 
921.82 7.87E-10 2472.55 8.70E-13 711.46 5.06E-08 
DDX28 Q9NUL7 Probable ATP-dependent RNA 
helicase DDX28 
65.61 2.81E-08 183.80 2.04E-14 80.78 1.86E-10 
DDX31 F8WAJ0 Probable ATP-dependent RNA 
helicase DDX31 





ATP-dependent RNA helicase 
DDX3X;ATP-dependent RNA helicase 
DDX3Y 
3.49 1.59E-04 9.83 4.58E-09 3.43 1.66E-03 
DDX47 Q9H0S4 Probable ATP-dependent RNA 
helicase DDX47 
130.82 9.97E-07 387.20 1.28E-09 92.17 1.54E-10 
DDX5 P17844 Probable ATP-dependent RNA 
helicase DDX5 
9.96 2.00E-07 33.15 4.87E-13 9.43 2.25E-08 
DDX50 Q9BQ39 ATP-dependent RNA helicase DDX50 9992221.73 3.93E-09 25952115.57 3.28E-10 11455426.44 9.58E-10 
DDX52 Q9Y2R4 Probable ATP-dependent RNA 
helicase DDX52 
13436805.27 2.91E-09 28875617.25 3.69E-13 9194186.68 2.31E-08 
DDX54 Q8TDD1 ATP-dependent RNA helicase DDX54 399.31 7.07E-08 1079.95 4.15E-10 347.60 6.02E-08 
DDX55 F5H5U2 ATP-dependent RNA helicase DDX55 4103122.32 4.53E-09 11375027.80 3.33E-09 3047703.77 3.93E-06 
DDX56 Q9NY93 Probable ATP-dependent RNA 
helicase DDX56 
15370010.43 1.85E-10 31975348.55 6.86E-13 8586305.57 1.76E-07 
DHX15 O43143 Pre-mRNA-splicing factor ATP-
dependent RNA helicase DHX15 
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DHX30 H7BXY3 Putative ATP-dependent RNA helicase 
DHX30 
389.83 6.32E-10 1041.95 1.40E-14 331.74 5.25E-09 
DHX36 Q9H2U1 ATP-dependent RNA helicase DHX36 720.71 6.45E-11 2280.39 2.01E-13 697.88 5.10E-12 
DHX37 Q8IY37 Probable ATP-dependent RNA 
helicase DHX37 
12987763.12 3.62E-12 31441107.41 4.62E-11 9841609.99 1.12E-11 
DHX57 Q6P158 Putative ATP-dependent RNA helicase 
DHX57 
125.34 1.29E-08 296.53 2.69E-12 113.41 2.22E-11 
DHX9 Q08211 ATP-dependent RNA helicase A 135.61 6.69E-09 571.86 1.27E-14 162.29 2.33E-10 
DIDO1 Q9BTC0 Death-inducer obliterator 1 8598205.34 1.67E-14 14315963.67 4.87E-10 4978360.21 2.14E-08 
DKC1 O60832 H/ACA ribonucleoprotein complex 
subunit 4 
6297101.43 2.78E-08 17548727.79 2.96E-13 5121861.46 6.20E-06 
DNAJA3 Q96EY1 DnaJ homolog subfamily A member 3, 
mitochondrial 
13.04 1.04E-06 17.65 4.80E-09 6.26 2.98E-03 
DNAJC9 Q8WXX5 DnaJ homolog subfamily C member 9 3871940.22 2.01E-08 6773458.13 1.67E-08 3106494.68 1.58E-08 
DNTTIP2 Q5QJE6 Deoxynucleotidyltransferase terminal-
interacting protein 2 
3377173.51 3.98E-08 7993573.40 2.63E-08 2338817.24 2.14E-08 
DSC1 Q08554 Desmocollin-1 0.13 2.13E-01 0.00 1.49E-01 0.00 1.49E-01 
DSG1 Q02413 Desmoglein-1 0.10 1.84E-01 0.00 1.45E-01 0.01 1.49E-01 
DSP P15924 Desmoplakin 0.33 2.96E-01 0.05 1.46E-01 0.05 1.46E-01 
DSTN P60981 Destrin 3.28 6.93E-04 2.90 1.35E-02 1.35 5.06E-01 
DUSP9 Q99956 Dual specificity protein phosphatase 9 2.25 1.57E-01 1.39 6.90E-01 0.97 9.51E-01 
DYNC1H1 Q14204 Cytoplasmic dynein 1 heavy chain 1 1064462.03 1.66E-01 4929765.90 5.12E-02 1.00 N/A 
EBNA1BP2 H7C2Q8 Probable rRNA-processing protein 
EBP2 
7613.76 7.73E-10 17887.54 4.55E-14 4864.73 1.46E-08 
EEF1A1P5 Q5VTE0 Putative elongation factor 1-alpha-like 
3 
4.03 2.47E-06 6.24 1.02E-09 2.88 7.66E-06 
EEF1D P29692 Elongation factor 1-delta 4.58 1.81E-05 5.20 3.81E-04 2.30 8.43E-02 
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EEF2 P13639 Elongation factor 2 3.62 5.63E-07 3.66 3.65E-06 2.37 6.16E-05 
EFEMP1 Q12805 EGF-containing fibulin-like 
extracellular matrix protein 1 
4.06 3.37E-06 4.84 3.42E-06 1.83 3.84E-02 
EGFR E9PFD7 Receptor protein-tyrosine kinase 3.79 5.51E-05 0.00 8.80E-03 0.42 1.92E-01 
EIF2S1 P05198 Eukaryotic translation initiation factor 
2 subunit 1 
32.33 6.19E-10 73.07 4.06E-08 24.80 7.76E-08 
EIF2S2 P20042 Eukaryotic translation initiation factor 
2 subunit 2 





Eukaryotic translation initiation factor 
2 subunit 3;Putative eukaryotic 
translation initiation factor 2 subunit 3-
like protein 
61.40 1.07E-10 128.85 9.58E-10 49.32 1.34E-08 
EIF3A Q14152 Eukaryotic translation initiation factor 
3 subunit A 





Eukaryotic translation initiation factor 
3 subunit C;Eukaryotic translation 
initiation factor 3 subunit C-like 
protein 
3.75 1.18E-02 6.12 1.15E-05 0.56 3.28E-01 
EIF3E P60228 Eukaryotic translation initiation factor 
3 subunit E 
1.80 3.56E-01 4.27 4.90E-09 1.08 8.81E-01 
EIF3I Q13347 Eukaryotic translation initiation factor 
3 subunit I 





Eukaryotic initiation factor 4A-
I;Eukaryotic initiation factor 4A-II 
2.94 1.03E-01 2.00 4.49E-01 1.65 2.71E-01 
EIF4G1 E7EX73 Eukaryotic translation initiation factor 
4 gamma 1 
6.75 1.06E-07 11.67 1.13E-05 3.64 7.20E-03 
EIF4H Q15056 Eukaryotic translation initiation factor 
4H 





Eukaryotic translation initiation factor 
5A;Eukaryotic translation initiation 
factor 5A-1;Eukaryotic translation 
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initiation factor 5A-2;Eukaryotic 
translation initiation factor 5A-1-like 
EIF6 P56537 Eukaryotic translation initiation factor 
6 
120.83 1.85E-09 280.55 5.77E-09 81.15 2.13E-09 
ELAVL1 Q15717 ELAV-like protein 1 8.65 8.20E-07 20.83 1.40E-08 12.73 2.54E-09 
ELMSAN1 Q6PJG2 ELM2 and SANT domain-containing 
protein 1 
1476645.25 5.74E-04 1873797.40 1.14E-03 328068.23 5.15E-02 
EMG1 Q92979 Ribosomal RNA small subunit 
methyltransferase NEP1 
390025.74 5.07E-02 2174942.23 2.29E-07 982778.80 1.54E-03 
ENO1 P06733 Alpha-enolase;Enolase 3.76 1.58E-05 3.83 2.61E-08 2.44 2.28E-04 
EP300 Q09472 Histone acetyltransferase p300 2.20 2.93E-03 0.04 3.82E-06 0.02 2.96E-06 
EPRS P07814 Bifunctional glutamate/proline--tRNA 
ligase 
5.64 4.15E-07 5.99 2.12E-03 0.45 2.73E-01 
ERC1 Q8IUD2 ELKS/Rab6-interacting/CAST family 
member 1 
4.00 3.02E-05 5.24 3.00E-09 2.29 3.75E-04 
ERH P84090 Enhancer of rudimentary homolog 59.19 2.24E-04 209.60 6.32E-08 116.52 1.23E-05 
EWSR1 Q01844; RNA-binding protein EWS 2.69 1.01E-01 4.28 8.77E-03 3.01 1.48E-01 
EXOSC1 Q9Y3B2 Exosome complex component CSL4 3878612.67 8.65E-07 10018548.33 2.89E-08 1976025.50 2.04E-08 
EXOSC10 Q0178 Exosome component 10 23562201.78 2.35E-10 53391911.16 1.01E-10 12181070.19 1.42E-07 
EXOSC2 Q13868 Exosome complex component RRP4 7688695.63 1.68E-09 18011622.03 1.95E-11 4248476.92 3.41E-09 
EXOSC3 Q9NQT5 Exosome complex component RRP40 384.49 2.59E-05 974.78 1.13E-09 192.08 1.03E-05 
EXOSC4 Q9NPD3 Exosome complex component RRP41 10472455.30 6.56E-10 24248284.97 1.40E-13 4767964.71 1.00E-04 
EXOSC5 Q9NQT4 Exosome complex component RRP46 876963.41 1.61E-03 3465910.24 5.25E-07 433674.70 1.22E-02 
EXOSC6 Q5RKV6 Exosome complex component MTR3 14379220.22 5.44E-09 31515619.11 2.21E-11 7376530.95 2.16E-08 
EXOSC7 Q15024 Exosome complex component RRP42 6266664.09 2.04E-06 15275343.50 3.45E-12 2898094.38 1.30E-06 
EXOSC8 Q96B26 Exosome complex component RRP43 5970974.03 8.78E-08 14235455.49 1.27E-09 2781336.36 1.11E-05 
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FABP5 Q01469 Fatty acid-binding protein, epidermal 0.40 3.58E-01 0.00 1.14E-01 0.00 1.14E-01 
FAM111B Q6SJ93 Protein FAM111B 1763366.18 3.91E-07 3902297.87 8.00E-08 1850788.57 8.91E-04 
FAM120A Q9NZB2 Constitutive coactivator of PPAR-
gamma-like protein 1 
30.19 1.11E-12 79.23 1.26E-12 40.44 4.10E-08 
FAU P62861 40S ribosomal protein S30 152.56 3.52E-11 301.48 3.87E-10 159.26 1.54E-08 
FBL P22087 rRNA 2-O-methyltransferase fibrillarin 408.43 1.57E-08 1439.75 6.67E-13 490.32 5.81E-10 
FBLL1 A6NHQ2 rRNA/tRNA 2-O-methyltransferase 
fibrillarin-like protein 1 
399.95 3.91E-09 1116.26 9.10E-10 428.17 7.36E-11 
FBLN1 P23142 Fibulin-1 3.33 2.47E-02 2.43 2.39E-01 2.75 4.74E-02 
FBN1 P35555 Fibrillin-1 0.80 4.86E-01 0.74 3.54E-01 0.35 3.27E-02 
FBN2 P35556 Fibrillin-2 1.63 6.78E-02 1.17 6.46E-01 0.72 3.61E-01 
FBXO5 Q9UKT4 F-box only protein 5 0.60 5.70E-01 0.00 1.11E-02 0.25 9.31E-02 
FGF6 P10767 Fibroblast growth factor 6 1425299.54 1.09E-02 8960782.46 5.95E-02 1.00 N/A 
FHL2 J3KNW4 Four and a half LIM domains protein 2 2.26 1.48E-01 0.00 1.74E-03 0.75 6.48E-01 
FIP1L1 Q6UN15 Pre-mRNA 3-end-processing factor 
FIP1 
6726560.39 1.67E-09 12325968.15 8.16E-11 5085534.07 8.87E-13 
FKBP4 Q02790 Peptidyl-prolyl cis-trans isomerase 
FKBP4 
3.73 3.53E-05 0.00 1.14E-03 0.75 6.38E-01 
FMR1 Q06787 Fragile X mental retardation protein 1 497927.15 7.29E-04 946704.12 1.03E-03 564211.88 4.64E-07 
FOXK1 P85037 Forkhead box protein K1 180862.73 5.06E-02 895961.60 4.33E-03 6787496.68 3.87E-06 
FRAS1 Q86XX4 Extracellular matrix protein FRAS1 1.85 1.62E-02 1.81 1.05E-02 1.03 8.97E-01 
FST P19883 Follistatin 2.15 7.00E-02 1.21 8.09E-01 0.00 1.54E-02 
FSTL1 Q12841 Follistatin-related protein 1 2.88 1.04E-01 0.00 1.16E-02 0.19 5.92E-02 
FSTL3 O95633 Follistatin-related protein 3 2.28 2.79E-04 2.79 2.22E-06 1.49 4.21E-02 
FTSJ3 Q8IY81 pre-rRNA processing protein FTSJ3 52379643.13 1.52E-11 143012501.03 2.65E-11 45317422.01 5.03E-09 
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FUS P35637 RNA-binding protein FUS 5.43 2.17E-02 13.06 4.25E-04 6.44 4.10E-02 
FXR1 P51114 Fragile X mental retardation syndrome-
related protein 1 
104.63 6.87E-04 364.16 6.90E-06 71.94 5.26E-02 
FXR2 P51116 Fragile X mental retardation syndrome-
related protein 2 
98.39 2.50E-10 233.41 1.17E-09 87.49 6.48E-11 
G3BP1 Q13283 Ras GTPase-activating protein-binding 
protein 1 
113.58 8.36E-08 446.56 6.26E-12 146.08 9.50E-09 
G3BP2 Q9UN86 Ras GTPase-activating protein-binding 
protein 2 
65.24 1.22E-08 202.81 8.06E-13 80.42 5.59E-08 
GADD45GIP1 Q8TAE8 Growth arrest and DNA damage-
inducible proteins-interacting protein 1 
109.90 3.88E-03 914.15 2.29E-08 447.77 5.17E-10 
GAPDH P04406 Glyceraldehyde-3-phosphate 
dehydrogenase 
2.98 2.16E-04 3.09 1.94E-05 1.21 5.12E-01 
GAR1 Q9NY12 H/ACA ribonucleoprotein complex 
subunit 1 
1997153.27 4.05E-05 6034282.04 2.06E-11 1216867.31 1.28E-05 
GBE1 Q04446 1,4-alpha-glucan-branching enzyme 808294.31 3.92E-03 3342038.70 1.83E-08 1390306.68 7.24E-03 
GCN1L1 Q92616 Translational activator GCN1 0.63 6.46E-01 0.88 9.04E-01 0.49 4.63E-01 
GEMIN5 Q8TEQ6 Gem-associated protein 5 60210.38 1.46E-01 87554.86 3.41E-01 174836.14 5.35E-02 
GLTSCR2 Q9NZM5 Glioma tumor suppressor candidate 
region gene 2 protein 
12715220.98 1.84E-10 23739029.12 7.08E-12 7488386.37 7.78E-08 
GLYR1 Q49A26 Putative oxidoreductase GLYR1 2477752.45 1.64E-04 5062076.59 2.03E-03 1794308.31 1.07E-03 
GNB2L1 P63244 Receptor of activated protein C kinase 
1 
4.78 1.25E-06 2.84 3.34E-01 1.28 6.49E-01 
GNL2 Q13823 Nucleolar GTP-binding protein 2 18074569.03 6.40E-10 42342858.18 2.61E-13 11567603.34 5.21E-11 
GNL3 Q9BVP2 Guanine nucleotide-binding protein-
like 3 
12721.33 1.37E-10 29545.12 4.72E-13 8909.59 5.66E-11 
GOLGB1 Q14789 Golgin subfamily B member 1 1.79 3.91E-01 2.09 1.69E-01 1.31 4.16E-01 
GPATCH4 Q5T3I0 G patch domain-containing protein 4 83782430.17 1.16E-14 174217469.64 1.30E-14 63726450.54 1.31E-10 







Gene Name Protein ID Protein Name 










GRSF1 Q12849 G-rich sequence factor 1 9877693.25 6.83E-09 24912338.61 1.59E-08 7419850.56 1.07E-09 
GRWD1 Q9BQ67 Glutamate-rich WD repeat-containing 
protein 1 
40.80 6.88E-07 121.76 2.52E-12 30.82 3.88E-06 
GTF3C1 Q12789 General transcription factor 3C 
polypeptide 1 
374.38 5.12E-13 704.79 3.91E-13 252.03 2.95E-11 
GTF3C2 Q8WUA4 General transcription factor 3C 
polypeptide 2 
2851123.99 1.30E-10 5806749.28 5.30E-08 2211590.98 1.03E-06 
GTF3C3 Q9Y5Q9 General transcription factor 3C 
polypeptide 3 
51.00 3.19E-05 109.28 5.81E-06 25.14 1.34E-03 
GTF3C4 Q9UKN8 General transcription factor 3C 
polypeptide 4 
3320640.50 1.78E-10 8861173.92 4.63E-09 1956093.65 7.19E-06 
GTPBP4 Q9BZE4 Nucleolar GTP-binding protein 1 1864.62 1.99E-11 4962.49 7.68E-15 1520.42 3.09E-12 
H1F0 P07305 Histone H1.0;Histone H1.0, N-
terminally processed 
941.15 2.59E-11 1905.35 5.51E-14 662.41 1.39E-10 





Histone H2A;Core histone macro-
H2A.1 
1.00 N/A 1314399.34 1.83E-01 87520.12 3.41E-01 
HBA1 P69905 Hemoglobin subunit alpha 1788171.45 1.47E-01 4768193.99 8.51E-04 1205616.12 1.47E-01 
hCG_1984214
;MRPS17 
Q9Y2R5 28S ribosomal protein S17, 
mitochondrial 
19691724.02 1.35E-07 70192579.19 1.37E-11 25829622.52 6.15E-07 
HIST1H1A Q02539 Histone H1.1 96820442.32 1.20E-10 253566882.08 2.07E-13 83398499.05 2.90E-13 
HIST1H1B P16401 Histone H1.5 430.85 1.00E-07 1141.45 3.14E-12 362.82 1.42E-09 















Histone H2A type 1-C;Histone H2A 
type 3;Histone H2A type 1-
B/E;Histone H2A type 1-A;Histone 
H2AX 







Gene Name Protein ID Protein Name 























Histone H2A type 1-J;Histone H2A 
type 1-H;Histone H2A.J;Histone H2A 
type 2-C;Histone H2A type 2-
A;Histone H2A type 1-D;Histone H2A 
type 1;Histone H2A 















Histone H2B;Histone H2B type 1-
M;Histone H2B type 1-N;Histone H2B 
type 1-H;Histone H2B type 2-
F;Histone H2B type 1-
C/E/F/G/I;Histone H2B type 1-
D;Histone H2B type 1-K;Histone H2B 
type F-S 
46.57 1.92E-09 172.98 6.69E-09 59.48 3.23E-12 










Histone H2B type 2-E;Histone H2B 
type 1-B;Histone H2B type 1-
O;Histone H2B type 1-J 













Histone H3.2;Histone H3.1t;Histone 
H3.1;Histone H3;Histone H3.3 
38.78 5.86E-12 106.98 4.42E-08 42.01 2.79E-06 
HIST2H3PS2 Q5TEC6 Histone H3 12.09 9.37E-02 98.49 3.51E-04 36.83 1.08E-01 
HMGA1 P17096 High mobility group protein HMG-
I/HMG-Y 







Gene Name Protein ID Protein Name 










HNRNPA0 Q13151 Heterogeneous nuclear 
ribonucleoprotein A0 






ribonucleoprotein A1; Heterogeneous 
nuclear ribonucleoprotein A1-like 2 
9.47 1.05E-12 25.01 1.90E-10 11.12 1.52E-09 
HNRNPA2B1 P22626 Heterogeneous nuclear 
ribonucleoproteins A2/B1 
6.23 1.65E-07 18.83 1.75E-08 10.40 1.13E-07 
HNRNPA3 P51991 Heterogeneous nuclear 
ribonucleoprotein A3 
5.83 1.97E-11 14.70 1.10E-10 7.22 3.50E-10 
HNRNPAB Q99729 Heterogeneous nuclear 
ribonucleoprotein A/B 


















ribonucleoprotein C-like 2 
75.16 3.65E-05 284.21 9.73E-13 175.76 1.58E-08 
HNRNPD Q14103 Heterogeneous nuclear 
ribonucleoprotein D0 
26.80 4.07E-06 130.81 8.26E-10 52.33 2.06E-08 
HNRNPDL O14979 Heterogeneous nuclear 
ribonucleoprotein D-like 





1.80 5.77E-01 17.57 6.84E-06 5.84 4.46E-02 
HNRNPF P52597 Heterogeneous nuclear 
ribonucleoprotein F 
16.60 4.75E-09 37.39 5.38E-12 13.33 8.80E-11 
HNRNPH1 P31943 Heterogeneous nuclear 
ribonucleoprotein H 







Gene Name Protein ID Protein Name 










HNRNPH3 P31942 Heterogeneous nuclear 
ribonucleoprotein H3 
2.42 1.64E-01 4.61 5.19E-02 3.22 1.32E-01 
HNRNPK P61978 Heterogeneous nuclear 
ribonucleoprotein K 
5.05 1.40E-06 16.65 7.26E-12 7.23 2.40E-10 
HNRNPL P14866 Heterogeneous nuclear 
ribonucleoprotein L 
7.12 1.07E-04 28.08 2.28E-09 10.71 1.95E-09 
HNRNPM P52272 Heterogeneous nuclear 
ribonucleoprotein M 
94.46 2.72E-11 223.39 1.03E-12 76.19 8.36E-10 
HNRNPM M0QZM1 Heterogeneous nuclear 
ribonucleoprotein M 
704.21 1.94E-12 1260.47 7.23E-11 401.45 3.65E-09 
HNRNPR O43390 Heterogeneous nuclear 
ribonucleoprotein R 
238.44 5.58E-06 1021.16 7.04E-12 369.77 6.63E-09 
HNRNPU Q00839 Heterogeneous nuclear 
ribonucleoprotein U 
104.13 1.78E-07 396.64 3.48E-16 147.77 7.66E-09 
HNRNPUL1 Q9BUJ2 Heterogeneous nuclear 
ribonucleoprotein U-like protein 1 







ribonucleoprotein U-like protein 2 
78.45 1.54E-06 275.37 8.09E-12 121.33 8.22E-09 
HP1BP3 Q5SSJ5; Heterochromatin protein 1-binding 
protein 3 
70.15 1.14E-05 234.53 2.21E-13 71.86 7.52E-10 
HSP90AA1 P07900 Heat shock protein HSP 90-alpha 3.12 1.01E-05 3.99 9.18E-08 1.98 5.54E-08 
HSP90AB1 P08238 Heat shock protein HSP 90-beta 2.92 1.12E-05 4.06 2.25E-10 1.94 2.42E-06 





Heat shock 70 kDa protein 1B;Heat 
shock 70 kDa protein 1A 
9.90 3.88E-09 20.70 1.84E-10 8.43 1.43E-08 





Heat shock 70 kDa protein 6;Putative 
heat shock 70 kDa protein 7 
5.71 6.88E-07 9.27 7.11E-10 3.74 1.93E-05 







Gene Name Protein ID Protein Name 










HSPA9 P38646 Stress-70 protein, mitochondrial 5.00 7.39E-06 9.78 1.33E-09 3.40 3.74E-03 
HSPB1 P04792 Heat shock protein beta-1 3.08 7.47E-03 1.91 3.42E-01 1.11 8.18E-01 
HSPD1 P10809 60 kDa heat shock protein, 
mitochondrial 
3.88 7.04E-03 5.15 4.20E-02 2.52 2.19E-02 
ICT1 Q14197 Peptidyl-tRNA hydrolase ICT1, 
mitochondrial 
3490079.59 2.74E-05 22213315.92 3.83E-09 9447895.76 5.45E-08 
IGF2BP1 Q9NZI8 Insulin-like growth factor 2 mRNA-
binding protein 1 
300.86 7.29E-12 672.97 5.49E-07 297.61 7.45E-06 
IGF2BP2 Q9Y6M1 Insulin-like growth factor 2 mRNA-
binding protein 2 
1500531.08 1.11E-06 4326720.31 1.33E-06 1769976.02 5.91E-06 
IGF2BP3 O00425 Insulin-like growth factor 2 mRNA-
binding protein 3 
495.48 5.24E-08 1646.54 7.08E-12 719.50 1.35E-08 
IGFBP4 P22692 Insulin-like growth factor-binding 
protein 4 
3.29 4.34E-06 4.37 1.24E-09 2.08 1.01E-03 
IGFBP7 Q16270 Insulin-like growth factor-binding 
protein 7 
2.43 7.78E-05 2.94 1.58E-07 1.55 4.62E-02 











Ig kappa chain V-II region TEW;Ig 
kappa chain V-II region Cum;Ig kappa 
chain V-II region GM607;Ig kappa 
chain V-II region RPMI 6410 
1.02 9.76E-01 2.72 8.11E-02 1.02 9.61E-01 
ILF2 Q12905 Interleukin enhancer-binding factor 2 359.32 1.31E-08 1214.69 4.55E-11 427.59 7.56E-09 
ILF3 Q12906 Interleukin enhancer-binding factor 3 1990.45 8.09E-11 6587.53 1.39E-13 2315.21 4.56E-12 
IMP3 Q9NV31 U3 small nucleolar ribonucleoprotein 
protein IMP3 
32.17 1.66E-02 56.72 1.10E-03 20.81 2.52E-03 
IMP4 Q96G21 U3 small nucleolar ribonucleoprotein 
protein IMP4 
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ISG20L2 Q9H9L3 Interferon-stimulated 20 kDa 
exonuclease-like 2 
11527547.81 4.18E-08 19228905.64 6.90E-12 6396093.10 2.17E-07 
ISYNA1 Q9NPH2 Inositol-3-phosphate synthase 1 6.89 1.68E-02 12.05 1.13E-06 7.51 1.65E-05 
ITGB1 P05556 Integrin beta-1 2.30 1.09E-03 1.72 4.30E-02 1.61 8.30E-03 
ITGB5 P18084 Integrin beta;Integrin beta-5 1.62 5.98E-01 0.00 6.56E-02 0.00 6.56E-02 
ITGB6 P18564 Integrin beta;Integrin beta-6 4.28 1.20E-02 4.18 3.19E-02 1.77 3.05E-01 





KH domain-containing, RNA-binding, 
signal transduction-associated protein 
1;KH domain-containing, RNA-
binding, signal transduction-associated 
protein 2 
1.55 5.01E-01 5.17 8.10E-03 3.33 6.25E-03 
KHSRP Q92945 Far upstream element-binding protein 2 2.75 3.49E-05 2.91 1.62E-09 1.73 5.63E-06 
KIAA0020 Q15397 Pumilio domain-containing protein 
KIAA0020 
14908491.71 1.48E-10 31461595.35 1.78E-12 7354469.29 3.32E-06 
KIF14 Q15058 Kinesin-like protein KIF14 1542857.72 7.89E-07 2939731.02 1.25E-08 979929.50 1.69E-07 
KIF23 Q02241 Kinesin-like protein 2842897.68 2.41E-07 5402431.84 1.16E-03 1471293.70 2.05E-08 
KNOP1 Q1ED39 Lysine-rich nucleolar protein 1 2794773.78 4.03E-07 6564636.58 2.01E-08 2057802.32 6.71E-12 
KPNA2 P52292 Importin subunit alpha-1 1111.02 2.49E-13 2619.30 5.29E-09 1158.80 3.49E-09 
KPNB1 Q14974 Importin subunit beta-1 3.16 1.05E-05 3.84 6.14E-03 1.86 2.15E-03 
KRI1 Q8N9T8 Protein KRI1 homolog 13197168.36 6.11E-07 43808662.20 2.63E-12 13222227.83 1.99E-08 
KRR1 Q13601 KRR1 small subunit processome 
component homolog 
321.72 2.06E-08 1075.55 3.04E-14 355.21 5.48E-09 
LAMA1 P25391 Laminin subunit alpha-1 3.36 2.47E-03 2.75 2.99E-03 1.75 1.04E-02 
LAMA5 O15230 Laminin subunit alpha-5 3.88 1.57E-05 4.19 1.94E-02 1.65 1.39E-01 
LAP3 P28838 Cytosol aminopeptidase 2.32 4.89E-04 5.74 9.49E-02 0.00 3.25E-07 







Gene Name Protein ID Protein Name 










LARP4 Q71RC2 La-related protein 4 33.93 1.26E-07 63.32 8.71E-09 30.52 4.62E-10 






L-lactate dehydrogenase A chain;L-
lactate dehydrogenase;L-lactate 
dehydrogenase A-like 6A;L-lactate 
dehydrogenase C chain;L-lactate 
dehydrogenase B chain 
2.35 1.37E-01 0.70 7.09E-01 2.04 2.18E-01 
LDLR P01130 Low-density lipoprotein receptor 1.95 5.36E-04 2.60 2.47E-06 1.14 4.67E-01 
LGALS1 P09382 Galectin-1 4.14 2.22E-05 5.10 3.06E-08 2.85 6.68E-04 
LGALS7 P47929 Galectin-7 0.00 5.03E-02 0.00 5.03E-02 0.00 5.03E-02 
LLPH Q9BRT6 Protein LLP homolog 6382746.43 5.06E-07 15252579.12 6.91E-08 3656428.77 1.77E-07 
LMNA P02545 Prelamin-A/C;Lamin-A/C 4.22 1.28E-06 4.87 1.54E-06 2.29 8.43E-04 
LRP1 Q07954 Prolow-density lipoprotein receptor-
related protein 1 
1.85 5.24E-02 1.53 2.51E-01 1.09 8.21E-01 
LRP1B Q9NZR2 Low-density lipoprotein receptor-
related protein 1B 
1.50 2.66E-01 0.39 2.30E-01 0.00 5.06E-03 
LRP8 Q14114 Low-density lipoprotein receptor-
related protein 8 
2.27 1.83E-03 2.37 5.10E-06 1.24 1.45E-01 
LRP8 E9PP15 Low-density lipoprotein receptor-
related protein 8 
0.00 1.24E-02 1.09 9.38E-01 0.00 1.24E-02 
LRRC16A Q5VZK9 Leucine-rich repeat-containing protein 
16A 
2943921.48 1.41E-03 9367209.44 1.18E-05 3979839.04 2.97E-07 
LTBP3 Q9NS15 Latent-transforming growth factor 
beta-binding protein 3 
3.37 3.43E-01 1.17 8.99E-01 0.00 1.51E-01 
LTV1 Q96GA3 Protein LTV1 homolog 10454494.52 2.03E-09 25146922.77 9.77E-12 10119309.63 5.86E-08 
LUC7L2;C7or
f55-LUC7L2 
Q9Y383 Putative RNA-binding protein Luc7-
like 2 
51.89 1.05E-09 132.63 2.37E-09 62.26 3.11E-07 
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LYAR Q9NX58 Cell growth-regulating nucleolar 
protein 
404.15 2.85E-11 985.80 5.69E-11 277.32 3.88E-09 
MAGEB2 P43366 Melanoma-associated antigen B2 32650900.72 1.74E-11 105269713.40 1.71E-09 31334388.40 3.53E-08 
MAGT1 Q9H0U3 Magnesium transporter protein 1 1727579.46 5.03E-05 4346758.51 2.15E-05 1292343.10 8.90E-06 
MAK16 Q9BXY0 Protein MAK16 homolog 132138.19 3.41E-01 232952.63 3.41E-01 515754.59 1.33E-07 
MAP4 P27816 Microtubule-associated protein 4 97.72 4.49E-08 233.96 1.10E-11 89.66 4.14E-06 
MAP7 Q14244 Ensconsin 110.06 4.71E-07 265.45 5.75E-17 108.61 2.62E-05 
MAP7D1 Q3KQU3 MAP7 domain-containing protein 1 242.30 7.33E-08 482.08 1.61E-12 224.17 5.43E-07 
MAT2A P31153 S-adenosylmethionine synthase 
isoform type-2 
2.30 1.54E-01 0.00 2.25E-05 0.00 2.25E-05 
MATR3 P43243 Matrin-3 17.95 3.27E-07 51.08 2.57E-12 21.19 1.60E-10 
MCM3 P25205 DNA replication licensing factor 
MCM3 
0.00 1.45E-01 0.00 1.45E-01 0.28 3.21E-01 
MCM7 P33993 DNA replication licensing factor 
MCM7 
6.93 9.25E-06 9.40 1.22E-06 3.53 1.36E-02 
MEPCE Q7L2J0 7SK snRNA methylphosphate capping 
enzyme 
121.75 7.02E-07 583.88 1.90E-14 309.98 8.05E-11 
MGP P08493 Matrix Gla protein 2.16 4.82E-02 2.94 8.34E-02 2.32 3.29E-02 
MKI67 P46013 Antigen KI-67 233.60 3.14E-05 525.15 6.16E-07 154.89 9.21E-10 
MMP3 P08254 Stromelysin-1 0.83 8.45E-01 0.69 7.12E-01 1.55 6.20E-01 
MMTAG2 Q9BU76 Multiple myeloma tumor-associated 
protein 2 
93.05 5.27E-10 336.25 2.01E-12 73.58 4.31E-07 
MNT Q99583 Max-binding protein MNT 416201.06 1.36E-03 1044563.37 1.11E-02 1191572.75 5.66E-12 
MOV10 Q5JR04 Putative helicase MOV-10 1910256.04 8.42E-07 7420466.24 3.31E-06 3668062.38 1.72E-07 
MPHOSPH10 O00566 U3 small nucleolar ribonucleoprotein 
protein MPP10 
5501343.26 8.32E-09 15260352.32 4.29E-12 4443435.28 3.79E-12 







Gene Name Protein ID Protein Name 










MRPL1 Q9BYD6 39S ribosomal protein L1, 
mitochondrial 
6763441.67 2.90E-05 43532713.49 1.23E-08 18235227.66 1.27E-09 
MRPL10 Q7Z7H8 39S ribosomal protein L10, 
mitochondrial 
468568.87 1.63E-01 8277684.14 1.10E-03 2169336.44 5.73E-04 
MRPL11 Q9Y3B7 39S ribosomal protein L11, 
mitochondrial 
47463967.27 7.93E-13 122522337.67 1.16E-13 42587643.23 1.79E-10 
MRPL12 P52815 39S ribosomal protein L12, 
mitochondrial 
8448120.93 2.69E-04 80239444.20 4.90E-11 25699020.71 9.64E-06 
MRPL13 Q9BYD1 39S ribosomal protein L13, 
mitochondrial 
8.74 9.36E-04 63.95 1.14E-08 26.66 5.07E-09 
MRPL14 Q6P1L8 39S ribosomal protein L14, 
mitochondrial 
12.80 6.07E-05 67.03 7.70E-12 34.32 4.04E-11 
MRPL15 Q9P015 39S ribosomal protein L15, 
mitochondrial 
498.97 1.43E-06 2723.10 1.98E-13 1071.61 9.85E-07 
MRPL16 Q9NX20 39S ribosomal protein L16, 
mitochondrial 
65.54 4.93E-04 471.36 3.34E-10 233.15 1.25E-08 
MRPL17 Q9NRX2 39S ribosomal protein L17, 
mitochondrial 
4828522.70 3.61E-04 31204413.37 4.03E-10 13849176.80 1.42E-08 
MRPL18 Q9H0U6 39S ribosomal protein L18, 
mitochondrial 
6993823.99 7.48E-06 41749318.60 2.60E-09 18231008.22 2.86E-09 
MRPL19 P49406 39S ribosomal protein L19, 
mitochondrial 
11.60 7.51E-02 104.14 4.90E-07 95.60 5.44E-07 
MRPL2 Q5T653 39S ribosomal protein L2, 
mitochondrial 
4070971.16 3.30E-04 35308942.22 4.91E-09 17132546.52 1.14E-09 
MRPL21 Q7Z2W9 39S ribosomal protein L21, 
mitochondrial 
1.00 N/A 154720.89 3.41E-01 343661.75 4.77E-03 
MRPL22 Q9NWU5 39S ribosomal protein L22, 
mitochondrial 
11274863.06 2.56E-05 59318423.29 1.97E-09 20685920.41 3.97E-09 
MRPL23 Q16540 39S ribosomal protein L23, 
mitochondrial 
4743357.56 1.85E-05 30020110.36 2.07E-09 12802152.13 5.34E-08 
MRPL24 Q96A35 39S ribosomal protein L24, 
mitochondrial 
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MRPL27 Q9P0M9 39S ribosomal protein L27, 
mitochondrial 
2812926.50 4.17E-03 31746372.20 2.33E-09 10459477.12 2.40E-07 
MRPL28 Q13084 39S ribosomal protein L28, 
mitochondrial 
336.74 1.66E-04 2026.75 1.11E-09 883.54 1.06E-08 
MRPL3 P09001 39S ribosomal protein L3, 
mitochondrial 
101.94 2.01E-04 625.01 2.44E-12 290.80 9.08E-10 
MRPL32 Q9BYC8 39S ribosomal protein L32, 
mitochondrial 
684984.58 8.24E-02 7906124.87 3.26E-10 3813231.31 1.96E-07 
MRPL33 O75394 39S ribosomal protein L33, 
mitochondrial 
803886.21 1.24E-04 5400432.85 1.31E-08 2413662.12 4.97E-05 
MRPL34 Q9BQ48 39S ribosomal protein L34, 
mitochondrial 
839442.31 3.22E-03 6836198.99 2.06E-11 2849590.87 1.83E-06 
MRPL35 Q9NZE8 39S ribosomal protein L35, 
mitochondrial 
1772815.17 3.66E-03 14706289.51 2.40E-10 5239664.30 3.07E-08 
MRPL37 Q9BZE1 39S ribosomal protein L37, 
mitochondrial 
2118354.37 1.78E-02 19881299.47 3.41E-10 8139506.73 1.35E-06 
MRPL38 Q96DV4 39S ribosomal protein L38, 
mitochondrial 
13.78 5.65E-03 122.02 4.75E-08 57.99 1.06E-06 
MRPL39 Q9NYK5 39S ribosomal protein L39, 
mitochondrial 
4546511.16 6.52E-04 32909854.13 1.97E-09 14352737.20 4.37E-11 
MRPL4 Q9BYD3 39S ribosomal protein L4, 
mitochondrial 
5392116.18 1.10E-04 28748192.24 1.50E-12 12632309.50 1.78E-07 
MRPL41 Q8IXM3 39S ribosomal protein L41, 
mitochondrial 
2894248.12 5.96E-04 18813761.07 2.50E-10 7905367.82 9.14E-07 
MRPL43 Q8N983 39S ribosomal protein L43, 
mitochondrial 
4.77 2.51E-01 19.01 6.66E-02 14.41 1.41E-03 
MRPL45 Q9BRJ2 39S ribosomal protein L45, 
mitochondrial 
50.43 7.64E-03 531.59 3.23E-11 208.50 1.35E-07 
MRPL46 Q9H2W6 39S ribosomal protein L46, 
mitochondrial 
1029753.53 4.57E-02 13480899.56 5.53E-13 4301219.96 1.13E-05 
MRPL47 Q9HD33 39S ribosomal protein L47, 
mitochondrial 
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MRPL48 Q96GC5 39S ribosomal protein L48, 
mitochondrial 
1093703.94 2.49E-02 15432917.43 1.72E-07 5192969.12 2.55E-08 
MRPL49 Q13405 39S ribosomal protein L49, 
mitochondrial 
2145603.85 3.41E-06 12063678.07 3.17E-10 6338146.08 3.49E-09 
MRPL50 Q8N5N7 39S ribosomal protein L50, 
mitochondrial 
1109546.60 5.23E-02 13766120.59 1.61E-07 4773677.03 2.56E-07 
MRPL51 Q4U2R6 39S ribosomal protein L51, 
mitochondrial 
404396.65 5.65E-02 4284861.61 3.29E-08 1613971.32 4.41E-03 
MRPL52 Q86TS9 39S ribosomal protein L52, 
mitochondrial 
382281.59 5.27E-02 5078089.22 1.32E-06 2576030.31 2.69E-06 
MRPL53 Q96EL3 39S ribosomal protein L53, 
mitochondrial 
324944.39 1.47E-01 6492234.75 4.73E-09 402977.74 3.41E-01 
MRPL54 Q6P161 39S ribosomal protein L54, 
mitochondrial 
1677040.39 2.17E-03 8193789.07 8.45E-04 1154038.29 6.37E-02 
MRPL55 Q7Z7F7 39S ribosomal protein L55, 
mitochondrial 
829776.40 1.25E-03 5160074.31 4.58E-08 6684281.07 2.55E-08 
MRPL57 Q9BQC6 Ribosomal protein 63, mitochondrial 2055411.69 9.88E-04 13359359.98 1.16E-11 5863619.47 1.04E-08 
MRPL9 Q9BYD2 39S ribosomal protein L9, 
mitochondrial 
448.93 4.98E-04 3524.44 1.61E-09 1147.41 1.25E-06 
MRPS11 P82912 28S ribosomal protein S11, 
mitochondrial 
5009181.56 2.98E-06 20021494.74 1.89E-10 7209260.16 1.15E-08 
MRPS12 O15235 28S ribosomal protein S12, 
mitochondrial 
32.88 1.14E-09 96.19 7.25E-10 27.45 1.42E-06 
MRPS14 O60783 28S ribosomal protein S14, 
mitochondrial 
9958493.87 1.62E-07 32319479.36 2.65E-10 13975338.15 4.92E-11 
MRPS15 P82914 28S ribosomal protein S15, 
mitochondrial 
12618196.25 1.61E-07 48089476.19 1.59E-11 19399793.96 1.24E-09 
MRPS16 Q9Y3D3 28S ribosomal protein S16, 
mitochondrial 
437.30 9.05E-06 1674.82 3.08E-09 596.75 9.97E-11 
MRPS18A Q9NVS2 28S ribosomal protein S18a, 
mitochondrial 







Gene Name Protein ID Protein Name 










MRPS18B Q9Y676 28S ribosomal protein S18b, 
mitochondrial 
176.47 1.55E-06 634.88 4.31E-12 226.21 6.99E-09 
MRPS18C Q9Y3D5 28S ribosomal protein S18c, 
mitochondrial 
414032.85 7.09E-02 2319868.38 3.56E-02 1000860.11 1.58E-03 
MRPS2 Q9Y399 28S ribosomal protein S2, 
mitochondrial 
1063.16 7.54E-07 4503.59 1.06E-11 1355.31 2.08E-07 
MRPS21 P82921 28S ribosomal protein S21, 
mitochondrial 
4341890.90 1.87E-06 16447209.39 9.08E-11 5593575.11 2.68E-04 
MRPS22 P82650 28S ribosomal protein S22, 
mitochondrial 
1357.63 1.36E-06 4987.36 1.18E-13 1793.17 5.34E-08 
MRPS23 Q9Y3D9 28S ribosomal protein S23, 
mitochondrial 
19374325.65 1.92E-07 68633496.74 3.36E-11 27646796.03 1.82E-07 
MRPS25 P82663 28S ribosomal protein S25, 
mitochondrial 
122.07 9.66E-09 430.10 3.80E-12 154.45 7.55E-10 
MRPS26 Q9BYN8 28S ribosomal protein S26, 
mitochondrial 
1837.33 6.65E-07 6593.44 1.32E-08 2350.28 5.02E-09 
MRPS27 Q92552 28S ribosomal protein S27, 
mitochondrial 
6390314.63 1.47E-03 34568933.29 3.54E-09 12642978.66 1.05E-07 
MRPS28 Q9Y2Q9 28S ribosomal protein S28, 
mitochondrial 
426.84 1.32E-05 2042.62 1.47E-10 686.61 3.89E-09 
MRPS30 Q9NP92 28S ribosomal protein S30, 
mitochondrial 
691590.76 7.23E-02 8721089.69 9.54E-09 3856229.45 2.01E-07 
MRPS31 Q92665 28S ribosomal protein S31, 
mitochondrial 
7748473.46 2.04E-06 26542990.05 1.53E-10 12363410.41 3.26E-07 
MRPS33 Q9Y291 28S ribosomal protein S33, 
mitochondrial 
2574583.11 1.17E-03 11421167.31 1.88E-09 5065200.37 1.73E-06 
MRPS34 P82930 28S ribosomal protein S34, 
mitochondrial 
471.48 6.72E-07 1826.27 1.15E-12 707.50 2.29E-09 
MRPS35 P82673 28S ribosomal protein S35, 
mitochondrial 
6275347.41 1.44E-06 24196815.26 6.87E-11 9505260.10 6.21E-08 
MRPS5 P82675 28S ribosomal protein S5, 
mitochondrial 
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MRPS6 P82932 28S ribosomal protein S6, 
mitochondrial 
5521589.12 2.80E-03 25247197.09 7.62E-08 6826616.95 3.95E-03 
MRPS7 Q9Y2R9 28S ribosomal protein S7, 
mitochondrial 
19977816.72 2.70E-06 93805904.52 1.13E-12 32417579.73 3.98E-09 
MRPS9 P82933 28S ribosomal protein S9, 
mitochondrial 
16678313.26 3.60E-06 69068796.12 1.48E-11 24528426.63 1.52E-08 
MRTO4 Q9UKD2 mRNA turnover protein 4 homolog 1761366.73 2.72E-07 4386362.98 3.92E-08 917956.09 1.02E-03 
MSN P26038 Moesin 0.00 3.41E-01 41.50 1.71E-02 20.13 2.36E-02 
MT2A P02795 Metallothionein-2 2.40 6.07E-02 1.45 1.82E-01 0.91 7.76E-01 
MTDH Q86UE4 Protein LYRIC 1026.03 4.81E-14 2507.03 1.32E-14 894.05 6.12E-12 
MTMR4 Q9NYA4 Myotubularin-related protein 4 3.16 3.91E-04 1.36 6.00E-01 0.65 4.03E-01 
MYBBP1A Q9BQG0 Myb-binding protein 1A 1373.66 3.51E-11 3532.57 7.26E-13 1069.15 7.02E-10 
MYL6;MYL6B P60660;P14
649 
Myosin light polypeptide 6;Myosin 
light chain 6B 
10.62 5.65E-11 17.96 1.30E-07 6.04 3.08E-06 
NAP1L1 P55209 Nucleosome assembly protein 1-like 1 2051778.24 4.16E-08 4233291.96 2.00E-06 938725.97 1.19E-02 
NAT10 Q9H0A0 N-acetyltransferase 10 25744229.90 1.42E-10 75187417.41 3.99E-13 20769505.57 6.20E-11 
NCBP1 Q09161 Nuclear cap-binding protein subunit 1 1838.27 1.67E-07 7036.28 1.15E-10 3085.13 3.13E-07 
NCBP2 P52298 Nuclear cap-binding protein subunit 2 9709076.79 2.24E-09 37412259.94 7.33E-10 16774094.78 3.21E-11 
NCL P19338 Nucleolin 373.58 1.06E-14 952.91 1.06E-11 330.88 8.30E-13 
NEMF O60524 Nuclear export mediator factor NEMF 590793.02 1.18E-03 1798585.94 1.49E-08 392987.38 5.83E-02 
NHP2 Q9NX24 H/ACA ribonucleoprotein complex 
subunit 2 
1349869.04 5.40E-02 5112824.50 1.21E-03 1618879.94 9.27E-04 
NHP2L1 P55769 NHP2-like protein 1 18.38 1.39E-07 58.17 2.83E-09 21.56 2.42E-07 
NIFK Q9BYG3 MKI67 FHA domain-interacting 
nucleolar phosphoprotein 
11820701.42 1.65E-12 32181893.66 1.15E-12 11666478.96 6.37E-09 
NIP7 Q9Y221 60S ribosome subunit biogenesis 
protein NIP7 homolog 
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NKRF O15226 NF-kappa-B-repressing factor 17399783.29 4.38E-14 37353572.25 5.39E-13 12136464.65 3.50E-11 
NOA1 Q8NC60 Nitric oxide-associated protein 1 1255921.82 1.12E-06 4182693.96 4.98E-08 1276787.42 1.61E-06 
NOC3L Q8WTT2 Nucleolar complex protein 3 homolog 9405343.23 7.00E-08 28194740.18 2.92E-12 7719310.47 6.95E-08 
NOL10 Q9BSC4 Nucleolar protein 10 5520583.68 2.73E-11 11866849.46 1.89E-10 3739129.86 9.64E-08 
NOL12 Q9UGY1 Nucleolar protein 12 1063101.74 7.62E-06 3042187.39 1.95E-07 987789.72 1.59E-06 
NOL6 Q9H6R4 Nucleolar protein 6 6662486.59 2.99E-12 15662893.19 4.67E-14 4523765.44 2.52E-10 
NOL9 Q5SY16 Polynucleotide 5-hydroxyl-kinase 
NOL9 
731693.84 1.34E-02 2203647.56 3.62E-09 120839.66 3.41E-01 
NOM1 Q5C9Z4 Nucleolar MIF4G domain-containing 
protein 1 
3186071.82 1.86E-09 5502095.24 3.20E-08 811244.70 7.80E-02 
NONO Q15233 Non-POU domain-containing octamer-
binding protein 
3.71 4.33E-08 4.62 3.72E-09 1.93 2.65E-05 
NOP16 Q9Y3C1 Nucleolar protein 16 35983012.35 1.58E-09 90084761.15 1.10E-10 26402663.08 7.10E-10 
NOP2 P46087 Probable 28S rRNA (cytosine(4447)-
C(5))-methyltransferase 
6839.28 1.11E-13 14689.22 3.61E-15 4375.95 8.18E-13 
NOP56 O00567 Nucleolar protein 56 1577.07 1.95E-05 5180.18 9.32E-13 1597.12 6.08E-09 
NOP58 Q9Y2X3 Nucleolar protein 58 572.36 5.67E-07 2140.14 1.57E-12 680.98 3.31E-11 
NOTCH1 P46531 Neurogenic locus notch homolog 
protein 1 
1.56 7.89E-02 0.98 9.40E-01 0.46 1.10E-01 
NOTCH2 Q04721 Neurogenic locus notch homolog 
protein 2 
2.84 1.81E-06 3.74 4.52E-08 1.51 1.68E-02 
NOTCH3 Q9UM47 Neurogenic locus notch homolog 
protein 3 
3.26 7.19E-07 3.85 1.72E-07 0.70 4.56E-01 
NPM1 P06748 Nucleophosmin 943.61 5.61E-11 2291.40 3.40E-13 607.88 1.76E-10 
NSUN2 Q08J23 tRNA (cytosine(34)-C(5))-
methyltransferase 
17.24 4.66E-12 32.10 1.21E-07 9.81 7.00E-07 
NUFIP2 Q7Z417 Nuclear fragile X mental retardation-
interacting protein 2 
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NUMA1 Q14980 Nuclear mitotic apparatus protein 1 1585.40 1.23E-12 4037.41 9.84E-13 966.07 4.49E-09 
NUPL2 O15504 Nucleoporin-like protein 2 3254670.08 8.09E-08 8450637.75 4.84E-11 3444572.54 2.35E-08 
NUSAP1 Q9BXS6 Nucleolar and spindle-associated 
protein 1 
1011118.33 3.01E-07 1758659.44 2.03E-08 1008529.29 7.34E-08 
NXF1 Q9UBU9 Nuclear RNA export factor 1 2167.62 9.25E-08 7355.69 7.93E-13 2058.37 1.01E-07 
OLFML3 Q9NRN5 Olfactomedin-like protein 3 3.28 1.63E-06 3.93 1.16E-05 1.67 2.52E-01 





Polyadenylate-binding protein 1; 
Polyadenylate-binding protein 3 
19.95 3.47E-10 40.15 7.66E-10 21.39 6.30E-10 
PABPC4 P0CB38 Polyadenylate-binding protein 4 57.66 4.35E-11 140.13 7.20E-15 72.76 9.11E-14 
PABPC4 H0Y5F5 Polyadenylate-binding protein 18086908.49 5.97E-10 33966732.14 2.10E-10 19751213.30 9.99E-11 
PABPN1 Q86U42 Polyadenylate-binding protein 2 10.83 7.15E-02 74.91 6.22E-09 49.90 1.61E-06 
PAK1IP1 Q9NWT1 p21-activated protein kinase-interacting 
protein 1 
4679443.72 7.33E-10 11671131.31 4.60E-10 4340018.74 4.14E-09 






binding protein 3 
9.10 1.14E-07 15.04 2.80E-09 7.28 7.76E-08 
PCNA P12004 Proliferating cell nuclear antigen 3.63 2.72E-04 1.94 3.22E-01 1.66 1.34E-01 
PDCD11 Q14690 Protein RRP5 homolog 982.87 5.02E-09 2440.43 3.26E-11 622.78 7.63E-06 
PDIA3 H7BZJ3 Protein disulfide-isomerase A3 1.59 3.24E-01 0.54 4.44E-01 0.46 1.51E-01 
PEG10 Q86TG7 Retrotransposon-derived protein 
PEG10 
20.15 6.12E-02 109.14 3.12E-08 55.51 2.00E-07 
PES1 O00541 Pescadillo homolog 21.52 4.80E-10 56.90 8.15E-10 18.63 3.59E-09 
PGAM5 Q96HS1 Serine/threonine-protein phosphatase 
PGAM5, mitochondrial 
53.62 8.81E-09 108.07 1.21E-11 32.95 9.20E-09 
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PHAX Q9H814 Phosphorylated adapter RNA export 
protein 
1675196.32 6.47E-04 8080855.37 1.63E-10 5044103.15 3.96E-08 
PHF5A Q7RTV0 PHD finger-like domain-containing 
protein 5A 
93.18 1.00E-05 204.43 5.91E-04 40.99 1.54E-01 
PHF6 Q8IWS0 PHD finger protein 6 512.31 2.03E-07 1629.95 4.55E-13 549.15 3.89E-09 
PHGDH Q5SZU1 D-3-phosphoglycerate dehydrogenase 3.32 5.37E-06 3.95 2.22E-10 2.15 6.40E-06 
PINX1 Q96BK5 PIN2/TERF1-interacting telomerase 
inhibitor 1 
1620948.56 1.38E-02 7106484.36 2.47E-08 2963194.52 8.55E-04 
PIP P12273 Prolactin-inducible protein 0.00 1.47E-01 0.00 1.47E-01 0.00 1.47E-01 
PKM P14618;P30
613 
Pyruvate kinase 4.02 4.19E-07 5.62 1.92E-09 2.51 1.20E-07 
PLAUR Q03405 Urokinase plasminogen activator 
surface receptor 
3.28 6.60E-05 4.24 1.94E-06 1.91 1.59E-02 
PLRG1 O43660 Pleiotropic regulator 1 3218017.48 9.37E-04 12579374.57 1.32E-11 4007265.42 3.37E-07 
POLR1A O95602 DNA-directed RNA polymerase I 
subunit RPA1 
9762227.88 3.27E-11 13890713.93 9.76E-13 4846030.44 1.48E-09 
POLR1B Q9H9Y6 DNA-directed RNA polymerase I 
subunit RPA2 
377.54 3.32E-11 540.62 2.01E-11 151.77 1.98E-12 
POLR1C O15160 DNA-directed RNA polymerases I and 
III subunit RPAC1 
7056915.20 4.79E-09 12680259.64 9.20E-12 3321847.02 4.72E-07 
POLR1D Q9Y2S0 DNA-directed RNA polymerases I and 
III subunit RPAC2 
1539082.76 5.33E-09 2613073.27 8.40E-09 683528.02 1.40E-02 
POLR1E E7EX70 DNA-directed RNA polymerase I 
subunit RPA49 
14935547.13 1.77E-16 31675525.01 7.63E-12 8772362.92 3.81E-09 
POLR1E Q9GZS1 DNA-directed RNA polymerase I 
subunit RPA49 
4570262.51 1.53E-03 11136890.17 5.32E-09 3121142.18 1.60E-10 
POLR2E P19388 DNA-directed RNA polymerases I, II, 
and III subunit RPABC1 
17.87 9.30E-11 29.15 1.07E-08 9.71 1.09E-07 
POLR2H P52434 DNA-directed RNA polymerases I, II, 
and III subunit RPABC3 
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POLR3B Q9NW08 DNA-directed RNA polymerase III 
subunit RPC2 
6432470.22 1.20E-02 18708545.21 2.76E-07 6552694.72 4.33E-07 
POLRMT O00411 DNA-directed RNA polymerase, 
mitochondrial 
4260084.84 3.30E-10 10798866.88 1.17E-11 3394622.37 1.75E-08 
POM121;PO
M121C 
Q96HA1 Nuclear envelope pore membrane 
protein POM 121;Nuclear envelope 
pore membrane protein POM 121C 
1976644.63 1.67E-09 4007702.50 1.40E-07 558936.07 5.55E-02 
POP1 Q99575 Ribonucleases P/MRP protein subunit 
POP1 
46283492.12 2.30E-10 149845146.56 9.61E-14 68289075.05 1.50E-14 
POP4 O95707 Ribonuclease P protein subunit p29 243170.16 6.13E-02 1744578.84 1.58E-09 1175386.16 9.87E-07 






Suppressor of SWI4 1 homolog 10792915.68 3.28E-08 27260678.78 1.90E-10 8713089.79 5.08E-09 
PPIA P62937 Peptidyl-prolyl cis-trans isomerase A 3.14 2.60E-05 4.12 3.45E-06 2.26 2.36E-05 
PPP1CC P36873 Serine/threonine-protein phosphatase 1365430.30 1.06E-02 3653128.01 6.93E-04 446044.03 1.48E-01 
PRDX1 P32119 Peroxiredoxin-1 3.91 9.54E-06 4.58 9.39E-07 2.53 5.96E-04 
PRKCDBP Q969G5 Protein kinase C delta-binding protein 3176977.18 6.66E-06 13833247.75 1.46E-06 2978113.10 8.79E-05 
PRKRA O75569 Interferon-inducible double-stranded 
RNA-dependent protein kinase 
activator A 
1239905.66 5.62E-09 3323777.23 8.57E-07 1230823.62 1.35E-05 
PRPF19 Q9UMS4 Pre-mRNA-processing factor 19 893.52 1.65E-10 2753.41 4.81E-09 745.42 1.67E-06 
PRPF3 O43395 U4/U6 small nuclear ribonucleoprotein 
Prp3 
4382.23 1.01E-11 10159.38 1.54E-14 3549.73 9.06E-15 
PRPF4 O43172 U4/U6 small nuclear ribonucleoprotein 
Prp4 
341.62 7.39E-13 1011.63 1.04E-10 327.56 3.30E-10 
PRPF40A O75400 Pre-mRNA-processing factor 40 
homolog A 
46.27 3.12E-11 98.30 2.30E-09 29.36 3.02E-06 
PRPF4B Q13523 Serine/threonine-protein kinase PRP4 
homolog 
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PRRC2A P48634 Protein PRRC2A 16734137.90 1.86E-08 32227811.09 6.30E-12 16074270.00 1.39E-08 
PRRC2B Q5JSZ5 Protein PRRC2B 5.44 9.17E-04 4.22 1.25E-01 2.06 8.38E-02 
PRRC2C Q9Y520 Protein PRRC2C 571.20 1.75E-10 1385.71 5.55E-11 647.73 1.62E-06 
PSMC2 P35998 26S protease regulatory subunit 7 1.43 5.87E-01 0.00 9.80E-07 0.00 9.80E-07 
PSMC5 P62195 26S protease regulatory subunit 8 1.52 5.21E-01 0.44 2.72E-01 0.00 9.16E-04 
PSMD14 O00487 26S proteasome non-ATPase 
regulatory subunit 14 
1.45 7.84E-01 0.00 1.67E-01 0.00 1.67E-01 
PSMD2 Q13200 26S proteasome non-ATPase 
regulatory subunit 2 
0.97 9.76E-01 2.38 2.46E-01 1.19 7.64E-01 
PTBP1 P26599 Polypyrimidine tract-binding protein 1 11.62 6.98E-08 36.09 8.88E-08 17.74 5.25E-10 
PTCD3 Q96EY7 Pentatricopeptide repeat domain-
containing protein 3, mitochondrial 
5784282.55 1.54E-03 20933180.42 9.50E-09 6068383.02 2.48E-06 
PTRF Q6NZI2 Polymerase I and transcript release 
factor 
1602.69 3.49E-06 5600.42 3.17E-11 1571.16 9.27E-12 
PUF60 Q9UHX1 Poly(U)-binding-splicing factor PUF60 27.62 1.51E-07 77.55 3.75E-10 38.61 1.95E-06 
PURA Q00577 Transcriptional activator protein Pur-
alpha 
4885855.49 1.09E-06 11833757.83 5.71E-07 6232217.97 1.58E-10 
PURB Q96QR8 Transcriptional activator protein Pur-
beta 
10210241.74 2.22E-09 26165267.90 3.15E-11 11280600.84 5.18E-08 
PWP1 Q13610 Periodic tryptophan protein 1 homolog 5577139.55 2.98E-07 14675751.92 3.43E-07 4081306.60 5.49E-11 
RAB14 P61106 Ras-related protein Rab-14 2.41 1.77E-01 0.00 1.45E-03 0.18 1.83E-02 
RAB7A P51149 Ras-related protein Rab-7a 0.50 4.84E-01 0.00 5.39E-02 0.00 5.39E-02 
RACGAP1 Q9H0H5 Rac GTPase-activating protein 1 3511033.82 1.44E-08 6362755.39 2.53E-12 1829831.84 1.13E-08 
RALY Q5QPM0 RNA-binding protein Raly 1390083.76 4.81E-08 6685676.46 4.75E-10 3062471.82 1.05E-07 
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RBBP6 Q7Z6E9 E3 ubiquitin-protein ligase RBBP6 2044443.12 2.31E-11 3617204.54 9.27E-12 854815.31 1.36E-02 
RBM14 Q96PK6 RNA-binding protein 14 7.17 7.70E-10 11.78 8.96E-11 4.31 8.07E-08 
RBM15 Q96T37 Putative RNA-binding protein 15 544339.68 1.21E-02 1426794.14 5.22E-02 1.00 N/A 
RBM17 Q96I25 Splicing factor 45 733.50 1.12E-08 1934.41 3.29E-11 716.14 6.74E-11 
RBM19 Q9Y4C8 Probable RNA-binding protein 19 1315135.57 1.12E-02 5912409.32 3.09E-10 1735175.66 4.41E-08 
RBM25 P49756 RNA-binding protein 25 35.40 3.70E-10 74.90 1.69E-11 26.35 9.64E-11 
RBM27 Q9P2N5 RNA-binding protein 27 658.92 2.13E-08 1141.21 3.38E-09 565.83 3.23E-07 
RBM28 Q9NW13 RNA-binding protein 28 57443392.52 3.36E-11 115210529.70 4.27E-17 33257650.76 1.65E-10 
RBM34 Q5TCT4 RNA-binding protein 34 5995675.80 1.85E-09 11413505.15 5.67E-11 2824414.86 1.23E-04 
RBM39 Q14498 RNA-binding protein 39 28.51 7.01E-11 68.92 2.25E-11 29.30 1.64E-10 
RBM42 Q9BTD8 RNA-binding protein 42 4468598.89 6.61E-06 19195369.82 1.52E-15 6026228.77 5.70E-07 





RNA-binding motif protein, X 
chromosome; RNA binding motif 
protein, X-linked-like-1 
219.44 5.22E-12 1585.01 4.46E-13 776.64 1.71E-11 
RBMX2 Q9Y388 RNA-binding motif protein, X-linked 2 1746947.84 3.71E-09 3993222.13 1.44E-08 1265738.67 8.15E-04 
REPIN1 Q9BWE0 Replication initiator 1 2383846.86 1.09E-05 3744301.96 1.67E-09 2295698.88 1.80E-02 
REXO4 Q9GZR2 RNA exonuclease 4 22343108.69 1.33E-08 51936656.49 4.45E-15 15389916.51 2.17E-08 
RFC1 P35251 Replication factor C subunit 1 648.98 3.35E-14 1546.42 1.49E-10 466.88 2.65E-10 
RFC2 P35250 Replication factor C subunit 2 4206202.52 5.86E-07 12717348.93 1.15E-09 2990078.24 5.04E-06 
RFC4 P35249 Replication factor C subunit 4 113.22 2.74E-06 313.00 1.92E-10 91.21 1.23E-07 
RFC5 P40937 Replication factor C subunit 5 1158703.02 1.18E-03 1384346.90 6.89E-02 591487.90 2.70E-02 
RNMTL1 Q9HC36 rRNA methyltransferase 3, 
mitochondrial 
4175925.14 7.36E-09 12716516.08 4.34E-06 2966811.02 1.11E-06 
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RPL10 P27635 60S ribosomal protein L10 185.59 5.47E-12 453.42 1.14E-14 167.48 8.10E-09 
RPL10A P62906 60S ribosomal protein L10a 364.81 7.58E-09 812.06 1.65E-13 265.52 3.49E-10 
RPL11 P62913 60S ribosomal protein L11 33.36 1.53E-12 99.21 1.71E-14 31.00 1.02E-08 
RPL12 P30050 60S ribosomal protein L12 56.64 5.02E-11 113.08 8.62E-11 35.84 5.40E-08 
RPL13 P26373 60S ribosomal protein L13 464.22 8.43E-10 981.77 1.42E-14 358.81 2.10E-08 
RPL13A P40429 60S ribosomal protein L13a 753.02 6.96E-13 1670.90 9.18E-15 615.47 3.59E-08 
RPL14 P50914 60S ribosomal protein L14 944.50 2.40E-11 1950.92 1.48E-13 662.78 1.81E-06 
RPL15 P61313 60S ribosomal protein L15 477.95 5.21E-11 1083.22 2.91E-11 338.64 7.66E-10 
RPL17 P18621 60S ribosomal protein L17 386.29 6.43E-12 940.61 8.63E-14 332.40 5.52E-11 
RPL18 Q07020 60S ribosomal protein L18 371.92 3.56E-08 698.99 2.81E-13 236.63 5.36E-10 
RPL18A Q02543 60S ribosomal protein L18a 546.92 5.45E-11 1188.16 6.34E-12 380.34 3.09E-11 
RPL19 P84098 60S ribosomal protein L19 210.99 1.22E-09 587.19 6.41E-13 238.41 1.64E-09 
RPL21 P46778 60S ribosomal protein L21 804.26 1.03E-10 1759.98 1.03E-12 664.08 1.12E-06 
RPL22 P35268 60S ribosomal protein L22 86.75 3.08E-07 396.31 2.33E-07 111.57 1.32E-10 
RPL23 P62829 60S ribosomal protein L23 58.32 1.20E-13 165.99 1.69E-10 58.76 2.17E-09 
RPL23A P62750 60S ribosomal protein L23a 272.77 1.64E-12 812.30 1.26E-11 298.94 1.03E-08 
RPL24 P83731 60S ribosomal protein L24 282.23 3.43E-09 588.35 5.37E-15 259.31 1.79E-10 
RPL26 P61254 60S ribosomal protein L26 175.48 2.77E-12 451.07 3.17E-12 187.86 6.82E-09 
RPL26L1 Q9UNX3 60S ribosomal protein L26-like 1 226.18 1.97E-08 679.54 6.15E-10 219.18 3.64E-10 
RPL27 P61353 60S ribosomal protein L27 2099.40 1.04E-13 4585.31 2.03E-12 1367.92 8.47E-09 
RPL27A P46776 60S ribosomal protein L27a 254.37 5.46E-10 606.99 1.21E-14 215.90 7.66E-09 
RPL28 P46779 60S ribosomal protein L28 338.54 5.78E-10 639.99 4.84E-13 239.42 8.10E-09 
RPL29 P47914 60S ribosomal protein L29 420.14 1.24E-08 792.41 1.35E-14 319.65 4.14E-09 
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RPL30 P62888 60S ribosomal protein L30 305.09 1.09E-08 637.13 7.00E-14 182.64 7.99E-11 
RPL31 P62899 60S ribosomal protein L31 259.20 3.59E-11 736.90 1.45E-14 322.97 2.57E-09 
RPL32 P62910 60S ribosomal protein L32 606.69 1.34E-12 1533.21 5.19E-13 435.23 7.74E-07 
RPL34 P49207 60S ribosomal protein L34 420.44 7.95E-10 798.74 2.06E-13 273.87 8.30E-09 
RPL35 P42766 60S ribosomal protein L35 319.71 1.06E-09 859.22 3.39E-13 331.90 2.06E-08 
RPL35A P18077 60S ribosomal protein L35a 768.86 5.64E-09 1681.73 8.14E-13 606.02 6.86E-10 






60S ribosomal protein L36a 254.08 3.49E-10 657.61 1.86E-14 217.55 5.62E-10 
RPL36AL Q969Q0 60S ribosomal protein L36a-like 328.21 2.54E-10 873.70 2.14E-11 306.22 4.44E-10 
RPL37 P61927 60S ribosomal protein L37 198.47 2.27E-07 431.68 8.94E-08 197.90 1.86E-11 
RPL37A P61513 60S ribosomal protein L37a 3009.23 3.99E-09 7033.06 1.50E-15 2303.99 9.22E-10 





60S ribosomal protein L39 560.81 1.73E-07 1276.89 1.47E-09 604.28 1.77E-07 
RPL4 P36578 60S ribosomal protein L4 678.42 9.68E-14 1413.07 1.43E-14 458.36 5.72E-09 
RPL5 P46777 60S ribosomal protein L5 458.01 3.81E-13 1957.36 1.29E-14 436.25 1.81E-07 
RPL6 Q02878 60S ribosomal protein L6 1314.50 9.30E-09 2710.91 2.56E-19 898.99 1.62E-08 
RPL7 P18124 60S ribosomal protein L7 620.36 6.96E-10 1308.88 1.27E-19 449.74 3.14E-12 
RPL7A P62424 60S ribosomal protein L7a 612.10 1.75E-11 1201.97 5.71E-16 426.88 8.10E-10 
RPL8 P62917 60S ribosomal protein L8 451.95 1.30E-10 877.18 1.81E-18 310.72 1.01E-08 





60S acidic ribosomal protein P0;60S 
acidic ribosomal protein P0-like 
114.12 3.23E-10 211.85 3.58E-07 79.02 2.37E-08 
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RPLP2 P05387 60S acidic ribosomal protein P2 432.52 1.40E-09 786.55 3.16E-08 281.79 1.98E-07 
RPN1 P04843 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1 
714.25 3.84E-09 2061.21 1.55E-11 562.99 6.68E-09 
RPP25 Q9BUL9 Ribonuclease P protein subunit p25 1205567.68 1.49E-07 2442240.47 2.26E-11 1546064.41 9.68E-04 
RPP30 P78346 Ribonuclease P protein subunit p30 1338493.38 3.28E-14 3520217.17 6.32E-08 2811676.16 9.30E-08 
RPP38 P78345 Ribonuclease P protein subunit p38 40.35 7.92E-09 101.02 7.42E-04 122.77 8.20E-06 
RPP40 O75818 Ribonuclease P protein subunit p40 1.00 N/A 480379.07 1.68E-01 1.00 N/A 
RPS10;RPS10
-NUDT3 
P46783 40S ribosomal protein S10 67.03 1.12E-12 132.23 2.21E-14 78.50 8.23E-08 
RPS11 P62280 40S ribosomal protein S11 92.07 7.50E-12 245.35 1.83E-12 83.96 5.11E-09 
RPS12 P25398 40S ribosomal protein S12 349.64 3.89E-06 1255.17 1.08E-07 437.50 5.61E-07 
RPS13 P62277 40S ribosomal protein S13 227.67 9.78E-14 679.19 3.20E-11 245.01 1.29E-12 
RPS14 P62263 40S ribosomal protein S14 143.12 2.83E-11 460.03 7.58E-11 157.33 7.47E-10 
RPS15 P62841 40S ribosomal protein S15 224.01 2.43E-12 685.52 1.91E-14 241.61 4.02E-07 
RPS15A P62244 40S ribosomal protein S15a 18.18 1.51E-11 57.71 1.01E-12 14.94 2.12E-12 





40S ribosomal protein S17-like;40S 
ribosomal protein S17 
68.56 1.22E-10 190.11 1.81E-08 54.94 3.89E-05 
RPS18 P62269 40S ribosomal protein S18 12.30 6.36E-09 24.08 2.44E-10 11.90 9.35E-07 
RPS19 P39019 40S ribosomal protein S19 160.74 3.20E-12 372.40 1.10E-09 190.35 3.60E-07 
RPS19BP1 Q86WX3 Active regulator of SIRT1 1843718.92 1.66E-06 4760920.49 7.82E-04 1353390.40 1.20E-08 
RPS2 P15880 40S ribosomal protein S2 178.46 5.09E-12 496.60 4.82E-13 178.26 6.98E-16 
RPS20 P60866 40S ribosomal protein S20 19.28 2.56E-13 48.24 1.59E-07 17.30 1.25E-07 
RPS23 P62266 40S ribosomal protein S23 226.80 1.91E-09 592.36 1.12E-13 192.19 2.94E-11 
RPS24 P62847 40S ribosomal protein S24 214.94 6.11E-11 533.19 3.68E-12 233.46 1.04E-08 







Gene Name Protein ID Protein Name 












P62854 40S ribosomal protein S26;Putative 
40S ribosomal protein S26-like 1 
177.70 1.03E-08 443.30 2.52E-12 159.34 8.35E-11 
RPS27 P42677 40S ribosomal protein S27 25.75 1.87E-09 62.94 1.21E-10 24.00 6.76E-08 
RPS27A P62979 40S ribosomal protein S27a 221.24 4.54E-10 704.31 1.26E-10 273.37 5.13E-12 
RPS27L Q71UM5 40S ribosomal protein S27-like 47.93 5.31E-05 95.75 9.55E-04 37.68 1.45E-03 
RPS28 P62857 40S ribosomal protein S28 19.17 3.44E-11 37.26 2.87E-10 17.81 1.42E-06 
RPS29 P62273 40S ribosomal protein S29 175.91 2.40E-06 456.19 7.06E-08 177.30 3.35E-05 
RPS3 P23396 40S ribosomal protein S3 11.75 3.88E-12 25.46 1.56E-11 10.16 2.77E-11 
RPS3A P61247 40S ribosomal protein S3a 214.07 2.16E-11 629.81 4.08E-13 239.83 1.41E-09 
RPS4X P62701; 40S ribosomal protein S4, X isoform 138.71 1.65E-11 406.07 1.85E-12 112.10 1.60E-11 
RPS5 P46782 40S ribosomal protein S5 53.54 3.54E-13 141.80 1.14E-08 51.85 2.51E-07 
RPS6 P62753 40S ribosomal protein S6 325.12 2.01E-13 834.97 1.93E-16 319.57 8.45E-10 
RPS7 P62081 40S ribosomal protein S7 394.24 3.30E-08 1255.27 5.58E-11 412.25 5.51E-06 
RPS8 P62241 40S ribosomal protein S8 286.76 1.77E-12 725.89 8.87E-15 266.01 1.21E-11 





40S ribosomal protein SA 4.41 1.42E-07 6.86 2.12E-09 2.41 2.84E-07 
RRBP1 Q9P2E9 Ribosome-binding protein 1 1940.34 5.75E-11 4350.98 3.14E-10 1348.23 3.65E-08 
RRP1 P56182 Ribosomal RNA processing protein 1 
homolog A 
11750617.85 3.48E-11 30014946.73 3.00E-10 11921855.73 1.25E-11 
RRP12 Q5JTH9 RRP12-like protein 44077013.59 2.94E-12 119691226.06 7.17E-15 39283618.33 5.41E-14 
RRP15 Q9Y3B9 RRP15-like protein 12169382.61 3.68E-11 34035191.85 7.12E-12 10322686.79 3.85E-08 
RRP1B Q14684 Ribosomal RNA processing protein 1 
homolog B 





Putative ribosomal RNA-processing 
protein 7 homolog B;Ribosomal RNA-
processing protein 7 homolog A 
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RRP8 O43159 Ribosomal RNA-processing protein 8 6628507.37 8.37E-07 17334298.43 6.53E-11 3569809.63 3.52E-04 
RRP9 O43818 U3 small nucleolar RNA-interacting 
protein 2 
1.28 8.65E-01 40.05 1.21E-10 35.97 2.52E-09 
RRS1 Q15050 Ribosome biogenesis regulatory 
protein homolog 
14047037.34 4.09E-09 43088530.45 1.89E-10 16249075.50 1.30E-12 
RSBN1 Q5VWQ0 Round spermatid basic protein 1 15241063.05 4.55E-10 35315049.74 2.19E-13 13310896.41 1.80E-12 
RSBN1L Q6PCB5 Round spermatid basic protein 1-like 
protein 
4823244.15 1.37E-14 11682680.07 4.40E-10 3436013.10 1.12E-09 
RSL1D1 O76021 Ribosomal L1 domain-containing 
protein 1 
1514.87 2.13E-09 3633.23 1.82E-13 1053.49 5.94E-07 
RTCB Q9Y3I0 tRNA-splicing ligase RtcB homolog 16.31 4.76E-09 42.19 1.74E-09 13.34 7.42E-08 
RUVBL1 Q9Y265 RuvB-like 1 4.37 1.13E-06 5.97 4.23E-05 1.95 2.58E-03 
RUVBL2 Q9Y230 RuvB-like 2 3.96 1.05E-08 6.12 4.99E-05 2.19 1.80E-05 
SAFB Q15424 Scaffold attachment factor B1 79542.37 3.41E-01 3426294.67 9.49E-09 1796779.53 2.37E-10 
SARS P49591 Serine--tRNA ligase, cytoplasmic 3.29 4.60E-04 4.58 6.33E-02 0.87 8.23E-01 
SART1 O43290 U4/U6.U5 tri-snRNP-associated 
protein 1 
5549992.73 6.57E-09 12937996.85 7.98E-11 4169231.76 7.45E-11 
SART3 Q15020 Squamous cell carcinoma antigen 
recognized by T-cells 3 
4474814.32 1.42E-08 14389142.82 1.55E-12 5123910.91 1.18E-07 
SCFD1 Q8WVM8 Sec1 family domain-containing protein 
1 
2.95 1.91E-04 3.71 1.93E-06 1.53 1.66E-01 
SEC23A Q15436 Protein transport protein Sec23A 3.65 7.15E-03 5.00 3.72E-02 2.47 1.04E-03 
SEC23B Q15437 Protein transport protein Sec23B 2.44 3.40E-05 2.66 1.51E-02 1.71 2.63E-03 
SEC24C P53992 Protein transport protein Sec24C 2.55 2.35E-03 0.47 1.63E-01 1.41 2.54E-01 
SEC24D O94855 Protein transport protein Sec24D 2.00 6.77E-03 1.99 5.49E-02 1.05 8.93E-01 
SEC31A O94979 Protein transport protein Sec31A 0.80 8.14E-01 0.00 3.07E-03 0.00 3.07E-03 
SERBP1 Q8NC51 Plasminogen activator inhibitor 1 
RNA-binding protein 
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SF3B1 O75533 Splicing factor 3B subunit 1 12.70 2.61E-10 32.65 7.12E-11 13.58 1.77E-08 
SF3B2 Q13435 Splicing factor 3B subunit 2 182.06 5.73E-07 447.07 1.57E-08 168.31 7.69E-09 
SF3B3 Q15393 Splicing factor 3B subunit 3 2.62 9.34E-04 3.80 1.32E-02 1.74 2.73E-01 
SF3B4 Q15427 Splicing factor 3B subunit 4 13.76 7.13E-02 37.28 5.54E-02 22.93 1.14E-05 
SF3B6 Q9Y3B4 Splicing factor 3B subunit 6 15.63 1.20E-08 36.30 6.14E-07 7.41 9.11E-02 
SFPQ P23246 Splicing factor, proline- and glutamine-
rich 
3.66 1.48E-06 4.66 2.60E-11 2.26 2.08E-06 
SHMT1 P34896 Serine hydroxymethyltransferase, 
cytosolic 
2.41 8.09E-04 2.75 3.75E-05 1.35 1.43E-02 
SKIV2L2 P42285 Superkiller viralicidic activity 2-like 2 2141445.00 8.81E-08 4199911.60 2.57E-09 1596110.86 8.52E-06 
SLC25A3 Q00325 Phosphate carrier protein, 
mitochondrial 





ADP/ATP translocase 2;ADP/ATP 
translocase 2, N-terminally 
processed;ADP/ATP translocase 1 
5.04 1.49E-08 8.52 9.74E-12 3.13 6.56E-08 
SLC25A6 P12236 ADP/ATP translocase 3 8.32 5.79E-06 9.91 2.09E-07 6.26 1.46E-05 
SLPI P03973 Antileukoproteinase 2.71 1.06E-01 2.29 4.08E-01 1.60 3.97E-01 
SLTM Q9NWH9 SAFB-like transcription modulator 4033198.70 4.67E-08 16206850.84 1.34E-10 7463089.81 1.60E-09 
SMARCA4 P51532;P51
531 
Transcription activator BRG1 5.86 2.39E-07 7.94 1.16E-07 3.20 8.05E-05 
SMARCA5 O60264 SWI/SNF-related matrix-associated 
actin-dependent regulator of chromatin 
subfamily A member 5 





SWI/SNF complex subunit 
SMARCC2;SWI/SNF complex subunit 
SMARCC1 
4.17 6.06E-07 7.47 3.21E-03 2.43 1.30E-04 
SMARCE1 Q969G3 SWI/SNF-related matrix-associated 
actin-dependent regulator of chromatin 
subfamily E member 1 
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SND1 Q7KZF4 Staphylococcal nuclease domain-
containing protein 1 
2.94 2.87E-05 3.99 5.32E-08 1.96 1.58E-05 
SNRNP70 P08621 U1 small nuclear ribonucleoprotein 70 
kDa 
84.62 2.08E-09 290.58 3.84E-13 120.28 4.94E-11 
SNRPA P09012;P08
579 
U1 small nuclear ribonucleoprotein A 5264082.84 8.96E-11 19638942.10 2.99E-10 8650662.12 1.95E-10 
SNRPC P09234 U1 small nuclear ribonucleoprotein C 5705972.67 6.10E-06 17694308.78 2.60E-10 5277157.06 3.23E-07 
SNRPD2 P62316 Small nuclear ribonucleoprotein Sm D2 18.22 1.56E-11 49.19 1.82E-09 18.67 7.85E-12 
SNRPD3 P62318 Small nuclear ribonucleoprotein Sm D3 22.99 2.83E-08 56.00 1.40E-08 24.84 2.93E-09 
SNRPE P62304 Small nuclear ribonucleoprotein E 3.18 9.78E-03 3.44 7.92E-03 2.74 1.99E-04 
SNRPF P62306 Small nuclear ribonucleoprotein F 5.52 4.98E-03 13.88 7.21E-08 5.74 4.20E-06 
SNRPG Q49AN9 Small nuclear ribonucleoprotein 
G;Putative small nuclear 
ribonucleoprotein G-like protein 15 
8.06 3.70E-03 10.72 9.82E-02 6.92 3.71E-03 
SP110 Q9HB58 Sp110 nuclear body protein 1175989.53 7.56E-08 3064779.65 1.27E-07 966877.52 1.08E-03 
SPATS2 Q86XZ4 Spermatogenesis-associated serine-rich 
protein 2 
8758549.79 1.80E-09 18667957.99 1.23E-11 6983861.53 1.22E-10 
SPATS2L Q9NUQ6 SPATS2-like protein 9581477.62 2.54E-07 18644138.67 1.23E-14 7004295.69 1.40E-06 
SPTY2D1 Q68D10 Protein SPT2 homolog 568.58 1.97E-09 846.29 4.19E-12 299.33 4.41E-11 
SRFBP1 Q8NEF9 Serum response factor-binding protein 
1 
10704871.34 1.29E-07 27153797.24 1.77E-13 11828465.39 2.46E-11 
SRP14 P37108 Signal recognition particle 14 kDa 
protein 
1604.34 1.58E-09 4430.29 2.84E-13 1537.14 5.96E-12 
SRP68 Q9UHB9 Signal recognition particle subunit 
SRP68 
1335065.92 1.14E-03 5056968.32 4.55E-09 1372625.04 1.43E-04 
SRP72 O76094 Signal recognition particle subunit 
SRP72 
2157234.94 6.56E-09 8036992.30 2.92E-08 1160467.75 1.14E-02 
SRP9 P49458 Signal recognition particle 9 kDa 
protein 
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SRPK1 Q96SB4 SRSF protein kinase 1 718.79 2.24E-08 1596.87 2.46E-14 841.64 2.45E-12 
SRPK2 P78362 SRSF protein kinase 2 1183.55 3.95E-10 1950.17 3.02E-08 974.98 1.53E-11 
SRRM1 Q8IYB3 Serine/arginine repetitive matrix 
protein 1 
1497.68 2.62E-08 3229.70 1.59E-12 1531.38 1.10E-11 
SRRM2 Q9UQ35 Serine/arginine repetitive matrix 
protein 2 
24.65 2.81E-09 49.38 2.44E-15 22.14 9.02E-14 
SRSF1 Q07955 Serine/arginine-rich splicing factor 1 4313.31 1.60E-08 31890.95 7.59E-11 47.78 1.17E-02 
SRSF10 Q8WXF0 Serine/arginine-rich splicing factor 10 584474.92 1.43E-02 10401100.97 6.55E-08 4287717.74 1.18E-09 
SRSF11 Q05519 Serine/arginine-rich splicing factor 11 278072.55 5.41E-02 1966376.08 8.77E-08 687182.86 1.06E-02 
SRSF2 Q01130 Serine/arginine-rich splicing factor 2 0.61 5.46E-01 1.07 9.13E-01 1788.83 1.01E-10 
SRSF3 P84103 Serine/arginine-rich splicing factor 3 682.37 3.06E-07 3280.19 3.45E-14 905.57 5.31E-09 
SRSF4 Q08170 Serine/arginine-rich splicing factor 4 3883068.59 5.75E-10 10741012.04 3.75E-08 5148243.03 2.19E-09 
SRSF5 Q13243 Serine/arginine-rich splicing factor 5 8179006.41 2.84E-07 20715697.30 2.34E-08 8669549.15 4.85E-09 
SRSF6 Q13247 Serine/arginine-rich splicing factor 6 537.07 1.01E-08 1395.31 7.49E-19 575.44 5.34E-12 
SRSF7 Q16629 Serine/arginine-rich splicing factor 7 21122141.82 1.53E-06 99865116.33 8.49E-10 36022591.57 9.16E-07 
SRSF9 Q13242 Serine/arginine-rich splicing factor 9 1589.55 1.81E-04 5018.78 2.48E-11 895.74 1.20E-04 
SSB P05455 Lupus La protein 210.20 1.41E-05 1011.94 3.55E-12 394.41 4.94E-08 
SSR4 P51571 Translocon-associated protein subunit 
delta 
3.88 4.74E-04 1.01 9.90E-01 2.26 2.19E-01 
STAU1 O95793 Double-stranded RNA-binding protein 
Staufen homolog 1 
1188852.61 1.33E-02 5560338.74 5.66E-07 1077324.63 1.11E-02 
STAU2 Q9NUL3 Double-stranded RNA-binding protein 
Staufen homolog 2 
12062303.51 1.27E-09 28142604.20 8.63E-11 10480574.33 1.49E-08 
STT3B Q8TCJ2 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
STT3B 
32528877.16 1.29E-09 88483481.31 4.00E-11 32990017.51 1.36E-13 
SUGP2 Q8IX01 SURP and G-patch domain-containing 
protein 2 
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SUPT16H Q9Y5B9 FACT complex subunit SPT16 1902265.43 1.46E-02 6083863.97 2.31E-07 528779.10 6.73E-02 
SURF6 O75683 Surfeit locus protein 6 4434.71 9.01E-12 8570.25 1.24E-12 3100.23 1.50E-09 
SUZ12 Q15022 Polycomb protein SUZ12 1327429.17 6.96E-04 2463489.08 4.72E-09 779367.48 6.60E-04 
SYNCRIP O60506 Heterogeneous nuclear 
ribonucleoprotein Q 
118.70 1.46E-07 512.33 3.41E-17 170.27 5.67E-09 
TAF15 Q92804 TATA-binding protein-associated 
factor 2N 
2.78 4.00E-02 5.29 1.14E-02 3.67 1.43E-01 
TAGLN2 P37802 Transgelin-2 2.63 3.34E-02 2.40 1.33E-01 2.34 1.07E-02 
TARDBP Q13148 TAR DNA-binding protein 43 3.70 1.84E-05 4.44 2.36E-06 2.66 5.76E-05 
TCEB1 Q15369 Transcription elongation factor B 
polypeptide 1 
30.37 3.75E-07 85.58 4.95E-07 17.83 3.09E-02 
TCEB3 Q14241 Transcription elongation factor B 
polypeptide 3 
10345290.29 2.22E-10 26563255.90 6.42E-10 9372990.60 4.70E-09 
TCP1 P17987 T-complex protein 1 subunit alpha 2.85 5.31E-05 3.38 9.31E-09 1.94 4.91E-05 
TDG Q13569 G/T mismatch-specific thymine DNA 
glycosylase 
4.27 1.57E-02 7.49 7.78E-07 4.98 1.79E-04 
TENM4 Q6N022 Teneurin-4 4.81 4.73E-02 9.05 1.55E-06 3.74 2.38E-02 
THRAP3 Q9Y2W1 Thyroid hormone receptor-associated 
protein 3 
257.27 8.80E-08 618.45 4.16E-12 470.32 1.33E-14 
THUMPD1 Q9NXG2 THUMP domain-containing protein 1 138706.73 2.64E-01 3176164.10 1.50E-02 30415956.28 6.74E-06 
TIMP1 P01033 Metalloproteinase inhibitor 1 0.52 4.50E-01 0.00 1.31E-02 2.08 3.03E-01 
TKT P29401 Transketolase 1.79 2.73E-01 2.21 2.41E-01 1.02 9.59E-01 
TLN2 Q9Y4G6 Talin-2 445.47 8.40E-04 803.94 1.03E-02 301.24 5.30E-02 
TOP1 P11387 DNA topoisomerase 1 1013.18 3.60E-09 2642.80 1.83E-11 962.68 1.23E-10 
TRA2A Q13595 Transformer-2 protein homolog alpha 4394790.63 9.52E-08 18552636.97 1.29E-10 9099389.85 5.46E-08 
TRA2B P62995 Transformer-2 protein homolog beta 345.92 2.02E-11 1633.37 5.87E-16 842.84 4.89E-11 
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TRIM28 Q13263 Transcription intermediary factor 1-
beta 
6.05 1.77E-10 9.95 5.18E-15 4.14 1.02E-08 
TRIM56 Q9BRZ2 E3 ubiquitin-protein ligase TRIM56 2748523.65 1.92E-10 6397124.06 3.10E-11 1930536.05 1.14E-03 
TRIP12 Q14669 E3 ubiquitin-protein ligase TRIP12 21945732.32 6.93E-11 46619230.34 9.74E-11 16610139.28 3.37E-12 
TRMT6 Q9UJA5 tRNA (adenine(58)-N(1))-
methyltransferase non-catalytic subunit 
TRM6 
10520419.24 3.17E-09 25031990.41 5.55E-08 9124505.59 2.20E-10 
TRMT61A Q96FX7 tRNA (adenine(58)-N(1))-
methyltransferase catalytic subunit 
TRMT61A 
1297729.74 6.72E-06 3401759.11 3.88E-11 1348956.14 9.73E-04 
TSR1 Q2NL82 Pre-rRNA-processing protein TSR1 
homolog 









Tubulin alpha-1B chain;Tubulin alpha-
1A chain;Tubulin alpha-1C 
chain;Tubulin alpha-3C/D 
chain;Tubulin alpha-3E chain;Tubulin 
alpha-8 chain 
3.70 8.63E-06 4.32 5.72E-09 2.31 5.30E-05 
TUBA4A P68366 Tubulin alpha-4A chain 3.64 1.16E-04 4.91 4.76E-05 2.32 1.94E-02 





Tubulin beta-4B chain;Tubulin beta-4A 
chain 
4.34 4.78E-06 5.07 3.55E-10 2.76 3.28E-06 
TUBB6 Q9BUF5 Tubulin beta-6 chain 1.00 N/A 221303.93 3.41E-01 1.00 N/A 
TUBB8 Q3ZCM7 Tubulin beta-8 chain 13.68 1.17E-06 18.71 4.66E-06 5.56 1.56E-03 
TUFM P49411 Elongation factor Tu, mitochondrial 4.49 1.73E-04 5.40 1.89E-05 2.75 8.44E-06 
U2AF1;U2AF
1L4 
Q01081 Splicing factor U2AF 35 kDa 
subunit;Splicing factor U2AF 26 kDa 
subunit 
53.78 7.44E-08 167.68 2.44E-07 76.76 2.09E-05 







Gene Name Protein ID Protein Name 










U2SURP O15042 U2 snRNP-associated SURP motif-
containing protein 
3646402.28 3.71E-06 11626157.78 1.00E-06 3348409.42 2.39E-07 
UBA1 P22314 Ubiquitin-like modifier-activating 
enzyme 1 
2.68 6.93E-05 2.80 8.66E-05 1.37 1.79E-01 
UBA52 P62987 Ubiquitin-60S ribosomal protein L40 2318561.97 5.26E-10 4953085.01 2.03E-05 1418999.06 1.42E-02 
UPF1 Q92900 Regulator of nonsense transcripts 1 38.16 1.31E-07 74.90 2.17E-09 42.63 5.81E-07 
UPF3B Q9BZI7 Regulator of nonsense transcripts 3B 2659610.98 4.27E-11 6368862.91 6.84E-13 3330948.96 2.84E-09 
UTP14A Q9BVJ6 U3 small nucleolar RNA-associated 
protein 14 homolog A 
12712364.62 1.48E-12 29661488.08 5.96E-11 10528233.95 3.16E-10 
UTP18 Q9Y5J1 U3 small nucleolar RNA-associated 
protein 18 homolog 
1488230.46 3.72E-12 3703342.73 1.49E-07 814605.86 7.72E-04 
UTP23 Q9BRU9 rRNA-processing protein UTP23 
homolog 
2.64 1.31E-05 2.84 2.03E-05 1.44 2.49E-02 
UTP3 Q9NQZ2 Something about silencing protein 10 3423172.28 3.22E-07 8982602.45 1.90E-09 3293918.33 1.14E-10 
VARS P26640 Valine--tRNA ligase 3.31 3.16E-07 2.37 2.85E-03 1.59 9.49E-02 
VIM P08670 Vimentin 4.25 1.75E-07 6.94 3.49E-09 2.60 2.37E-04 
VLDLR P98155 Very low-density lipoprotein receptor 2.19 5.12E-04 2.27 2.22E-04 0.92 6.55E-01 
WDR5 P61964 WD repeat-containing protein 5 17.16 4.84E-07 26.51 2.16E-07 7.64 1.78E-03 
WHSC1 O96028 Histone-lysine N-methyltransferase 
NSD2 
1104039.21 5.69E-04 2615810.54 1.05E-08 817288.05 2.97E-07 
WIBG Q9BRP8 Partner of Y14 and mago 14498547.38 2.78E-10 56167499.89 8.77E-13 23780781.49 5.47E-08 
WNK1 Q9H4A3 Serine/threonine-protein kinase WNK1 2.03 1.02E-02 0.06 6.71E-04 0.02 4.58E-04 
XRCC5 P13010 X-ray repair cross-complementing 
protein 5 
78.06 2.70E-06 351.21 7.61E-07 203.22 1.33E-09 
XRCC6 P12956 X-ray repair cross-complementing 
protein 6 
79.45 9.46E-09 348.78 8.80E-07 202.30 2.13E-10 







Gene Name Protein ID Protein Name 










YBX1 P67809 Nuclease-sensitive element-binding 
protein 1 
114.21 9.45E-11 292.94 3.37E-09 148.23 6.71E-09 
YBX3 P16989 Y-box-binding protein 3 271.32 1.48E-09 595.68 8.83E-09 269.94 8.61E-08 
YTHDC1 Q96MU7 YTH domain-containing protein 1 619838.91 1.31E-02 3789564.21 8.52E-06 2084746.48 5.67E-08 
YTHDC2 Q9H6S0 Probable ATP-dependent RNA 
helicase YTHDC2 
99.62 2.23E-13 218.76 1.77E-07 90.71 9.16E-07 
YWHAE P62258 14-3-3 protein epsilon 117.07 5.82E-07 31.82 1.13E-03 7.97 7.14E-03 
YWHAG P61981 14-3-3 protein gamma;14-3-3 protein 
gamma, N-terminally processed 
11.57 1.82E-06 4.61 2.61E-06 2.91 4.70E-02 
YWHAQ P27348 14-3-3 protein theta 5.45 6.07E-06 4.88 3.37E-07 0.73 6.22E-01 
YWHAZ P63104 14-3-3 protein zeta/delta 6.79 8.76E-08 4.82 7.95E-07 1.96 7.64E-02 
ZC2HC1A Q96GY0 Zinc finger C2HC domain-containing 
protein 1A 
1339005.24 6.23E-07 2968808.35 1.63E-08 1345277.02 1.79E-05 
ZC3H15 Q8WU90 Zinc finger CCCH domain-containing 
protein 15 
1120530.51 2.85E-07 2116948.75 7.29E-04 107668.97 3.41E-01 
ZC3H8 Q8N5P1 Zinc finger CCCH domain-containing 
protein 8 
7317483.49 3.60E-09 20762392.04 1.21E-11 8680178.13 1.17E-09 
ZC3HAV1 Q7Z2W4 Zinc finger CCCH-type antiviral 
protein 1 
494.30 1.55E-13 1302.90 6.13E-17 533.91 6.05E-12 
ZCCHC8 Q6NZY4 Zinc finger CCHC domain-containing 
protein 8 
1924270.47 1.63E-10 4058716.92 1.96E-08 1608574.62 6.44E-02 
ZFR Q96KR1 Zinc finger RNA-binding protein 476.44 2.12E-05 1865.09 2.54E-12 632.49 9.12E-09 
ZNF326 Q5BKZ1 DBIRD complex subunit ZNF326 409.31 1.31E-03 1488.52 5.88E-10 519.38 6.17E-10 
ZNF512 Q96ME7 Zinc finger protein 512 709263.44 1.05E-02 1286471.16 5.90E-02 456909.93 4.95E-02 









Supplementary Table 2: IP-MS dataset for the endogenous mESC interactome (described in Section 4.3.3). Fold enrichment over wt (untagged cells) 
and p-values for all hits obtained in the IP-MS experiments using with SRSF1-T7 or SRSF1-NRS-T7 (Clone 1) mESCs. Only processed data values are 
shown, raw intensity values and LFQ values omitted for ease. For processing methods used, see Section 4.3.3 for details. Where N/A is shown for p-
value and 1.00 is shown for fold enrichment, this represents a scenario where there was no binding in either condition tested. All values are given to 
two decimal places. Hits are in alphabetical order according to Gene Name as imputed from the UniProt database. Protein ID refers to the given UniProt 
ID for each protein identified. Where multiple proteins are listed, this indicates that the interacting peptide identified could map to multiple proteins 
or isoforms of a protein. Database search to map the raw data hits was carried out by Jimi Wills of the IGMM Mass Spectrometry facility. 
Gene Name Protein ID Protein Name 
SRSF1-T7 SRSF1-NRS-T7 (Clone 1) 




5430403G16Rik D3Z5L4 RIKEN cDNA 5430403G16 gene 11.65 4.23E-02 8.53 9.76E-02 
Aatf Q9JKX4 Protein AATF 916412.75 5.73E-02 808975.25 2.44E-02 
Abcf1 Q6P542 ATP-binding cassette sub-family F member 1 4526675.00 4.53E-02 4254300.25 1.61E-01 
Abt1 Q9QYL7 Activator of basal transcription 1 2951625.00 9.10E-04 2383050.00 2.85E-05 
Acin1 Q9JIX8 
Apoptotic chromatin condensation inducer in the 
nucleus 
117.51 2.19E-02 218.02 9.31E-02 
Adgrl1 Q80TR1 Adhesion G protein-coupled receptor L1 10.80 1.80E-02 13.68 9.22E-02 
Aebp2 Q9Z248 Zinc finger protein AEBP2 607775.50 1.35E-01 1717105.00 1.84E-02 
Ap2a2 P17427 AP-2 complex subunit alpha-2 12.41 1.91E-01 16.75 2.20E-01 
Apobec3 Q99J72 DNA dC->dU-editing enzyme APOBEC-3 578875.75 3.56E-01 1.00 N/A 
Arpc1b Q9WV32 Actin-related protein 2/3 complex subunit 1B 2128050.50 1.49E-01 2089825.50 1.34E-01 







Gene Name Protein ID Protein Name 
SRSF1-T7 SRSF1-NRS-T7 (Clone 1) 




Bclaf1 Q8K019 Bcl-2-associated transcription factor 1 166.76 4.79E-02 300.82 9.83E-02 
Blm O88700 Bloom syndrome protein homolog 1001125.00 9.81E-05 303775.50 1.40E-01 
Bms1 Q6PGF5 
BMS1 homolog, ribosome assembly protein 
(Yeast) 
13.58 6.51E-03 5.70 8.42E-02 
Brd7 O88665 Bromodomain-containing protein 7 573560.25 4.55E-02 838987.75 1.07E-01 
Brix1 Q9DCA5 Ribosome biogenesis protein BRX1 homolog 10.63 3.17E-03 8.59 3.04E-03 
Bud13 Q8R149 BUD13 homolog 3577350.00 7.18E-04 3614550.00 3.10E-03 
C12orf66 Q6P1I3 KICSTOR complex protein C12orf66 homolog 325930.00 9.81E-04 531550.50 2.97E-01 
Cactin Q9CS00 Cactin 166.77 3.39E-03 156.10 2.23E-02 
Ccar1 Q8CH18 
Cell division cycle and apoptosis regulator protein 
1 
1.00 N/A 402875.75 3.56E-01 
Ccdc137 Q8R0K4 Coiled-coil domain-containing protein 137 2178925.00 2.15E-03 1153067.50 3.51E-04 
Ccdc59 Q8R2N0 
Thyroid transcription factor 1-associated protein 
26 
16.14 1.35E-03 13.13 4.82E-03 
Ccnk O88874 Cyclin-K 2263575.50 1.48E-01 1572700.50 1.34E-01 
Cd3eap Q76KJ5 DNA-directed RNA polymerase I subunit RPA34 27.34 1.50E-02 21.34 4.64E-04 
Cd40lg P27548 
CD40 ligand;CD40 ligand, membrane form;CD40 
ligand, soluble form 







Gene Name Protein ID Protein Name 
SRSF1-T7 SRSF1-NRS-T7 (Clone 1) 




Cdk11b P24788 Cyclin-dependent kinase 11B 20.92 1.03E-03 23.49 5.45E-03 
Cdk13 Q69ZA1 Cyclin-dependent kinase 13 825300.50 1.34E-01 1338577.50 1.77E-02 
Cfap20 Q8BTU1 Cilia- and flagella-associated protein 20 2317225.00 2.72E-02 2662117.75 1.27E-01 
Chchd2 Q9D1L0 
Coiled-coil-helix-coiled-coil-helix domain-
containing protein 2 
26.80 1.68E-01 48.45 1.44E-01 
Chtop Q9CY57 Chromatin target of PRMT1 protein 10.20 1.25E-03 14.85 5.30E-02 
Clasrp Q8CFC7 CLK4-associating serine/arginine rich protein 7774550.00 1.97E-02 6790150.00 7.50E-02 
Cpsf1 Q9EPU4 
Cleavage and polyadenylation specificity factor 
subunit 1 
9.30 1.31E-02 10.09 1.85E-02 
Cwc25 Q9DBF7 Pre-mRNA-splicing factor CWC25 homolog 11.73 5.48E-03 8.70 1.82E-03 
Cxxc1 Q9CWW7 CXXC-type zinc finger protein 1 2273767.50 5.56E-02 1780975.50 1.46E-01 
D2Wsu81e Q3UHX9 Putative methyltransferase C9orf114 homolog 411005.25 5.73E-02 377647.75 7.19E-02 
Ddx18 Q8K363 ATP-dependent RNA helicase DDX18 12.54 2.86E-03 7.35 5.21E-04 
Ddx24 Q9ESV0 ATP-dependent RNA helicase DDX24 22.36 5.85E-05 17.09 1.92E-03 
Ddx27 Q921N6 Probable ATP-dependent RNA helicase DDX27 33.39 1.42E-02 18.37 2.43E-02 
Ddx31 Q6NZQ2 Probable ATP-dependent RNA helicase DDX31 1998502.50 4.60E-03 1515625.00 1.38E-05 
Ddx50 Q99MJ9 ATP-dependent RNA helicase DDX50 22.34 1.79E-03 23.88 1.65E-03 







Gene Name Protein ID Protein Name 
SRSF1-T7 SRSF1-NRS-T7 (Clone 1) 




Ddx54 Q8K4L0 ATP-dependent RNA helicase DDX54 44.85 6.91E-03 30.80 1.25E-02 
Dhx15 O35286 
Pre-mRNA-splicing factor ATP-dependent RNA 
helicase DHX15 
41.48 3.91E-02 34.51 6.49E-02 
Dhx30 Q99PU8 Putative ATP-dependent RNA helicase DHX30 86.48 6.80E-03 52.43 2.52E-02 
Dhx37 Q6NZL1 DEAH (Asp-Glu-Ala-His) box polypeptide 37 14.13 1.29E-03 10.46 8.66E-04 
Dhx8 A2A4P0 ATP-dependent RNA helicase DHX8 1156425.25 3.06E-02 1125875.00 1.65E-03 
Dido1 Q8C9B9 Death-inducer obliterator 1 19.72 1.81E-03 20.04 1.91E-02 
Dkc1 Q9ESX5 H/ACA ribonucleoprotein complex subunit 4 1078325.00 1.10E-02 1059115.00 9.48E-02 
Dlgap5 Q8K4R9 Disks large-associated protein 5 1792900.50 2.10E-01 572025.75 3.56E-01 




37.08 1.96E-01 38.63 1.76E-01 
Enox1 Q8BHR2 
Ecto-NOX disulfide-thiol exchanger 
1;Hydroquinone [NADH] oxidase;Protein 
disulfide-thiol oxidoreductase 
2332350.50 1.48E-01 1865725.50 1.61E-01 
Erbb3 Q61526 Receptor tyrosine-protein kinase erbB-3 1072425.50 2.11E-01 1478900.50 1.37E-01 
Erh P84089 Enhancer of rudimentary homolog 26.61 8.05E-02 33.18 1.14E-01 







Gene Name Protein ID Protein Name 
SRSF1-T7 SRSF1-NRS-T7 (Clone 1) 




Exosc10 P56960 Exosome component 10 10.65 1.66E-01 7.11 1.95E-01 
Exosc4 Q921I9 Exosome complex component RRP41 14.91 8.06E-03 11.83 1.89E-04 
Ezh1 P70351 Histone-lysine N-methyltransferase EZH1 813782.75 6.37E-02 1158225.00 9.27E-05 
Fam136a Q9CR98 Protein FAM136A 6.53 2.16E-01 14.65 1.66E-01 
Fam60a Q8C8M1 Protein FAM60A 1321975.50 1.50E-01 1900075.50 1.93E-01 
Fam76a Q922G2 Protein FAM76A 1076900.50 1.52E-01 1652325.50 1.68E-01 
Fkbp9 Q9Z247 Peptidyl-prolyl cis-trans isomerase FKBP9 932705.50 2.15E-01 805725.50 1.39E-01 
Fmr1 P35922 Fragile X mental retardation protein 1 homolog 26.60 2.32E-02 24.02 1.74E-01 
Ftsj3 Q9DBE9 pre-rRNA processing protein FTSJ3 19.29 5.58E-04 12.05 3.91E-03 
Gab1 Q9QYY0 GRB2-associated-binding protein 1 6.53 5.57E-02 10.76 6.32E-02 
Gatad2a Q8CHY6 Transcriptional repressor p66 alpha 6.94 1.18E-01 10.46 9.60E-02 
Gm10130 F6ZHM5 Predicted gene 10130 1909900.75 3.56E-01 1011275.75 3.56E-01 
Gnai2 P08752 
Guanine nucleotide-binding protein G(i) subunit 
alpha-2 
5454425.50 1.90E-01 6789000.25 1.07E-01 
Gnl2 Q99LH1 Nucleolar GTP-binding protein 2 14.49 1.30E-03 18.89 5.49E-02 
Gpatch1 Q9DBM1 G patch domain-containing protein 1 1406382.75 8.97E-02 1.00 N/A 







Gene Name Protein ID Protein Name 
SRSF1-T7 SRSF1-NRS-T7 (Clone 1) 




Gpc4 P51655 Glypican-4;Secreted glypican-4 1370150.50 1.88E-01 1877950.50 1.40E-01 
Gtf3c1 Q8K284 General transcription factor 3C polypeptide 1 262960.50 1.58E-01 1.00 N/A 
H1f0 P10922 
Histone H1.0;Histone H1.0, N-terminally 
processed 
10.58 6.13E-04 7.70 1.16E-01 













Histone H2A.J;Histone H2A;Histone H2A type 1-
H;Histone H2A type 1-K;Histone H2A type 1-
F;Histone H2A type 3;Histone H2A type 1 
3343400.00 3.11E-02 261725.75 3.56E-01 
H2afx P27661 Histone H2AX 95.42 1.33E-01 21.47 1.14E-01 
Hdac6 Q9Z2V5 Histone deacetylase 6 808328.00 1.85E-01 1154650.50 1.69E-01 
Hic2 Q9JLZ6 Hypermethylated in cancer 2 protein 1.00 N/A 1118050.50 1.64E-01 
Hmga1 P17095 High mobility group protein HMG-I/HMG-Y 6443410.25 2.63E-01 1583775.25 1.96E-01 
Hp1bp3 Q3TEA8 Heterochromatin protein 1-binding protein 3 1078150.25 2.90E-02 1321605.00 8.95E-03 
Igf2bp2 Q5SF07 
Insulin-like growth factor 2 mRNA-binding 
protein 2 







Gene Name Protein ID Protein Name 
SRSF1-T7 SRSF1-NRS-T7 (Clone 1) 







Immunoglobulin heavy variable 5-15 1.00 N/A 275750.75 3.56E-01 
Isg20l2 Q3U1G5 Interferon-stimulated 20 kDa exonuclease-like 2 3935400.00 1.91E-03 2421975.00 1.40E-04 
Itga3 Q62470 
Integrin alpha-3;Integrin alpha-3 heavy 
chain;Integrin alpha-3 light chain 
239.34 1.52E-01 320.71 1.50E-01 
Itgb4 A2A863 Integrin beta-4 1.00 N/A 128090.75 3.56E-01 
Jarid2 Q62315 Protein Jumonji 9.08 7.75E-04 11.87 5.08E-03 
Kiaa0020 Q8BKS9 Pumilio domain-containing protein KIAA0020 66.87 1.47E-02 37.10 5.35E-03 
Kiaa1429 A2AIV2 Protein virilizer homolog 2584155.25 9.99E-02 2588625.25 1.29E-01 
Kif23 E9Q5G3 Kinesin-like protein KIF23 37.45 1.55E-03 33.16 3.44E-02 
Llph Q9D945 Protein LLP homolog 9.69 9.53E-02 15.36 1.94E-03 
Luc7l3 Q5SUF2 Luc7-like protein 3 11.41 2.11E-02 17.00 1.73E-01 
Magt1 Q9CQY5 Magnesium transporter protein 1 445290.50 1.36E-01 887402.75 1.29E-01 
Mak16 Q8BGS0 Protein MAK16 homolog 2177650.00 2.27E-03 1246850.25 2.50E-02 
Mcm2 P97310 DNA replication licensing factor MCM2 17.81 1.87E-01 12.76 1.73E-01 
Mina Q8CD15 
Bifunctional lysine-specific demethylase and 
histidyl-hydroxylase MINA 
390700.75 3.56E-01 392550.50 2.02E-01 







Gene Name Protein ID Protein Name 
SRSF1-T7 SRSF1-NRS-T7 (Clone 1) 




Mreg Q6NVG5 Melanoregulin 3275300.50 1.93E-01 3504175.50 1.45E-01 
Mri1 Q9CQT1 Methylthioribose-1-phosphate isomerase 8.89 2.70E-01 38.93 2.07E-01 
Mrpl11 Q9CQF0 39S ribosomal protein L11, mitochondrial 132.98 3.39E-02 108.50 5.51E-05 
Mrpl15 Q9CPR5 39S ribosomal protein L15, mitochondrial 1877010.00 8.74E-02 1716820.25 1.18E-01 
Mrpl2 Q9D773 39S ribosomal protein L2, mitochondrial 6529147.75 1.41E-01 6272077.75 1.48E-01 
Mrpl23 O35972 39S ribosomal protein L23, mitochondrial 12.91 1.16E-01 15.44 1.59E-01 
Mrpl24 Q9CQ06 39S ribosomal protein L24, mitochondrial 8.27 1.44E-01 12.66 1.76E-01 
Mrpl32 Q9DCI9 39S ribosomal protein L32, mitochondrial 785747.75 1.64E-01 896550.50 1.66E-01 
Mrpl41 Q9CQN7 39S ribosomal protein L41, mitochondrial 2337067.75 1.30E-01 2635050.50 1.34E-01 
Mrpl42 Q9CPV3 39S ribosomal protein L42, mitochondrial 24.79 7.38E-02 19.81 1.71E-01 
Mrpl43 Q99N89 39S ribosomal protein L43, mitochondrial 965795.50 2.98E-01 1759657.75 1.19E-01 
Mrpl47 Q8K2Y7 39S ribosomal protein L47, mitochondrial 11.17 1.35E-01 4.33 2.64E-01 
Mrpl49 Q9CQ40 39S ribosomal protein L49, mitochondrial 307475.75 3.56E-01 351800.75 3.56E-01 
Mrpl9 Q99N94 39S ribosomal protein L9, mitochondrial 2136035.00 1.39E-01 958487.75 4.59E-02 
Mrps16 Q9CPX7 28S ribosomal protein S16, mitochondrial 15.41 1.42E-01 19.66 1.53E-01 
Mrps17 Q9CQE3 28S ribosomal protein S17, mitochondrial 412225.50 1.41E-01 459905.50 1.34E-01 







Gene Name Protein ID Protein Name 
SRSF1-T7 SRSF1-NRS-T7 (Clone 1) 




Mrps26 Q80ZS3 28S ribosomal protein S26, mitochondrial 67.28 3.44E-02 77.91 1.10E-01 
Mrps30 Q9D0G0 28S ribosomal protein S30, mitochondrial 863260.25 3.60E-02 629837.50 1.03E-04 
Mrps33 Q9D2R8 28S ribosomal protein S33, mitochondrial 1119980.25 7.38E-02 1087260.00 1.01E-02 
Mrps34 Q9JIK9 28S ribosomal protein S34, mitochondrial 33.53 3.48E-02 31.31 6.08E-02 
Mrps5 Q99N87 28S ribosomal protein S5, mitochondrial 19.66 3.39E-02 20.69 9.90E-02 
Mrps6 P58064 28S ribosomal protein S6, mitochondrial 2387257.50 7.17E-02 1734365.00 6.31E-02 
Mrto4 Q9D0I8 mRNA turnover protein 4 homolog 32.31 2.64E-02 23.40 4.02E-03 
Mtf2 Q02395 
Metal-response element-binding transcription 
factor 2 
11.94 2.16E-04 12.16 1.99E-03 
Nav3 Q80TN7 Neuron navigator 3 1946450.75 3.56E-01 1.00 N/A 
Ncbp1 Q3UYV9 Nuclear cap-binding protein subunit 1 841325.50 1.40E-01 1.00 N/A 
Nepro Q8R2U2 Nucleolus and neural progenitor protein 14.79 1.92E-03 13.98 5.03E-04 
Ngdn Q9DB96 Neuroguidin 27.80 7.11E-04 26.47 3.66E-03 
Nifk Q91VE6 
MKI67 FHA domain-interacting nucleolar 
phosphoprotein 
10712400.00 4.47E-04 8981575.00 2.70E-03 
Noc3l Q8VI84 Nucleolar complex protein 3 homolog 566750.50 1.37E-01 574110.25 3.18E-02 
Nol10 Q5RJG1 Nucleolar protein 10 13.02 2.73E-03 15.21 3.89E-03 







Gene Name Protein ID Protein Name 
SRSF1-T7 SRSF1-NRS-T7 (Clone 1) 





Probable 28S rRNA (cytosine-C(5))-
methyltransferase 
17.07 2.50E-03 12.52 4.80E-04 
Nop53 Q8BK35 Ribosome biogenesis protein NOP53 35.19 2.14E-03 34.90 3.68E-03 
Nsa2 Q9CR47 Ribosome biogenesis protein NSA2 homolog 12.93 9.28E-05 13.24 1.36E-02 
Numa1 E9Q7G0 Nuclear mitotic apparatus protein 1 6.06 3.40E-03 13.59 5.63E-02 
Oxa1l Q8BGA9 Mitochondrial inner membrane protein OXA1L 251250.75 3.56E-01 1318620.00 2.33E-02 
P2rx7 Q9Z1M0 P2X purinoceptor 7 11.70 1.92E-01 32.51 1.88E-01 
Pbrm1 Q8BSQ9 Protein polybromo-1 66030.75 3.56E-01 491980.25 4.68E-02 
Pdcd11 Q6NS46 Protein RRP5 homolog 65.49 8.94E-04 50.02 1.31E-04 
Pinx1 Q9CZX5 PIN2/TERF1-interacting telomerase inhibitor 1 78638.25 3.56E-01 92603.00 1.39E-01 
Pnn O35691 Pinin 8.63 7.19E-02 25.04 1.63E-01 
Polr1e Q8K202 DNA-directed RNA polymerase I subunit RPA49 16.07 1.88E-02 12.79 6.17E-04 
Polr2h Q923G2 
DNA-directed RNA polymerases I, II, and III 
subunit RPABC3 
668892.75 3.22E-02 973932.75 1.31E-01 
Popdc3 Q9ES81 Popeye domain-containing protein 3 809500.75 3.56E-01 1.00 N/A 
Ppan Q91YU8 Suppressor of SWI4 1 homolog 16.74 4.60E-03 16.44 1.66E-02 
Ppig A2AR02 Peptidyl-prolyl cis-trans isomerase G 54.78 1.05E-02 96.69 8.96E-02 
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Prpf38a Q4FK66 Pre-mRNA-splicing factor 38A 1116725.50 1.98E-01 790032.75 7.86E-02 
Prpf38b Q80SY5 Pre-mRNA-splicing factor 38B 5102825.00 5.43E-03 4397275.25 7.55E-02 
Prpf4b Q61136 Serine/threonine-protein kinase PRP4 homolog 62.72 3.20E-04 71.84 2.33E-02 
Ptcd3 Q14C51 
Pentatricopeptide repeat domain-containing 
protein 3, mitochondrial 
1.40 8.25E-01 12.01 6.65E-02 
Pwp1 Q99LL5 Periodic tryptophan protein 1 homolog 3768475.00 1.08E-02 2001522.50 1.72E-02 
Raly Q64012 RNA-binding protein Raly 940842.75 1.08E-01 2558957.50 9.77E-02 
Rbm15 Q0VBL3 RNA-binding motif protein 15 101.35 1.10E-03 87.69 2.59E-03 
Rbm19 Q8R3C6 Probable RNA-binding protein 19 33.68 1.19E-02 23.95 8.18E-05 
Rbm28 Q8CGC6 RNA-binding protein 28 99.42 2.10E-03 66.91 2.89E-03 




RNA binding motif protein, X-linked-like-
1;RNA-binding motif protein, X 
chromosome;RNA-binding motif protein, X 
chromosome, N-terminally processed 
43.35 6.45E-02 56.12 1.26E-01 
Rbmxl2 Q9DAE2 RNA-binding motif protein, X-linked-like 2 87.01 1.62E-02 101.12 1.93E-01 
Rcl1 Q9JJT0 RNA 3-terminal phosphate cyclase-like protein 622475.50 1.34E-01 443325.50 1.68E-01 
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Rnf20 Q5DTM8 E3 ubiquitin-protein ligase BRE1A 4.88 3.11E-01 12.31 1.86E-01 
Rnf40 Q3U319 E3 ubiquitin-protein ligase BRE1B 12.77 2.15E-01 18.37 2.30E-01 
Rnps1 Q99M28 RNA-binding protein with serine-rich domain 1 47.06 6.29E-03 65.06 1.24E-01 
Rpf2 Q9JJ80 Ribosome production factor 2 homolog 16.30 1.96E-03 10.98 3.38E-03 
Rpp38 Q80UU2 Ribonuclease P protein subunit p38 8.22 1.60E-03 10.68 1.11E-02 
Rrp15 Q9CYX7 RRP15-like protein 13.89 1.12E-04 9.85 7.05E-03 
Rrp7a Q9D1C9 Ribosomal RNA-processing protein 7 homolog A 34.47 2.16E-03 22.44 2.95E-04 
Rrp8 Q9DB85 Ribosomal RNA-processing protein 8 3984750.00 1.35E-03 3337575.00 2.25E-03 
Rrs1 Q9CYH6 Ribosome biogenesis regulatory protein homolog 16.33 4.18E-03 13.57 1.68E-03 
Rsl24d1 Q99L28 Probable ribosome biogenesis protein RLP24 1666225.25 1.15E-01 1520512.75 9.74E-02 
Safb D3YXK2 Scaffold attachment factor B1 1522100.25 6.88E-02 1383902.75 1.25E-01 
Sap18 O55128 Histone deacetylase complex subunit SAP18 178.06 5.55E-02 315.13 1.23E-01 
Sap30bp Q02614 SAP30-binding protein 2514482.50 5.04E-03 2573825.00 1.59E-04 
Setd5 Q5XJV7 SET domain-containing protein 5 65090000.75 3.56E-01 1.00 N/A 
Sf3a1 Q8K4Z5 Splicing factor 3A subunit 1 3216377.50 3.62E-02 489538.00 1.93E-01 
Sgol2 Q7TSY8 Shugoshin-like 2 2917825.00 7.49E-04 6217700.00 1.85E-02 
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Snap23 O09044 Synaptosomal-associated protein 23 11.13 1.95E-01 23.16 1.91E-01 
Snrnp27 Q8K194 
U4/U6.U5 small nuclear ribonucleoprotein 27 
kDa protein 
607050.50 1.54E-01 258975.75 3.56E-01 
Snrnp70 Q62376 U1 small nuclear ribonucleoprotein 70 kDa 16.21 8.26E-02 24.98 2.04E-01 
Snrpa Q62189 U1 small nuclear ribonucleoprotein A 15.81 8.41E-02 19.38 1.57E-01 
Snrpb2 Q9CQI7 U2 small nuclear ribonucleoprotein B 743075.50 1.53E-01 1.00 N/A 
Snrpc Q62241 U1 small nuclear ribonucleoprotein C 14.47 1.38E-01 17.59 2.14E-01 
Snrpd1 P62315 Small nuclear ribonucleoprotein Sm D1 35.87 1.52E-01 45.57 1.27E-01 
Snrpd2 P62317 Small nuclear ribonucleoprotein Sm D2 9.48 9.50E-02 11.67 1.82E-01 
Snrpd3 P62320 Small nuclear ribonucleoprotein Sm D3 10.34 1.54E-01 11.77 1.96E-01 
Snrpf P62307 Small nuclear ribonucleoprotein F 7.49 2.14E-01 12.08 2.59E-01 
Snrpg P62309 Small nuclear ribonucleoprotein G 18.07 1.26E-01 22.03 2.02E-01 
Son Q9QX47 Protein SON 64.29 1.48E-02 81.69 5.83E-02 
Sparc P07214 SPARC 13.38 1.58E-01 17.30 2.09E-01 
Srp72 F8VQC1 Signal recognition particle subunit SRP72 1.00 N/A 268875.75 3.56E-01 
Srpk1 O70551 SRSF protein kinase 1 13.88 6.97E-04 8.82 3.43E-03 
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Srrm2 Q8BTI8 Serine/arginine repetitive matrix protein 2 12.17 2.10E-02 24.80 7.37E-02 
Srsf1 Q6PDM2 Serine/arginine-rich splicing factor 1 210.59 1.01E-02 158.24 4.72E-02 
Srsf10 Q9R0U0 Serine/arginine-rich splicing factor 10 8126150.00 5.85E-03 13184675.00 4.27E-02 
Srsf3 P84104 Serine/arginine-rich splicing factor 3 8.87 5.69E-03 12.00 9.79E-02 
Srsf4 Q8VE97 Serine/arginine-rich splicing factor 4 36.95 2.63E-03 57.14 8.96E-02 
Srsf5 O35326 Serine/arginine-rich splicing factor 5 13.99 5.33E-05 17.52 4.67E-02 
Srsf6 Q3TWW8 Serine/arginine-rich splicing factor 6 13.04 2.83E-04 21.17 7.16E-02 
Srsf7 Q8BL97 Serine/arginine-rich splicing factor 7 15.17 1.26E-03 22.34 7.28E-02 
Srsf9 Q9D0B0 Serine/arginine-rich splicing factor 9 13.78 2.55E-02 9.80 1.02E-01 
Stau1 Q9Z108 
Double-stranded RNA-binding protein Staufen 
homolog 1 
1210307.50 3.41E-03 1.00 N/A 
Suz12 Q80U70 Polycomb protein Suz12 25.69 3.70E-03 36.84 4.74E-04 
Tbc1d31 Q6NXY1 TBC1 domain family member 31 957900.75 3.56E-01 5563250.75 3.56E-01 
Tes P47226 Testin 876475.50 1.64E-01 955125.50 1.74E-01 





Transducin-like enhancer protein 1;Transducin-
like enhancer protein 4;Transducin-like enhancer 
protein 2 
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Tle3 Q08122 Transducin-like enhancer protein 3 1133825.50 1.61E-01 1305950.50 1.71E-01 
Tra2a Q6PFR5 Transformer-2 protein homolog alpha 67.95 5.51E-03 96.71 6.60E-02 
Tra2b P62996 Transformer-2 protein homolog beta 28.42 3.28E-02 41.73 9.38E-02 
Trim33 Q99PP7 E3 ubiquitin-protein ligase TRIM33 13.83 2.27E-01 23.21 1.50E-01 
Ubr7 Q8BU04 Putative E3 ubiquitin-protein ligase UBR7 4313525.50 1.46E-01 5467950.50 1.95E-01 
Utp18 Q5SSI6 
U3 small nucleolar RNA-associated protein 18 
homolog 
2730850.00 3.81E-05 1956535.00 1.16E-02 
Utp23 Q9CX11 rRNA-processing protein UTP23 homolog 2070550.25 3.90E-02 283490.50 2.10E-01 
Wtap Q9ER69 Pre-mRNA-splicing regulator WTAP 8.17 1.64E-01 17.82 2.72E-01 
Ythdc1 E9Q5K9 YTH domain-containing protein 1 1977110.00 1.03E-02 3699105.00 1.46E-01 
Zc3h13 E9Q784 Zinc finger CCCH domain-containing protein 13 52.16 7.25E-03 114.45 7.02E-02 
Zcchc8 Q9CYA6 Zinc finger CCHC domain-containing protein 8 1073400.50 1.44E-01 2033350.25 3.82E-02 
Zfp715 G3X9T1 Zinc finger protein 715 672300.50 1.45E-01 976300.50 1.50E-01 
Zfp869 Q9DC47 Zinc finger protein 869 23.97 1.83E-01 18.70 1.63E-01 
Zfyve1 Q810J8 Zinc finger FYVE domain-containing protein 1 125810.50 1.46E-01 96740.75 3.56E-01 
Znf319 Q497V9 Zinc finger protein 319 669530.50 2.20E-01 512928.00 1.68E-01 
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Znf48 Q3US17 Zinc finger protein 48 9.93 1.26E-03 12.88 5.04E-02 
Znf569 Q80W31 Zinc finger protein 569 11.18 1.41E-02 9.60 1.11E-01 
Znf638 Q61464 Zinc finger protein 638 68.73623526 1.01E-04 84.93609984 3.25E-02 
 
 
 
 
 
